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Abstract 
 
Kynurenine 3-monooxygenase (K3MO) lies on the kynurenine pathway, the major 
pathway for the catabolism of L-tryptophan. It converts kynurenine to 3-hydroxy 
kynurenine. Inhibition of K3MO is important in several neurological diseases and 
there is evidence that inhibition of K3MO could also be targeted for the prevention 
of multiple organ failure, secondary to acute pancreatitis. 
A structure activity relationship based upon the 1,2,4-oxadiazoles motif was carried 
out which revealed amide 207 as an inhibitor of P. fluorescens K3MO. Further 
structure activity relationships were developed based upon 207. This revealed 3,4-
dichloro substitution in 235 and 245 as optimum for inhibition. Co-crystalisation of 
these inhibitors with P. fluorescens K3MO revealed their interactions with the 
enzyme. It also highlighted new, potential interactions between the inhibitors and 
K3MO. This led to the synthesis of 271 and 272, which were also potent inhibitors 
of K3MO. These amides were successfully co-crystalised with P. fluorescens 
K3MO. Further development of the amides followed, with amide 282 providing the 
most potent inhibitor of P. fluorescens K3MO to date (Ki = 29.1 nM). 
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Chapter 1 
Introduction 
 
1.1 Kynurenine pathway 
The kynurenine pathway is the major route for the catabolism of tryptophan 1 
ultimately leading to the de novo synthesis of NADH. The link between NADH 
synthesis and tryptophan catabolism was discovered in 1947.1 Initial interest in the 
pathway waned when the important neurotransmitter 5-hydroxytryptamine 2 was 
revealed as an alternative catabolite of tryptophan.2 It is estimated that in 
peripheral tissue 95% of tryptophan is metabolised to kynurenine 3 whilst less than 
1% is metabolised to 5-hydroxytryptamine 2 (Figure 1.1).2 
 
Figure 1.1. The majority (95%) of L-tryptophan is metabolised via the kynurenine pathway. 
Interest in the kynurenine pathway increased when several of the catabolites were 
shown to be neurologically active. Quinolinic acid 13, was shown to be an agonist 
of the NMDA receptor in 1981.3 The activation of the NMDA receptor by 13 leads 
to neurodegeneration.4 Shortly after this discovery in 1982, it was found that 
kynureninic acid 5 is an antagonist of the NMDA receptor.5, 6 A major research 
interest in the pathway involved altering the ratio of neurotoxic quinolinic acid 13 to 
neuroprotective kynureninc acid 5 through enzyme inhibition.4 
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Scheme 1.1. The kynurenine pathway: a) TDO or IDO, O2, haem; b) aryl formamidase, H2O; c) kynurenine 
aminotransferase, PLP; d) kynureninase, H2O, PLP; e) kynurenine-3-monooxygenase (K3MO), FAD, NADH, 
O2; f) non specific hydroxylation in the liver; g) kynureninase, H2O, PLP; h) 3-hydroxyanthranilate 3,4-
dioxygenase, O2, haem; i) aminocarboxymuconate-semialdehyde decarboxylase; j) non-enzymatic 
rearrangement; k) non-enzymatic rearrangement; l) quinolinate phosphoribosyltransferase. 
The metabolism of tryptophan 1 via the kynurenine pathway, as illustrated in 
Scheme 1.1, commences with the oxidative cleavage of the indole C2-C3 carbon-
carbon double bond by either tryptophan 2,3-dioxygenase (TDO) or indoleamine 
2,3-dioxygenase (IDO). These haem-dependent enzymes use molecular oxygen 
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for this cleavage. The product of the reaction is formylkynurenine 4, which is then 
hydrolysed by an aryl formamidase enzyme to give kynurenine 3.2, 4 
At this point there is a branch in the pathway and kynurenine 3 has three distinct 
fates. The first is that kynurenine 3 is acted upon by kynurenine aminotransferase 
(KAT) to give kynurenic acid 5. KAT catalyses a transamination reaction, using 
pyridoxal-5’ phosphate (PLP) as a co-factor. Another PLP-dependent enzyme, 
kynureninase transforms kynurenine 3 into anthranilic acid 6 and alanine 7. 
Anthranilic acid 6 is used in the biosynthesis of aromatic amino acids.2 The third 
enzyme that catabolises kynurenine 3 is kynurenine-3-monooxygenase (K3MO). 
This FAD-dependent enzyme catalyses the selective oxidation of the phenyl ring of 
3 to give 3-hydroxykynurenine 8. 2, 4 
Kynureninase also catalyses the cleavage of 3-hydroxykynurenine 8 to give 3-
hydroxyanthranilic acid 9. 3-Hydroxyanthranilic acid 9 can also be generated by the 
non-selective oxidation of anthranilic acid 6 by an, as yet, unknown enzyme.7 3-
Hydroxyanthranilic acid 9 is oxidatively cleaved by 3-hydroxyanthranilate 3,4-
dioxygenase (3HAO), an iron dependent enzyme, to give 2-amino-3-
carboxymuconate-semialdehyde 10. 2-Amino-3-carboxymuconate-semialdehyde 
10 has two fates. It is either decarboxylated by aminocarboxymuconate-
semialdehyde decarboxylase (ACMSD) or it cyclises non-enzymatically, to 
quinolinic acid 13.8 The decarboxylation by ACMSD gives amino-muconate-
semialdehyde 11, which can either undergo a non-enzymatic cyclisation to give 
picolinic acid 12 or it is further metabolised to glutaryl CoA and acetyl CoA. 
Quinolinate phosphoribosyl trasferase (QPRTase) converts quinolinic acid 13 into 
nicotinic acid mononucleotide 14 and carbon dioxide. 2, 4 
Under normal physiological conditions the majority of 2-amino-3-carboxymuconate-
semialdehyde 10 formed is decarboxylated to 11. Intermediate 10 had a half life of 
33 mins in assays on bovine kidney 3HAO,9 which is long enough for 
decarboxylation by ACMSD. This means that under physiological conditions only a 
small amount of de novo NADH is made.10  
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Figure 1.2. The effects that cytokines produce on the flux of the kynurenine pathway. (3-HK) = 
3-hydroxykynurenine, (3-HAA) = 3-hydroxyanthranilic acid 
However, under inflammatory conditions, pro-inflammatory cytokines interferon 
gamma (INFγ) and tumour necrosis factor alpha (TNFα) activate IDO (Figure 1.2). 
This has the effect of increasing the metabolism of tryptophan via the kynurenine 
pathway. After lipopolysaccharide (LPS) injection into mice brains it was found that, 
4 h after the injection, the expression of the K3MO gene was statistically reduced 
in the cortex but not in the hippocampus.11 After 24 h the expression of the K3MO 
gene in both the cortex and hippocampus was increased. There was also an 
increase in pro-inflammatory cytokines 4 h post injection, in both the cortex and 
hippocampus and it has been proposed that these cytokines regulate the 
expression of K3MO.11 The expression of K3MO in the brain appears to be tightly 
regulated.12 
The kynurenine pathway has been linked to several neurodegenerative diseases 
including AIDS-related dementia, Huntingtons disease, Lyme disease and 
septecemia.2 It is thought that quinolinic acid 13 has a role in all of these diseases.  
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Figure 1.3. Comparison of quinolinic acid 13, N-methyl-D-aspartic acid 15 and kynurenic acid 5. 
A comparison of the structures of quinolinic acid 13 and N-methyl-D-aspartic acid 
(NMDA) 15, shows that quinolinic acid has a restricted conformation, and the 
dicarboxylic motif is similar to NMDA 15. The binding mode of quinolinic acid 13 
and NMDA 15 must be similar as both are agonists of the glutamate-NMDA 
receptor. Removal of the β-carboxylate appears to change the activity at the 
glutamate-NMDA receptor as kynurenic acid 5 is an antagonist of the NMDA 
receptor. 
The following is a review of the enzymes that play a major role in certain human 
diseases such as AIDS related dementia, Huntingtons disease, schizophrenia and 
bipolar disorder. The enzyme mechanisms and known inhibitors will be discussed. 
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1.2 TDO and IDO 
1.2.1 Biological and structural data for TDO 
 
Scheme 1.2. The reaction catalysed by TDO or IDO. 
Human TDO is a protein of 406 amino acids in length. It forms a tetramer13 with a 
molecular weight of ~190 KDa.14 The tetramer contains four haem units each 
capable of catalysing the oxidative cleavage of L-tryptophan 1. TDO only catalyses 
the oxidative cleavage of L-tryptophan and derivatives e.g 6-fluoro-tryptophan, as 
illustrated in Scheme 1.2.15 TDO has less affinity for L-tryptophan than IDO with a 
Km of 222 µM, however, it has a similar Kcat.16 TDO is only found in the liver of 
humans.17 
A protein crystal structure for TDO from the bacterium Xanthomonas campestris 
was obtained in 2007.15 Sequence alignment shows that human TDO and X. 
campestris enzymes have 34% sequence identity and it is thought that the key 
active site residues are conserved. Careful use of anaerobic conditions allowed the 
ferrous form of the enzyme to be crystallised with L-tryptophan bound at the active 
site. The oxidised ferric form of the enzyme has a much lower affinity for L-
tryptophan. Interestingly the TDO monomer contains 12 α helices and no β-
sheets.15 
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Figure 1.4. Crystal structure of dimeric X. campestris TDO, showing two haem-cofactors and L -tryptophan in 
the active site. L-Tryptophan can also be observed in an allosteric binding site. 
The crystal structure revealed the binding site for L-tryptophan and its position 
relative to the haem units (Figure 1.4). The crystal structure shows the haem iron is 
five co-ordinate with His-240. This histidine that co-ordinates to the iron is 
conserved across all species.18 The indole ring has several hydrophobic 
interactions in the active site. The carboxylic acid of L-tryptophan has a hydrogen 
bonding interaction with Tyr-113 and an ion-pair interaction with Arg-117. It is 
thought that induced fit is important as changes in the orientation of the loops are 
visible when comparing the free and the substrate bound enzyme. Arg-117 has an 
alternative orientation in the free enzyme and it is proposed that substrate 
recognition by Arg-117 alters the shape of the active site allowing the substrate to 
bind. 
There are four allosteric binding sites where four L-tryptophan molecules are 
located.15 The allosteric site is formed at the interfaces of the monomers. It is 
proposed that TDO is activated by allosteric binding of L-tryptophan.19 
  
Haem 
binding site 
Haem 
binding site 
Allosteric L-
tryptophan 
binding site 
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1.2.2 Biological and structural data for IDO 
In humans there are two isoforms of IDO. IDO 1 is a monomeric protein with 403 
amino acids and a molecular weight of ~45 kDa.20 There is 21% sequence 
homology between human IDO 1 and human TDO. In 2007 a new gene with 
homology to IDO was found. Several groups have shown that the protein is able to 
metabolise tryptophan, and as such it has been named IDO 2.19 In humans IDO 1 
is expressed in placenta, lung, small and large intestine, spleen, liver, kidney, 
stomach and the brain, whereas IDO 2 is mainly expressed in the kidneys but is 
also found in the testicles and liver. In humans IDO 1 and IDO 2 genes are found 
beside each other on chromosome 8. It has been suggested that these genes 
arose via gene duplication. IDO and IDO 2 have a more similar amino acid 
sequence with 44% sequence homology.  
The Km of IDO for L-tryptophan is ~20 µM.20 This high affinity allows the enzyme to 
deplete the local environment of L-tryptophan. It has been proposed that the rapid 
depletion of L-tryptophan is a mechanism for tumour evasion from the immune 
system. Several of the downstream metabolites of kynurenine were able to 
modulate the immune system by preventing T-cell proliferation.21 IDO oxidises 
several indoleamine substrates, e.g. 5-hydroxytryptamine, as well as D- and L-
tryptophan.2 
IDO is naturally regulated in the body by nitric oxide.22 IDO and nitric oxide 
synthase (NOS) are often induced at the same time. It is not clear what occurs 
when IDO and NOS are induced in the same cell. 
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Figure 1.5. Crystal structure of monomeric IDO with phenylimidazole 32 and CHES bound in the active site. 
A crystal structure for the human form of IDO was obtained in 200623 Crystals were 
obtained with phenyimidazole (an inhibitor of the enzyme) and cyanide bound at 
the active site at resolutions of 2.3 Å and 3.4 Å respectively. The crystal structure 
showed that IDO is a monomer, which folds into two distinct domains, a large and 
a small domain (Figure 1.5). The structure shows that His-346 is bound to the 
haem iron. Two molecules of N-cyclohexyl-2-aminoethanesulfonic acid (CHES) 
from the crystalisation buffer were observed in the active site entrance of both 
structures. 
The active site has a large number of hydrophobic side chains with only one polar 
residue (Ser-167). It appears that Phe-163 makes π-π interactions with the bound 
phenylimidazole. 
Mutants F226A and F227A showed much lower dioxygenase activity. 23 The crystal 
structure shows that both L-phenylalanine side chains are orientated into the active 
site. It is likely that they have key π-π interactions when L-tryptophan is bound. 
CHES 
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Mutant R231A also had reduced dioxygenase activity, providing evidence for the 
role of Arg-231 for binding L-tryptophan. 23 
 
1.2.3 TDO and IDO mechanistic information 
The mechanisms of TDO and IDO are still not clear after 40 years of study. It is 
proposed that IDO and TDO use similar chemical mechanisms to carry out their 
oxidative cleavages. They may have a close evolutionary relationship. 
Both IDO and TDO require Fe in the ferrous (FeII) state to catalyse the oxidative 
cleavage of L-tryptophan. The ferrous-oxy complex for TDO has not been 
observed. It has been argued that the complex will be unstable and shortlived. It 
was not possible to determine whether substrate binding stabilises the complex, as 
this leads to turnover.16 This observation is consistent with TDO requiring L-
tryptophan to bind before molecular oxygen binds. On the other hand, IDO can 
bind oxygen freely and as such the IDO haem is readily oxidised to the ferric (FeIII) 
form. TDO shows more resistance to autoxidation than IDO. 
IDO and TDO need to be kept in the reduced ferrous (FeII) form in vivo to be 
catalytically active. Numerous agents have been suggested as the in vivo reducing 
agents including superoxide, flavin mononucleotide and cytochrome b5.13 
Interestingly activity of IDO is diminished in the presence of superoxide dismutase 
suggesting that IDO is reduced by superoxide.13  
In the crystal structure of TDO from X. campestris there is a distal histidine residue 
(His-55) that forms hydrogen bonds to the indole proton on N-1. This has lead to 
the suggestion that deprotonation of the indole nitrogen is relevant for the 
mechanism. However, several studies have argued against this for TDO and IDO. 
Whilst TDO has a distal base in the active site, human IDO has no such distal 
base. The position of (His-55) in TDO is replaced by a serine residue in IDO. 
Without an active site base it was proposed that proton abstraction of the idole 
proton by the bound oxygen was a relevant mechanism. Mutagensis studies on X. 
campestris TDO have shown that the H55A mutant was still catalytically active, but 
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at a much lower level (kcat ~10% of wild type).24 This suggests that His-55 is not 
acting as a base but merely holds tryptophan in the correct orientation for the 
oxidative cleavage. 
In 1991 it was shown that N-methyl tryptophan is an inhibitor of IDO.25 It was 
proposed that inhibition of the enzyme was due to the inability to form an L-
tryptophan anion. As there was no turnover with N-methyl tryptophan as a 
substrate a reaction mechanism involving singlet oxygen was ruled out. 
 
Scheme 1.3. The proposed mechanisms for the initiation of oxidative cleavage of tryptophan: 16 Nucelophilic 
attack on the bound oxygen; 17 a radical process for catalysis. 
However, recent LC-MS work has shown that N-methyl tryptophan is a substrate 
for human IDO and histidine-mutants of human and X. campestris TDO. When His-
55 is mutated there is room for N-methyl tryptophan to bind as a substrate. The 
fact that human IDO and the mutant TDO can turnover N-methyl tryptophan rules 
out the possibility of a base catalysed proton abstraction as a starting point in the 
mechanism.26 As a result of this work two alternative mechanisms for initiation of 
catalysis by TDO and IDO have been proposed, as illustrated in Scheme 1.3. 
The first mechanism, envisages the indole ring as a nucleophile in an electrophilic 
aromatic substitution at C-3 with the bound oxygen. An alternative mechanism has 
been investigated using computational chemistry, which proposes that the oxygen 
attacks C-2 in a radical process. 
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Scheme 1.4. Dioxetane (red) and Criegee (black) mechanism were initially proposed for TDO and IDO. 
Criegee27 and dioxetane mechanisms28 have been proposed for the formation of 
the final product (Scheme 1.4). However, there is no experimental evidence for 
either mechanism. Criegee mechanisms are known to occur in enzymology.29 
 
Scheme 1.5. Alternative mechanisms for the production of tryptophan by IDO and TDO. 
Computational studies do not support either of these mechanisms. 30 The 
dioxetane appears to be thermodynamically unfavourable. The breakdown of the 
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dioxetane would also be very exothermic and the expected emission of light has 
never been observed. Computational studies support epoxide formation,30 as 
illustrated in Scheme 1.5. This could either be a radical or an ionic process. There 
is discussion on whether the protonated amine of the amino acid plays a role in the 
epoxide ring opening, although none of this has experimental evidence. 30, 31 
 
1.2.4 IDO inhibitors 
 
Figure 1.6. 1-Methyl-DL-tryptophan 28 and furan and thiophene analogues of tryptophan 29 and 30. 
IDO has been implicated as a key protein in the evasion of tumours from the 
immune system. Work by Munn et al. showed that IDO plays a central role in 
protecting foetuses from their mothers immune system during pregnancy.32 IDO 
expression has been found in patients with ovarian carcinoma, hepatocellular 
carcinoma, invasive cervical carcinoma, non-small lung carcinoma, colon 
carcinoma and endometrial carcinoma.33 The discovery that the substrate 
analogues 1-methyl-DL-tryptophan 28 and the oxo-29 and thio-30 derivatives of 
tryptophan inhibit IDO (28 with a Ki of 6.6 µM) has led to 28 being used to study the 
role of IDO in immune escape (Figure 1.6).25 Interestingly the D-isomer of 1-
methyltryptophan 28 has entered clinical trials. IDO has a greater affinity for L-
tryptophan and thus it is expected that the L-isomer of 1-methyltryptophan 28 
would have the greatest chemotherapeutic effect. Whilst 1-methyl-D-tryptophan 28 
showed inhibition of IDO in some cells, poor inhibition against the purified enzyme 
was puzzling. This was resolved with the identification of IDO 2 as the main target 
for 1-methyl-D-tryptophan 28.34 1-Methyl-D-tryptophan 28 in conjuction with a 
chemotherapeutic agent showed a greater effect than the L-isomer, in in vivo 
Ki =6.6 µM 
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preclinical testing.35 It has been proposed that IDO2 is more important in immune 
escape than IDO. 
 
Figure 1.7. Norharman 31 and 4-phenylimidazole 32 are uncompetitive inhibitors of IDO. 
Norharman 31 was the first organic inhibitor of IDO discovered (Figure 1.7). It was 
found to be an uncompetitive inhibitor with a Ki of 120 µM.36 Further investigation of 
norharman 31 revealed that it competes with oxygen in binding to the haem in its 
ferrous form.37 4-Phenylimidazole 32 was also discovered as an uncompetitive 
inhibitor of IDO with a Ki of 10 µM.37 Unlike norharman 31, 4-phenylimidazole 32 
preferentially binds to the inactive ferric form of the enzyme. 
A number of IDO inhibitors are natural products, or their derivitaves.  
 
Figure 1.8.  Brassinin 33 highlighted where alterations were made and its most potent analogue 34. 
Brassinin 33 is a natural product obtained from cruciferous plants. It is a 
phytoalexin, which is a modest inhibitor of IDO (Ki of 98 µM). A study into the 
structure-activity relationship of brassinin analogues was undertaken by Gaspari et 
al. 38 (Figure 1.8) 
Altering the aromatic indole core was generally well accepted by the enzyme. 
Changing the indole to a single aromatic ring was also well accepted. The most 
surprising observation was that complete removal of the aromatic system was 
tolerated. The enzyme tolerated replacement of the aromatic ring with the bulky 
Ki =120 µM 
Ki =10 µM 
Ki =11.5 µM 
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adamantyl group, although the affinity for IDO was lower than brassinin (Ki of 179.6 
µM). Increasing the alkane chain length improved the inhibition, with the propyl 
linker being optimal. However, when the alkyl linker and S-alkyl chain were both 
modified, extension of the alkyl linker did not increase inhibition. Changes to the 
thiocarbamate reduced or totally destroyed inhibition of IDO. Alterations to the S-
alkyl chain produced the most potent analogue of brassinin, 34 (Figure 1.8). 
Increasing the S-alkyl chain length did not improve inhibition, however, the 
introduction of aromatic rings did, indicating that the S-alkyl chain was binding into 
a large hydrophobic pocket.38 
 
Figure 1.9. The annulin family are potent inhibitors of IDO. 
Several polyketides isolated from the marine hydroid Garveia annulata are IDO 
inhibitors.39 The most potent series of compounds against IDO where annulins 35-
37. Annulin B 37 and C 36 show strong inhibition with a Ki of 0.12 and 0.14 nM, 
respectively. Annulin A 35 is less potent with a Ki of 0.69 nM. However, in a yeast 
based study, the annulins did not inhibit IDO, suggesting that the annulin family are 
too polar to pass through the cell membrane.39 
 
Figure 1.10. Exigauamine A 38 is a potent IDO inhibitor (Ki =41±3 nM), analogue studies showed 39 and 40 
(Ki = 190±20 nM and 200±10 nM respectively) to be less potent than 38 but much more readily accessible. 
Ki = 0.12 nM Ki =0.69 nM 
Ki =0.14 nM 
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Exiguamine A 38, a marine natural product isolated from the sponge Neopetrosia 
exiguais, is a potent IDO inhibitor40 (Figure 1.10). As the natural product is 
relatively complex, a structure activity relationship was explored. The hypothesis 
that the tryptamine quinone motif is key to IDO inhibition was tested. This was 
confirmed when unsubstituted indole quinone 39 was assayed against IDO 
showing a Ki of 190 nM. However, as 39 is likely to have off-target effects, the 
hydantoin moiety was reintroduced, with compound 40 showing good inhibition 
with a Ki of 200 nM. As analgoue 40 is readily accessible and shows good 
inhibition of IDO it has emerged as an important tool for understanding the role IDO 
plays in immune escape and other diseases.41 
 
 
Figure 1.11. Tsitsikammamine family of natural products and the analogue 43 developed as an IDO inhibitor. 
The tsitsikammamine family of alkaloids 41 and 42 have been isolated from South 
African sponges.42 Due to their activity against cancer cells43 and their structural 
similarity to Exiguamine A 38, a series of tsitsikammamine analogues were 
synthesised and tested against isolated and purified human IDO and in a whole 
cell assay. The assays proved that the compounds were inhibiting IDO and not 
interacting with the external reductant, methylene blue.44 The whole cell assay also 
allowed an evaluation of how easily the compounds passed through the cell 
membrane. Analogue 43 (as shown in Figure 1.11) was a potent inhibitor of 
isolated IDO (IC50 = 0.9 µM), however, inhibition in the whole cell assay was poor 
in comparison with other analogues.44 
IC50 =0.9 µM 
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Figure 1.12. Structural relationship activity investigation into 4-phenylimidazole 32 gave analogue 44 as the 
most potent compound in the series. 
Starting from the co-crystal structure obtained with 4-phenylimidazole 32 bound to 
IDO, analogues were prepared to improve inhibition of this motif.45 The 
investigation focused upon improving binding at the active site entrance, the 
interior of the active site and the heam iron. Interactions with the entrance of the 
active site were probed by altering substitution on the imidazole ring. Binding in the 
active site was probed by varying substitution on the phenyl ring. Interactions of the 
imidazole ring with the heam iron were probed by changing the heterocycle and the 
effect of electronic changes caused by substitution of the phenyl ring was 
explored.45 
Substitution at N-1 and C-2 of the imidazole ring was ineffective, whereas 
substitution at N-3 was tolerated. In silico docking experiments predicted hydrogen 
bonding interactions at the 2- and 3- positions of the phenyl ring and possible 
disulfide linkages between thiol substituted phenyl rings and IDO. The most potent 
inhibitor was the 2-hydroxy substituted phenylimidazole 44 (Figure 1.12), which 
had an IC50 of 4.8 µM. The 3- and 4- thiols also showed good inhibition of IDO with 
IC50s’ of 7.6 µM and 7.7 µM respectively.45 
 
Figure 1.13. High throughput screening revealed 45 as a potent inhibitor of IDO. Investigations into the 
structural activity relationship yielded 46 and 47, as very potent inhibitors of IDO. 
IC50 =4.8 µM 
Ki =1.5 µM 
IC50 =67 nM IC50 =59 nM 
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Identification of 4-amino-1,2,5-oxadiazole-3-carboximidamide 45 as a low 
micromolar inhibitor of IDO in a high throughput screen led to the development of 
improved inhibitors after structure activity relationship studies.46 Inhibitor 45 had 
good selectivity for IDO over TDO. Changes to the hydroxylamidine functional 
group led to complete loss of inhibition against IDO. It was proposed that this 
moiety was important as it forms a dative bond to the haem iron. Changing the 
benzyl for a phenyl group generated further potent compounds. There was a clear 
preference for meta-substitution with halogens and small alkyl groups. The addition 
of a fluorine atom at the para-position alongside a meta-chlorine or bromine 
substitution provided the most potent compounds of this series 46 and 47 with 
IC50s’ of 67 nM and 59 nM respectively. The addition of the fluorine atom at the 
para position lowers the clearance of these compounds in vitro, presumably by 
preventing metabolism at the para position.46 
 
Figure 1.14. Ebslen 48, a potent inhibitor of IDO. 
The selenium based heterocycles ebselen (2-phenyl-1,2-benzioselenazol-3(2H)-
one) 48 was a potent inhbitior of IDO with a Ki of 94 nM.47 Through elegant 
mechanism studies it was shown that ebselen reacts with the cysteine residues in 
IDO and prevents IDO catalysis.47  The number of cysteine residues that react was 
dependent upon the dose of ebselen delivered. It was thought that covalent 
modification with ebselen perturbs the three dimensional structure of IDO making 
the protein unstable.47 As ebselen 48 is a strong electrophile, it will react with 
endogenous glutathione lowering its potential as an IDO drug, but it remains a 
powerful tool for understanding the role IDO plays in disease models. 
 
Ki =94 nM 
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1.3 Kynurenine aminotransferase 
1.3.1 Kynurenine aminotransferase biology and structural data 
Kynurenine aminotransferase (KAT) is a member of the PLP-dependent 
aminotransferase enzymes. It catalyses the reaction of kynurenine 3 to the α-keto 
acid 51 with concomitant formation of an amino acid from an alternative keto acid. 
 
Scheme 1.6. A general scheme showing the catalytic cycle of KAT. 
There are four different enzymes that all have kynurenine aminotransferase 
activity: KAT I, also known as glutamine transaminase k or cysteine conjugate 
beta-lyase48; KAT II, also known as aminoadipate aminotransferase48; KAT III, also 
known as cysteine conjugate beta-lyase II48 and KAT IV, also known as glutamic-
oxaloacetic transaminase or mitochondrial aspartate aminotransferase.48 In 
humans KAT I and KAT III have the highest sequence identity of 52%. All of the 
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KAT enzymes can be found in the mitochondria, but only KAT I and II have been 
observed in the cytoplasm.48 
KAT I is an enzyme that has many functions. As well as converting kynurenine to 
kynurenic acid it also has cysteine conjugate beta lyase activity. The enzyme is 
most active against large, neutral or aromatic and sulfur containing amino acids. It 
can also employ a number of keto acids as amino group acceptors. 48 KAT I is 
mostly expressed in the liver and kidney in humans and rats.49  
KAT II, like KAT I has many functions, however, it is more selective than KAT I. It 
uses aminoadipate, kynurenine, L-methionine and L-glutamate. Unlike KAT I, it is 
not able to use a large range of keto acids as amino group acceptors.48 It is thought 
that in mammalian brains KAT II is responsible for the majority of kynurenic acid 
production.50 In KAT II knockout mice the levels of kynurenic acid in the brain is low 
in young mice but recovers as they mature. This suggests that one of the other 
enzymes is upregulated to increase kynurenic acid production.51  
KAT III is present in rat, mouse and human brains as determined by studies on the 
mRNA levels and protein activity assays.48, 52 The enzyme is able to use aromatic 
and sulfur containing amino acids and a selection of 13 α-keto acids in the 
transamination reaction.48 
KAT IV was initially reported as a mitochondrial aspartate aminotransferase in E. 
coli 53 before being found in rat, mouse and human mitochondria.50 As the enzyme 
had activity with kynurenine it was called KAT IV. As well as an involvement in 
kynurenic acid synthesis, KAT IV allows glutamate to enter the citric acid cycle. It is 
able to produce the neurotransmitter glutamate and it plays a role in the malate-
aspartate shuttle, which is important for the ATP production in the brain.48 
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Figure 1.15. The crystal structure of KAT I with the PLP as the internal aldimine. 
Crystal structures of KAT I54 (Figure 1.15) and KAT II55, 56 (Figure 1.16), from 
humans, have been obtained. KAT III from mice57 was successfully crystallised and 
a structure solved. There has been no human crystal structure of KAT IV reported, 
but structures from chicken and mice58 have been obtained. 
 
Figure 1.16. The crystal structure of KAT II was obtained with L-kynurenine bound at the active site. 
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The crystal structure of human KAT I was solved to 2.0 Å, with the enzyme in both 
PLP and PMP forms.54 The crystal structure of human KAT II has also been 
solved. It was not possible to build a three dimensional model of KAT II, from KAT I 
as there is poor sequence alignment (11%) between the two enzymes. Work by 
two different groups generated three crystal structures of human KAT II, which 
were published concurrently in 2008.55, 56 
 
1.3.2 Kynurenine aminotransferase mechanism  
The mechanism of kynurenine aminotransferases has not been well studied. A 
combined quantum mechanical and molecular mechanical modelling study was 
undertaken using the crystal structure of KAT II.59 KAT II was used as the 
availability of both substrate bound and unbound structures meant that the 
substrate did not require modelling into the active site.59 
A proposed mechanism is illustrated in Scheme 1.7. 
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Scheme 1.7. A proposed mechanism of KAT. 
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1.3.3 Kynurenine aminotransferase inhibitors 
Inhibition of KAT is important for investigation of the neuroprotective properties of 
kynurenic acid. It is also important as a number of diseases are associated with 
high levels of kynurenic acid. High concentrations of kynurenic acid have been 
found in the cerebal spinal fluid of schizophrenic patients and patients suffering 
from bipolar disorder.60-62 
 
Figure 1.17. Kynurenine analogues were tested as KAT inhibitors, the L-isomer of 66 was the most potent 
inhibitor. 
A series of kynurenine analogues were prepared by Varasi et al. to build a 
structure activity relationship for kynurenine aminotransferase (Figure 1.17).63 
Modification to the aniline group or to the acylalanine moiety, shown in 65, was 
ineffective, suggesting that both structural features are required for substrate-like 
inhibition. A series of racemic kynurenines with alternative chlorine substitutions on 
the phenyl ring showed that KAT inhibition was most potent with the 5-chloro 66 
and 6-chloro substituted kynurenines. Synthesis and subsequent assay of 
enantiopure 4-chloro kynurenine and 5-chloro kynurenine showed that the L-
isomers were the most potent of the enantiomers. 5-Chloro-L-kynurenine 66 had an 
IC50 of 63 µM against KAT. A series of alterations to the substitution at the 5-
position provided inhibition of KAT in all cases. Both racemic 5-bromo-kynurenine 
and 5-n-propyl-kynurenine had similar inhibition to racemic 5-chloro-kynurenine. 
When 4-chloro-L-kynurenine and 5-chloro-L-kynurenine 66 where incubated with 
KAT, formation of 7-chloro-kynurenic acid and 6-chloro-kynurenic acid was 
observed. As 5-chloro-kynurenine 66 is a tighter binder to KAT, unsurprisingly, the 
production of 6-kynurenic acid was higher than 7-kynurenic acid.63 
 
IC50 =63 µM 
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Figure 1.18. A high throughput screening revealed lactam 67 as a hit. Further testing showed it was the 
impurity 68 that actually inhibits KAT II. 
A high throughput screen of compounds against KAT II revealed 
aminodihydroquinolone 67 as an interesting hit.64 Further investigation showed that 
authentic 67 did not inhibit KAT II, but the inhibitor was an impurity (Figure 1.18). 
Through co-crystallisation with KAT II and elegant 13C NMR experiments it was 
shown that 68 is an irreversible inhibitor that forms an enamine adduct with the 
enzyme. Inhibitor 68 had good selectivity for KAT II over KAT I, KAT III and KAT 
IV. KAT II is hypothesised to play the major role in kynurenic acid biosynthesis in 
mammalian brains. Investigation into the stereochemistry of the 3-amino group 
showed that the S-enantiomer was approximately ten times more potent than the 
R-enantiomer.64 Alterations to the hydroxamic acid moiety removed inhibition. 
Investigation into different substitutions on the aromatic ring revealed that small 
substituents at C-5 and C-8 (e.g. fluorine) are tolerated, however, none of the 
substituted analogues were as potent as the original hit. Substitution at C-6 and C-
7 was accepted by the enzyme and gave an inhibition profile similar to 68. 
Pharmacokinetic studies proved that 68 can pass through the blood brain barrier 
and reduced kynurenic acid levels in rats.64 
 
 
Figure 1.19. Further development of lactam 68 led to an increase in potency. Crystal structural data led to the 
development of 71. 
Further studies on the hydroxamate scaffold were undertaken with alterations at 
the C-6 and C-7 positions (Figure 1.19).65 The introduction of the methoxy group at 
C-7 gave 69, which had a similar IC50 to 68 but a higher Kinact/Ki. Co-crystal 
Ki = 14.2 nM 
Ki = 7.7 nM Ki = 7.1 nM Ki = 1.6 nM 
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structures with 69 and 70 bound revealed previously unseen lipophilic interactions. 
Compound 71 was prepared as a hybrid of both analogues. The phenoxy ether 
was changed to the benzyl moiety to prevent the formation of reactive catechol 
metabolites. Inhibitor 71 showed a 4-fold increase in potency as observed by 
Kinact/Ki. Administration of 71 to rats showed that there was a high degree of non-
specific binding in the brain, however, 71 lowers the kynurenic acid levels over a 
longer time period than 68 at the same dose. The poor pharmacokinetics of 71 
lowered its period of in vivo efficacy.65  
 
 
Figure 1.20. The development of triazolines 72 and 73 and triazoles 74 and 75, to improve the 
pharmacokinetics of the hydroxamate scaffold. 
As 68 was cleared quickly in human hepatocytes and liver microsomes as the O-
glucoronide, further analogues 72-75 were synthesised with the aim of maintaining 
KAT inhibition whilst improving the pharmacokinetics of the compounds (Figure 
1.20).66 Analysis of the crystal structure of 68 bound to KAT II led to the 
identification of key interactions, including the amine-PLP interaction that leads to 
formation of an enamine and the hydrogen bond interactions of the hydroxamate 
moiety to Arg-399 and Asp-202. Modeling studies66 suggested that a triazole or 
triazoline heterocycle could mimic the hydroxamate moiety. The triazoline 
analogues 72 and 73 had an increased IC50 (84 and 60 nM respectively), although 
73 has a lower Ki than 68 showing that it binds more tightly in the active site. The 
triazoles 74 and 75 were less effective with IC50s’ of 201 nM and 122 nM 
Ki = 5.1 nM 
IC50 = 65 nM 
Ki = 16.7 nM 
IC50 = 122 nM 
Ki = 81.5 nM 
IC50 = 210 nM 
Ki not defined 
IC50 = 84 nM 
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respectively. A co-crystal of 72 with KAT established that the triazoline was fulfilling 
hydrogen bonding interactions to Arg-399 and Asp-202 (Figure 1.21). 
Pharmacokinetic analysis showed that 73 and 74 were more stable and had a 
lower clearance than 68. Furthermore both 73 and 74 were able to maintain 
penetration of the blood brain barrier.66  
 
Figure 1.21. Crystal structure of KAT II with 72 bound to the PLP co-factor.66  
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1.4 Kynurenine monooxygenase 
1.4.1 Kynurenine monooxygenase biology and structural 
information 
Kynurenine 3-monooxygenase (K3MO), also known as kynurenine 3-hydroxylase, 
is a flavin-dependent enzyme that selectively oxidises L-kynurenine to 3-hydroxy- L-
kynurenine. The enzyme can use either NADH or NADPH as a reductant. When 
NADPH is the electron donor the Vmax of the enzyme increases and the Km for L-
kynurenine is slightly lower than with NADH, suggesting a preference for NADPH.2 
It has been shown that the oxygen required for turnover is derived from molecular 
oxygen.2 The reaction of L-kynurenine with K3MO can either be monitored using 
[3-3H]-kynurenine67 or by following the decrease in absorption due to the NADPH. 
Recently a new fluorometric method has been developed for investigating the 
binding of inhibitors to flavin-dependent monooxygenases.68 
The mammalian enzyme is found on the outer membrane of the mitochondria.69-71 
Unfortunately, mammalian K3MOs are not stable and it is difficult to express the 
proteins in significant quantity.72, 73 Fortunately K3MO from the bacterial source 
Pseudomonas fluorescens is amenable to over-expression and purification.74 P. 
fluorescens is one of a small number of bacteria that metabolise kynurenine by 3-
hydroykynurenine. K3MO from P. fluorescens has 36% sequence identity to the 
human K3MO. Biochemical studies indicate that there is only one FAD associated 
with each K3MO molecule, although it is not covalently bound in the active site.72 
The use of stereospecifically deuterated NADH and NADPH has shown that the 
pro-R hydrogen of the nicotinamide is transferred to the FAD.2 
The human enzyme is larger than the P. fluorescens  enzyme with an amino acid 
length of 486 and 461 residues respectively. 
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Figure 1.22. Crystal structure of S. cerevisiae K3MO with 76 bound at the active site. 
A truncated form of K3MO from Saccharomyces cerevisiae has been expressed 
and crystallised in 2013.75 The crystal structure was published during the writing of 
this thesis (Figure 1.22). The 396 amino acid truncate retained activity against 
kynurenine and was inhibited by 76. The structure was solved at a resolution of 
1.85 Å showing a dimer in the asymmetric unit cell.75 The structure obtained had a 
similar fold to other flavin-dependent hydroxylases. There was disorder in residues 
380-396 and residues 96-97 and 101-104. Comparison of the 76-bound co-crystal 
with the unbound structure revealed key interactions in the binding of the inhibitor. 
As 76 is similar to kynurenine it appears that the key interactions are maintained 
for both inhibitor and substrate. There is a hydrophobic pocket in which the 3,4-
dichloro-phenyl ring binds, with the hydrophobic Phe-322 moving away from the 
active site to accommodate the chlorine atoms. The carboxylate of 76 makes 
hydrogen bonding interactions to both Arg-83 and Tyr-97. Upon binding of 76 there 
is a reorientation of several residues that are hypothesised to occlude the binding 
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site for O2 in the enzyme. This hypothesis is not entirely firm because when 76 
binds to S. cerevisiae K3MO there is a 20-fold increase in the production of 
hydrogen peroxide.75 The hydrogen peroxide is formed by destabilisation of the 
flavin-hydroperoxide intermediate, suggesting that O2 can still bind at the active 
site. It was suggested that the truncated S. cerevisiae K3MO structure would be 
useful for the development of novel K3MO drugs that are able to pass through the 
blood brain barrier. Nevertheless it has been shown that the C-terminal domain, 
absent in the crystal structure of S. cerevisiae K3MO, plays a key role in the 
catalytic activity of mammalian K3MO.71  
 
Figure 1.23. A) Crystal structure of P. fluorescens K3MO; B) Overlaying the L-kynurenine bound (red) and 
unbound (blue) structures reveals that the C-terminal domain shifts towards L-kynurenine. 
Recently the crystal structure of the full length K3MO from P. fluorescens has been 
solved by our collaborators at Edinburgh University with both the substrate bound 
and unbound at resolutions of 3.4 Å and 2.25 Å respectively (Figure 1.23).76 The 
structures show two domains, the C-terminal domain and a large second domain. 
The FAD co-factor is well placed in the middle of the large domain. Some of the 
loops are too disordered to be accurately assigned. The active site of the enzyme 
is found deep in the large domain. Upon binding of the kynurenine substrate the C-
terminal domain shifts towards the active site to hold the substrate in place. It is 
A 
B 
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thought that the movement of the C-terminal domain is mediated by a hydrogen 
bonded network (Figure 1.23). 
The phenyl ring of kynurenine is situated in a hydrophobic pocket and is flanked on 
one side by the FAD isoxazoline ring. Other important residues for the formation of 
the hydrophobic pocket are Pro-318, Phe-238, Tyr-193, Leu-213 and 226, Ile-224 
and Met-222. The substrate amino group makes a strong hydrogen bond with the 
carbonyl of the FAD with a distance of 2.8 Å. This correlates well with observations 
that benzoylalanine inhibitors allow uncoupled reduction of the FAD by NADPH to 
give hydrogen peroxide. The turnover of NADPH occurs concomitant with binding 
of the inhibitor to the active site showing that the amino group is not required for 
substrate specificity. However, the rate of reaction is rapidly diminished without the 
amino group, suggesting that the amino-carbonyl interaction helps optimise 
turnover. The carboxylate forms a salt bridge with Arg-84, at a distance of 2.6 Å. 
Interestingly the ketone of the substrate does not appear to make any polar 
interactions with the protein. The amino group is orientated towards a hydrophilic 
pocket made up by Tyr-404 and Thr-408 and some of the main chain amides. 
 
1.4.2 Kynurenine 3-monooxygenase mechanism 
Two different mechanisms have been proposed for the selective oxidation of 
kynurenine 3 by K3MO.77, 78 The first was based on early kinetic and 
spectrophotometric data as well as available information on the mechanisms of 
other flavin hydroxylases. A single electron transfer from the substrate phenyl ring 
to the peroxy-flavin adduct is envisaged,77 as is summarised in Scheme 1.8.  
Stop-flow experiments with P. fluorescens K3MO suggest an alternative ionic 
mechanism78 as shown in Scheme 1.9. The key step involves electrophilic 
aromatic substitution promoted by the lone pair of electrons on the substrate 
nitrogen. This mechanism is similar to that used by other flavin hydroxylases and is 
the preferred mechanism for the action of K3MO upon kynurenine. 
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Scheme 1.8. A proposed single electron transfer mechanism for the formation of 3-hydroxykynurenine 8.77 
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Scheme 1.9. An alternative ionic mechanism for the formation of 3-hydroxykynurenine 8.78 
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1.4.3 Kynurenine-3-monooxygenase inhibitors 
The literature reports relatively few articles on inhibitors of kynurenine 3-
monooxygenase, although there are approximately 16 patents79-94 on various 
inhibitor claims. 
 
Figure 1.24. Benzoylalanine based inhibitors of K3MO 82 and 83.  
In 1994 Pellicciari et al.77 developed some inhibitors based on the kynurenine 
motif. Four were tested, one replacing the phenyl ring with a pyridine 82 and the 
other three were isomers of nitrobenzoylalanine (meta, ortho and para) (Figure 
1.24). The best inhibition was achieved with the meta-isomer 83, which had good 
selectivity for K3MO over kynureninase. A molecular modelling study was 
undertaken using a “pseudo-active site”. 77 It was shown that one of the oxygens in 
the nitro group locates to the binding site of molecular oxygen and is hydrogen 
bonded to the FAD co-factor.77  
 
Figure 1.25. 3,4-Dichlorobenzoylalanine 84 developed as a K3MO inhibitor. 
In 1996 Giordani et al.95, 96 synthesised the dichlorobenzoylalanine K3MO inhibitor 
84 (Figure 1.25). It had low micromolar activity and in vivo testing in rats induced 
an increase in kynurenic acid 5, associated with the inhibition of kynurenine 3-
hydroxylase. Although benzoylalanine is a weak inhibitor of K3MO an investigation 
into the substitution pattern around the phenyl ring was undertaken.96 Adding 
fluorine at C-3 resulted in a selective and potent inhibitor. Chlorine at C-3 created a 
more potent but less selective inhibitor and a C-3 bromine reduced the activity. 
None of the other substituents tested displayed activity.96 Fluorine and chlorine at 
IC50 = 900 ± 180 µM IC50 = 0.9 ± 0.1 µM 
IC50 = 0.2 µM 
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C-4 also resulted in good inhibitors, but were less effective than the C-3 substituted 
analogues. This led to the 3,4-dichloro compound 84, which had low micomolar 
activity (IC50 = 0.2 µM).95 Further studies exploring 83 and 84 with P. fluorescens 
K3MO showed that although benzoylalanines inhibit the production of 3-
hydroxykynurenine, they allowed uncoupled NADPH reduction of the flavin ring 
leading to hydrogen peroxide production.78  
 
Figure 1.26. 3,4-Dichlorobenzoylalanine analogues 85 and 86 tested as K3MO inhibitors. 
In 1998 Giordani et al.97 developed compounds based upon their 
dichlorobenzoylalanine inhibitor 84 (Figure 1.26). They made modifications α to the 
carboxylic acid including methoxy, halogen or phenyl groups. However, they found 
the best inhibitors had a hydroxyl group 85 or a benzyl group 86. In each case the 
S-enantiomer was the more active. Assays against kynureninase, kynurenine 
aminotransferase and other mono-oxidases showed that these compounds had 
good selectivity for KMO.97 
 
 
Figure 1.27. Enol analogues of 87 were tested against K3MO. 
In 1999, Drysdale et al. investigated methyl esters and carboxylic acid derivatives 
of 87 and 88 (Figure 1.27).98 In the synthesis of their targets they found that 87 
existed entirely in the enol form.  
IC50 = 0.42 ±0.03 µM 
IC50 = 2.3 ± 0.5 µM 
IC50 = 120 nM IC50 = 270 nM 
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The compounds were initially tested on K3MO isolated from a rat liver 
homogenate. The series based upon 88 were generally poor inhibitors of K3MO. 
Analogues of 87 gave much better inhibition. Carboxylic acids analogues were 
more potent than the methyl esters and substitution at the 3- and 4- positions also 
gave potent inhibiton. The 3-chloro and 3-fluoro derivatives were very potent 
inhbitors with IC50 values of 320 nM and 580 nM respectively. 3,4-Dihalogenation 
further increased potency; the 3,4-difluoro and 3-chloro-4-fluoro compounds 89 
and 90 were the most potent compounds tested, with IC50 values of 120 nM and 
270 nM respectively. Interestingly the 3,4-dichloro derivative was less potent than 
either the 3,4-difluoro or 3-chloro-4-fluoro derivatives.  When the potent 
compounds were tested in macrophages the trend of the acid being better than the 
ester was broken indicating problems with the carboxylic acid passing through the 
cell membrane.98 
 
 
Figure 1.28. Isoxazoles 70 and 92 and thiazole sulfonamide 71 developed as K3MO inhibitors. 
In 1997 Röver et al. 67 reported some of the most potent K3MO inhibitors in the 
literature to date. Starting from m-nitrobenzoylalanine 83 a series of modifications 
were made. The first modification was the removal of the amino group. This gave a 
less potent inhibitor by one order of magnitude, suggesting that the amino group is 
not bound to the enzyme via a salt bridge. Changing the ketone functionality to an 
isoxazole resulted in increased inhibition. However, due to the poor 
pharmacological properties of the free carboxylic acid, the tetrazole bioisostere 
was also prepared and the two isoxazoles 91 and 92 had very similar activity 
(Figure 1.28). This suggested that carboxylic acid bioisoterism was important for 
IC50 = 2.68 ± 0.41 µM IC50 = 1.16 ± 0.29 µM IC50 = 37 ± 3 nM 
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binding. Screening a library of sulfonamides produced better inhibitors of K3MO 
and the thiazole sulfonamide 93 emerged as the most potent inhibitor. (IC50 = 37 
nM)67 
3,4-Dichloro and 3-nitro substitution also improved inhibition suggesting that phenyl 
ring A binds in a similar orientation to 83 and 84. Substitution of phenyl ring B with 
electron donating substituents gave much better inhibitors of K3MO. The best of 
these were the 3,4-dimethoxy and 4-amino derivatives. Whilst some of the 
compounds had similar activity in vitro, when tested in rats and gerbils it was found 
that the 3,4-dimethoxy derivative had a much greater activity in vivo. The nitro 
analogue was problematic as it is potentially mutagenic. 2-Fluoro-5-
(trifluoromethyl) substitution on phenyl ring A gave good inhibition without the 
mutagenic effects.67 
 
Figure 1.29. The proposed structure of lanthellamide A 94. 
In 2012, Feng and co-workers reported that the marine natural product 
lanthellamide A 94 (Figure 1.29),99 isolated from the Australian sponge Lanthella 
quadrangulata, showed a reduction in 3-hydroxykynurenine production in an in 
vitro assay. Although there was good analytical evidence for the carbon skeleton of 
lanthellamide A 94 the stereochemistry was uncertain. A tentative assignment of 
the stereochemistry was based on a comparison with the optical rotation of R-
octopamine.99  
Inhibitors described in the literature and patents can be classified into three distinct 
groups: 
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Figure 1.30. A general motif for the sulfonamide inhibitors in the patent literature. 
The first are the heterocyclic sulfonamides 95, similar to the compounds developed 
by Röver et al. (Figure 1.30). 67, 79-81 
 
Figure 1.31. A general structure for substrate based inhibitors found in the patent literature. 
The second class are substrate like inhibitors, which are compounds based on 
kynurenine with alterations that mimic the ketone or the addition of functionality, 
such as hydroxy groups (Figure 1.31).82-89, 93 
 
Figure 1.32. Tricyclic inhibitor 97 found in the patent literature. 
The third group are a set of bicyclic and tricyclic compounds which have at least 
one heterocyclic component (Figure 1.32).90-94  
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1.5 3-Hydroxyanthrinilate-3,4-dioxygenase 
1.5.1 3-Hydroxyanthranilate-3,4-dioxygenase biology and 
structure 
3-Hydroxyanthranilate-3,4-dioxygenase (3HAO) is a non-haem ferrous (FeII) 
dependent enzyme that cleaves the aromatic ring of 3-hydroxyanthranilic acid 9 
between C-3 and C-4. This oxidative cleavage forms 2-amino-3-carboxymuconic 
acid semialdehyde (ACMSA) 10. This metabolic intermediate can either cyclise to 
form quinolinic acid 13 or it can be decarboxylated by aminocarboxymuconate-
semialdehyde decarboxylase to give 11. 
 
Scheme 1.10. The product of 3HAO catalysis ACMSA 10 has two fates, decarboxylation to give 11 or 
cyclisation to give quinolinic acid 13. 
3HAO is found widely in eukaryotes as well as some bacteria.100 3HAO from 
mammals has been difficult to isolate in significant amounts as a pure stable 
protein.9, 101, 102 Work on the bacterium Ralstonia metallidurans showed that the 
bacterial enzyme is more stable and amenable to over-expression than mammalian 
3HAO.103 3HAO from R. metallidurans has 174 amino acids per monomer and a 
molecular weight of 22 kDa however, the enzyme functions as a dimer. After 
purification the enzyme was found to be inactive, but this was reversed by adding 
ferrous iron and DTT as a thiol reducing agent. The crystal structure of the enzyme 
has been solved (Figure 1.33).103 
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In humans the enzyme is found in the cytosol as a functional monomer.101 It has 
been overexpressed in E. coli cells.102 The human enzyme is 286 amino acids long 
with a molecular weight of 32.6 kDa. In both purified human and bovine 3HAO the 
rate of the reaction decreases with time.9, 102 It has been proposed that this is due 
to inhibition of the enzyme by some unknown species, however, it could also be 
due to inactivation of the enzyme by oxidation of the ferrous to ferric iron or 
complete loss of the iron centre, which is known for this enzyme.102 A crystal 
structure of the human enzyme (PDB ID 2QNK, http://www.rcsb.org) has been 
deposited in the protein databank although it lacks an accompanying publication. 
The PDB shows that the iron has been displaced from the active site by a nickel 
atom, which is presumed to have occurred during the purification step. A crystal 
structure of the bovine form of the enzyme has also been solved.104 The bovine 
form has 286 amino acids, like the human enzyme, but it has a slightly lower 
molecular mass of 32.5 kDa. 
  
Figure 1.33. Crystal structure of R. metallidurans 3HAO monomer with 98 (Figure 1.34) bound in the active 
site. 
The crystal structure of R. metallidurans 3HAO was solved in 2005 by Zhang et 
al.103 and reveals a dimer with two iron binding sites in each monomer (Figure 
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1.33). The overall structure of the protein has been classified as a cupin barrel fold. 
There are two six stranded anti parallel β-sheets that form the cupin barrel. 
The catalytic iron is found in the active site in a distorted octahedral geometry. The 
co-ordination ligands to the iron are two histidine resdiues, His-51 and His-95, and 
a bidentate glutamate residue, Glu-57. Water takes up the final co-ordination 
sites.103 The second iron binding site is found 24 Å away from the catalytic ferrous 
iron and four cysteine residues are coordinated to the iron. This binding site has a 
structure similar to that found in the rubredoxin proteins, a class which participates 
in electron transfer reactions. It is not known why the bacterial form of the enzyme 
contains the additional rubredoxin motif.103 
 
Figure 1.34. 3-Hydroxyanthranilic acid 9 and 4-chloro-3-hydroxyanthranilic acid 98 were co-crystallised with 
3HAO. 
Both 3-hydroxyanthranilic acid 9 and an inhibitor 4-chloro-3-hydroxyanthranilic acid 
98 were successfully co-crystallised with the bacterial enzyme.103 The inhibitor co-
crystal was obtained with either oxygen or nitric oxide bound to the iron. With the 
inhibitor bound the iron is six coordinate with His-51 and His-95, Glu-57, the phenol 
of the inhibitor and O2 or NO. In the substrate structure glutamate is no longer 
bidentate and both the amine and the phenol of the substrate coordinate to the 
iron.  Important residues for binding are Glu-57 and Arg-99. Arg-99 forms two 
hydrogen bonds to the carboxylate of the substrate. There is a hydrophobic pocket 
made up of Val-25, Phe-121, Ile-142 and Leu-146. The hydrophobic pocket 
appears to interact with the non-polar area of the substrate and inhibitor.  
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Figure 1.35. Crystal structure of bovine 3HAO. The ball represents FeII. 
The bovine crystal structure was solved in 2009.104 It shows that the enzyme exists 
as a monomer with two distinct domains (Figure 1.35). The larger domain 
correlates quite well to the monomer of the yeast 3HAO. This domain in the bovine 
structure has a cupin barrel fold. Two, six stranded anti-parallel β-sheets generate 
a characteristic shape. The smaller domain has a six and four stranded anti-
parallel β-sheet. It is thought that the smaller domain in the bovine 3HAO 
correlates to the interface generated between the monomers in the bacterial and 
yeast enzymes. The main interactions between the domains are hydrophobic, 
however, some hydrogen bonding interaction between the domains occur. The 
bovine structure is similar to the human enzyme structure. 
Comparison of the bovine and the bacterial structures shows that the three 
residues responsible for binding iron are conserved and in total 40 residues are 
conserved between the bovine, bacterial and yeast proteins.104 The crystal 
structure shows the iron is bound deep into the active site and is 5-coordinate. His-
47 and His-91 and a bidentate Glu-53, complex to the iron (Figure 35). The fifth co-
ordination site has unusual electron density and it was not possible to determine 
the difference between a chloride ion or two water molecules due to the resolution 
of the crystal structure.104 
The entrance to the active site has both hydrophobic and hydrophilic 
characteristics. The hydrophilic character is generated by the side chains of Glu-
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140, Asp-24 and Thr-139, the hydrophobic character is generated by the side 
chains of Gly-138, Val-22 and Leu-141. Gly-138 has an important role as a side 
chain at this position would block the active site. There are a large number of 
hydrophilic residues inside the active site which include Arg-43, 95 and 108, Asp-
45 and 114 and Glu-105. There is also a hydrophobic pocket formed by Val-22 and 
Leu-116, 137 and 141. Overlaying the bovine structure with the structure from R. 
metallidurans shows that the conformations of the side chains in the two active 
sites are similar.104 
 
1.5.2 Mechanism of 3HAO 
 
Scheme 1.11. A proposed mechanism for the oxidation of 3-hydroxyanthranilic acid 9 to ACMSA 10. 
A mechanism for 3HAO has been proposed based upon the mechanism of the 
related reaction of catechol dioxygenase105 (Scheme 1.11). 
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Scheme 1.12. Confomer 106 is the most stable form of ACMSA 10 in aqueous solutions. 
The transformation of 3-hydroxyanthranilic acid to ACMSA 10 produces the initial 
product 105 with two Z-configured double bonds with the carboxylate groups trans 
to each other (Scheme 1.12).8 Cyclisation to quinolinic acid requires a 
configurational change to the double bond geometry placing the two carboxylates 
cis. Interestingly in solution it has been shown that the all trans isomer 106 is the 
most stable form.8 It is proposed that in solution the isomerisation of the double 
bonds is relatively facile through enol tautomerisation.8 
There are two candidate mechanisms for the cyclisation of ACMSA 10 to quinolinic 
acid 13.8 The first involves attack upon the aldehyde by amine, highlighted in black 
(Scheme 1.13), to form the six membered ring 107 followed by aromatisation. 
However, there are several problems with this mechanism. The amine of 10 is not 
a strong nucleophile, the overlap of the amine lone pair and the antibonding orbital 
of the aldehyde is poor and electron donation through the extended π-system 
reduces the electrophilicity of aldehyde 10.8 When ACMSA 10 is treated with a 
strong nucleophile, for example hydroxylamine, there is no reaction. The low pKa of 
the amine reduces it basicity.106 
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Scheme 1.13. Two proposed mechanisms for the cyclisation of ACMSA to quinolinic acid. The cyclisation 
mechanism is shown in black, the tautomerisation and electrocyclic mechanism is shown in red. 
An alternative mechanism, in red (scheme 1.13), involves tautomerisation of 
aldehyde 10 to enol 109. Enol 109 can then undergo an electrocyclic reaction to 
form the six-membered ring 108. A model study into the reverse reaction of a 
similar product showed such an electrocyclic reaction could occur.8 
 
1.5.3 3HAO inhibitors 
 
Figure 1.36. Metabolism of 6-chlorotryptophan yields 87, an inhibitor of 3HAO. 
4-Chloro-3-hydroxyanthranilic acid 98 (Figure 1.36) is a metabolite of 6-
chlorotryptophan with an IC50 of 3 nM against rat brain 3HAO. Analysis of 98 with 
R. metallidurans 3HAO by mass spectrometry did not indicate covalent 
modification.105 EPR spectroscopy revealed that the inhibited enzyme was in the 
ferric state,105 whilst superoxide production by the inhibited enzyme was assessed 
using 2-methyl-6-(4-methoxyphenyl)-3,7-dihydroimidazo[1,2-a]pyrazin-3-one 
IC50 = 3 nM 
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(MCLA), which undergoes chemiluminescence in the presence of superoxide. This 
indicates that when 98 binds to 3HAO, oxidation of the iron centre and generation 
of superoxide occurs. This evidence suggests that 98 is a reversible inhibitor of 
3HAO.105  
 
Figure 1.37. Analogues of 3-hydroxyanthranilic acid were tested as inhibitors of 3HAO. 
A structure activity analysis of the 3-hydroxyanthranilic phenyl ring was undertaken 
(Figure 1.37).107 The best in vitro inhibitors were 110-115.  However, not all of the 
compounds were stable in PBS buffer after 24 h. Although 110 has an IC50 of 
0.3 nM, only 21% of 110 was left after 24 h in the stability assay. Key determinants 
for good inhibition of 3HAO are small electron withdrawing groups at C-6 and 
lipophilic, electron-withdrawing groups at C-5. Compounds 114 and 115 retained 
inhibition in an in vivo rat study, and although some of the compounds were highly 
potent in the in vitro study, the compounds show similar activity in the in vivo 
assay. 
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1.6 QPRTase 
1.6.1 QPRTase biology and structural data 
 
Scheme 1.14. The reaction catalysed by QPRTase to form nicotinic mononucleotide 14. 
Quinolate phosphoribosyltransferase (QPRTase) is found widely in both 
eukaryotes and prokaryotes. QPRTase catalyses the reaction between quinolinic 
acid 13 and 5-phosphoribosyl-1-pyrophosphate 116 forming nicotinic acid 
mononucleotide 14 and carbon dioxide. This transformation is unique in the family 
of phophoribosyltransfer reactions as the enzyme catalyses two discrete chemical 
reactions; coupling of the ribose ring to the pyridine forming quinolinic acid 
mononucleotide and the subsequent decarboxylation of quinolinic acid 
mononucleotide to give the product.2 
QPRTase has been isolated from bacterial,108, 109 plant110 and mammalian sources, 
including rat, hog and human.111 All forms of the enzyme utilise Mg2+ ions as co-
factors. QPRTase forms monomers, dimers and hexamers depending upon the 
source of the enzyme. The human form of the enzyme is a hexamer, which 
correlates with other mammalian sources of QPRTase. Purification of QPRTase 
from human brain and liver revealed the hexamer had a molecular weight between 
167-170 KDa. Investigations into Mg2+ concentrations revealed an optimum 
magnesium concentration at 1 mM. Incubating the purified human QPRTase with 
tritiated nicotinic acid mononucleotide showed there was no reverse reaction to 
quinolinic acid and 5-phosphoribosyl-1-pyrophosphate 116. The human QPRTase 
has an optimum pH of 6.5-7.0.112 
Kinetic analysis of human QPRTase expressed in E. coli revealed that its specific 
activity was similar to the reported values for bacterial QPRTases.112 Kinetic 
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analysis has revealed that the affinity for quinolinic acid 13 is independent of the 
concentration of 116. 112 This indicates that quinolinic acid binds at the active site 
before 5-phosphoribosyl-1-pyrophosphate 116. Variation in the 5-phosphoribosyl-
1-pyrophosphate 116 concentration revealed that above a concentration of 0.3 mM 
the enzyme becomes inhibited (quinolinic acid 13 fixed at 0.3 µM).112 Further 
investigation into the substrate inhibiton of the enzyme by 116 revealed that it is a 
mixed inhibitor of human QPRTase, suggesting that 116 binds at both the active 
site and a second allosteric site that influences and inhibits reaction at the active 
site.112 Initial reports on substrate binding in QPRTase isolated from E. coli 
suggested that 116 binds before quinolinic acid.113 However, analysis of QPRTase 
from Salmonella typhimurium and humans showed that the actual order of binding 
is quinolinic acid followed by 116. 112, 114 
Crystal structures have been obtained for QPRTase from S. typhimurium,115 
Mycobacterium tuberculosis,116 Themotoga maritime,117 Helicobacter pylori,118 
Human112, 119 and Saccharomyces cerevisiae.120 Prokaryote forms of QPRTase 
were crystallised as dimers, eukaryotic forms as hexamers. All of the structures 
have the same fold consisting of an N-terminal four stranded open-face β-sandwich 
domain and a C-terminal α/β-barrel domain. 
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Figure 1.38. Crystal structure of hexameric human QPRTase. 
It is useful to focus on the crystal structures obtained from human QPRTase as it is 
intricately involved in some disease states. The activity of 3HAO is approximately 
100 times greater than the activity of QPRTase. This means that quinolinic acid 13 
is formed faster than it is metabolised, leading to its accumulation.2 The structure 
of human QPRTase is important in building a mechanistic model for QPRTase to 
understand the relative kinetics. 
Human QPRTase enzyme crystalised as a hexamer with tartaric acid bound at the 
active site (Figure 1.38).112 A structure was solved to 2.0 Å. The overall fold is 
similar to other QPRTases studied. A dimer is formed by the placement of the N-
terminal domain of one subunit beside the C-terminal domain of the other. Three 
dimers arrange to form a hexamer with three fold symmetry. The active site is 
located between the interface of the α/β-barrel of one monomer and the β 
sandwich of the other monomer. The quinolinic acid binding site is composed of 
Arg-138, Arg-161, Arg-102, Lys-139 and Lys-171 and His-159. This generates a 
positively charged surface which can interact with the carboxylates of quinolinic 
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acid, as modelled in the structure by tartaric acid. Mutagenesis studies showed that 
Arg-138, Lys-139 and Lys-171 are essential for enzyme activity, Arg-102 and Arg-
162 are important for substrate recognition but are not absolutely required for 
activity. 
 
1.6.2 QPRTase mechanism 
 
 
Scheme 1.15. There is debate whether QPRTase forms the nucleotide via an SN2 mechanism as shown in A 
or an SN1 mechanism as shown in B. 
There are two distinct chemical steps in the reaction catalysed by QPRTase, these 
involve coupling of the substrates and decarboxylation. The full mechanism of the 
reaction has not been established, but details about the order of binding and a 
theory study on a model system of the reaction has allowed the development of a 
working hypothesis. A computational study into the reaction of quinolinic acid to 2-
chlorotetrahydrofuran, as a model for 116, showed that formation of the nucleotide 
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and subsequent decarboxylation is more energetically favourable than 
decarboxylation followed by nucleotide formation.121 Acid-promoted 
decarboxylation of quinolinic acid was not a mechanism studied computationally, 
however, as quinolinic acid 13 decarboxylates with a half life of approximately 
three days at a pH of 1 and at 95 ˚C this mechanism seems unlikely.2 
The mechanism of nucleotide formation is still unclear. The reaction proceeds with 
an inversion of stereochemistry at C-1 of the ribose, as illustrated in Scheme 1.15. 
Kinetic isotope investigations into a related enzyme, orotate phosphoribosyl 
transferase, revealed that the transition state of the reaction resembled the 
classical oxocarbenium ion formed during an SN1 mechanism.122 Clearly the 
required stereochemistry of the product is obtained by QPRTase holding the 
quinolinic acid substrate in the correct orientation for nucleophilic attack. In M. 
tuberculosis the crystal structure supports the SN1 reaction mechanism as the 
residues Glu-201 and Asp-222 are orientated to aid stabilisation of the developing 
positive charge on the ribose ring.116 It has also been proposed that the 
magnesium ions required for catalysis aid stabilisation of the oxocarbenium 
intermediate. 
 
Scheme 1.16. A proposed mechanism for the decarboxylation of quinolinate mononucleotide 117 to give 
nicotinic mononucleotide 14. 
There has been debate as to whether the intermediate quinolinate mononucleotide 
117 decarboxylates free from the enzyme. The spontaneous decarboxylation of 
quinolinic acid requires very low pH and the current working hypothesis suggest 
the aid of QPRTase (Scheme 1.16).  
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1.7 Acute pancreatitis and the role of kynurenines in secondary 
multiple organ failure 
1.7.1 The pancreas 
The pancreas is a gland that sits below the stomach and above the first loop of the 
gut (Figure 1.39). The role of the pancreas as an endocrine and exocrine gland is 
important for digesting food and maintaining homeostasis of several systems in the 
body. Maintenance of glucose levels in the blood is the major homeostatic role 
performed by the pancreas.123 
 
 
Figure 1.39. A diagram showing the location of the pancreas in relationship to other digestive organs. 
Courtesy of National Cancer Institute. 
The pancreas produces pancreatic juice containing an alkaline solution of sodium 
hydrogen carbonate and powerful digestive enzymes. The enzymes and alkaline 
solution are created in clusters of secretory cells known as acini. These clusters 
are connected to ducts that ultimately flow into the gut.  The pancreatic digestive 
enzymes work at their optimum in an environment that is neutral or slightly alkaline. 
The sodium hydrogen carbonate solution is important in neutralising the acidic 
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contents of the stomach to protect the gut wall and create an optimum environment 
for the pancreatic enzymes.123 
Pancreatic enzymes are classified into three separate groups, depending on the 
food type they break down. These are: proteolytic enzymes, which break down 
proteins; pancreatic amylase, which breaks down polysaccharides into 
disaccharides; pancreatic lipase, which break down fats and oils. 123 
The endocrine system produces hormones that are released directly into the 
bloodstream. The four hormones produced by the pancreas are insulin, glucagons, 
somatostatin and pancreatic polypeptide. These hormones are produced in 
clusters of cells called the islets of Langerhans. Each hormone is produced by a 
specific cell and the ratio of cells in the islets of Langerhans varies along the length 
of the pancreas.123 
 
 1.7.2 Acute pancreatitis 
Acute pancreatitis is the inflammation of the pancreas, which can affect the 
pancreas as well as other organs. 
Compared to chronic pancreatitis, acute pancreatitis is reversible, causes no 
significant structural changes in the organ and the endocrine and exocrine systems 
return to their normal function upon reversal of the condition. Although there are 
numerous causes, over 80% of cases are due to either gallstones or excessive 
alcohol consumption. It is important to identify the underlying cause to assess the 
chance of a recurrence of the disease. For example, if an NSAID was causing the 
acute pancreatitis it is important that the patient does not use the drug.  In about 
10% of cases no underlying cause (idiopathic pancreatitis) can be found, although 
two studies have found that in two thirds of cases diagnosed as idiopathic 
pancreatitis, small gallstones and biliary sludge were observed using endoscopic 
retrograde cholangiopancreatography.124, 125 
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The average stay in intensive care for patients with acute pancreatitis is 7 days 
with a total time in hospital ranging from 40 days to 226 days. At a cost of £1500 
per day, intensive care is a very expensive resource. It is the secondary injury to 
organs that means that patients need to enter intensive care. This makes the 
prevention of the secondary injury important, as it will help reduce costs to 
hospitals.124 
 
1.7.3 Multiple organ failure Induced by acute pancreatitis 
In approximately 20% of acute pancreatitis patients the pancreatic injury is severe, 
furthermore, 15-25% of these patients will die. Up to 55% of acute pancreatitis 
cases result in secondary lung injury ranging from mild hypoxemia to acute 
respiratory distress syndrome.126 Measurement of the partial pressure of oxygen in 
the blood has been used as an indicator for the severity of acute pancreatitis. It has 
been reported that in approximately 60% of cases the patients were suffering from 
hypoxia within 48 h after admission to hospital. The lower oxygen concentrations in 
hypoxia, can be correlated directly to damage to the lungs. Secondary lung injury is 
followed by renal failure.126 
A 1999 study into acute pancreatitis cases in Scotland (from 1984 to 1995) found 
that multiple organ failure within the first week of admission led to 54% of patients 
dying.127 In patients who overcome the early multiple organ failure, the mortality 
drops rapidly and in a 2002 study there were no deaths in patients in which the 
multiple organ failure was resolved. 
It has been shown that interleukin 1β and TNF-α play an important role in the 
development of acute pancreatitis.126 As the kynurenine pathway is upregulated by 
cytokines, it is possible that the increase in expression of cytokines produces an 
increase in the metabolism of tryptophan via the kynurenine pathway.  
The mechanism of how acute pancreatitis affects organs, especially the lungs, is 
not yet entirely clear. It has been suggested that small molecule mediators have a 
role to play. For example, an increase in L-tryptophan metabolites from the 
  55 
kynurenine pathway in the lymph were found in a rat model of acute pancreatitis.128 
In hospitalised patients with acute pancreatitis the concentration of L-tryptophan 
metabolites showed an increase in line with the occurrence of multiple organ 
failure.128 
 
Figure 1.40. Proposed steps between acute pancreatitis and secondary MOF.129 
A hypothesis for how acute pancreatitis causes multiple organ failure has been 
proposed (Figure 1.40).129 The initial events of acute pancreatitis sets off an 
immunological state of alert. This causes gut inflammation, which includes 
activation of dendritic cells and macrophages by numerous cytokines.130 It has 
been shown that gut inflammation has a role in the way that acute pancreatitis 
causes multiple organ failure. Dendritic cells, a type of immune system cell, move 
to the mesenteric lymph nodes. Here the dendritic cells induce tolerance of the 
autoreactive T-cells through small molecule metabolites.  
Kynurenines have been identified as relevant metabolites. Kynurenine 3-
monooxygenase is a constitutively active enzyme, therefore any kynurenine 3 
formed by the breakdown of L-tryptophan 1 would be converted to 3-
hydroxykynurenine 8. These kynurenines overflow into the mesenteric lymph. The 
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treated with 3­hydroxykynurenine. Morphological and kinetic abnormalities are 
evident from 4 to 6 hours after addition of 3­hydroxykynurenine..
PR3. Metabolic activity of A549 cells 
measured by reduction of Alamar
blue after treatment with kynurenine
pathway metabolites. A dose 
response to 3HK, but not KYN or TRYP 
is seen.
TRANSLATION
PR4. Cellular composition of mouse mesenteric lymph collected 
continuously over 6 hours via an indwelling catheter. Selective cannulation
of the murine mesenteric lymph duct shows a majority of T and B lymphocytes in 
efferent lymph. 
! Acute pancreatitis is inflammation in the pancreas usually triggered 
by gallstones or excessive consumption of alcohol
! Patients die from multiple organ failure, predominantly lung injury
! Organ failure occurs early and is usually a sterile event
Norman Salvesen 
Research Trust
! Preferred pathway of 
tryptophan metabolism
! Neurotoxic (e.g. QUIN) and 
neuroprotective elements (e.g. 
KYNA) known for many years, 
acting via NMDA receptor 
amongst other mechanisms 
(Stone et al. 1988)
! Placental IDO shown to be 
important in protecting against 
maternal T cell­mediated foetal 
loss (Munn and Mellor 1998)
! Kynurenines implicated in 
dendritic cell­mediated 
regulation of T cell proliferation 
and induction of a regulatory 
phenotype
! IDO1­deficient mice 
experience worse graft vs. 
host disease and more severe 
experimental colitis, 
suggesting a potential role for 
the pathway in protecting 
against T cell­mediated injury 
to self.
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Experimental acute pancreatitis in rats. Mesenteric lymph from rats 4 hours after 
the induction of AP becomes toxic to endothelial cells in culture. KYN and 3HK 
concentrations are elevated in the same time frame as lymph cytotoxicity.
Clinical acute pancreatitis in humans. Peripheral serum concentrations of KYN 
correlate with severity of organ dysfunction by scoring systems, requirement for 
kidney dialysis and mechanical ventilation.
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lymph travels through the body arriving at the lungs. Lung damage is attributed to 
the “toxicity” of the kynurenine metabolites. Further studies into the kynurenine 
metabolites showed that 3-hydrokynurenine 8 is cytotoxic to lung cells. 
 
1.8. Aims of research 
The aims of this project are to develop novel inhibitors of K3MO and the synthesis 
of kynurenine analogues for both mechanistic and inhibition studies. K3MO plays 
an important role in mediating multiple organ failure secondary to acute 
pancreatitis, as well as several neurologically important diseases for example, 
AIDS related dementia and Huntingtons disease. The development of novel 
inhibitors of K3MO is important as current generations of inhibitors trigger 
hydrogen peroxide through uncoupled NADPH oxidation. The production of 
hyrdgogen peroxide is undesirable as it is a strong oxidising agent, which can 
cause damage within cells. 
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Chapter 2 
Exploring Chemical Space To Generate 
Inhibitors of K3MO 
2.0 Introduction 
 
The pivotal role that kynurenine-3-monooxygenase (K3MO) plays in the 
metabolism of L-tryptophan 1 makes it an attractive target for drug discovery. The 
main pathway for kynurenine metabolism in mammals is its conversion to 3-
hydroxykynurenine 8 by K3MO. Inhibition of K3MO not only limits the production of 
the toxic metabolite 3-hydroxykynurenine 8, but it also prevents the downstream 
formation of quinolinic acid 13, a potent NMDA receptor agonist and neurotoxic 
agent, and it increases the concentration of kynurenic acid 5 in the brain.131, 132 
 
Figure 2.41. Kynurenine 3 and one of the target 1,2,4-oxadiazoles 120. 
A survey of the patent literature reveals a number of structural motifs that have 
been developed as K3MO inhibitors. The large number of sulfonamides in the 
patent literature for K3MO meant that alternative functionalities were explored. In 
addition the ketone functionality of kynurenine 3 is commonly replaced with a 
heterocycle. The 1,2,4-oxadiazole ring motif, illustrated in 120, emerged as an 
attractive motif because 1,2,4-oxadiazoles were not covered in any of the previous 
patents. 1,2,4-Oxadiazoles have also been used as bioisosteres of both esters and 
amides.133-136 1,2,4-Oxadiazoles are relatively accessible synthetic targets.  
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Figure 2.42. Initial targets for assay against K3MO. 
The initial targets are shown in Figure 2.2. The meta-nitro phenyl group was 
retained as a structural motif, as it was already demonstrated to have high affinity 
for the enzyme. The amino acid and amine functionalities were retained in an 
attempt to replicate the amino acid functionality of kynurenine 3.  
 
Scheme 2.1. The most common methods for synthesis of the 1,2,4-oxadiazole ring. 
The two most common methods for generating 1,2,4-oxadiazoles, are shown in 
Scheme 2.1. The first involves formation of an O-acyl amidoxime 125 from an 
amidoxime 123. Cyclisation of the resultant O-acyl amidoxime 125 to the 1,2,4-
oxadiazole 126 is achieved under thermal conditions. The cyclisation of 125 to the 
1,2,4-oxadiazole 126 can also be achieved using catalytic TBAF at room 
temperature.137 The alternative synthetic route to 1,2,4-oxadiazoles 126 involves a 
1,3-dipolar cycloaddition of a nitrile oxide 129 with a nitrile 130. Nitrile oxides are 
readily synthesied from oxime 127, via an oximyl chloride 128. Interestingly both 
synthetic routes involve the use of a nitrile, which allows the synthesis of isomeric 
compounds with R at either C-3 or C-5 in the 1,2,4-oxadiazole.138  
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Scheme 2.2. The proposed mechanism of fluoride ion catalysis for formation of 1,2,4-oxadiazoles. 
The proposed mechanism, as shown in Scheme 2.2, for the cyclisation of O-acyl 
amidoxime 125 to 1,2,4-oxadiazole 126, with TBAF catalysis, involves 
intramolecular cyclisation of the amidoxime to form ionic intermediate 131. Fluoride 
anion acts as a base and catalyses a proton transfer step. Investigations into the 
thermal cyclisation suggested that proton transfer is rate-limiting.139 
 
2.1 Target validation 
 
The sulfonamides 93 and 135 were synthesised following literature protocols.67 As 
93 and 135 are known inhibitors of rat and gerbil K3MO, they were required to 
validate the working hypothesis that inhibition of K3MO prevents multiple organ 
failure following acute pancreatitis in a rat model.  
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Scheme 2.3. Reagents and conditions: a) Pyridine, DCM, RT, 16 h, 24%; b) pyridine, DCM, RT, 16 h, 58%. 
Initially, the synthesis of the sulfonamides using 2-aminothiazoles 136 and 138 and 
3,4-dimethoxybenzenesulfonyl chloride 137 under basic conditions gave the 
desired products. However, the sulfonamides were not isolated due to difficulties 
with recrystallisation.67 Purification of the sulfonamides by column chromatography 
was also complicated by the difficulty in separating the sulfonamide and sulfonic 
acid. This problem was overcome by carrying out the reaction in DCM with a 
stoichiometric volume of pyridine as shown in Scheme 2.3. The solvent was 
removed and the residue was run directly through a silica column. This gave both 
of the desired sulfonamides 93 and 135, with yields comparable to those previously 
reported.67  
The sulfonamide inhibitors 93 and 135 were assayed against K3MO from Homo 
sapiens and P. fluorescens. The sulfonamides 93 and 135 have a Ki of 1 µM and 2 
µM against the bacterial enzyme, respectively (Dr Chris Mowat and Martin 
Wilkinson, Edinburgh University), showing that 93 and 135 do not inhibit the 
bacterial enzyme to the same extent as rat K3MO. Against H. sapiens K3MO, 
sulfonamide 93 has an IC50 of 2.8 µM (Dr Scott Webster, Edinburgh University). 
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From the bacterial and human assays it is clear that sulfonamides 93 and 135 are 
not as potent. In a rat model of acute pancreatitis, secondary multiple organ failure 
(MOF) was reduced when sulfonamide 93 was given before and after the induction 
of acute pancreatitis (Dr Damian Mole, Edinburgh University).129 
 
2.2 Initial amine and amino acid targets 
 
Scheme 2.4. Synthesis of 1,2,4-oxadiazoles via the amidoxime: a) Hydroxylamine; b) carboxylic acid, coupling 
reagent; c) Heat or TBAF.  
A general procedure for the synthesis of the 1,2,4-oxadiazole ring 142 via the O-
acyl amidoxime 141 is shown in Scheme 2.4. The O-acyl amidoxime 141 is 
prepared by reaction of an amidoxime 140 with a carboxylic acid using a suitable 
coupling reagent such as DCC. An alternative method for the preparation of the O-
acyl amidoxime involves the reaction of amidoxime 140 with an acid chloride. The 
amidoxime 140 required as a substrate, was formed by the reaction of 
hydroxylamine upon benzonitrile 139 as shown in Scheme 2.4. In this study, the 
cyclisation of the O-acyl amidoximes 141 to the 1,2,4-oxadiazole ring 142 was 
achieved through the use of catalytic TBAF.137 
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Scheme 2.5. Reagents and conditions: a) NH2OH.HCl, K2CO3, MeOH, 80 ˚C for 2 h, then RT for 16 h, 84%. 
Synthesis of meta-nitrobenzamidoxime 140 was accomplished using meta-
nitrobenzonitrile 139, hydroxylamine hydrochloride and potassium carbonate, as 
illustrated in Scheme 2.5. Heating the mixture under reflux was crucial to achieve a 
good yield. The product was recovered by recrystallisation from toluene. 1H NMR 
spectroscopy confirmed the amidoxime 140 exists as the tautomer shown. 
 
Figure 2.3. 1H NMR spectrum of 140 in D6-DMSO confirming the tautomer shown. 
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Scheme 2.6. Reagents and conditions: a) DCC, DMAP, DCM, RT, 16 h, 88%; b) DCC, DMAP, DCM, RT, 16 h, 
57%. 
Protected aspartic acid 143 and glutamic acid 145 were then coupled to amidoxime 
140 using DCC under Steiglich esterification conditions as illustrated in Scheme 
2.6. The nature of the protecting groups allowed for a one step global deprotection 
using TFA in future steps. The synthesis of the O-acyl amidoximes 144 and 146 
was also achieved through reaction of the respective amino acid-protected acid 
chlorides. However, usual routes to acid chlorides were not possible due to the 
acidic conditions used in their preparation. Cyanuric chloride allowed for the 
preparation of the protected acid chlorides under basic conditions.140 Both the 
Steiglich esterification and acid chloride methods gave 144 and 146 in modest to 
good yields. Due to the ease of Steiglich esterification, this route was subsequently 
employed. Crystallisation of 146 allowed single crystal X-ray diffraction analysis of 
the product, confirming its identity, as illustrated in Figure 2.4. 
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Figure 2.4. X-ray crystal structure of 146. 
 
 
Scheme 2.7. Reagents and conditions: a) TBAF, THF, RT, 16 h, 83%; b) TBAF, THF, RT, 16 h, 60%. 
With the acyl amidoximes 144 and 146 in hand, cyclisation using TBAF was 
explored. This reaction went smoothly and the corresponding 1,2,4-oxadiazoles 
147 and 148 were generated in good yields.  
146 
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Scheme 2.8. Reagents and conditions: a) TFA, triethylsilane, RT, 16 h, followed by HCl, 50%; b) TFA, 
triethylsilane, RT, 16 h, followed by HCl, 18%. 
The final step in the synthesis of this class of compounds involved global 
deprotection of 147 and 148 with TFA to give amino acids 120 and 121, as 
illustrated in Scheme 2.8. Triethylsilane was added as a scavenging reagent for the 
2-methylprop-1-ene formed in the reaction. This method gave the products as their 
TFA salts, which had poor solubility in all solvents explored, making the products 
difficult to characterise. Accordingly, the TFA salts were redissolved in a large 
volume of 1 M HCl solution and the solvent was removed under reduced pressure. 
This gave the amino acids as their hydrochloride salts. However, the hydrochloride 
salts were still found to be relatively insoluble.  
With the amino acids 120 and 121 successfully in hand, attention turned to the 
synthesis of the amine side chain. There was evidence that the sulfonamides in 
inhibitors 93 and 135 were acting as carboxylic acid bioisosteres.67 The amine side 
chain allowed investigation into possible amine binding interactions in the active 
site of K3MO. 5-Ethylamine-1,2,4-oxadiazole 122 became a target compound and 
the planned synthesis commenced from β-alanine. 
 
Scheme 2.9. Reagents and conditions: a) Boc2O, dioxane:water 2:1, RT, 16 h, 82%. 
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The initial step, as illustrated in Scheme 2.9, was to protect the amine functionality 
of β-alanine 149. Boc protection of the amine was chosen due to the ease with 
which the protecting group could be removed in the final step. The amine was 
protected in aqueous alkaline conditions, using a literature method,141 to give 
carboxylic acid 150 in good yield. 
 
Scheme 2.10. Reagents and conditions: a) DCC, DMAP, DCM, RT, 16 h, 73%; b) TBAF, THF, RT, 16 h, 99%; 
c) HCl solution in dioxane, DCM, RT, 16 h, 78%. 
Coupling of amidoxime 140 and carboxylic acid 150 was achieved using Steiglich 
esterification conditions to give O-acyl amidoxime 151, as illustrated in Scheme 
2.10. O-Acyl amidoxime 151 was then cyclised using TBAF to give 1,2,4-
oxadiazole 152 in excellent yield. Single crystal X-ray crystallography confirmed 
the expected structure of 152, as illustrated in Figure 2.5.  
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Figure 2.5. X-ray crystal structure of 152. 
Deprotection of 152, as illustrated in Scheme 2.10 was accomplished in a straight-
forward manner through the use of HCl solution in 1,4-dioxane to give 122 as its 
hydrochloride salt.  
 
2.3 Investigation into alternative motifs for inhibition of K3MO 
 
Figure 2.6. The sulfonamides 93 and 135 and the general structure for the SAR 153. The two atoms targeted 
for structural change are highlighted in red. 
152 
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The sulfonamides 93 and 135 originated as hits from a high throughput screen. 
There is no information on alteration of the sulfonamide functionality to alternative 
2-atom linkers between the heterocycle and the 3,4-dimethoxy phenyl ring, such as 
in 153. The relative ease of access to the 1,2,4-oxadiazole motif renders these 
compounds a good scaffold to replace the sulfonamide with carbon-carbon and 
carbon heteroatom bonds. To gain a greater understanding of the three-
dimensional binding requirements the two-carbon linker was also varied with 
different functionalities. 
 
Scheme 2.11. Reagents and conditions: a) DCC, DMAP, DCM, RT, 16 h, 16%; b) TBAF, THF, RT, 16 h, 94%. 
The 1,2,4-oxadiazole 156, shown in Scheme 2.11, was prepared as a reference 
compound for this series. This compound does not have the 3,4-dimethoxy groups. 
Amidoxime 140 and 3-phenylpropionic acid 154 were coupled using Steiglich 
conditions to form O-acyl amidoxime 155. The yield was poor, but enough material 
was obtained to carry out the TBAF cyclisation of O-acyl amidoxime 155, to give 
1,2,4-oxadiazole 156. This second reaction was accomplished in an excellent yield, 
as illustrated in Scheme 2.11.  
 
Scheme 2.12. Reagents and conditions: a) DCC, DMAP, DCM, RT, 16 h, 31%; b) TBAF, THF, RT, 16 h, 54%. 
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Oxadiazole 159 was targeted for investigation. In this compound the sulfonamide 
of 93 has been replaced with two methylene units. This enabled an exploration of 
the effect, if any, that the sulfonamide has on binding. O-Acyl amidoxime 158 was 
prepared using DCC and DMAP, as illustrated in Scheme 2.12. The product 158 
was obtained in poor yield, however, enough material was obtained to complete 
the TBAF cyclisation to give 1,2,4-oxadiazole 159.  
 
Scheme 2.13. Reagents and conditions: a) DCC, DMAP, DCM, RT, 16 h, 49%; b) TBAF, THF, RT, 16 h, 45%. 
The introduction of a carbon-carbon double bond offered some versatility as it can 
be further elaborated. O-Acyl amidoxime 161 was synthesised using DCC, DMAP, 
carboxylic acid 160 and amidoxime 140, as illustrated in Scheme 2.13. Initially, the 
product was purified by flash column chromatography, however, it proved easier to 
recrystallise 161 from ethanol and water. TBAF-mediated cyclisation of O-acyl 
amidoxime 161 gave the desired 1,2,4-oxadiazole 162 in a moderate yield. The 
product was difficult to purify and handle, as it had poor solubility in many solvents. 
This poor solubility made flash column chromatography difficult, as large volumes 
of solvent were required. This problem was overcome by recrystallisation of 162 
from hot ethanol. The conjugated π system gave 162 an orange colour. 
 
Scheme 2.14. Reagents and conditions: a) BH3.THF (0.5 eq), THF, H2O2, NaOH; b) BH3.THF (2 eq), THF, 
H2O2, NaOH, 45%. 
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With 162 in hand, elaboration of the double bond was explored. Hydroboration 
using 2 eq of the borane-THF complex was carried out, as illustrated in Scheme 
2.14. This reduced the double bond to give a saturated ethane spacer 159 instead 
of the desired alcohol 163. 
 
Scheme 2.15. Reagents and conditions: a) mCPBA, DCM, RT, 16 h; b) H2O2, NaOH, MeOH; c) KHSO5, 
K2CO3, acetone. 
The synthesis of epoxide 164 directly from alkene 162 was unsuccessful (Scheme 
2.15). Epoxidation using mCPBA, dimethyldioxirane142 and alkaline hydrogen 
peroxide was explored, however, these conditions did not show any conversion to 
the desired epoxide. Therefore, an alternative two-step route to epoxide 164 via a 
bromohydrin was explored, as illustrated in Scheme 2.16. 
 
Scheme 2.16. Reagents and conditions: a) NBS (1.3 eq), THF, H2O, exclusion of light, RT, 16 h, 75%; b) 
K2CO3, MeOH, 64%, RT, 16 h, 64%. 
Alkene 162 was treated with NBS in aqueous THF to generate bromohydrin 165 
(Scheme 2.16).143 The reaction was optimal when alkene 162 was fully dissolved in 
the THF/water solution, however, an excess of water lead to alkene precipitation, 
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lowering the yield. The yield of the reaction was also reduced by the formation of 
side-product 166, which arose from electrophilic aromatic substitution of the 
anisole ring. Optimal results were obtained with 1.3 eq of NBS; with less than 1.3 
eq the reaction did not go to completion, which complicated purification. More than 
1.3 eq led to increased formation of side-product 166. 
Bromohydrin 165 was recovered in good yield as a racemic single diasteroeisomer. 
The regiochemistry of the bromohydrin was confirmed by 2D HMBC NMR analysis. 
Single crystal X-ray crystallography of the product also confirmed the regio- and 
relative stereo- chemistry of 165 as illustrated in Figure 2.7. 
 
Figure 2.7. X-Ray crystal structure of 165, proving the anti relationship of the bromohydrin. 
Epoxide 164 was formed by intramolecular cyclisation of bromohydrin 165 using 
potassium carbonate, as illustrated in Scheme 2.16. Smaller scale reactions could 
be purified by careful column chromatography. On a larger scale (≥ 1 g), the 
product was found to precipitate on top of the column bed, causing the product to 
streak over a long elution. Attempts at recrystallisation were unsuccessful.  
With epoxide 164 in hand, a series of reactions were explored to further 
functionalise the epoxide and generate more substrates for inhibition studies. 
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Scheme 2.17. Reagents and conditions: a) KOH, H2O, MeOH, THF, 70 ˚C, 2 h, 50%. 
Initial attempts to open the epoxide with hydroxide ion did not furnish the expected 
diol. Analysis of the product by single crystal X-ray crystallography (Figure 2.8) 
revealed the re-arranged heterocyclic product 167, as illustrated in Scheme 2.17 
        
Figure 2.8. X-Ray crystal structure of 167, confirming the rearrangement of the 1,2,4-oxadiazole (Scheme 
2.17). 
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Scheme 2.18. A plausible mechanism for the rearrangement of the 1,2,4-oxadiazole heterocycle. 
A plausible mechanism for this transformation is illustrated in Scheme 2.18. 
Product 167 exists as an amide as the carbonyl C=O distance is 1.212 Å. A typical 
carbonyl C=O bond length is 1.22 Å compared to a typical C-O single bond length 
of 1.43 Å.  
With basic conditions favouring attack at C-5 of the 1,2,4-oxadiazole heterocycle, 
hydrolytic ring opening of the epoxide under acidic conditions was explored. 
 
Scheme 2.19. Reagents and conditions: a) HCl, MeOH, THF, H2O, 70 ˚C, 3 h; b) HCl, THF, H2O, 70 ˚C, 3 h, 
98%. 
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When epoxide 164 was treated with acidic methanol solution, the major product 
isolated was an inseparable mixture of the methoxy diastereoisomers 171. In the 
absence of methanol, an inseparable mixture of the diol diastereoisomers 172 was 
generated, as illustrated in Scheme 2.19. Separation of these diastereoisomers 
was not possible directly, however, a resolution of the diastereoisomers could be 
achieved after formation of acetonides 173 and 174. 
 
Scheme 2.20. Reagents and conditions: a) 2,2-Dimethoxypropane, p-TSA, DCM, RT, 16 h, 37% 173, 57% 
174. 
The acetonides 173 and 174 were formed in good yield using 2,2-dimethoxy-
propane under acid catalysis, as illustrated in Scheme 2.20. Stereoisomer 173, 
obtained by column chromatography, had a 1H NMR spectrum where H-9 and H-
10 were sufficiently resolved to conduct an NOE experiment. In the 1H NMR 
spectrum of stereoisomer 174, the chemical shifts of H-9 and H-10 were too close 
for NOE resolution. 
 
Figure 2.9. An NOE enhancement of H-12 and H-16 was observed for 173. No such enhancement should 
exist for 174. 
For 173, irradiation of H-9 led to a weak enhancement of the aromatic protons H-
12 and H-16. This allowed a tentative assignment as the anti isomer. H-9 in the 
anti isomer is close enough in space to the aromatic protons to have an NOE 
enhancement , whereas a model of the syn stereoisomer indicates that H-9 is too 
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far from the aromatic protons for such an enhancement. Further confirmation of the 
relative configurations of 173 and 174 was obtained by X-ray crystallography. 
(Figure 2.10) 
 
Figure 2.10. X-Ray crystallography confirmed the relative stereochemistry of acetonides 173 and 174 as anti 
and syn 
With the diastereoisomers separated, removal of the acetonide groups gave the 
diols 175 and 176.  
 
Scheme 2.21. Reagents and conditions: a) Camphor sulfonic acid, HCl, MeOH, 90 ˚C, 2 h, 67%; b) camphor 
sulfonic acid, HCl, MeOH, 90 ˚C, 2 h, 64%. 
173 174 
  76 
The acetonide protecting groups of 173 and 174 were removed under acidic 
conditions to give diols 175 and 176 in good yield, as illustrated in Scheme 2.21. 
Confirmation of the relative stereochemistry of each diol was achieved by single 
crystal X-ray crystallography (Figure 2.11). 
 
Figure 2.11. X-Ray crystallography confirmed the relative stereochemistry of diols 175 and 176. 
 
Scheme 2.22. Reagents and conditions: a) NaN3, NH4Cl, MeOH, H2O, 70 ˚C, 2 h, 88%. 
Ring opening of epoxide 164 was also explored using sodium azide under acidic 
conditions, as illustrated in Scheme 2.22. This reaction was successful and azido 
alcohol 177 was obtained in good yield as a single diastereoisomer. The product 
was obtained as a single regioisomer, presumably because the electron-rich 
aromatic ring promotes epoxide ring opening at C-10.  The product could be 
purified by column chromatography and was stable for many months. The 
regioselectivity of the reaction was confirmed by 2D HSQC and HMBC NMR 
experiments, which showed that the azide was attached adjacent to the phenyl 
ring.  
Initial attempts at reduction of the azide to the amine were unsuccessful. A 
Staudinger reduction using PPh3 or a reduction using ferric chloride with sodium 
iodide144 or zinc borohydride145 did not furnish the desired amino alcohol. 
Reduction of the azide in the presence of the free alcohol was potentially 
175 176 
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complicating the reaction, therefore, the alcohol was protected as a silyl ether, as 
illustrated in Scheme 2.23.  
 
Scheme 2.23. Reagents and conditions: a) TBSCl, imidazole, DCM, RT, 16 h, 71%. 
Protection of alcohol 177 was accomplished using TBSCl and imidazole to give 
TBS ether 178 in good yield. TBS protection provides some acid stability and 
removal of the protecting group could be easily achieved using a fluoride source, 
most commonly TBAF.  
 
 
Scheme 2.24. Reagents and conditions: a) Resin bound triphenyl phosphine, THF, H2O, 70 oC, 16 h, 62%; b) 
PMe3, NaOH, THF, H2O, RT, 16 h, 55% 
Initial attempts at the Staudinger reduction using triphenylphosphine146, 147 worked 
well to give amine 179, however, co-elution of the triphenylphosphine oxide 
byproduct complicated the purification. Using resin bound triphenylphosphine, as 
illustrated in Scheme 2.24, it was possible to separate the triphenylphosphine 
oxide by filtration of the solid support. This allowed amine 179 to be recovered by 
column chromatography in moderate yield. Resin bound triphenylphosphine is 
relatively expensive and so an alternative Staudinger reduction using 
trimethylphosphine148, 149 was explored. Trimethylphosphine oxide is water soluble 
and could be removed by careful washing during reaction work up. In the event 
trimethylphosphine gave a slightly lower yield of 179, but it benefited from lower 
cost and milder reaction conditions. 
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Scheme 2.25. Reagents and conditions: a) TBAF, THF, RT, 3 h, 68%. 
With amine 179 in hand, the next step involved removal of the TBS protecting 
group. This was achieved using TBAF to give the desired amino alcohol 180 in a 
relatively straightforward manner,150 as illustrated in Scheme 2.25. 
 
Scheme 2.26. Reagents and conditions: a) Ac2O, DMAP, DCM, RT, 16 h, 51%; b) TBAF, THF, RT, 2 h, RT, 
71%. 
Acetamide 182 was prepared to explore differences between amine and amide 
functionality at the C-10 position. Thus, amine 179 was treated with acetic 
anhydride in the presence of DMAP to give acetamide 181 in a moderate yield, as 
illustrated in Scheme 2.26. With the protected acetamide 181 in hand, the TBS 
protecting group was successfully removed using TBAF to give alcohol 182. 
 
Scheme 2.27. Reagents and conditions: a) NaN3 DMSO, 50 ˚C, 16 h. 
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Any attempt to directly substitute the bromide in bromohydrin 165 for azide, to give 
the alternative regioisomer of the azido alcohol 183, was unsuccessful (Scheme 
2.27). The product had identical 1H and 13C NMR spectra to the original isomer 
177. It is probable that under the SN2 conditions the epoxide is generated and is 
then opened by the azide. Protection of the alcohol was then investigated to 
determine whether substitution of the bromide by azide could be favoured over 
epoxide formation.  
 
Scheme 2.28. Reagents and conditions: a) TBSCl, imidazole, DCM, RT, 8 h, 78%; b) NaN3, DMSO, 50 ˚C, 16 h. 
Protection of bromohydrin 165 as the TBS silyl ether was accomplished in good 
yield, as illustrated in Scheme 2.28.151, 152 With the protected bromohydrin 184 in 
hand, azide substitution was explored under SN2 conditions.153 However, the 
reaction only returned starting material, even over extended reaction times. A 
similar reaction with the TMS silyl ether 186 was also unsuccessful, as illustrated in 
Scheme 2.29.  
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Scheme 2.29. Reagents and conditions: a) TMSCl, imidazole, DCM, RT, 8 h, 66%; b) NaN3, DMSO, 50 ˚C, 16 h. 
 
 
Scheme 2.30. Reagents and conditions: a) Ac2O, pyridine, DCM, RT, 16 h, 87%; b) NaN3, DMSO, 50 ˚C, 2h, 
58%. 
As the bulky silyl ethers did not show any reactivity, the free alcohol was protected 
as acetate 188, as illustrated in Scheme 2.30. Azide substitution of the bromine 
was then explored. Analysis of the product by 1H and 13C NMR spectroscopy 
revealed that an elimination reaction had occured to produce 189. Single crystal X-
ray crystallography confirmed the structure of the elimination product illustrating 
that the Z-alkene had formed (Figure 2.12). 
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Figure 2.12. X-Ray crystal structure of elimination product 189.  
 
 
Scheme 2.31. Reagents and conditions: a) NaBH4, MeOH, RT, 16 h. 
Reduction of epoxide 164 to give the alcohol 190 was explored. Traditionally, the 
reduction of an epoxide is achieved using LiAlH4, however, 1,2,4-oxaidazoles are 
not stable to LiAlH4 as they are also susceptible to reduction. The less reactive 
sodium borohydride was explored, however, this was unreactive and only starting 
material was returned (Scheme 2.31). 
189 
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Scheme 2.32. Proposed synthesis of the ketone by Claisen condensation, via deprotonation of the 5-methyl-
1,2,4-oxadiazole 191. 
The 5-methyl 1,2,4-oxadiazole 191 offered a potential synthetic route to ketone 
193. Strong bases154, 155 are able to deprotonate the methyl group of 191. The 
resulting carbanion is relatively stable due to resonance stabilisation by the 1,2,4-
oxadiazole (Scheme 2.32). There was an opportunity to use the resulting 
carbanion (195-197) in a Claisen or aldol-“like” reaction to give the desired 
products. 
 
Scheme 2.33. Reagents and conditions: a) Ac2O, Et3N, DCM, RT, 16 h, 75%; b) TBAF, THF, RT, 16 h, 83%. 
The synthesis of 5-methyl-1,2,4-oxadiazole 191 began with the reaction of 
amidoxime 140 and acetic anhydride to give O-acyl amidoxime 198, as illustrated 
in Scheme 2.33. It was found that approximately 6% of the product had cyclised 
directly to 1,2,4-oxadiazole 191. The purified O-acyl amidoxime 198 was readily 
cyclised to 191 using TBAF in good yield, as illustrated in Scheme 2.33.  
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Scheme 2.34. Reagents and conditions: a) n-BuLi, THF, -78 ˚C, 2 h; b) NaH, DMF, 0 ˚C, 3 h; c) NaOEt, THF, 
RT, 16 h. 
With 5-methyl-1,2,4-oxadiazole 191 in hand the “Claisen”-like condensation was 
explored using ester 192, as illustrated in Scheme 2.34. Deprotonation of 191 
using LDA, n-BuLi, NaOEt and NaH were each attempted. Upon addition of any of 
these bases, a colour change occurred. However, the desired product 193 was not 
obtained in any of these cases. Attempts at an “aldol”-like reaction with 
trifluorobenzaldehyde also did not return the expected product and only starting 
material was recovered. 
 
Figure 2.13. Ketone 199 has been previously reported. Enamine 200 offers an additional scaffold for enzyme 
assay. 
A literature search revealed that ketone 199 had previously been synthesised156 
through the 1,3-dipolar cycloaddition of a nitrile oxide and an enaminonitrile, 
followed by hydrolysis (Figure 2.13). This was an attractive route to both ketone 
193 but also gave an additional functionality for assay, namely enamine 200. 
 
 
Scheme 2.35. Reagents and conditions: a) Hydroxylamine hydrochloride, NaOAc, acetonitrile:H2O (2:1), RT, 
16 h, 88%. 
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The nitrile oxide required for the 1,3-dipolar cycloaddition was generated in situ 
from oxime 202. The oxime was synthesised by condensation of hydroxylamine 
with meta-nitrobenzaldehyde 201, as illustrated in Scheme 2.35. Neutralisation of 
the acetic acid with sodium bicarbonate and the use of decolourising charcoal 
allowed the recovery of clean product in good yield. 
 
Scheme 2.36. Reagents and conditions: a) Acetonitrile, potassium tert-butoxide, toluene, RT, 16 h, 71%. 
Enaminionitrile 204 was synthesised by the Thorpe reaction using acetonitrile, 3,4-
dimethoxybenzonitrile 203 and potasium tert-butoxide as the base to give 
enaminonitrile 204 in good yield, as illustrated in Scheme 2.36.157 1H NMR and 13C 
NMR spectroscopy showed the product existed as the enamine rather than the 
imine tautomer. 
 
Scheme 2.37. Reagents and conditions: a) Sodium hypochlorite solution (1.6M), DCM, 3 min; b) Et3N, 16 h, 
1.7% (after recrystallisation). 
With oxime 202 and enaminonitrile 204 in hand, attention turned to the 1,3-dipolar 
cycloaddition, as illustrated in Scheme 2.37. Oxime 202 was reacted with bleach 
as an electrophilic chlorine source and this generated oximyl chloride 205. The 
oximyl chloride was used without any further purification and was added to a 
solution of enaminonitrile 204 in triethylamine. Triethylamine promotes the 
formation of the nitrile oxide. It is important that the dipolarophile is in the same 
solution as the triethylamine as nitrile oxides are known to dimerise, forming 
furoxans. In the event the yield from this reaction was very poor (10-15% before 
recrystallisation) and could not be improved. 
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Scheme 2.38. Reagents and conditions: a) HCl, EtOH, 80 ˚C, 3 h, 13%. 
Hydrolysis of enamine 200 to ketone 193 was undertaken, using concentrated 
hydrochloric acid in ethanol, as illustrated in Scheme 2.38. The hydrolysis was 
successful, however, purification of the product by column chromatography proved 
difficult. Purification of 193 by recrystallisation circumvented this problem. Despite 
the low yield, enough material was obtained to assay 193 against both the human 
and bacterial enzymes. 
 
Scheme 2.39. Reagents and conditions: a) HCl (3 M solution), DCM, RT, 16 h, 60%. 
Acid hydrolysis of enamine 204 was also investigated and this gave ketone 206 
with retention of the nitrile functionality, as illustrated in Scheme 2.39.158 
 
Scheme 2.40. Reagents and conditions: a) Sodium hypochlorite solution (1.6M), DCM, 3 min; b) Et3N, 16 h. 
Due to the poor reaction of enamine 204, an investigation into the 1,3-dipolar 
cycloaddition reaction with ketone 206 was undertaken, however, this reaction 
proved unsuccessful returning none of the desired ketone 193 (Scheme 2.40). 
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Scheme 2.41. Retrosynthetic analysis for the synthesis of amide 207. 
1,2,4-Oxadiazole 207 was synthesised for direct comparison with thiazole 
sulfonamide 93. The connectivity of an amide and a sulfonamide are similar, 
however, their three-dimensional structures differ. This affects the interactions that 
each motif can make with the enzyme. The planned synthesis was to conduct the 
amide bond formation as the final step, as illustrated in Scheme 2.41. The required 
5-amino-1,2,4-oxadiazole 208 would be synthesised through a 1,3-dipolar 
cycloaddition of the nitrile oxide intermediate, formed from oxime 202 and 
cyanamide 210, or guanidine 211, as illustrated in Scheme 2.41.159, 160  
 
Scheme 2.42. Reagents and conditions: a) Sodium hypochlorite (1.6 M solution), DCM, 3 min then cyanamide, 
Et3N, 68%. 
The 1,3-dipolar cycloaddition was initially investigated using guanidine 211 as the 
dipolarophile, however, this gave low yields of 5-amino-1,2,4-oxadizole 208. The 
low reactivity was attributed to poor leaving group characteristics of the ammonia 
formed in the reaction. Changing the dipolarophile to cyanamide 210 increased the 
yield to 30%. Optimisation of the reaction, by altering the order of addition, further 
improved the yield to 68%, as illustrated in Scheme 2.42. 
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Scheme 2.43. Reagents and conditions: a) DCC, DCM, RT, 16 h, 21%. 
With 5-amino-1,2,4-oxadiazole 208 in hand, amide 207 was prepared using DCC 
as a coupling agent, as illustrated in Scheme 2.43. The poor reactivity was 
attributed to the poor nucleophilicty of 208. The nucleophilicity of 208 is reduced by 
the electron withdrawing effect of the 1,2,4-oxadiazole. 
 
Scheme 2.44. Reagents and conditions: a) DCC, DMAP, DCM, RT, 16 h, 4%. 
The synthesis of 213 was undertaken. It is an analogue of amide 207, with an 
additional methylene group between the amide carbonyl and the 3,4-
dimethoxyphenyl ring. The insertion of a carbon here introduces a new tetrahedral 
center adjacent to the amide. This allowed a comparison to be made with 
sulfonamide 93. Amide 213 was synthesised with DCC as a coupling agent, as 
illustrated in Scheme 2.44. In the event, the reaction gave the amide 213 in poor 
yield, however, enough material was isolated for characterisation and enzyme 
assay. 
 
Scheme 2.45. Reagents and conditions: a) Pyridine, DCM, RT, 16 h. 
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The synthesis of sulfonamide 214 from 5-amino-1,2,4-oxadiazole 208 and sulfonyl 
chloride 137 proved unsuccessful, even after several attempts, changing the 
solvent and the reaction temperature. It would appear that the low nucleophilicity of 
amine 208 impeded successful coupling. 
 
 
Figure 2.14. Alternative sulfonamide 215.  
Sulfonamide 215 was prepared for structure activity comparison with the thiazole 
sulfonamides 93 and 135. As 5-amino-1,2,4-oxadiazole 208 did not react with 
sulfonyl chloride 137, a methylene group was introduced between the oxadiazole 
and the amine in a bid to improve the reaction with sulfonyl chloride 137. To ensure 
that any inhibition observed was due to the oxadiazole-sulfonamide motif all 
substituents from the aromatic rings were removed. If inhibition is observed, 
substitution could be reintroduced to increase inhibition.  
 
Scheme 2.46. Reagents and conditions: a) Hydroxylamine hydrochloride, K2CO3, MeOH, 80 ˚C for 4 h, then 
RT for 16 h, 32%. 
The synthesis of sulfonamide 215 began with the formation of phenyl amidoxime 
217, as illustrated in Scheme 2.46. Column chromatography gave enough material 
to proceed through the next steps. 
 
Scheme 2.47. Reagents and conditions: a) Boc2O, NaOH, 1,4-dioxane:H2O 1:1, RT, 8 h, 87%. 
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The amino acid glycine 218 gave the required functionality for formation of the 
amino-1,2,4-oxadiazole. Protection of the amine with the Boc protecting group 
allowed for a relatively easy future deprotection step. In the event glycine 218 was 
protected as its Boc carbamate in good yield, as illustrated in Scheme 2.47.  
 
Scheme 2.48. Reagents and conditions: a) DCC, DMAP, DCM, RT, 8 h, 32%; b) TBAF, THF, RT, 2 h, 75%; c) 
HCl in dioxane, DCM, RT, 2 h, 63%; d) pyridine, RT, 8 h, quant. 
Phenyl amidoxime 217 and Boc-protected glycine 219 were coupled to form O-acyl 
amidoxime 220, as illustrated in Scheme 2.48. Cyclisation of the O-acyl amidoxime 
220 with TBAF proceeded efficiently to give the desired 1,2,4-oxadiazole 221.  
Removal of the Boc group was accomplished under acidic conditions to give amine 
22 as its hydrochloride salt. With 222 in hand, attention focused on the synthesis of 
sulfonamide 215. This was successfully accomplished by dissolving the 1,2,4-
oxadiazole amine salt 222 in pyridine, followed by the addition of benzenesulfonyl 
chloride. Sulfonamide 215 was obtained in an excellent yield. 
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2.4 Enzymatic assays of first generation compounds against 
K3MO 
 
Compounds 120-122, 156, 159, 162, 164-165, 167, 173-176, 180, 193, 200, 207, 
213 and 215, shown in Figure 2.16, were assayed against bacterial K3MO from P. 
fluorescens (Dr Chris Mowat and Martin Wilkinson). A cell lysate containing the 
human form of K3MO was also used to assay this set of compounds (Dr Scott 
Webster and Miss Kris McGuire). K3MO from Pseudomonas fluorescens is a 
relatively stable enzyme, allowing for its ready isolation and purification. 
 
Scheme 2.49. Reaction catalysed by K3MO. 
The compounds were initially screened as solutions in DMSO using a single cell 
cuvette assay. By following the rate of change in the absorption of NADH (340 nm) 
the rate of the reaction could be observed. L-Kynurenine 3, NADPH and the 
inhibitor were all added to the assay buffer and left to equilibrate for approximately 
1 min. The volume of the DMSO solution added was adjusted to give a final DMSO 
concentration of 2% (v/v). A higher concentration of DMSO inhibits the enzyme 
reaction. K3MO was then added and the cuvette inverted to mix the solution. The 
change in absorbance at 340 nm was recorded for the initial linear period. The 
reaction was also run with neat DMSO several times as a control reaction. Each of 
the rates were then converted into percentages by comparison to the neat DMSO 
rate. This gave the percentage activity of the enzyme with the inhibitor and is 
quoted as a percentage inhibition by subtracting the activity from 100%.  
The best inhibitors were then subjected to further testing. Using the same setup for 
measuring the percentage inhibition, but varying the concentration of inhibitor and 
kynurenine, a Ki value was calculated. The rate of the reaction per molecule of 
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enzyme was then calculated. Dixon plots were used to calculate the Ki. Using this 
linear graphical method, the Ki is calculated by plotting 1/ν at each inhibitor 
concentration. In the case of competitive inhibition, these lines converge above the 
x-axis. For non-competitive binding, the lines converge on the x-axis.161, 162 Non-
linear regression was also used for the calculation of Ki.76 
 
Figure 2.15. (S)-[2,4,5,6,7-2H5]-Tryptophan 223 used as an internal standard in the human K3MO assay. 
Testing of the compounds against the human K3MO was achieved using a cell 
lysate of HEK293 cells (Dr Scott Webster and Miss Kris McGuire). The cells were 
transfected with the human K3MO gene. L-kynurenine 3, the inhibitors in DMSO 
and NADP were added to the lysate in 96-well plates. NADP is converted to 
NADPH in the assay by the addition of glucose-6-phosphate dehydrogenase. The 
volume of inhibitor solution added was kept constant to give a final DMSO 
concentration of 1% v/v. The solution was spiked with a known concentration of 
(2S)-[2,4,5,6,7-2H5]-tryptophan 223. Analysis of the lysate by LC-MS/MS and the 
area of the peak of 3-hydroxykynurenine 8 was compared to the D5-tryptophan 223 
peak to give a ratio. This was then compared to a standard curve of 3-
hydroxykynurenine 8/ D5-tryptophan 223 ratios to calculate how much 3-
hydroxykynurenine 8 was produced in each assay. Comparison with positive and 
negative controls allowed for the calculation of an IC50.163 
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Figure 2.16. A summary of all the compounds from this series that were tested against human and P. 
fluorescens K3MO. 
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Compounds K3MO activity 
% at 5 µM 
K3MO  activity 
% at 10 µM 
K3MO inhibition 
% at 10 µM 
 Ki (µM) 
120 99 - - - 
121 95 - - - 
122 100 - - - 
156 86 - - - 
159 99 - - - 
162 86 - - - 
164 95 - - - 
165 91 84 16 - 
167 - 100 - - 
173 - 104.7 ± 5.8 - - 
174 - 96.9 ± 2.2 3 - 
175 - 101.1 ± 2.5 - - 
176 - 97.6 ± 4.0 
 
2 - 
180 - 106.0 ± 6.3 - - 
193 - 85.1 ± 20.6 15 - 
200 - 85.6 ± 22.8 14 - 
207 82 68.0 ± 11.7 32 1.30 ± 0.21 
213 - 68.0 ± 11.7 32 1.82 ± 0.38 
215 - 97.9 ± 3.2 2 - 
Table 2.1. Enzymatic assay of selected compounds against P. fluorescens K3MO (Dr Chris Mowat, Martin 
Wilkinson, Helen Bell and Annemette Kjeldsen) 
Only amides 207 and 213 showed interesting activity against K3MO from P. 
fluorescens. Determination of the Ki of 207 and 213 was undertaken giving values 
of 1.30 ± 0.21 µM and 1.82 ± 0.38 µM, respectively. The Dixon plot used to 
calculate the Ki of 207 is shown in Figure 2.17. When the compounds were 
assayed against the human K3MO they showed little or no inhibition. 
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Figure 2.17. A Dixon plot obtained in the calculation of the Ki of 207. 
 
2.5 Conclusions 
 
A wide range of potential inhibitors of K3MO were prepared based on a 1,2,4-
oxadiazole motif. They were tested against bacterial and human K3MO. Amides 
207 and 213 showed the most promise with Ki’s of 1.3 µM and 1.8 µM respectively. 
Amide 207 bears a resemblance to the sulfonamide inhibitor 93 and has a similar 
Ki. With the heterocycle-aryl linker optimised as the amide, the substitution on the 
phenyl rings was next to be explored. This is discussed in the subsequent chapter. 
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Chapter 3 
The synthesis and development of 1,2,4-
oxadiazole amides as inhibitors of K3MO 
 
3.1 Synthesis and enzymatic assay of a first generation library of 
1,2,4-oxadiazole amides 
 
 
Figure 3.1. Lead compounds from structural activity relationship investigation (Chapter 1). 
Amides 207 and 213 proved to be the best inhibitors of P. fluorescens K3MO 
synthesised thus far, and establishment of structure activity relationships around 
this motif was targeted to develop more potent inhibitors. Therefore, a small library 
of amides was envisaged, changing the substituents on both phenyl rings. It is 
known that nitro groups give toxic and mutagenic properties to compounds164-166 so 
the meta nitro group was removed in this phase of development. A first series 
involved changing the substituents on phenyl ring A of 207 and keeping phenyl ring 
B unsubstituted. A second series involved introducing the 3,4-dimethoxy 
substitution into ring B. 
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Figure 3.2. The selected substitution for phenyl ring A. 
Substitutions were made predominately at the 3-position, as illustrated in Figure 
3.2. Analogue 224g was included in the library to explore the regiochemistry of 
substitution as an alternative to 224e and 224f. The 3,4-dichloro substitution was 
chosen, as it had already shown good inhibition e.g 84 (Chapter 1). The synthesis 
of the amides followed a similar route to that previously used in the synthesis of 
207 and 213 (Chapter 2). 
 
Scheme 3.1. Reagent and conditions: a) NH2OH.HCl, NaOAc, acetonitrile:water, 2:1, 60-88%; b) sodium 
hypochlorite solution 1.6 M, DCM; c) cyanamide, Et3N, 50-76%. 
Formation of oxime intermediates 226a-i, using hydroxylamine hydrochloride and 
sodium acetate, was accomplished in good yield for all the substitutions except for 
the 3-methoxy derivative 226i, as illustrated in Scheme 3.1. The 3-methoxy 
derivative 226i was a liquid and was, therefore, purified by distillation. The 
trifluoromethyl derivative 226c was purified by removing excess 3-
(trifluoromethyl)benzaldehyde 225c through distillation under reduced pressure. 
  97 
Upon cooling, the residue solidified and was characterised as a white solid. In 
order to obtain clean oximes it was important to neutralise all of the acetic acid that 
had formed in the reaction. This was accomplished using sodium bicarbonate. The 
addition of decolourising charcoal also helped remove any coloured contaminants 
from the products. 
The oximes 226a-i were transformed into the corresponding 5-amino-1,2,4-
oxadiazoles 224a-i by 1,3-dipolar cycloaddition of the corresponding nitrile oxides 
and cyanamide (Scheme 3.1). 5-Amino-1,2,4-oxadiazoles 224a-i, were furnished in 
moderate to good yield using the protocol developed for 5-amino-1,2,4-oxadiazole 
208 (Chapter 2). In an alteration to the purification of 208, 5-amino-1,2,4-
oxadiazoles 224a-i were recrystallised from ethanol and water. This made their 
purification quicker and easier, as they had a tendency to precipitate on the column 
bed. 
 
Scheme 3.2. Reagents and conditions: a) DCC, DMAP, DCM or acetonitrile, RT, 8 h, 12-63%. 
The amides 228-236 were prepared in poor to moderate yields through a DCC 
coupling, as illustrated in Scheme 3.2. In all cases, sufficient material was prepared 
for assays against the human and P. fluorescens K3MO enzymes. 
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Scheme 3.3. Reagents and conditions: a) DCC, DMAP, DCM, RT, 8 h, 12-63%; b) EDCI, DMAP, DCM, RT, 
8 h, 18-76%. 
The 3,4-dimethoxy substitution targeted in series 2 was achieved by using 3,4-
dimethoxy benzoic acid, as illustrated in Scheme 3.3. For 3-phenyl-5-amino-1,2,4-
oxadiazole 238, DCC and DMAP was used to prepare the amide in moderate yield. 
However, for the alternative substitutions on phenyl ring A 239-246, the 
dicyclohexyl urea side product co-eluted with the product during flash column 
chromatography, complicating the purification. Although the majority of the urea 
was removed from the reaction by filtration, some still remained in solution. 
Accordingly, EDCI was employed as a coupling agent. EDCI generates a water-
soluble urea, allowing for easy removal of the urea through dilute aqueous acid 
washes. The remaining amide couplings with EDCI gave poor to good yields of the 
amides. Again, enough material was obtained for assays against both the human 
and P. fluorescens K3MO enzymes. 
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Compound R1 R2 R3 R4 
Bacterial activity (as 
a % of uninhibited 
enzyme) at 10 µM 
Bacterial Ki 
(µM) 
228 H H H H 89.7 ± 9.5 19.99 ± 3.59 
229 Me H H H 91.6 ± 9.6 - 
230 CF3 H H H 78.8 ± 14.8 - 
231 F H H H 106.4 ± 3.9 - 
232 Cl H H H 86.5 ± 18.2 2.77 ± 0.43 
233 Br H H H 88.2 ± 8.4 1.58 ± 0.20 
234 H Br H H 87.2 ± 10.1 - 
235 Cl Cl H H 13.1 ± 8.7 0.11 ± 0.01 
236 OMe H H H 97.7 ± 10.8 - 
238 H H OMe OMe 94.6 ± 4.6 - 
239 Me H OMe OMe 98.3 ± 10.8 - 
240 CF3 H OMe OMe 63.5 ± 18.2 - 
241 F H OMe OMe 97.3 ± 12.2 1.06 ± 0.30 
242 Cl H OMe OMe 47.1 ± 16.9 0.78 ± 0.05 
243 Br H OMe OMe 36.9 ± 17.1 1.33 ± 0.08 
244 H Br OMe OMe 52.4 ± 16.7 - 
245 Cl Cl OMe OMe 6.5 ± 2.7 0.14 ± 0.02 
246 OMe H OMe OMe 83.7 ± 14.0 - 
Table 3.1. Table showing %inhibition and Ki against K3MO from P. fluorescens (Dr Chris Mowat, Martin 
Wilkinson, Helen Bell and Annemette Kjeldsen) 
The data in Table 3.1 reports the bacterial K3MO assay using a plate reader and 
carried out in triplicate. There is a clear pattern; the 3,4-dichloro substitution 235 
and 245 provided the best inhibition. The incorporation of the 3,4-dimethoxy 
substitution to phenyl ring B also increased the inhibition of K3MO. Ki values were 
determined through the use of a Dixon-plot or by non-linear regression. The Dixon 
plots showed that the amides were acting as competitive inhibitors of K3MO. 
The compounds showed little or no inhibition against the human enzyme. 
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Scheme 3.4 Reagents and conditions: a) Acetic anhydride, DMAP, DCM, RT, 16 h, 81%; b) 
cyclohexylcarbonyl chloride, DMAP, DCM, RT, 16 h, 84%. 
The 3,4-dichloro substitution on phenyl ring A gave the best assay results (see 
Table 3.1). Thus, two compounds were prepared; removing the benzoate amide 
ring B and replacing it with either an acetamide or a cyclohexyl carboxamide. The 
acetamide was generated by reacting 5-amino-1,2,4-oxadiazole 224h with acetic 
anhydride and this gave acetamide 247 in good yield, as illustrated in Scheme 3.4. 
Cyclohexyl amide 248 was prepared using cyclohexylcarbonyl chloride, also in 
good yield.  
 
Figure 3.3. % Inhibition values against K3MO from Pseudomonas fluorescens for the 247 and 248 compared 
to 235. 
Enzymatic inhibition of the amides with P. fluorescence K3MO in a single cell 
cuvette assay gave percentage inhibition values, as illustrated in Figure 3.3. 
Acetamide 247 has a Ki of 1.99 µM. The cyclohexyl amide 248 proved to be a 
better inhibitor than acetamide 247. However, neither were as potent as 235, the 
original compound with the phenyl group. 
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3.2 Protein X-ray crystallography of first generation amides with 
P. fluorescens K3MO 
 
Figure 3.4. The crystal structure of Pseudomonas fluorescens K3MO with 235 bound in the active site 
Co-crystallisation of the two most potent amides 235 and 245 with P. fluorescens 
K3MO was successfully achieved by our collaborators (Martin Wilkinson and Dr 
Chris Mowat, University of Edinburgh).76 A crystal structure was obtained with 235 
bound into the active site at a resolution of 2.18 Å. There are three non-equivalent 
protein molecules in the unit cell. Overlays of the three separate molecules showed 
there were small conformational changes in the side chains, however, the 
conformational changes were minor and presumably reflect the dynamic nature of 
the protein. 
  102 
 
Figure 3.5. X-Ray studies of the active site and the orientation of the 3,4-dichlorophenyl ring and through 
space distance from the flavin co-factor. Distance is in (Å). 
Examination of the crystal structure reveals that the 3,4-dichloro amides bind well 
into to the active site. The orientation of the 3,4-dichloro phenyl ring has the 3-
chlorine atom orientated away from the FAD, into a hydrophobic pocket. Although 
the 5-H of the 3,4-dichloro ring appears to be in the correct orientation for 
oxidation, it is not oxidised by the FAD in the assays. 
             
Figure 3.6. Representation of the Van der Waals surface as a wire mesh to show the hydrophobic pocket in 
the active site of K3MO. 
The 3,4-dichloro phenyl ring sits in a hydrophobic pocket. This pocket is flanked by 
the flavin on one side. The side chains of Phe-238 and 319, Leu-213 and 226, Ile-
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215 and 224 and Ala-225 modulate the shape of the hydrophobic pocket (Figure 
3.6). The hydrophobic pocket is just large enough to accept both chlorine atoms. 
 
Figure 3.7. Interaction of the hydroxylamine portion of the 1,2,4-oxadiazole ring of 235 with the hydrophilic 
pocket. The surface shown is the Van der Waals surface. Distances are in (Å). 
The 1,2,4-oxadiazole ring sits in a hydrophilic pocket of the active site (Figure 3.7). 
It makes potential hydrogen bonding contact with a water molecule, which is  
potentially stabilised by hydrogen bonding to the main chain amide of Gly-321. The 
second hydrogen atom of the water molecule prospeculatively sits almost 
equidistant between the nitrogen and oxygen of the 1,2,4-oxadiazole ring and 
appears to make a hydrogen bond to either the nitrogen or oxygen atoms of the 
ring (Figure 3.8). 
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Figure 3.8. A) A graphical representation of the speculative hydrogen bonding between K3MO and 235 B) 
PyMol167 representation of the interaction between the water molecule, the 1,2,4-oxadiazole of 235 and K3MO. 
 
 
Figure 3.9. Co-crystallisation of amide 235 showing polar interactions in the active site. 
The 1,2,4-oxadiazole amide carbonyl may make hydrogen bonding interactions 
with a bound water molecule, which is held in place by Asn-369 and the main chain 
amide of His-320 and Phe-319. This water molecule speculatively forms hydrogen 
bonds to the carbonyls of amide 235 and Asn-369. The water molecule could also 
act as a hydrogen bond acceptor, forming a hydrogen bond (2.8 Å), to the 
hydrogen of the main chain amide between His-320 and Phe-319. Asn-369 forms a 
A B 
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hydrogen bond (3.1 Å) to the carbonyl of 235.  The nitrogen on amide 235 makes a 
relatively short hydrogen bond (2.5 Å) to Tyr-404 (Figure 3.9). 
 
Figure 3.10. Short contacts suggest evidence for a π-cation interaction between 235 and Arg-84. 
The co-crystal of 235 with the bacterial enzyme revealed that the nitrogens in the 
side chain of Arg-84 are all within 4 Å of the phenyl ring (Figure 3.10). The parallel 
orientation of the phenyl ring and Arg-84 suggests that there is a π-cation 
interaction between the phenyl ring and the guanadinium cation.168 Such an 
interaction cannot occur to acetamide 247 or cyclohexylamide 248.  
It appears that the entire molecule contributes to the strong binding to the active 
site. The Van der Waals surface around the amide indicates that the active site 
prefers the flat motif of the amide compared to the tetrahedral sulfonamide, 
possibly explaining why the sulfonamides 93 and 135 (from Chapter 2) are not as 
potent against the bacterial enzyme. 
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Figure 3.11. The disorder in the co-crystal of 245 and P. fluorescens K3MO arise due to the various different 
orientations of the 3,4-dimethoxy phenyl ring. 
Co-crystals were also obtained with 245 bound in the active site of K3MO.76 A 
structure at 2.25 Å resolution was achieved and is shown in Figure 3.11. There is 
again some disorder around the 3,4-dimethoxy phenyl ring, probably due to the 
active site opening up and allowing the phenyl ring to rotate. 
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3.3 Synthesis and K3MO enzyme assays of a second generation 
series of 1,2,4-oxadiazole amides 
 
 
Figure 3.12. First generation lead compound 245 and the compounds 249 and 250, targeted as second 
generation inhibitors. 
A next generation of compounds was designed to address two objectives. The first 
was to increase water solubility, as the first generation compounds were highly 
lipophillic. The second was to exploit polar interactions with residues located near 
to the binding of the phenyl ring B. In this context, the introduction of a phosphate 
group at the 3- or 4- positions, such as 250, may accomodate such polar 
interactions, particularly to Arg-84. Additionally, it was envisaged that the methoxyl 
ethers could be converted to the corresponding phenols, such as 249, to possibly 
make polar interactions in the active site. 
 
Scheme 3.5. Reagents and conditions: a) MeOH, concentrated H2SO4, 80 ˚C, 4 h, 89%. 
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3,4-Dihydroxybenzoic acid was converted to its methyl ester 252 in good yield, as 
illustrated in Scheme 3.5, using the method of Kita et al. 169 
 
Scheme 3.6. Reagents and conditions: a) TBSCl, imidazole, 0 ˚C to RT, 16 h, 77%; b) TBSCl (1.1 eq), DIPEA, 
DMF, 0 ˚C, 20 min, 31%. 
Reaction of 3,4-dihydroxybenzoate ester 252 with TBSCl (2.25 eq) and imidazole 
gave the di-protected benzoate ester 253 in good yield, as illustrated in Scheme 
3.6. Selective protection at the 4-hydroxyl position of 252 was achieved using 
TBSCl and Hünig’s base at 0 ˚C for 20 min. Careful control of the reaction time was 
critical in achieving selective protection at this site. Longer reaction times gave 
more of the di-protected product 253 and shorter reaction times resulted in low 
yields. The yield of product 254 was low, due to a low conversion within the short 
reaction time. The 2D HMBC spectrum (Figure 3.13) confirmed the regiochemistry 
and showed that the hydroxyl proton is coupled to carbons 3,4 and 5.  
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Figure 3.13. 2D 1H-13C HMBC spectrum of 254 showing coupling of the phenol proton to carbons 3,4 and 5. 
 
Scheme 3.7. Reagent and conditions: a) NaH, diethyl chlorophosphate, THF, 0 ˚C to 4 ˚C, 16 h, 71%. 
Formation of the phosphate ester 255 at the 4- position was achieved by reaction 
of phenol 254 with sodium hydride and diethyl chlorophosphate in good yield, as 
illustrated in Scheme 3.7.170  
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Scheme 3.8. Reagents and conditions: a) NaOH, MeOH, RT, 16 h; b) porcine pancreatic lipase, H2O, DMSO, 
38 ˚C, 72 h. 
Hydrolysis of the methyl ester moieties of 253 and 255 failed under basic 
conditions. In both cases, even with a careful acidic workup, the TBS protecting 
group was removed, but the methyl ester remained. 
An alternative protecting group for the carboxylic acid was required. The benzyl 
ester was chosen as it can be removed under neutral conditions by hydrogenation 
to give the parent carboxylic acid. 
 
Scheme 3.9. Reagents and conditions: a) Cs2CO3, BnBr, DMF, RT, 16 h, 44%. 
The benzyl ester 258 was formed using caesium carbonate and benzyl bromide, as 
illustrated in Scheme 3.9. The yield for the reaction was poor in comparison to that 
previously reported.171 This was, in part, due to the difficulty of keeping the 
caesium salt in solution. Initially, deprotonation was carried out in an aqueous 
methanol solution. Removal of the aqueous solvent gave a solid, which was 
suspended in DMF. However, the solid did not dissolve as the reaction progressed 
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and thus, both steps were undertaken in DMF. This gave slightly better yields of 
benzyl ester 258. The 2D HMBC confirmed the regiochemistry of 258. 
 
Figure 3.14. 2D 1H-13C HMBC spectrum of 258 showing the coupling from C-8 to C-7, proving protection of the 
carboxylic acid as the benzyl ester. 
 
 
Scheme 3.10. Reagents and conditions: a) TBSCl (1.1 eq), DIPEA, DMF, 0 ˚C, 20 min; b) TBSCl, imidazole, 
DMF, 50 ˚C, 2 h, 90%. 
Selective protection of phenol 258 was unsuccessful and the two regioisomers 
were inseparable by column chromatography. Full protection of benzyl ester 258 
provided 260 through the use of TBSCl and imidazole at 50 ˚C, as illustrated in 
Scheme 3.10.  
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Scheme 3.11. Reagents and conditions: a) Pd black, H2, MeOH, RT, 36 h, 45%. 
Under hydrogenation conditions Pd/C has been shown to cleave TBS protecting 
groups.172 It has been proposed that such unexpected deprotections are due to 
residual acid or PdCl2 that are contaminants from the production of Pd/C. By using 
palladium black these potential problems were avoided. Cleavage of the benzyl 
ester 260, as illustrated in Scheme 3.11, was accomplished in moderate yield and 
purification of the acid 261 by recrystallisation proved to be straightforward. 
 
Scheme 3.12. Reagents and conditions: a) EDCI, DMAP, DCM, RT, 16 h, 30%; b) TBAF, THF, RT, 30 min, 
85%. 
With the di-protected carboxylic acid 251 in hand, amide 262 was synthesised 
using EDCI as the coupling agent, as illustrated in Scheme 3.12. Although the yield 
for the reaction was poor, enough material was obtained for characterisation and to 
achieve the final deprotection step. 
Silyl deprotection of amide 262 with TBAF proceeded in good yield to give catechol 
249, however, purification of the product by column chromatography proved to be 
difficult due to the polar nature of the catechol. 
  113 
 
Scheme 3.13. Reagents and conditions: a) Cs2CO3, BnBr, DMF, RT, 16 h, 80%; b) Cs2CO3, BnBr, DMF, RT, 
16 h, 83%. 
Benzyl esters 265 and 266 were prepared from the benzoic acids 263 and 264, 
respectively, using caesium carbonate and benzyl bromide, as illustrated in 
Scheme 3.13. 2D HMBC analysis showed cross-peaks between the carbonyl of the 
ester and the CH2 of the benzyl group in both 265 and 266, confirming that the 
benzyl ester rather than the benzyl ether had formed (Figures 3.15 and 3.16). 
 
Figure 3.15. 2D 1H-13C HMBC spectrum of 266 showing the coupling between H-8 and C-7. 
266 
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Figure 3.16. 2D 1H-13C HMBC spectrum of 265 showing the coupling between H-8 and C-7. 
 
 
Scheme 3.14. Reagents and conditions: a) Sodium hydride, diethyl chlorophosphate, THF, 0 ˚C to 4 ˚C, 16 h, 
92%; b) sodium hydride, diethyl chlorophosphate, THF, 0 ˚C to 4 ˚C, 16 h, 80%; c) Pd/C, H2, EtOAc, RT, 48 h, 
68%; d) Pd black, H2, EtOAc, RT, 48 h, 56%. 
265 
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Diethyl chlorophosphate were reacted with 265 and 266 in the presence of sodium 
hydride to generate the diethyl phosphates 267 and 268 in good yield, as illustrated 
in Scheme 3.14.  
Deprotection of benzyl ester 267 using Pd/C, under a positive pressure of 
hydrogen, gave the benzoic acid 269 in good yield, as illustrated in Scheme 3.14. 
This product could easily be purified by recrystallisation from ethanol and water. 
Deprotection of benzyl ester 268 to give 270 was achieved using palladium black. 
The more reactive palladium black was no better than Pd/C for this deprotection. 
Recrystallisation of product 270 was unsuccessful, therefore, the product was 
purified by flash column chromatography, although the yield was compromised. 
 
 
Scheme 3.15. Reagents and conditions: a) EDCI, DMAP, DCM, RT, 22 h, 49%; b) EDCI, DMAP, DCM, RT, 
22 h, 85%. 
With the benzoic acids 269 and 270 in hand, attention turned to forming amides 
271 and 272, as illustrated in Scheme 3.15. These amides were formed in 
moderate to good yield through EDCI coupling reactions with amine 224h. 
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Scheme 3.16. The proposed mechanism for ethyl deprotection. 
Deprotection of diethyl phosphates has been achieved using TMSBr173, 174 and 
TMSI, 175 a reaction which gives the disilylphosphate 279 as an intermediate. This 
intermediate is then hydrolysed in the work up to give the free phosphate, as 
illustrated in Scheme 3.16. 
 
Scheme 3.17. Reagents and conditions: a) TMSI, CDCl3, RT, 1 h, then H2O and MeOH. 
TMSI rather than TMSBr was used for the deprotection of 271 and 272 as it had 
been reported as a milder method (Scheme 3.17). The deprotection was carried 
out in deuterated chloroform, which aided monitoring of the reaction directly by 1H 
and 31P NMR. 
The 1H NMR spectrum of the reaction showed the presence of ethyl iodide. The 
31P NMR spectra showed that the diethyl phosphate peak disappeared and two 
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new peaks appeared at -13.5 and -24.2 ppm, which reasonably correspond to the 
monosilyl and disilyl phosphates respectively. After hydrolysis with water/MeOH 
attempts were made to purify the product. However, the products 273 and 274 
could not be obtained after either recrystallisation or flash column chromatography. 
 
 
Compound R1 R2 Bacterial KI (nM) 
245 OMe OMe 136.4 ± 16.7 
249 OH OH 66.7 ± 17.8 
271 OPO(OEt)2 OMe 46.8 ± 7.6 
272 OMe OPO(OEt)2 65.5 ± 7.5 
Table 3.2. Inhibition data for 245, 249, 271 and 272 (Dr Chris Mowat, Martin Wilkinson, Helen Bell and 
Annemette Kjeldsen) 
Although the free phosphates 273 and 274 proved elusive, 249, 271 and 272 were 
subject to assay against both bacterial and human K3MO enzymes. The change 
from the dimethoxy ether 245 to the phenol 249 provided better inhibition against 
the bacterial enzyme. Both diethyl phosphate compounds 271 and 272 are even 
better inhibitors than 245. Calculation of the Ki was achieved using non-linear 
regression, from the single cell cuvette assay. This gave Ki values of 46.8 nM and 
65.5 nM for 271 and 272, respectively. The Dixon plot for 272 is shown in Figure 
3.17. 271 binds to bacterial K3MO approximately three times better than 245 which 
has a Ki of 136 nM. The Dixon plots show that 249, 272 and 273 are competitive 
inhibitors of K3MO. The compounds showed little or no inhibition at 10 µM against 
human K3MO. 
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Figure 3.17. A Dixon plot obtained for competitive inhibitor 272 against P. fluorescens K3MO. 
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3.4 Protein X-ray crystallography of second generation amides 
with P. fluorescens K3MO 
 
Figure 3.18. The crystal structure of P. fluorescens K3MO with 271 bound in the active site. 
A co-crystal structure, at a resolution of 2.40 Å, was obtained with 271 bound into 
the active site of K3MO from P. fluorescens, as illustrated in Figure 3.18 (Dr Chris 
Mowat and Martin Wilkinson, Edinburgh University).76 There are three non-
equivalent protein molecules in the unit cell. This is due to changes in the 
orientation of the amino acid side chains. The large void at the entrance to the 
active site allows the diethyl phosphate substituted phenyl ring to change its 
orientation, creating three “snapshots” of how the inhibitor is bound. Changes 
between the three structures are minor and the key interactions are homologous. 
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Figure 3.19. Comparison of the crystal structures with 235 and 271 bound in the active site. Inhibitor 271 
(yellow) has a different binding mode to 235 (blue) 
Alignment of the co-crystal structure of P. fluorescens K3MO with 235 (blue) and 
271 (yellow) allows comparisons of the two binding modes. The 3,4-dichloro phenyl 
ring orients similarly for both 235 and 271. However, the orientation of the amide 
changes by almost 180 degrees (Figure 3.19). Such a change allows the diethyl 
phosphate to orientate into free space. It also allows the phosphate to interact with 
Arg-84. The change in orientation of the amide means that the inhibitor is closer to 
the left-hand side of the active site moving the 1,2,4-oxadiazole ring further into the 
hydrophilic pocket. 
235 
271 
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Figure 3.20. A view of the hydrophilic pocket with 271 bound in the active site and the interactions of the 1,2,4-
oxadiazole and the amide carbonyl with the hydrophilic pocket. Distances are in (Å). 
One of the benefits of the alternative binding mode of 271 is that it allows the 
amide carbonyl to interact with the hydrophilic pocket. The amide carbonyl is 3.1 Å 
from a water molecule, which is in the correct range for a hydrogen bonding 
interaction, as illustrated in Figure 3.20. The amide carbonyl is further stabilised in 
this orientation by a hydrogen bond (2.8 Å) to Thr-408, as illustrated in Fig. 3.21. 
 
 
Figure 3.21. Angles and distances between the oxygen atom of the 1,2,4-oxadiazole ring, the inhibitor 
carbonyl and the main chain amides of P. fluorescens K3MO. Distances are in (Å). 
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Figure 3.22. An overlay of K3MO (green) with 235 (blue) bound and K3MO (pink) when 271 (yellow) bound 
and the movement of Tyr-404 that is cause by the different binding mode of 271. 
The alternative orientation of the amide affects the orientation of the Tyr-404 side 
chain in the active site. With both substrate and 235 co-crystals, Tyr-404 adopts 
the orientation shown in green. In the co-crystal with 235 there is a hydrogen bond 
between the amide NH and the tyrosine OH, which stabilises this orientation. 
However, with 271, the change in amide orientation forces the phosphate phenyl 
ring to sit in the space that is occupied by Tyr-404 in the co-crystal with 235. This 
produces a change in orientation of the tyrosine side chain away from the 
diethylphosphate phenyl ring. The orientation of Tyr-404 in the co-crystal of 271 is 
stabilised by a hydrogen bond (3.1 Å) to Glu-372. 
235 
271 
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Figure 3.23. A) Interactions of 271 with some of the polar residues and water in the active site visualised with 
PyMol.167 Distances are in (Å); B) A simplified representation of the interactions of the diethyl phosphate, 
amide NH and the 4-N of the 1,2,4-oxadiazole and bound water molecules. 
The phosphate 271 interacts with the side chain of Arg-84 and potentially forms a 
hydrogen bond (2.7 Å) to water molecule 748. A speculative hydrogen bonding 
network is formed by water molecules-748, 935, 392 and 750, the side chains of 
Arg-84, Tyr-98 and Asp-369, the amide nitrogen of 271 and a nitrogen atom in the 
1,2,4-oxadiazole of 271. The amide NH of 271 possibly makes a relatively short 
hydrogen bond (2.7 Å) to water 392. This speculative hydrogen-bonding network 
appears to stabilise 271 in the active site. (Figure 3.23) 
A B 
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Figure 3.24. Bond angles in the speculative hydrogen bonding network suggests the locations of the water 
hydrogen atoms are found on the angle lines. 
 
 
Figure 3.25. The crystal structure of Pseudomonas fluorescens K3MO with 272 bound in the active site. 
A co-crystal structure, at a resolution of 2.30 Å, was obtained with 272 bound into 
the active site of K3MO from P. fluorescens, as illustrated in Figure 3.25 (Dr Chris 
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Mowat and Martin Wilkinson Edinburgh University).76 Again, there are three non-
equivalent  protein molecules in the unit cell. 
  
 
 
  
Figure 3.26. Comparison of the crystal structures with 235 and 272 bound in the active site. 272 (yellow) has a 
similar binding mode for the amide as 235 (blue). 
Allignment of the co-crystal structures with 235 (blue) and 272 (yellow) allows 
comparisons of the different binding modes (Figure 3.26). The 3,4-dichloro 
substituted phenyl ring binds in the same orientation in both cases. In contrast to 
the crystal structure with 271 bound at the active site, the amide of 272 has a 
similar orientation to the amide of 235. 
235 272 
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Figure 3.27. The Van der Waals surface of the active site and 272 showing the phosphate group orientating 
itself into space. 
Addition of the Van der Waals surface to the protein structure helps rationalise why 
an alternative orientation of the phenyl ring is adopted (Figure 3.27). The phenyl 
ring is not able to form a π-cation interaction with Arg-84 as found with 235. This 
alternative orientation allows the diethyl phosphate to sit in space because the 
phenyl ring has moved towards the left hand side of the active site. The interaction 
of the 1,2,4-oxadiazole with the hydrophilic pocket is nearly identical to that 
observed for 235. The amide also makes similar interactions to that found for 235. 
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Figure 3.28. An overlay of K3MO with 272 (blue) bound and K3MO when 271 (yellow) bound and the 
movement of Tyr-404 to an orientation that has not previously been observed. Distances are in (Å). 
Interestingly, when 272 (in blue) was bound into the active site, the side chain of 
Tyr-404 rotates by approximately 180 degrees. It is not clear why Tyr-404 adopts 
this orientation relative to that found for 271. It is possible that the two phenyl rings 
come too close together and the relative orientations make π-π stacking difficult. 
Without any stabilising interactions the tyrosine simply moves into free space 
(Figure 3.28 and Figure 3.29). 
272 271 
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Figure 3.29. Tyr-404 moves into free space to avoid any clashes with 272, in the active site of K3MO. 
The co-crystals of 271 and 272 provide important information for the development 
of next generation inhibitors. Both 271 and 272 are accepted into the active site, 
although they employ different binding modes. It is clear from the inhibition data 
that 271 is a stronger binder than 272. This is presumably due the fact that the 
binding orientation allows the phosphate to come in close contact with Arg-84 and 
allow additional electrostatic interaction in the hydrophilic pocket.  
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3.5 Synthesis and assay of a third generation series of 1,2,4-
oxadiazole amides 
With the diethyl phosphates 271 and 272 showing excellent inhibition of the 
bacterial enzyme, the synthesis of some derivatives was undertaken to progress a 
third generation of compounds. 
 
Figure 3.30. Comparison between the second generation compound 271 and the third generation compounds 
containing phosphate bioisosteres. 
Replacement of the diethylphosphate group of 271 with phosphate bioisosteres, 
namely a sulfamate 281 and a carboxylic acid 282, was explored.176  The methyl 
and ethyl esters 283 and 284 were included in the series as the parent carboxylic 
acids are ionised at physiological pH, preventing the molecule from passing 
through cell membranes. The esters are potentially prodrugs for the carboxylic 
acid.177 However, sulfamates, unlike carboxylic acids, are able to cross cell 
membranes. With a pKa of 15.6 methyl sulfamate is not ionised under 
physiological conditions.176   
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Scheme 3.18. Reagents and conditions: a) TBSCl, imidazole, DCM, RT, 16 h, 97%; b) TBSCl, imidazole, 
DCM, RT, 16 h, 84%; c) Pd black, H2, MeOH, RT, 72 h, 34%; d) Pd black, H2, MeOH, RT, 72 h, 82%. 
The planned route for introduction of the sulfamate was to incorporate the 
functionality in the final step. The phenol required for sulfamate incorporation 
requires protection during the amide formation step. Protection of the phenol as a 
TBS ether, allowed for a facile deprotection post amide formation. Protection of the 
phenols 265 and 266 was accomplished using TBSCl and imidazole, to give 285 
and 286 in good yield, as illustrated in Scheme 3.18. 
Hydrogenation of the benzyl esters 285 and 286 gave benzoic acids 287 and 288 
in moderate to good yields, as illustrated in Scheme 3.19. Carboxylic acids 287 
and 288 were not amenable to recrystallisation, thus column chromatography was 
used to purify them. 
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Scheme 3.19: Reagents and conditions: a) EDCI, DMAP, DCM, RT, 16 h, 52%; b) EDCI, DMAP, DCM, RT, 
16 h, 51%. 
The carboxylic acids 287 and 288 were reacted with 224h using EDCI as the 
coupling agent to give amides 289 and 290, as illustrated in Scheme 3.19. Both 
amides 289 and 290 required two sequential purifications by flash column 
chromatography to obtain clean products.  
 
 
Scheme 3.20. Reagents and conditions: a) TBAF, THF, RT, 30 min, 58%; b) TBAF, THF, RT, 30 min, 68%. 
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Deprotection of amides 289 and 290 using TBAF gave the phenols 291 and 292, 
respectively, in moderate yields (Scheme 3.20). However, enough material was 
obtained for characterisation, preparation of the sulfamates and for enzymatic 
assay. 
  
Scheme 3.21. Reagents and conditions: a) HCO2H, DCM. 
The incorporation of the sulfamate group is generally undertaken through the 
reaction of an alcohol with sulfamoyl chloride. The sulfamoyl chloride can be 
produced by the acid mediated decomposition of isocyanate 293 to give a solution 
of 294 in DCM (Scheme 3.21).178 This was stored and used without any further 
purification as a 1 M solution of 294 in DCM. 
 
Scheme 3.22: Reagents and conditions: a) Sulfamoyl chloride (1 M in DCM), DMA, 0 ˚C to RT, 16 h, 87%; 
b) sulfamoyl chloride (1 M in DCM), DMA, 0 ˚C to RT, 16 h, 61%. 
Sulfamoylation of the phenols 291 and 292 following the procedure developed by 
Okada et al. 179 was undertaken. In that protocol, DMA was used as the solvent. 
The reaction proceeded well to give the sulfamates 281 and 293 in good yield, as 
illustrated in Scheme 3.22.  
 
  133 
 
Scheme 3.23: Reagents and conditions: a) Allyl bromide 294, K2CO3, DMF, 50 ˚C, 3 h, quant.; b) CrO3, 
H2SO4, acetone, H2O, 0 ˚C to RT, 3 h, 44%. 
The planned synthesis for the carboxylic acid 282 involved a late stage RuO4 
oxidative cleavage of a double bond. However, the presence of the double bond at 
this stage ruled out hydrogenation of a benzyl ester, so oxidation of the aldehyde to 
the carboxylic acid was investigated. Synthesis of benzaldehyde 296 was achieved 
using allyl bromide 294 in the presence of potassium carbonate, as illustrated in 
Scheme 3.23.180 Chromate oxidation of aldehyde 296 to benzoic acid 297 worked 
in moderate yield, as illustrated in Scheme 3.23, following a modified procedure of 
that used by Koning et al.180  
 
Scheme 3.24. Reagents and conditions: a) EDCI, DMAP, DCM, RT, 16 h, 80%. 
Amide 298 was then prepared using EDCI as a coupling agent in good yield, as 
illustrated in Scheme 3.24.  
 
Scheme 3.25. Reagents and conditions: a) RuCl3, NaIO4, CCl4, MeCN, H2O, RT, 16 h. 
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Oxidation of the allyl group of 298 to give the carboxylic acid 282 was attempted 
using the RuO4 method developed by Sharpless et al.181 However, the published 
procedure did not afford any carboxylic acid. The major product, isolated after flash 
column chromatography, still had the allyl group intact. 
 
Scheme 3.26. Reagents and conditions: a) K2CO3, ethyl bromoacetate 299, DMF, 60 ˚C, 3 h, 96%; b) Pd/C, 
H2, MeOH, RT, 48 h, 60%. 
With the failure of the ruthenium oxidation, focus switched to the synthesis of the 
ethyl and methyl esters. The esters could clearly be hydrolysed to give the desired 
carboxylic acid. Ester 300 was prepared using ethyl bromoacetate 299 and benzyl 
ester 265 following a modified procedure used by Shah et al.182 Heating the 
mixture at 60 ˚C for 3 h gave 300 in an excellent yield, as illustrated in Scheme 
3.26. 
The benzyl ester moiety of 300 was then deprotected using hydrogenation to give 
the benzoic acid 301 in good yield, as illustrated in Scheme 3.26. The product 
could be purified by recrystallisation or by flash column chromatography. 
Recrystallisation proved to be the preferred method of purification. 
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Scheme 3.27. Reagents and conditions: a) K2CO3, methyl bromoacetate 302, DMF, 60 ˚C, 3 h, 88%; b) Pd/C, 
H2, MeOH, RT, 48 h, 71% 
In a similar manner to that used to produce 300, methyl bromoacetate 302 and 
benzyl ester 265 were reacted at 60 ˚C for 3 h, as illustrated in Scheme 3.29. 
Product 303 was recovered in good yield. Palladium-catalysed hydrogenation of 
benzyl ester 303 generated benzoic acid 304 in good yield, as illustrated in 
Scheme 3.27. The product was not amenable to recrystallisation and so 
purification of the carboxylic acid was carried out by flash chromatography. Due to 
the polar nature of the compound 5% MeOH in DCM was required to elute the 
compound on silica.  
 
Scheme 3.28. Reagents and conditions: a) EDCI, DMAP, DCM, RT, 16 h, 75%; b) EDCI, DMAP, DCM, RT, 
16h, 74%. 
With benzoic acids 301 and 304 in hand, focus turned to forming amides 283 and 
284. The amides were formed in good yield using EDCI as the coupling agent, as 
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illustrated in Scheme 3.28. Purification of methyl ester 283 by flash 
chromatography proved difficult, due to its poor solubility. Ethyl ester 284 was 
purified by recrystallisation form ethanol. 
 
Scheme 3.29. Reagents and conditions: a) NaOH, H2O, THF, RT, 1 h, then HCl solution, 61%. 
Hydrolysis of methyl ester 283 to the corresponding carboxylic acid 282 was 
carried out under basic conditions in a sodium hydroxide solution (Scheme 3.29). 
THF was added to aid the dissolution of the ester and the product was isolated 
after neutralisation. 
 
 
Figure 3.31. Third generation compounds tested against both human and bacterial K3MO. 
Assays were then conducted with 281-284 and 291-293 (Figure 3.31) against P. 
fluorescens and human K3MO (Table 3.3). Initial indications suggest sulfamates 
281 and 293 are not as good inhibitors as the diethyl phosphates 271 and 272 
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based upon their percentage inhibition at 10 µM. There does appear to be some 
preference for having the sulfamate at the 3- position over the 4- position, however, 
this cannot be assumed until Ki data becomes availble. Both of the phenols 291 
and 292 gave very similar values for inhibition. A trend can be obsereved with the 
carboxylic acid and its esters. The carboxylic acid 282 gave the best inhibition of 
the third generation compounds and of the whole series with a Ki of 29.1 ± 11.8  
nM. It is possible that the carboxylic acid is forming a salt bridge with Arg-84. The 
increase in inhibition from the ethyl ester 284 to methyl ester 283 presumably 
reflects the importance of the interaction of Arg-84 with the ester, as 284 cannot 
approach Arg-84 as closely as 283. Co-crystals of these potent inhibitors will be 
important for determining the key interactions and the development of further 
inhibitors. Although 282 shows good inhibition against the isolated K3MO, it is 
unlikely to cross through membranes. 
 
 R1 R2 Bacterial inhibition 
% at 10 µM 
Bacterial KI (nM) 
291 OH OMe 95 68.1 ± 36.5 
292 OMe OH 95 120.1 ± 29.1 
281 O-SO2NH2 OMe 90 150.4 ± 96.0 
293 OMe O-SO2NH2 85  
284 O-CH2CO2Et OMe 93 39.0 ± 23.1 
283 O-CH2CO2Me OMe 96  
282 O-CH2CO2H OMe 99 29.1 ± 11.8 
271 O-PO(OEt)2 OMe 97.6 ± 0.1 65.5 ± 7.5 
Table 3.3. Inhibition data for phosphate bioisosteres. (Dr Chris Mowat and Martin Wilkinson, Helen Bell and 
Annemette Kjeldsen) 
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3.6 Conclusions 
 
 
Figure 3.32. A summary of the best inhibitors of K3MO from each generation. 
A small library of amides were synthesised and it was shown that the best 
inhibition against P. fluorescens K3MO was achieved when 3,4-dichloro 
substitution was introduced (for example with compounds 235 and 245). Co-
crystallisation of 235 and 245 with P.fluorescens K3MO revealed the interactions 
within the active site. It also revealed potential interactions that could be developed 
by changing substituents on the aromatic ring. All of the co-crystals show the role 
that the 1,2,4-oxadiazole plays in binding. The 1,2,4-oxadiazole locates in a 
hydrophilic pocket in the active site and does not act as a bioisostere of the 
kynurenine ketone. The introduction of the diethyl phosphate group in 271 and 272 
generated compounds with a higher affinity for P. fluorescens K3MO. Co-
crystallisation of 271 and 272 showed that the phosphate-substituted aromatic ring 
could bind in two different orientations. The orientation of 271 allows the interaction 
of the diethyl phosphate with Arg-84. The orientation of 272 does not allow the 
same interaction to be made. Both of the co-crystal structures revealed that the 
active site becomes more accommodating around the phosphate-bound aromatic 
ring. The co-crystal structures of 271 and 272 led to the replacement of the diethyl 
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phosphate with phosphate bioisosteres. Sulfonamides 281 and 293 were less 
potent than was expected. Carboxylic acid 282 has the highest binding affinity in 
this study against isolated P. fluorescens K3MO, however, it may not pass through 
membranes.  
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Chapter 4 
Unfinished business: Synthesis of kynurenine 
analogues 
 
4.1 Introduction 
 
Figure 4.1. Synthetic targets: analogues of kynurenine. 
The synthesis of kynurenine analogues 305 and 307 was considered, each a 
rationally designed (potential) inhibitor of K3MO. Kynurenine analogues have not 
been reported as inhibitors of K3MO. Unlike previously reported benzoylalanine 
inhibitors, kynurenine analogue 305 may mitigate the formation of hydrogen 
peroxide by uncoupled NADPH oxidation through interactions of the pyridine 
nitrogen with the FAD co-factor. The pyridine nitrogen should orientate towards the 
flavin-hydroperoxide and may generate N-oxide 306 in situ. This N-oxide 306 was 
also identified as a synthetic target as an authentic sample could be used to verify 
the biotransformation of 305 to 306 by K3MO. These compounds have not been 
previously reported. 
3-Fluoro-kynurenine 307 had the potential to offer both a substrate-like inhibitor 
and an NMR probe for substrate-enzyme interactions of K3MO. If the enzyme 
accepts 3-fluoro-kynurenine 307 as a substrate this would allow the reaction to be 
monitored by 19F NMR spectroscopy. Shifts in the 19F NMR spectrum may provide 
insight into substrate binding and add detail to understanding K3MO binding. 
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4.2 Previous syntheses of kynurenine analogues 
 
Figure 4.2. Previously synthesised kynurenine derivatives. 
The synthesis of some related kynurenine analogues have previously been carried 
out. The kynurenines 308 were studied as KAT inhibitors (Chapter 1).63 [2-2H]-
Kynurenine 309 has been used in a study on the kinetic isotope effect of 
kynureninase183 and [3-3H]-kynurenine 310 has been used in assays to monitor 
inhibition of K3MO.67 
 
Scheme 4.1. The general route employed to generate racemic kynurenine analogues 308. 63 
Analogues 308 were all synthesised by Varasi et al.63 as racemates, as illustrated 
in Scheme 4.1. 5-Chlorokynurenine was also synthesised in an enantiospecific 
manner in a separate synthesis. The first step in the formation of racemic 
kynurenine analogues was a Hoesch reaction using chloroacetonitrile with Lewis 
acid catalysis to form the α-chloroacetophenone 312. Reaction of 312 with diethyl 
acetamidomalonate 313, generated acetamidomalonate 314. Finally acid mediated 
decarboxylation and deprotection yielded the desired racemic kynurenines 308. 63 
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Scheme 4.2. An enantiospecific synthesis of L-5-chloro-kynurenine 320.63 (dba) = dibenzylideneacetone.  
The reported enantiospecific synthesis of L-5-chloro-kynurenine 320 is illustrated in 
Scheme 4.2. The key step involved a Stille coupling between 317 and 318. 63 This 
route lends itself to the synthesis of alternative L-kynurenine analogues, although 
the use of toxic trimethylstannyl chloride is not so attractive, especially when the 
final analogues are destined for biological testing. 
 
Scheme 4.3. The initial route to L-[2-2H]kynurenine 309 starting from DL-kynurenine 321.183 
Two routes were developed towards the synthesis of L-[2-2H]kynurenine 309 by 
Ross et al.183 The first started from racemic kynurenine, as illustrated in Scheme 
4.3. The deuterium was incorporated at the C-2 position during the acylation 
reaction. A key step in this route involved the enzymatic hydrolytic resolution of 
322183 although clearly only a maximum of 50% can be recovered. 
  143 
 
Scheme 4.4. Synthesis of L-[2-2H]kynurenine 309 starting from L-[2-2H]tryptophan 325.183 
Racemisation of L-tryptophan followed by an acylase resolution, similar to that 
used in Scheme 4.3, generated L -[2H]-tryptophan 325 with an enantiomeric excess 
of 99%. Sequential protection of the carboxylic acid and amine moieties generated 
326. The indole ring was then oxidatively cleaved at the C-2,C-3 double bond to 
provide deuterated formylkynurenine 327. Finally sequential removal of the three 
protecting groups gave L-[2-2H]kynurenine 309.183 
 
Scheme 4.5. Synthesis of L-[3-3H]-kynurenine 310 via a Stille coupling.67 (dba) = dibenzylideneacetone.  
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Isotopically labelled L-[3-3H]-kynurenine 310 was prepared by Röver et al.67 from 
the 3-bromokynurenine analogue 334. L-3-Bromokynurenine was synthesised via a 
Stille coupling with 318, giving 333, as illustrated in Scheme 4.5. Reaction of 3-
bromokynurenine 334 under a tritium atmosphere using Pd/C catalysis gave the 
desired L-[3-3H]-kynurenine 310. 67 
 
Scheme 4.6. Route to L-5-fluorokynurenine 337 taken from K.Muirhead and  N.Botting (2002).184 
Previously within the group a route was developed to 5-fluorokynurenine 337.184 
This route is shown in Scheme 4.6, where the key step was a Friedel-Crafts 
acylation. It was possible to acylate a protected 4-fluoroaniline 335 using BF3.Et2O 
as a Lewis acid catalyst with the protected aspartic acid chloride 318 in good yield. 
Deprotection of the amino acid under acidic conditions gave the fluorinated 
analogue 337.184 However, the synthesis was not so efficient and the product was 
recovered in a relatively low yield.  
 
Figure 4.3. Previous benzoylalanine inhibitors of K3MO. 
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Benzoylalanines are known substrate-like inhibitors of K3MO.77, 96, 185 Investigation 
into benzoylalanines as inhibitors of kynureninase186, 187 and kynurenine 
aminotransferase188 have also been carried out. 
 
Scheme 4.7. The most common route to benzoylalanines is through α-bromoacetophenone. 
Key steps in the general method for the preparation of benzoylalanines186, 187 are 
illustrated in Scheme 4.7. If the α−bromoacetophenone is not commercially 
available it can generally be prepared by the reaction of the required acetophenone 
338 with Cu(II)Br2. Nucleophilic substitution of 339, by diethyl acetamidomalonate 
(DEAM) gave 340, which is an immediate precursor to the required amino acid. 
Acid mediated decarboxylation/deprotection then allowed preparation of the 
benzoylalanine 341 as a racemate. Single enantiomers can be prepared by a 
modification of this route using the Schollköpf method in place of diethyl 
acetamidomalonate. 
 
4.3 Aims and objectives in the synthesis of kynurenine analogues 
 
The aim for this work was to synthesise the kynurenine analogues 305, 306 and 
307. The compounds were initially targeted as their racemates to simplify their 
preperation and to carry out an initial assay to determine whether they are 
substrates for K3MO. The use of trimethylstannyl chloride was avoided to prevent 
any toxic tin by-products from potentially affecting the bioassays. An analogous 
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route to that used in the synthesis of benzoylalanines, using Cu(II)Br2 was initially 
envisaged to generate the amino acid. 
 
4.4 Routes towards the synthesis of a pyridyl-kynurenine 
analogue 
 
Scheme 4.8. Reagents and conditions: a) Trimethylacetyl chloride, DMAP, DCM, 0 ˚C to RT, 16 h, 91%; b) 
n-BuLi, acetylmorpholine, THF, -50 ˚C to 0 ˚C, 1.5 h, then -40 ˚C, 1 h, 63%; c) Cu(II)Br, CHCl3, EtOAc, 80 ˚C, 
16 h. 
Ketone 344 had already been reported by Murray et al. and it was envisaged that 
the bromide 345 could be directly prepared from pyridine 344 through the use of 
Cu(II)Br2, following a similar procedure to that used to form benzoylalanines. 
2-Aminopyridine 342 was initially protected as its pivaloyl amide 343 using 
trimethylacetyl chloride and DMAP in an excellent yield (Scheme 4.8).189, 190 Ortho-
lithiation of 343 was then accomplished using n-butyllithium (2.5 eq). 
It is proposed (Scheme 4.9) that the first equivalent of n-butyllithium deprotonates 
the amide of 343, and then the second equivalent selectively deprotonates at C-3 
of the pyridine.190 A colourless precipitate formed after complete addition of n-
butylithium, which is assumed to be the dilithio species 347. Upon addition of the 
electrophile, in this case N-acetyl morpholine, the precipitate starts to dissolve. 
Purification using the literature conditions gave an impure product. However, 
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optimisation of the solvent system during column chromatography provided ketone 
344 in good yield.191 
 
 
Scheme 4.9. Proposed mechanism for ortho-lithiation of amino pyridines. 
 
Scheme 4.10. Reagents and conditions: a) Cu(II)Br, CHCl3, EtOAc, 80 ˚C, 16 h; b) HBr, Br2, AcOH, 0 ˚C to 75 ˚C, 
8 h. 
Bromination of ketone 344 was attempted using Cu(II)Br2 in chloroform/ethyl 
acetate, as illustrated in Scheme 4.10.192 However, the reaction was unsuccessful 
under the reported conditions and only starting material was returned. Attempts at 
brominating 344 using HBr and elemental Br2 only returned the hydrobromide salt 
of 344. 
Due to the failure of the bromination step a modified approach was taken involving 
acylation with an α-hydroxy ether. This required synthesis of the functionalised N-
acetyl morpholine 352. By deploying a silyl ether the alcohol could undergo readily 
accessible protecting group manipulations. Conversion of the alcohol could then be 
explored to give bromide, chloride or tosyl leaving groups. 
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Scheme 4.11. Reagents and conditions: a) TBSCl, imidazole, DCM, RT, 16 h, 89%; b) KOH, EtOH, RT, 16 h, 
67%; c) DCC, DMAP, morpholine, DCM, RT, 16 h, 38%. 
The alcohol moiety of ethyl glycolate 349 was protected as its TBS ether 350 in 
very good yield, as illustrated is Scheme 4.11. However, the product proved 
difficult to purify. Flash column chromatography gave 350 with traces of the TBS 
silol, although this was volatile and was removed under high vacuum, affording 
pure 350.193  
Hydrolysis of the silyl protected ester 350 to carboxylic acid 351 was achieved 
using potassium hydroxide in ethanol. Instead of acidifying the product with 
concentrated HCl,194 saturated ammonium chloride and DCM were added, 
affording the carboxylic acid 351 in higher yield than had previously been 
reported.193 
With carboxylic acid 351 in hand attention turned to the formation of morpholine 
amide 352. This could be achieved, but in poor yield (38%), using DCC and DMAP. 
Nonetheless, sufficient material was prepared to progress. 
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Scheme 4.12. Reagents and conditions: a) n-BuLi, THF, -50 ˚C to 0 ˚C, 1.5 h, then addition of morpholino-
amide 352, -40 ˚C for 1 h, 38%; b) n-BuLi, THF, -50 ˚C to 0 ˚C, 1.5 h, then addition of ethyl ester 350, -40 ˚C 
for 1 h, 61%. 
With the morpholine amide 352 in hand a direct acylation between pyridine 343 
and amide 352 was attempted, following the procedure used in Scheme 4.8. In the 
event the reaction worked to give the acylated product 353 in 38% yield.  
Due to the low yields for the ester hydrolysis and amide formation steps (Scheme 
4.11) acylation of pyridine 343 was carried out directly with ethyl ester 350 
(Scheme 4.12). This gave a superior yield compared to that with morpholine amide 
352. 
 
Scheme 4.13. The reaction of TBAF with 353 leads to acyl migration. Reagents and conditions: a) TBAF, THF, 
RT, 2 h, 32%. 
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With ketone 353 in hand, removal of the TBS protecting group was explored using 
a fluoride anion source. TBAF in THF did not give the expected product although 
depletion of the starting material was almost instantaneous as monitored by TLC 
analysis. The TBAF solution turned the reaction solution black when added. 
Purification by flash column chromatography on silica gave 354 as the major 
product. The 2D HMBC spectrum showed that the pivaloyl group had migrated to 
the alcohol. A crosspeak between the CH2 adjacent to the ketone and the carbonyl 
of the pivaloyl group proved the migration. 
A proposed mechanism for the acyl migration involves intermediate alkoxide 355 
as is illustrated in Scheme 4.13. 
 
Scheme 4.14. Reagents and conditions: a) Acetyl chloride, MeOH, RT, 3 h, 57%; b) tosyl chloride, Et3N, DCM, 
RT, 16 h; c) SOCl2, DCM, RT, 8 h; d) PPh3, CBr4, DCM, exclusion of light, RT, 8 h, 32%. 
Silyl ether deprotection of 353 was eventually achieved using a non-basic 
approach. A solution of acetyl chloride in dry methanol was used to selectively 
cleave the TBS ether, giving alcohol 357 in a moderate yield, as illustrated in 
Scheme 4.14. 
It was now required to convert alcohol 357 into a good leaving group. Tosylation of 
357 proved unsuccessful. The starting material was consumed, however, none of 
the desired product 358 could be recovered. Chlorination to generate 359 was also 
unsuccessful. However, the synthesis of alkyl bromide 345 was accomplished by 
an Appel reaction of 357 with CBr4/PPh3. The product 345 was isolated in a 
relatively low yield. In reactions of less than 250 mg of alcohol 357, separation of 
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the alkyl bromide 345 and triphenyl phosphine oxide was achievable by column 
chromatography. However, on larger scales this proved difficult and the product 
was always contaminated with triphenylphosphine oxide. Attempts at improving the 
conversion using resin bound triphenylphosphine proved unsuccesful. 
 
Scheme 4.15. Reagents and conditions: a) NaH, DEAM, DMF, 0 ˚C, 16 h. 
A substitution reaction of α-bromo-ketone 345 with the sodium salt of diethyl 
acetamidomalonate was unsuccessful and none of the desired product was 
obtained. At this point it was clear that the functionalised pyridine motif was 
interfering with the desired reactivity. This synthesis was not progressed further. 
 
4.5 Attempted synthesis of 3-fluorokynurenine 
 
Scheme 4.16. Published route to the fluoro-ketone 370.195 
The reaction of anthranilic acid 361 with methylmagnesium bromide in THF to give 
the ketone 362 was reported in 2001.195 Normally the reaction of a carboxylic acid 
with a Grignard reagent would provide the tertiary alcohol and perhaps low yields 
of the ketone. However, the high yield (80%) of ketone 362 made this an attractive 
reaction. It was envisaged that the methyl ketone 362 could then be converted to 
the corresponding α-bromo-ketone, an attractive intermediate for progressing to 3-
fluoro-kynurenine 308. 
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Scheme 4.17. Reagents and conditions: a) NaOH, H2O2, H2O, 50 ˚C, 30 min, 55%; b) Boc2O, NaOH, THF:H2O 
1:1, RT, 16 h, 65%. 
As a starting point for this synthesis an oxidative cleavage of 7-fluoroisatin 363 
using hydrogen peroxide under basic conditions was used to give 3-fluoro-
anthranilic acid 364 (Scheme 4.17).196  
 
Scheme 4.18. Proposed mechanism for the formation of 3-fluoro-anthranilic acid 372 from 7-fluoroisatin 371. 
A proposed mechanism for the reaction of hydrogen peroxide with 7-fluoroisatin 
363 is illustrated in Scheme 4.18. 
Boc protection of anthranilic acid 364 was not always reproducible, therefore the 
unsubstituted anthranilic acid 6 was explored in a model study for direct 
preparation of the desired brominated ketone 372. 
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Scheme 4.19. Reagents and conditions: a) Boc2O, NaOH, H2O:1,4-dioxane 1:1, RT, 16 h, 51%; b) MeMgBr (5 
eq), THF, 0 ˚C to RT, 16 h, 49%; c) HCl (4 M in 1,4-dioxan), Et2O, RT, 1 h, 53%; d) Ac2O, pyridine, RT, 16 h, 
73%; e) Cu(II)Br, CHCl3, EtOAc, 80 ˚C, 16 h. 
Boc protection of anthranilic acid 6 gave 368 in moderate yield.197, 198 With 368 in 
hand attention turned to the preparation of ketone 369 using the original conditions. 
These conditions worked well giving ketone 369 in 49% yield, higher than the 
previously reported.195   
The Boc protecting group was removed under acidic conditions to generate amine 
hydrochloride 370 as illustrated in Scheme 4.19.199 The amine was then protected 
as its acetamide 371. This exchange of protecting groups was carried out because 
the acetamide is more stable than the Boc protecting group under the acidic 
conditions required for the bromination reaction.200, 201  
Bromination of 371 was explored using Cu(II)Br2 in chloroform and ethyl acetate. 
This reaction did not work and TLC analysis indicated that very little reaction had 
occurred and only starting material was returned. 
As bromination of 371 proved difficult, it is unlikely that 3-fluorokynurenine could be 
synthesised via this route. At this point, modification of the route used in the 
preparation of 5-fluorokynurenine 337 (Scheme 4.6) looked attractive for the 
synthesis of 3-fluorokynurenine 308. 
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Scheme 4.20. Reagents and conditions: a) Boc2O, 80 ˚C, 2 h, 56%. 
Protection of aniline 373 was achieved using the method developed by Thomas et 
al.201 to give the Boc protected aniline 374 in moderate yield, as illustrated in 
Scheme 4.20. 
 
Scheme 4.21. Reagents and conditions: a) Paraformaldehyde, p-TSA, toluene, 120 ˚C, 5 h; b) oxalyl chloride, 
toluene, DMF, 120 ˚C, 3 h, 71%. 
Cbz-protected aspartic acid 375 was converted to oxazolidine 376 to prevent 
racemisation of the amino acid, as illustrated in Scheme 4.21. 202 After purification 
the product was obtained as a colourless oil and then scratching of the oil initiated 
crystallisation to give a white solid. Carboxylic acid 376 was converted into the acid 
chloride 318 by oxalyl chloride in a similar yield to that previously reported.184, 203, 
204 The acid chloride was then used without any further purification in the Friedel-
Crafts acylation.  
 
Scheme 4.22. Reagents and conditions: a) BF3.Et2O, DCM, RT, 16 h. 
A Friedel-Crafts acylation was carried out, as illustrated in Scheme 4.22.184 
However, this reaction provided little of the desired product 377. 1H NMR 
spectroscopy showed multiple products and although mass spectrometry gave a 
peak, which corresponded to the expected molecular mass, m/z 373, however, it 
was not clear whether acylation had occurred on the amine or the aromatic ring. In 
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the reported synthesis of 5-fluorokynurenine the Boc protecting group was 
removed in the Friedel-Crafts acylation step and it was expected that the Boc 
group would also be removed under the reaction conditions. A model investigation 
using acetyl chloride was undertaken to explore whether electrophilic aromatic 
substitution could occur. Under the reported Friedel-Crafts acylation conditions the 
only product obtained was acetamide 379, indicating that the Boc protecting group 
is readily cleaved under the conditions and formation of the acetamide 379 can 
then occur. 
 
Scheme 4.23. Reagents and conditions: a) BF3.Et2O, DCM, RT, 16 h; b) Ac2O, Et3N, DCM, RT, 16 h, 54%. 
To confirm that acetamide 379 had formed in the Friedel-Crafts acylation an 
authentic sample of acetamide 379 was synthesised from 2-fluoroaniline 373, as 
illustrated in Scheme 4.23. The 1H and 13C NMR spectra were identical to that 
obtained from the Friedel-Crafts acylation with acetyl chloride. 
 
Scheme 4.24. Reagents and conditions: a) Et3N, trimethylacetyl chloride, DCM, 0 ˚C to RT, 16 h, quant. 
An alternative amine protecting group that is stable to BF3 was desired. This led to 
the use of the pivaloyl protecting group. Aniline 373 was protected using 
trimethylacetyl chloride under basic conditions, to give amide 380 in very good 
yield, as illustrated in Scheme 4.24.  
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Scheme 4.4,5. Reagents and conditions: a) BF3.Et2O, DCM, RT, 16 h. 
In the end Friedel-Crafts acylation between 380 and 318 proved unsuccessful. In 
view of this and the unsuccessful Friedel-Crafts acylations in model systems, this 
route to 3-fluorokynurenine reached an unsatisfactory conclusion. As the project 
was nearing its close no further investigations into the synthesis of 3-
fluorokynurenine 307 were conducted and this remains unfinished business. 
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Chapter 5 
Experimental 
 
5.1 General Considerations 
 
All chemicals and solvents were purchased from Sigma Aldrich UK, Acros 
Organics UK, Alfa Aesar UK, Fisher Scientific UK, Fluorochem UK and VWR UK. 
These were used without further purification unless otherwise specified.  
All air and moisture sensitive reactions were performed under an inert argon 
atmosphere in flame-dried apparatus. Anhydrous reagents were handled under 
argon using standard techinques. 
Dry DCM, toluene, diethyl ether and THF were obtained from an mBraun MB SPS-
800 solvent purification system by passage of the solvent through a drying column 
and dispensing under an argon atmosphere. Methanol was distilled from calcium 
hydride in a recycling still under argon. Anhydrous DMF was purchased from 
Merck UK 
Hydrogenations were carried out using an autoclave with a hydrogen pressure of 
30 bar.   
Thin layer chromatography (TLC) analyses was run on glass plated 0.2 mm thick 
silica gel 60 F254 plates (Merck). They were visualised under a 254 nm ultraviolet 
lamp and/ or by treatment with alkaline potassium permanganate dip or an 
ethanolic anisaldehyde dip, followed by thermal development with a heat gun. 
Column chromatography was conducted using Merck Geduran Si-60 silica-gel (40-
63 µm particle size) under a positive pressure of compressed air. Petroleum ether 
refers to the fraction with boiling point 40-60 ˚C. 
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Melting points were determined using Griffin Melting Point Apparatus. Values are 
reported to the nearest 1 °C and are uncorrected. 
Infrared spectra were recorded using a Perkin-Elmer Spectrum GX FT-IR 
spectrometer. Samples were analysed as nujol mulls or thin films on NaCl plates. 
Absorption maxima are reported in wavenumbers (cm-1) 
Nuclear magnetic resonance (NMR) spectra were recorded on Bruker Avance 300, 
Bruker Avance II 400, Bruker Avance 500 and Bruker Avance III 500 instruments. 
1H NMR spectra were recorded at 300, 400 and 500 MHz. 13C NMR spectra were 
recorded at 75, 100 and 125 MHz. 19F NMR spectrum were recorded at 282, 376 
and 470 MHz. 31P NMR spectrum were recorded at 121, 162 and 202 MHz. 
Chemical shifts were recorded as δ values in parts per million (ppm). The spectra 
were internally referenced to the residual solvent peaks in the 1H and 13C NMR 
spectra. Spectra were obtained using CDCl3, D6-DMSO, CD3OD as solvents. 1H 
NMR data are reported as following: chemical shift (δ), relative integral, mulitplicity 
(defined as: s = singlet, d = doublet, dd = doublet of doublets, ddd = doublet of 
doublet of doublet, dddd = doublet of doublet of doublet of doublet, dt = doublet of 
triplets, ddt = doublet of doublet of triplets, t = triplets, q = quartet, quin = quintet), 
coupling constant(s) J (Hz), assignment. Identical coupling constants were 
averaged and are reported to the nearest 0.1 Hz. The assignment of signals 
observed in NMR spectra was assisted by conducting homonuclear (1H-1H) 
correlation spectroscopy (COSY), heteroneuclear (1H-13C) single quantum 
correlation spectroscopy (HSQC), heteronuclear (1H-13C) multiple bond correlation 
spectroscopy (HMBC) and Nuclear Overhauser effect spectroscopy (NOESY). 
Electrospray mass spectrometry was performed on a Thermo Fisher exactive 
orbitrap mass spectrometer or on a Waters micromass, LCT to Time of Flight mass 
spectrometer, coupled to a Waters 2975 HPLC using methanol, acetonitrile and 
water as solvents. Chemical ionisation was performed on a Waters micromass 
GCT Time of Flight mass spectrometer. m/z values are reported in Daltons and 
followed by their percentage abundance in parenthesis.  
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Optical rotations were measured using a Perkin-Elmer model 341 polarimeter, 
referenced to the sodium D line (589 nm) at 20 ˚C. Measurements were made in 
spectroscopic grade solvents specified at the concentration (c, g/100 mL) 
indicated. The measurements were made using a cell with a path length of 1 dm. 
Specific rotations are reported in the implied units of 10-1 deg cm2 g-1. 
Freeze drying was carried out using a Christ Alpha 1-2LD Plus freeze dryer 
equipped with an Edwards RV3 rotary-vane oil pump. 
Room temperature varied between 19-25 ˚C. “Removed under reduced pressure” 
refers to the use of a rotary evaporator attached to a diaphragm pump, with a water 
bath temperature of 40 ˚C. 
HPLC analysis was performed on a Varian Prostar system consisting of a Varian 
Prostar Auto Sampler 400, Varian Prostar 240 solvent delivery system and a 
Varian Prostar UV-Vis 325 module. Compound elution was monitored at 254 nm. A 
Phenomonex kingsorb 3µ C18 (150 mm × 4.6 mm, 3 µM) column was used for 
analysis. Solvents used were 1% formic acid in water and 1% formic acid in 
methanol. A linear gradient from 50:50 water:methanol to 0:100 water:methanol 
over 35 min was used. After each run the column was equilibrated for 15 min. The 
flow rate was set at 1 mL/min.  
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5.2 Characterisation 
 
3,4-Dimethoxy-N-(4-(3-nitrophenyl)thiazol-2-yl)benzenesulfonamide 93 67 
 
4-(3-Nitrophenyl)thiazol-2-amine (275 mg, 1.2 mmol), 3,4-dimethoxybenzene 
sulfonyl chloride (353 mg, 1.49 mmol) and pyridine (485 µl, 6 mmol) were added to 
a flask containing 4 Å molecular sieves. DCM (2 mL) was added and the mixture 
was stirred for 16 h. The mixture was filtered and the filtrate was concentrated 
under reduced pressure. The residue was purified by column chromatography 
(20% ethyl acetate/petroleum ether to 40% ethyl acetate/petroleum ether) to give 
the product 93 as a yellow solid (120 mg, 24%): m.p. 95-100 ˚C (Lit.67 185 ˚C); δH 
(300 MHz, CDCl3), 8.21-8.18 (1H, m, 2-H), 8.01 (1H, ddd, J= 8.2, 2.2, 1.0 Hz, 4-H), 
7.75 (1H, ddd, J= 7.8, 1.8, 1.0 Hz, 6-H), 7.57 (1H, d, J= 8.6, 2.2 Hz, 15-H), 7.47 
(1H, d, J= 2.2 Hz, 11-H), 7.45-7.39 (1H, m, 5-H), 6.84 (1H, s, 8-H), 6.81 (1H, d, J= 
8.6 Hz, 14-H), 3.82 (3H, s, OMe), 3.81 (3H, s, OMe), 1.98 (1H, s, NH). 
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N-(4-(2-fluoro-5-(trifluoromethyl)phenyl)thiazol-2-yl)-3,4-
dimethoxybenzenesulfonamide 135 67 
 
4-(2-Fluoro-5-(trifluoromethyl)phenyl)thiazol-2-amine (77 mg, 0.29 mmol), 3,4-
dimethoxybenzene-1-sulfonyl chloride (104 mg, 0.44 mmol) and pyridine (111 µl, 
1.47 mmol) were added to a flask containg 4 Å molecular sieves. DCM (2 mL) was 
added. After 16 h the mixture was filtered and the filtrate was concentrated under 
reduce pressure. The residue was purified by column chromatography on silica 
(20% ethyl acetate/ petroleum ether to 30% ethyl acetate/ petroleum ether) to give 
the product 135 as a white solid (78 mg, 58%): m.p. 78-80 ˚C (Lit.67 126-128 ˚C);  
δH (300 MHz, CDCl3) 7.71 (1H, dd, J= 6.7, 1.7 Hz, 4-H), 7.58 (1H, dd, J= 8.5, 2.1 
Hz, 15-H), 7.47 (1H, d, J= 2.1 Hz, 11-H), 7.46-7.39 (1H, m, 6-H), 7.13-7.05 (1H, m, 
3-H), 6.96 (1H, d, J= 1.1 Hz, 8-H), 6.82 (1H, d, J= 8.5 Hz, 14-H), 3.86 (6H, s, 
OMe); m/z (ES+) 460.73 ([M+Na]+, 100%). 
 
N-Hydroxy-3-nitrobenzimidamide 140 205 
 
Hydroxylamine hydrochloride (5.87 g, 91.1 mmol) and anhydrous potassium 
carbonate (12.8 g, 91.1 mmol) were added to a solution of 3-nitrobenzonitrile (10 g, 
67.5 mmol) in methanol (200 mL). The mixture was heated under reflux for 2 h 
then left to stir at room temperature for 16 h. The mixture was filtered and the 
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filtrate was concentrated under reduced pressure to yield a yellow solid, which was 
recrystallised from toluene to give the product 140 as yellow crystals (10.31 g, 
84%): m.p. 178-182 ˚C (Lit.205 180-182 ˚C); νmax/cm-1 (nujol) 3498, 3400, 1666, 
1598, 1535, 1147, 1089, 949; δH (300 MHz, D6-DMSO) 9.96 (1H, br s, OH), 8.50 
(1H, ddd, J= 2.3, 1.7, 0.4 Hz, 2-H), 8.21 (1H, ddd, J= 8.2, 2.3, 1.0 Hz, 4-H), 8.11 
(1H, ddd, J= 7.9, 1.7, 1.0 Hz, 6-H), 7.67 (1H, ddd, J= 8.2, 7.9, 0.4 Hz, 5-H), 6.09 
(2H, br s, NH2); δC (75 MHz, D6-DMSO) 149.9 (C-3), 148.6 (C-7), 135.76 (C-1), 
132.4 (C-6), 130.6 (C-5), 124.3 (C-4), 120.8 (C-2); HRMS m/z (ES+) 182.0560 
([M+H]+, 100%) C7H8O3N3 requires 182.0560. 
 
(S)-tert-Butyl-4-(((amino(3-nitrophenyl)methylene)amino)oxy)-2-((tert-
butoxycarbonyl)amino)-4-oxobutanoate 144 
 
(S)-4-(tert-Butoxy)-3-((tert-butoxycarbonyl)amino)-4-oxobutanoic acid (267 mg, 
0.92 mmol), DCC (190 mg, 0.92 mmol) and DMAP (51 mg, 0.41 mmol) were added 
to a solution of amidoxime 140 (150 mg, 0.84 mmol) in DCM (20 mL). After stirring 
for 16 h the solid was filtered off. The filtrate was concentrated under reduced 
pressure to give a yellow oil. The product was purified by column chromatography 
on silica (20% ethyl acetate/petroleum ether to 35% ethyl acetate/petroleum ether) 
to give the product 144 as a white solid (334 mg, 88%): m.p.136-140 ˚C; νmax/cm-1 
(nujol) 3502 (NH), 3394 (NH), 3350 (NH), 1737 (C=O), 1725 (C=O), 1695 (C=N); 
δH (300 MHz, CDCl3) 8.48-8.44 (1H, m, 2-H), 8.36 (1H, ddd, J= 8.0, 2.0, 1.1 Hz, 4-
H), 8.13 (1H, ddd, J= 8.0, 2.0, 1.1 Hz, 6-H), 7.68-7.62 (1H, m, 5-H), 5.57-5.43 (3H, 
m, 8,12-H), 4.67-4.60 (1H, m, 11-H), 3.11 (2H, d, J= 5.1 Hz, 10-H), 1.51 (9H, s, 
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(CH3)3), 1.47 (9H, s, (CH3)3); δC (75 MHz, CDCl3) 207 (C-16), 171 (C-9), 155 (C-
13), 149 (C-3) , 133 (C-5), 130 (C-6), 127 (C-1), 126 (C-4), 122 (C-2), 83.3 
(C(CH3)3), 80.4 (C(CH3)3),  51 (C-11), 37 (C-10), 28 (2 × tBu); HRMS m/z (ES+) 
475.1814 ([M+Na]+,100%) C20H28 N4O8Na requires 475.1805. 
 
(S)-tert-Butyl-5-(((amino(3-nitrophenyl)methylene)amino)oxy)-2-((tert-
butoxycarbonyl)amino)-5-oxopentanoate 146 
 
5-(tert-Butoxy)-4-((tert-butoxycarbonyl)amino)-5-oxopentanoic acid (919 mg, 3.03 
mmol), DCC (625 mg, 3.03 mmol) and DMAP (169 mg, 1.38 mmol) were added to 
a solution of amidoxime 140 (500 mg, 2.76 mmol) in DCM (20 mL). After stirring for 
16 h the mixture was filtered and the filtrate was concentrated under reduced 
pressure. The product was purified by column chromatography on silica (30% ethyl 
acetate/petroleum ether to 50 % ethyl acetate/petroleum ether) to give the product 
146 as a yellow solid (739 mg, 57%): m.p. 112-114 ˚C; νmax/cm-1 (nujol) 3461 (NH), 
3397 (NH), 3359 (NH), 1757 (C=O), 1731 (C=O), 1713 (C=N), 1699 (C=O); δH (300 
MHz, CDCl3) 8.49-8.46 (1H, m, 2-H), 8.27 (1H, ddd, J= 8.2, 2, 1.1 Hz, 4-H), 8.07-
8.05 (1H, m, 6-H), 7.58-7.53 (1H, m, 5-H), 5.56 (2H, br s, 8-NH2), 5.12 (1H, d, J= 
8.4 Hz, 13-H), 4.28-4.18 (1H, m, 12-H), 2.58-2.48 (2H, m, 12-H), 2.26-2.14 (1H, m, 
11-H), 1.95-1.82 (1H, m, 11-H), 1.41 (9H, s, (CH3)3), 1.39 (9H, s, (CH3)3); δC (75 
MHz, CDCl3) 171.3 (C-17), 170.5 (C-9), 155.7 (C-14), 148.1 (C-3), 133.1 (C-1) 
133.0 (C-6), 129.7 (C-5), 125.4 (C-4), 121.9 (C-2), 82.8 (C(CH3)3), 80.1 (C(CH3)3),  
53.4 (C-12), 29.3 (C-10), 28.5 (C-11), 28.3 (tBu), 28.0 (tBu); m/z 489.1948 
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([M+Na]+, 37%), 423.2230 ([M+H]+, 100), 367.1605 (38), 311.0980 (93); HRMS m/z 
(ES+) 489.1948 (M+Na+, 37%) C21H30O8N4Na requires 489.1961 
 
(S)-tert-Butyl-2-(tert-butoxycarbonylamino)-3-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-
yl)propanoate 147 
 
TBAF (47µl, 1 M in THF, 0.04 mmol) was added to a solution of O-acyl amidoxime 
144 (215 mg, 0.48 mol) in THF (5 mL) and the solution was stirred for 16 h. When 
TLC analysis indicated the consumption of all the starting material, ethyl acetate 
(25 mL) was added. The solvent was removed under reduced pressure and the 
product was purified by column chromatography on silica (10% ethyl 
acetate/petroleum ether) to give the product as a white solid (170 mg, 83%): m.p. 
86-90 ˚C; νmax/cm-1 (nujol) 3390 (NH), 1728, 1691; δH (300 MHz, CDCl3) 8.99-8.97 
(1H, m, 2-H), 8.45 (1H, ddd, J= 8.0, 1.9, 1.1 Hz, 4-H), 8.40 (1H, ddd, J= 8.0, 1.9, 
1.1 Hz, 6-H), 7.75-7.70 (1H, m, 5-H), 5.25 (1H, d, J= 5.8 Hz, 11-NH), 4.4 (1H, q, J= 
5.8 Hz, 10-H), 3.20-3.00 (2H, m, 9-H), 1.54 (9H, s, (CH3)3), 1.48 (9H, s, (CH3)3); δC 
(75 MHz, CDCl3) 177.3 (C-15), 168.9 (C-8), 166.7 (C-7), 155.1 (C-12), 148.6 (C-3), 
133.0 (C-6), 130.1 (C-5), 128.5 (C-1), 125.8 (C-4), 122.5 (C-2), 83.3 (C(CH3)3), 
80.4 (C(CH3)3), 51.7 (C-10), 30.0 (C-9), 28.3 (tBu), 27.9(tBu); HRMS m/z (ES+) 
457.1695 ([M+Na]+, 100%) C20H26N4O7Na requires 457.1699. 
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(S)-tert-Butyl 2-((tert-butoxycarbonyl)amino)-4-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-
yl)butanoate 148 
 
TBAF (45 µl, 1M in THF, 0.045 mmol) was added to a solution of O-acyl 
amidoxime 146 (208 mg, 0.45 mmol) in dry THF (5 mL). The mixture was allowed 
to stir for 16 h. When TLC analysis indicated the consumption of the starting 
material, ethyl acetate (25 mL) was added. The solvent was removed under 
reduced pressure. The product was purified by column chromatography on silica 
(20% ethyl acetate/petroleum ether to 30% ethyl acetate/petroleum ether) to give 
the product 148 as a yellow solid (120 mg, 60%): m.p. 126-130 ˚C; νmax/cm-1 (nujol) 
3404 (NH), 3383 (NH), 1735 (C=O), 1729 (C=O), 1697 (C=N); δH (300 MHz, 
CDCl3) 8.88-8.85 (1H, m, 2-H), 8.34 (1H, ddd, J= 8.0, 1.9, 1.1 Hz, 4-H), 8.29 (1H, 
ddd, J= 8.0, 1.9, 1.1 Hz, 6-H), 7.65-7.58 (1H, m, 5-H), 5.15 (1H, d, J= 7.2 Hz, 12-
NH), 4.29 (1H, q, J= 6.2 Hz, 11-H), 3.09-2.89 (2H, m, 9-H), 2.45-2.32 (1H, m, 10-
H), 2.19-2.05 (1H, m, 10-H), 1.41 (9H, s, (CH3)3), 1.37 (9H, s, (CH3)3); δC (75 MHz, 
CDCl3) 179.8 (C-16), 170.8 (C-8), 166.7 (C-7), 155.4 (C-13) 148.7 (C-3), 133.0 (C-
6), 130 (C-5), 128.7 (C-1), 125.6 (C-4), 122.5 (C-2), 82.8 (C(CH3)3), 80.1 
(C(CH3)3), 53.3 (C-11), 29.8 (C-9), 28.3 (tBu), 28.1 (tBu), 23.0 (C-10); HRMS m/z 
(ES+) 471.1837 ([M+Na]+, 100%) C21H28O7N4Na requires 471.1851. 
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(S)-2-Amino-3-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)propanoic acid 120 
 
Triethylsilane (270 µl, 1.7 mmol) was added to a solution of 1,2,4-oxadiazole-147 
(291 mg, 0.66 mmol) in trifluoroacetic acid (10 mL). The solution was stirred for 16 
h. The solvent was removed under reduced pressure and the solid was redissolved 
in HCl solution (1M, 25 mL). The solvent was removed under reduced pressure to 
yield an off-white solid, which was recrystallised from water and ethanol to give the 
product as an off-white solid as the hydrochloride salt 120 (104 mg, 50%): m.p. 
210-212 ˚C; νmax/cm-1 (nujol) 3359 (NH), 3182 (OH), 1698 (C=N); δH (400 MHz, D6-
DMSO) 8.72-8.71 (1H, m, 2-H), 8.45-8.44 (1H, m, 4-H), 8.43-8.42 (1H, m, 6-H), 
7.90-7.86 (1H, m, 5-H), 3.77 (1H, dd, J= 7.9, 5.9, 10-H), 3.54 (1H, dd, J= 16.1, 5.9, 
9-H), 3.29 (1H, dd, J= 16.1, 7.9, 9’-H); δc (75 MHz, D6-DMSO), 178.6 (C-12), 167.5 
(C-8), 165.9 (C-7), 148.3 (C-3), 133.0 (C-6), 131.2 (C-5), 127.8 (C-1), 126.1 (C-4), 
121.5 (C-2), 51.6 (C-9), 29.3 (C-10); m/z (ES+) 301 ([M+Na]+, 100%), (ES-) 277 
([M-H]-, 53%), 260 (100). 
 
(S)-2-Amino-4-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)butanoic acid 121 
 
Triethysilane (515 µl, 3.22 mmol) was added to a solution of 1,2,4-oxadiazole 148 
(579 mg, 1.3 mmol) in trifluoroacetic acid (5 mL) and was stirred for 16 h. The 
solvent was removed under reduced pressure and the solid was redissolved in 1M 
HCl (25 mL) and the solvent was removed under reduced pressure. The product 
was purified by recrystallisation from water and ethanol to give the product 121 as 
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an off-white solid (78 mg, 18%): m.p. 207-209 ˚C (decomp.); νmax/cm-1 (nujol) 3399 
(NH), 1719 (C=N); δH (400 MHz, D6-DMSO) 8.70-8.69 (1H, m, 2-H), 8.46-8.42 (2H, 
m, 4,6-H), 7.89 (1H, dd, J= 8.2, 7.9 Hz, 5-H), 3.22-3.10 (2H, m, 9-H), 2.24-2.22 
(2H, m, 10-H), 1.98-1.97 (1H, m, 11-H); δc (125 MHz, D6-DMSO) 180.5 (C-13), 
168.9 (C-8), 166.0 (C-7), 148.2 (C-3), 133.0 (C-6), 131.2 (C-5), 127.7 (C-1), 126.0 
(C-4), 121.4 (C-3), 52.8 (C-11), 27.6 (CH2), 22.8 (CH2); m/z (ES+) 315 ([M+Na]+, 
100%), 292.95 ([M+H]+, 65%), (ES-) 291 ([M-H]-, 100%). 
 
3-((tert-butoxycarbonyl)amino)propanoic acid 150 141, 206 
 
β-Alanine (2.0 g, 22.6 mmol) was added to a solution of sodium hydroxide (992 
mg, 24.8 mmol) in water and 1,4-dioxane (1:1 50 mL). The mixture was cooled to 0 
˚C for 10 min. Di-tert-butyl dicarbonate (5.5 g, 24.8 mmol) was added in small 
portions. The temperature was kept at 0 ˚C for 20 min with stirring and allowed to 
warm to room temperature overnight. The solvent was removed under reduced 
pressure and water (50 mL) was added. The reaction mixture was washed with 
diethyl ether (3 × 30 mL). The pH was adjusted to pH4 using citric acid. The 
product was extracted with ethyl acetate (3 × 50 mL). The organic layer was dried 
with magnesium sulfate and the solvent was removed under reduced pressure to 
yield the product 150 as a white solid (3.54 g, 82%): m.p. 70-72 ˚C (Lit. 141 71-72 
˚C); νmax/cm-1 (nujol) 3441, 1714, 1513, 1249, 1238, 1167, 979; δH (300 MHz, D6-
DMSO) 12.16 (1H, s, 4-H), 3.10 (2H, td, J= 7.1, 5.8 Hz, 3-H), 2.33 (2H, t, J= 7.1 
Hz, 2-H), 1.35 (9H, s, 7-H); δC (75 MHz, D6-DMSO) 173.7 (C-1), 156.3 (C-5), 78.5 
(C-6), 37.0 (C-3), 35.1 (C-2), 29.1 (C-7); HRMS m/z (ES+) 212.0890 ([M+Na]+, 
100%) C8H15O4NNa requires 212.0899 
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tert-Butyl(3-(((amino(3-nitrophenyl)methylene)amino)oxy)-3-oxopropyl)carbamate 
151 
 
Carboxylic acid 150 (573 mg, 3.03 mmol), DCC (625 mg, 3.03 mmol) and DMAP 
(169 mg, 1.38 mmol) were added to a solution of amidoxime 140 (500 mg, 2.76 
mmol) in DCM (20 mL). The mixture was stirred overnight. The mixture was filtered 
and the filtrate was concentrated under reduced pressure. The product was 
purified by column chromatography on silica (30% ethyl acetate/petroleum ether to 
70% ethyl acetate/petroleum ether) to give the product 151 as a white solid (715 
mg, 73%): m.p. 128-136 ˚C; νmax/cm-1 (nujol) 3437 (NH), 3331 (NH), 1752, 1740; δH 
(300 MHz, CDCl3) 8.47-8.45 (1H, m, 2-H), 8.28 (1H, ddd, J= 8.0, 2.0, 1.1 Hz, 6-H), 
8.04 (1H, ddd, J= 8.0, 2.0, 1.1 Hz, 4-H), 7.59-7.54 (1H, m, 5-H), 5.31 (2H, br s, 8-
NH2), 4.97 (1H, s, 12-NH), 3.47 (2H, q, J= 5.9 Hz, 11-H), 2.68 (2H, t, J= 5.9 Hz, 10-
H), 1.37 (9H,s, (CH3)3); δC (100 MHz, CDCl3) 169.8 (C-9), 156.1 (C-13), 154.6 (C-
7), 148.2 (C-3), 133.0 (C-1), 132.9 (C-6), 129.9 (C-5), 125.6 (C-4), 121.8 (C-2), 
36.0 (C-11), 33.9 (C-10), 28.4 (C-15); HRMS m/z (ES+) 375.1276 ([M+Na]+, 100%) 
C15H20N4O6Na requires 375.1281. 
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tert-Butyl(2-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)ethyl)carbamate 152 
 
TBAF (163 µl, 1 M in THF, 0.16 mmol) was added to a solution of O-acyl 
amidoxime 151 (576 mg, 1.63 mmol) in dry THF (5 mL) and the reaction was 
stirred for 16 h. The mixture was poured into ethyl acetate (30 mL) and the solvent 
was removed under reduced pressure. The product was purified by column 
chromatography on silica (25% ethyl acetate/petroleum ether) to give the product 
152 as a white solid (538 mg, 99%): m.p. 102-104 ˚C; νmax/cm-1 (nujol) 3362, 1824, 
1752, 1678, 1622, 1593, 1574, 1519, 1162, 1072, 978, 914, 870; δH (300 MHz, 
CDCl3) 8.91-8.90 (1H, m, 2-H), 8.39 (1H, ddd, J= 8.0, 1.9, 1.1 Hz, 4-H), 8.34 (1H, 
ddd, J =8.0, 1.9, 1.1 Hz, 6-H), 7.66-7.59 (1H, m, 5-H), 5.05-4.95 (1H, m, 11-NH), 
3.66 (2H, q, J= 6.1 Hz, 10-H), 3.16 (2H, t, J= 6.1 Hz, 9-H), 2.14 (9H, s, (CH3)3); δC 
(75 MHz, CDCl3) 167.1 (C-7),165.6 (C-8), 156 (C-12), 149.0 (C-3), 133.4 (C-6), 
130. 5 (C-5), 129.0 (C-1), 126.2 (C-4), 123.0 (C-2), 77.6 (C-13) 37.7 (C-10), 28.8 
(C-14), 28.1 (C-9); HRMS m/z (ES+) 357.1171 ([M+Na]+, 100) C15H18N4O5Na 
requires 357.1175. 
 
2-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)ethanamine hydrochloride 122 
 
HCl in 1,4 dioxan (4M, 1.2 mL, 4.8 mmol) was added to a solution 1,2,4-oxadizole 
152 (537 mg, 1.6 mmol) in DCM (5 mL) and the mixture was stirred for 16 h. The 
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solvent was removed under reduced pressure and the oil was titurated with diethyl 
ether to yield the product 122 as a white solid (338 mg, 78%): m.p. 184-190 ˚C; 
νmax/cm-1 (nujol) 3423 (NH), 1715 (C=N); δH (300 MHz, CD3OD) 8.92-8.90 (1H, m, 
2-H), 8.49 (1H, ddd, J= 8.1, 2.0, 1.0 Hz, 4-H), 8.44 (1H, ddd, J= 8.1, 2.0, 1.0, 6-H), 
7.86-7.79 (1H, m, 5-H), 3.60-3.53 (2H, m, 10-H), 3.49-3.43 (2H, m, 9-H); δC (75 
MHz, CD3OD) 179.1 (C-8), 168.6 (C-7), 150.5 (C-3), 134.5 (C-4), 132.2 (C-6), 
130.0 (C-1), 127.4 (C-5), 123.6 (C-2), 37.8 (C-10), 26 (C-9); HRMS m/z (CI+) 
235.0827 ([M+H]+, 37%) C10H11N4O3 requires 235.0831 
 
3-Nitro-N'-((3-phenylpropanoyl)oxy)benzimidamide 155 
 
3-Phenylpropanoic acid (455 mg, 3.03 mmol), DCC (625 mg, 3.03 mmol) and 
DMAP (169 mg, 1.38 mmol) were added to a solution of amidoxime 140(500 mg, 
2.76 mmol) in dry DCM (20 mL) and the mixture was stirred overnight. The mixture 
was filtered and the filtrate was concentrated under reduced pressure. The product 
was purified by column chromatography on silica (20% ethyl acetate/petroleum 
ether to 35% ethyl acetate/petroleum ether) to give the product 155 as a white solid 
(136 mg, 16%): m.p. 82-85 ˚C; νmax/cm-1 (nujol) 3432, 3174, 1746, 1574, 1543, 
1155; δH (300 MHz, CDCl3) 8.43-8.40 (1H, m, 2-H), 8.26 (1H, J= 8.0, 2.0, 1.1 Hz, 
6-H), 8.01 (1H, ddd, J= 8.0, 2.0, 1.1 Hz, 4-H), 7.58-7.51 (1H, m, 5-H), 7.29-7.20 
(4H, m, 13,14-H), 7.18-7.13 (1H, m, 15-H), 4.89 (2H, br s, 8-NH2), 3.01 (2H, t, J= 
7.5 Hz, 11-H), 2.82-2.76 (2H, m, 10-H); δC (75 MHz, CDCl3) 170.1 (C-9), 154.2 (C-
8), 148.1 (C-3) 140.3 (C-12), 132.9 (C-6), 132.9 (C-1) 130.0 (C-5), 128.7 (C-14), 
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128.4 (C-13), 126.5 (C-15), 125.7 (C-4), 121.6 (C-2), 34.8 (C-10), 31.1 (C-11); 
HRMS m/z (ES-) 312.0985 ([M-H]-, 100%) C16H14N3O4 requires 312.0990. 
 
3-(3-Nitrophenyl)-5-phenethyl-1,2,4-oxadiazole 156 
 
TBAF (61 µl, 1M in THF, 0.06 mmol) was added to a solution of O-acyl amidoxime 
155 (190 mg, 0.61 mmol) in THF (5 mL). The mixture was stirred for 16 h at room 
temperature. The mixture was then poured into ethyl acetate (25 mL) and the 
solvent was removed under reduced pressure. The product was purified by column 
chromatography on silica (10% ethyl acetate/petroleum ether) to give the product 
156 as a yellow solid (169 mg, 94%): m.p. 51-53 °C; νmax/cm-1 (nujol) 1717 (C=N); 
δH (300 MHz, CDCl3) 8.94 (1H, ddd, J= 2.3, 1.6, 0.5 Hz, 2-H), 8.41 (1H, ddd, J= 
7.8, 1.6, 1.1 Hz, 4-H), 8.36 (1H, ddd, J= 8.3, 2.3, 1.1 Hz, 6-H), 7.69 (1H, ddd, 
J=8.3, 7.8, 0.5 Hz, 5-H), 7.33-7.29 (2H, m, 12-H), 7.28-7.26 (2H, m, 13-H), 7.26-
7.23 (1H, m, 14-H), 3.34-3.27 (2H, m, 9-H), 3.26-3.17 (2H, m, 10-H); δC (75 MHz, 
CDCl3) 179.9 (C-8), 166.7 (C-7), 148.7 (C-3), 139.2 (C-11), 133.0 (C-6), 130.0 (C-
5), 128.8 (C-1), 128.7 (C-12), 128.3 (C-13), 126.9 (C-14), 125.7 (C-4), 122.6 (C-2), 
32.6 (C-10), 28.5 (C-9); HRMS m/z (ES+) 318.0856 ([M+Na]+) C16H13N3O5Na 
requires 318.0855. 
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N'-((3-(3,4-Dimethoxyphenyl)propanoyl)oxy)-3-nitrobenzimidamide 158 
 
3-(3,4-dimethoxyphenyl)propanoic acid (636 mg, 3.03 mmol), DCC (625 mg, 3.03 
mmol) and DMAP (340 mg, 2.76 mmol) were added to a solution of amidoxime 140 
(500 mg, 2.76 mmol in DCM (20 mL). The mixture was stirred for 16 h. The mixture 
was filtered and the filtrate was concentrated under reduced pressure. The product 
was purified by column chromatography on silica (30% ethyl acetate/petroleum 
ether to 50% ethyl acetate/petroleum ether) to give the product 158 a yellow solid 
(322 mg, 31%): m.p. 102-106 ˚C; νmax/cm-1 (nujol) 3486, 3326, 1739, 1619, 1575, 
1546, 1258, 1137, 897; δH (300 MHz, CDCl3) 8.50 (1H, ddd, J= 2.3, 1.4, 0.4 Hz, 2-
H), 8.33 (1H, ddd, J= 8.2, 2.3, 1.7 Hz, 4-H), 8.08 (1H, ddd, J= 7.8, 1.7, 1.4 Hz, 6-
H), 7.62 (1H, ddd, J= 8.2, 7.8, 0.4 Hz, 5-H), 6.82-6.79 (3H, m, 13,16,17-H), 5.01 
(2H, br s, 8-NH2), 3.88 (3H, s, OMe), 3.86 (3H, s, OMe), 3.02 (2H, t, J= 7.5 Hz, 10-
H), 2.85-2.81 (2H, m, 11-H); δC (75 MHz, CDCl3) 170.6 (C-9), 154.6 (C-7), 148.9 
(C-OMe), 148.0 (C-OMe), 147.5 (C-3), 133.0 (C-12), 132.8 (C-6), 129.8 (C-5), 
125.5 (C-4), 121.8 (C-2), 120.2 (C-17), 111.8 (C-16), 111.5 (C-13), 55.9 (OMe), 
55.8 (OMe), 35.0 (C-11), 30.6 (C-10); HRMS m/z (ES+) 396.1170 ([M+Na]+, 100%) 
C18H19N3O6Na requires 396.1172. 
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5-(3,4-Dimethoxyphenethyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole 159 
 
TBAF (210 µl, 1M in THF, 0.21 mmol) was added to a solution O-acyl amidoxime 
158 (156 mg, 0.42 mmol) in THF (5 mL). The mixture was stirred for 16 h at room 
temperature. The mixture was poured into ethyl acetate (30 mL) and the solvent 
was removed under reduced pressure. The product was purified by column 
chromatography on silica (10% ethyl acetate/ petroleum ether) to give the product 
159 as a yellow solid (81 mg, 54%): m.p. 74-76 ˚C; νmax/cm-1 (nujol) 1715 (C=N); δH 
(300 MHz, CDCl3) 8.88 (1H, ddd, J= 2.3, 1.6, 0.5 Hz, 2-H), 8.34 (1H, ddd, J= 7.8, 
1.6, 1.1 Hz, 4-H), 8.29 (1H, ddd, J= 8.3, 2.3, 1.1 Hz, 6-H), 7.62 (1H, ddd, J= 8.3, 
7.8, 0.5 Hz, 5-H), 6.75-6.72 (2H, m, 15,16-H), 6.70 (1H, s, 12-H), 3.80 (3H, s, 
OMe), 3.79 (3H, s, OMe), 3.25-3.18 (2H, m, 9-H), 3.07 (2H, ddd, J= 8.5, 6.8, 1.7 
Hz, 10-H); δC (75 MHz, CDCl3) 180.0 (C-8), 166.7 (C-7), 149.1 (C-OMe × 2), 147.9 
(C-3), 133.0 (C-6), 131.7 (C-11), 130.1 (C-5), 128.7(C-1), 125.7 (C-4), 122.6 (C-2), 
120.2 (C-16), 111.6 (C-12), 111.5 (C-15), 56.0 (OMe), 55.9 (OMe), 32.2 (C-10), 
28.8 (C-9); HRMS m/z (ES+) 378.1066 ([M+Na]+, 100%) C18H17N3O5Na requires 
378.1066. 
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N'-(((E)-3-(3,4-dimethoxyphenyl)acryloyl)oxy)-3-nitrobenzimidamide 161 
 
3,4-Dimethoxycinnamic acid (630 mg, 3.03 mmol), DCC (625 mg, 3.03 mmol) and 
DMAP (340 mg, 2.76 mmol) were added to a solution of amidoxime 140 (500 mg, 
2.76 mmol in dry DCM (20 mL). The mixture was stirred for 16 h. The mixture was 
then filtered and the filtrate was concentrated under reduced pressure. The product 
was purified by column chromatography on silica (30% ethyl acetate/petroleum 
ether to 60% ethyl acetate/petroleum ether) to give the product 161 as a yellow 
solid (503 mg, 49%): m.p. 146-148 ˚C; νmax/cm-1 (nujol) cm-1 3321 (NH), 1717 
(C=N), 1634 (C=O); δH (300 MHz, CDCl3) 8.58-8.54 (1H, m, 2-H), 8.30-8.26 (1H, 
m, 4-H), 8.17-8.11 (1H, m, 6-H), 7.76 (1H, d, J= 15.9 Hz, 11-H), 7.61-7.55 (1H, m, 
5-H), 7.12 (1H, dd, J= 8.3, 1.9 Hz, 17-H), 7.07 (1H, d, J= 1.9 Hz, 13-H), 6.86 (1H, 
d, J= 8.3 Hz, 16-H), 6.45 (1H, d, J= 15.9 Hz, 10-H), 5.59 (2H, br s, 8-NH2), 3.9 (3H, 
s, OCH3), 3.89 (3H, s, OCH3); δC (75 MHz, CDCl3) 165.2 (C-8), 154.9 (C-7), 
151.8(C-OMe), 149.6 (C-OMe), 148.6 (C-3), 146.5 (C-10), 133.5 (C-1), 133.4 (C-
6), 130.2 (C-5), 127.6 (C-12), 125.9 (C-4), 123.3 (C-17), 122.2 (C-2), 113.4 (C-9), 
111.5 (C-16), 110.1(C-13), 56.4 (OMe), 56.3 (OMe); HRMS m/z (ES+) 394.1008 
([M+Na]+, 42%) C18H17O6N3Na requires 394.1010. 
N.B. On larger scales (1 g- 5 g) recrystallisation from ethanol/ water was used 
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(E)-5-(3,4-Dimethoxystyryl)-3-(3-nitrophenyl)-1,2,4-oxadiazole 162 
 
TBAF (171 µl, 1M in THF, 0.17 mmol) was added to a solution of O-acyl 
amidoxime 161 (635 mg, 1.71 mmol) in THF (10 mL). The mixture was stirred for 
16 h at room temperature and then poured into ethyl acetate (25 mL). The solvent 
was removed under reduced pressure. The product was purified by column 
chromatoraphy on silica (30% ethyl acetate/petroleum ether) to give the product 
162 as an orange solid (270 mg, 45%): m.p. 148-151 ˚C; νmax/cm-1 (nujol) 1717 
(C=N), 974 (C=C); δH (300 MHz, CDCl3) 8.80 (1H, dd, J= 2.3, 1.6 Hz, 2-H), 8.29 
(1H, ddd, J= 7.7, 1.6, 1.1 Hz, 4-H), 8.23 (1H, ddd, J= 8.3, 2.3, 1.1 Hz, 6-H), 7.73 
(1H, d, J= 16.2 Hz, 10-H), 7.62-7.54 (1H, m, 5-H), 7.09 (1H, dd, J= 8.5, 2.0 Hz, 16-
H), 7.03 (1H, d, J= 2.0 Hz, 12-H), 6.81 (1H, d, J= 16.2 Hz, 9-H), 6.79 (1H, d, J= 8.5 
Hz, 15-H), 3.81 (3H, s, OCH3), 3.76 (3H, s, OCH3); δC (100 MHz, D6-DMSO), 176.5 
(C-8), 166.4 (C-7), 151.3 (OMe), 149.0 (OMe), 148.2 (C-3), 143.7 (C-10), 133.0 (C-
6), 131.1 (C-5), 127.9 (C-1), 127.0 (C-11), 126.0 (C-4), 123.4 (C-9), 121.5 (C-2), 
111.5 (C-15), 110.3 (C-12), 107.3 (C-16), 55.7 (OMe), 55.6 (OMe); HRMS m/z 
(ES+) 376.0907 ([M+Na]+, 100%) C18H15N3O5Na requires 376.0909 
 
N.B On larger scales (1 g- 5 g) the product was purified by recrystallisation from 
ethanol. 
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2-Bromo-1-(3,4-dimethoxyphenyl)-2-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)ethanol 
165 
 
N-Bromosuccinimide (1.62 g, 9.1 mmol) was added to a solution of 1,2,4-
oxadiazole 162 (2.92 g, 8.3 mmol) in THF (300 mL) and water (20 mL) and the 
mixture was stirred for 16 h. DCM was added and the layers were sperarted. The 
aqueous layer was re-extracted with DCM (3 × 30 mL). The combined organic 
layers were washed with brine solution. The organic layer was separated and then 
dried with magnesium sulfate. The solvent was removed under reduced pressure. 
The product was purified by column chromatography on silica (20% ethyl 
acetate/petroleum ether to 30% ethyl acetate/petroleum ether) to give the product 
165 as a yellow solid (2.82 g, 75%): m.p. 157-160 ˚C; νmax/cm-1 (nujol) 3465, 1773, 
1699, 1593, 1571, 1516, 1142, 1024; δH (300 MHz, CDCl3) 8.90 (1H, ddd, J= 2.2, 
1.6, 0.5 Hz, 2-H), 8.37 (1H, ddd, J= 7.8, 1.6, 1.1 Hz, 4-H), 8.33 (1H, ddd, J= 8.1, 
2.2, 1.1 Hz, 6-H), 7.65 (1H, ddd, J= 8.1, 7.8, 0.5 Hz, 5-H), 6.95 (1H, dd, J= 8.3, 1.9 
Hz, 16-H), 6.90 (1H, d, J= 1.9 Hz, 12-H), 6.82 (1H, d, J= 8.3 Hz, 15-H), 5.32 (1H, 
dd, J= 8.0, 4.4 Hz, 10-H), 5.16 (1H, d, J= 8.0 Hz, 9-H), 3.81 (6H, s, OMe), 2.97 
(1H, d, J= 4.4 Hz, OH); δC (75 MHz, CDCl3) 177.7 (C-8), 167.5 (C-7), 149.9 
(COMe), 149.5 (COMe), 148.94 (C-3), 133.5 (C-6), 131.6 (C-11), 130.6 (C-5), 
128.3 (C-1), 126.5 (C-4), 123.0 (C-2), 120.1 (C-16), 111.3 (C-15), 109.9 (C-12), 
76.3 (C-10), 56.3 (OMe), 56.2 (OMe), 41.7 (C-9); HRMS m/z (ES+) 472.0114 
([M+Na]+, 100%) C18H16O6N379BrNa requires 472.0115. 
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5-(3-(3,4-Dimethoxyphenyl)oxiran-2-yl)-3-(3-nitrophenyl)-1,2,4-oxadiazole 164 
 
Potassium carbonate (270 mg, 1.95 mmol) was added to a solution of bromohydrin 
165 (800 mg, 1.78 mmol) in methanol (20 mL) and the mixture was stirred for 16 h. 
The mixture was then filtered and the filtrate was concentrated under reduced 
pressure. On a small scale the product was purified by column chromatography 
(20% ethyl actetate/petroleum ether) to give the product 164 as an off-white solid 
(419 mg, 64%): m.p. 136-138 ˚C; νmax/cm-1 (nujol) 3079, 1721, 1597, 1573, 1520, 
1269, 1240, 1156, 1143, 1025, 916; δH (300 MHz, CDCl3) 9.00 (1H, ddd, J= 2.2, 
1.6, 0.5 Hz, 2-H), 8.47 (1H, ddd, J= 7.8, 1.6, 1.1 Hz, 4-H), 8.42 (1H, ddd, J= 8.3, 
2.2, 1.1 Hz, 6-H), 7.74 (1H, ddd, J= 8.3, 7.8, 0.5 Hz, 5-H), 7.03 (1H, dd, J= 8.4, 2 
Hz, 16-H), 6.94 (1H, d, J= 8.4 Hz, 15-H), 6.87 (1H, d, J= 2, 12-H), 4.53 (1H, d, J= 
1.8 Hz, 10-H), 4.27 (1H, d, J= 1.8 Hz, 9-H), 3.95 (3H, s, OMe), 3.94 (3H, s, OMe); 
δC (75 MHz, CDCl3) 176.2 (C-8), 167.6 (C-7), 158.4 (C-11), 150.5 (COMe), 150.0 
(COMe),149.1 (C-3), 133.5 (C-6), 130.6 (C-5), 128.5 (C-1), 126.5 (C-4), 123.1 (C-
2), 119.4 (C-16), 111.7 (C-15), 108.4 (C-12), 61.2 (C-10), 56.5 (OMe), 56.4 (OMe), 
53.3 (C-9); HRMS m/z (ES+) 392.0867 ([M+Na]+, 100) C18H15N3O6Na requires 
392.0859. 
N.B On larger scales the product was taken on to the next step in its crude form. 
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(3,4-dimethoxyphenyl)(hydroxy)methyl)-3-(3-nitrophenyl)-4H-1,2,4-oxadiazin-
5(6H)-one 167 
 
Potassium hydroxide (33 mg, 0.6 mmol) was added to a solution of epoxide 164 
(200 mg, 0.54 mmol) in methanol (10 mL). THF (10 mL) and water (5 mL) were 
added. The mixture was heated under reflux for 2 h. The solvent was removed 
under reduced pressure. The mixture was then acidified with 2M HCl. The aqueous 
layer was extracted with ethyl acetate (3 × 50 mL) and the organic layers were 
dried with magnesium sulfate. The solvent was removed under reduced pressure 
and the crude product was purified by column chromatography on silica (30% ethyl 
acetate/petroleum ether to 50% ethyl acetate/petroleum ether) to give the product 
167 as a white solid (105 mg, 50%): m.p. 188-190 ˚C; νmax/cm-1 (nujol) 3474 (OH), 
1718; δH (400 MHz, D6-DMSO) 11.59 (1H, s, OH), 8.47-8.46 (1H, m, 2-H), 8.36 
(1H, ddd, J= 8.3, 2.3, 1.0 Hz, 4-H), 8.11 (1H, ddd, J= 7.9, 1.7, 1.0 Hz, 6-H), 7.78-
7.74 (1H, m, 5-H), 7.01 (1H, d, J= 1.8 Hz, 12-H), 6.88 (1H, dd, J= 8.4, 1.8 Hz, 16-
H), 6.85 (1H, d, J= 8.4 Hz, 15-H), 5.83 (1H, d, J= 5.3 Hz, OH), 4.94 (1H, dd, J= 5.3, 
5.1 Hz, 10-H), 4.58 (1H, d, J= 5.1 Hz, 9-H), 3.70 (3H, s, OMe), 3.68 (3H, s, OMe); 
δC (100 MHz, D6-DMSO) 164.7 (C-8), 163.4 (C-7), 148.9 (C-OMe), 148.2 (C-3) 
147.7 (C-OMe), 133.1 (C-11), 132.8 (C-6), 130.6 (C-5), 130.3 (C-1), 125.5 (C-4), 
121.3 (C-2), 119.3 (C-15), 111.0 (C-16), 110.7 (C-12), 79.8 (C-9), 70.4 (C-10), 55.4 
(OMe), 55.4 (OMe); m/z (ES+) 410.0952 ([M+Na]+, 100%) C18H17N3O7Na requires 
410.0964. 
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1-(3,4-Dimethoxyphenyl)-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethane-1,2-diol 172 
 
HCl (2N, 560 µl, 1.2 mmol) was added to a solution of epoxide 164 (2.2 g, 5.96 
mmol) in THF/ water (100/20 mL) and the solution was heated under reflux for 3 h. 
The solution was allowed to cool and water (20 mL) was added. The mixture was 
extracted with DCM (3 × 100 mL) and the organic layer was dried with magnesium 
sulfate. The solvent was removed under reduced pressure. The diastereoisomers 
were inseparable and were purified together using column chromatography on 
silica (30% ethyl acetate/ petroleum ether to 50% ethyl acetate/ petroleum ether) to 
give the diastereoisomers 172 as a solid (2.26 g, 98%) 
 
threo-5-(3,4-Dimethoxyphenyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-(3-nitrophenyl)-
1,2,4-oxadiazole 173 and erythro-5-(3,4-dimethoxyphenyl)-2,2-dimethyl-1,3-
dioxolan-4-yl)-3-(3-nitrophenyl)-1,2,4-oxadiazole 174 
 
Diol 172, as an inseperable mixture of diastereoisomers, (422 mg, 1.09 mmol) was 
dissolved in DCM (20 mL). p-Toluenesulfonic acid (21 mg, 0.1 mmol) and 2,2-
dimethoxypropane (147 µl, 1.2 mmol) was added and the mixture was stirred for 16 
h. Water (20 mL) and DCM (20 mL) were added and the layers were separated. 
The aqueous layer was re-extracted with DCM (2 × 20 mL). The combined organic 
layers were washed with brine solution (30 mL). The organic layer was dried with 
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magnesium sulfate and the solvent was removed under reduced pressure. The 
product was purified by column chromatography on silica (20% ethyl acetate/ 
petroleum ether) to give 
threo-5-(3,4-dimethoxyphenyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-(3-nitrophenyl)-
1,2,4-oxadiazole 173 as a yellow solid (172 mg, 37%): m.p 78-80 ˚C; νmax/cm-1 
(nujol) 1734, 1686, 1598, 1520; δH (300 MHz, CDCl3) 8.94 (1H, ddd, J= 2.3, 1.6, 
0.4 Hz, 2-H), 8.44 (1H, ddd, J= 7.8,1.6, 1.1 Hz, 4-H), 8.37 (1H, ddd, J= 8.3, 2.3, 1.1 
Hz, 6-H), 7.70 (1H, ddd, J= 8.3, 7.8, 0.4 Hz, 5-H), 7.03 (1H, d, J= 2.0 Hz, 12-H), 
6.99 (1H, ddd, J= 8.2, 2.0, 0.4 Hz, 16-H), 6.88 (1H, dd, J= 8.2 Hz, 15-H), 5.47 (1H, 
d, J= 8.0 Hz, 10-H), 5.07 (1H, d, J= 8.0 Hz, 9-H), 3.90 (3H, s, OMe), 3.88 (3H, s, 
OMe), 1.71 (3H, s, Me), 1.67 (3H, s, Me); δC (75 MHz, CDCl3) 177.1 (C-8), 167.0 
(C-7), 149.7 (C-OMe), 149.4 (C-OMe), 148.6 (C-3), 133.1 (C-4), 130.1 (C-5), 128.2 
(C-1), 128.1 (C-11), 125.9 (C-6), 122.6 (C-2), 119.2 (C-16), 112.2 (C-17), 111.3 (C-
15), 109.4 (C-12), 81.7 (C-10), 76.4 (C-9), 55.9 (OMe × 2), 27.0 (Me), 26.1 (Me); 
HRMS m/z (ES+) 450.1285 ([M+Na]+, 100%) C21H21N3O7Na requires 450.1277. 
 
and erythro-5-(3,4-dimethoxyphenyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-3-(3-
nitrophenyl)-1,2,4-oxadiazole 174 as a yellow solid (266 mg, 57%): m.p 121-125 
˚C; νmax/cm-1 (nujol) 1746, 1724, 1570, 1544, 1521; δH (300 MHz, CDCl3) 8.75 (1H, 
ddd, J= 2.3, 1.6, 0.5 Hz, 22-H), 8.32 (1H, ddd, J= 8.2, 2.3, 1.1 Hz, 26-H), 8.24 (1H, 
ddd, J= 7.8,1.6, 1.1 Hz, 24-H) 7.63 (1H, ddd, J= 8.2, 7.8, 0.5 Hz, 25-H), 6.85 (1H, 
ddd, J= 8.3, 2.0, 0.4 Hz, 36-H), 6.73 (1H, d, J= 2.0 Hz, 32-H), 6.72 (1H, d, J= 8.3 
Hz, 35-H), 5.63 (1H, d, J= 6.7 Hz, 29-H), 5.60 (1H, d, J= 6.7 Hz, 30-H), 3.76 (3H, s, 
OMe), 3.72 (3H, s, OMe), 1.94 (3H,s, Me), 1.63 (3H, s, Me); δC (75 MHz, CDCl3) 
177.5 (C-28), 166.4 (C-27), 149.2 (C-OMe), 149.0 (C-OMe), 148.6 (C-23), 132.9 
(C-24), 130.0 (C-25) 128.3 (C-21), 126.0 (C-31), 125.8 (C-26), 122.5 (C-22), 119.2 
(C-36), 112.0 (C-37), 110.8 (C-35), 108.6 (C-32), 80.4 (C-30), 75.3 (C-29), 55.8 
(OMe), 55.8 (OMe), 26.8 (Me), 25.5 (Me); HRMS m/z (ES+) 450.1266 ([M+Na]+, 
100%) C21H21N3O7Na requires 450.1277. 
  181 
threo 1-(3,4-Dimethoxyphenyl)-2-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)ethane-
1,2-diol 175 
 
 
Camphor-sulfonic acid (35 mg, 0.15 mmol) was added to a solution of acetonide 
173 (666 mg, 1.5 mmol) in methanol (20 mL). The mixture was stirred for 2 h. HCl 
(2N, 2 mL) was added and the solution was heated to 90 ˚C for 2 h. When TLC 
analysis indicated consumption of the starting material a saturated solution of 
sodium bicarbonate (20 mL) and ethyl acetate (30 mL) was added. The layers 
were separated and the aqueous layer was re-extracted with ethyl acetate (3 × 30 
mL). The combined organic layers were dried with magnesium sulfate and the 
solvent was removed under reduced pressure. The product was purified by column 
chromatography on silica (30% ethyl acetate/petroleum ether to 50% ethyl 
acetate/petroleum ether) to give the product 175 as a yellow solid (389 mg, 
67%): m.p 124-126 ˚C; νmax/cm-1 (nujol mull) 3504, 3330, 1730, 1593; δH (300 MHz, 
CDCl3) 8.86 (1H, ddd, J= 2.2, 1.7, 0.4 Hz, 2-H), 8.35-8.28 (2H, m, 4,6-H), 7.62 (1H, 
ddd, J= 8.2, 7.8, 0.4 Hz, 5-H), 6.87-6.84 (2H, m, 12,16-H), 6.77 (1H, d, J= 8.2 Hz, 
15-H), 5.11 (1H, d, J= 5.0 Hz, 10-H), 5.06 (1H, d, J= 5.0 Hz, 9-H), 3.79 (6H, s, 
OMe); δC (75 MHz, CDCl3) 178.7 (C-8), 166.6 (C-7), 149.4 (C-OMe), 149.3 (C-
OMe), 148.7 (C-3), 133.1 (C-4), 130.7 (C-11), 130.2 (C-5), 128.1 (C-1), 126.0 (C-
6), 122.7 (C-2), 119.0 (C-16), 111.2 (C-15), 109.5 (C-12), 75.3 (C-10), 71.5 (C-9), 
56.0 (OMe), 56.0 (OMe); HRMS m/z (ES+) 410.0964 ([M+Na]+, 100%) 
C18H17N3O7Na requires 410.0964. 
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erythro 1-(3,4-Dimethoxyphenyl)-2-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)ethane-
1,2-diol 176 
 
Camphor-sulfonic acid (30 mg, 0.13 mmol) was added to a solution of acetonide 
174 (561 mg, 1.3 mmol) in methanol (20 mL). The mixture was stirred for 2 h. HCl 
(2N, 2 mL) was added and the solution was heated to 90 ˚C for 2 h. When TLC 
analysis indicated consumption of the starting material a saturated solution of 
sodium bicarbonate (20 mL) and ethyl acetate (30 mL) was added. The layers 
were separated and the aqueous layer was re-extracted with ethyl acetate (3 × 30 
mL). The combined organic layers were dried with magnesium sulfate and the 
solvent was removed under reduced pressure. The product was purified by column 
chromatography on silica (30% ethyl acetate/petroleum ether to 50% ethyl 
acetate/petroleum ether) to give the product 176 as a yellow solid (320 mg, 64%): 
m.p 164-168 ˚C; νmax/cm-1 (nujol) 3457, 3469, 1675, 1594, 1515, 1138, 1025; δH 
(300 MHz, D6DMSO) 8.75 (1H, ddd, J= 2.2, 1.8, 0.4 Hz, 2-H), 8.49-8.44 (2H, m, 
4,6-H), 7.91 (1H, ddd, J= 8.3, 7.8, 0.4 Hz, 5-H), 7.07 (1H, d, J= 1.7 Hz, 12-H) 6.97 
(1H, dd, J= 8.3, 1.7 Hz, 16-H), 6.93 (1H, d, J= 8.3 Hz, 15-H), 6.33 (1H, d, J= 6.1 
Hz, 9-OH), 5.77 (1H, d, J= 4.6 Hz, 10-OH), 4.88 (1H, dd, J= 8.3, 6.1 Hz, 9H), 4.82 
(1H, dd, J= 8.3, 4.6 Hz, 10-H), 3.76 (3H, s, OMe), 3.75 (3H, s, OMe); δC (75 MHz, 
D6DMSO) 181.6 (C-8), 162.0 (C-7), 148.4 (C-OMe), 148.3 (C-OMe), 148.3 (C-1), 
134.5 (C-11), 133.0 (C-4), 131.3 (C-5), 127.7 (C-3), 126.1 (C-6), 121.6 (C-2), 119.6 
(C-16), 111.3 (C-15), 110.8 (C-12), 74.5 (C-10), 70.3 (C-9), 55.6 (OMe), 55.4 
(OMe); HRMS m/z (ES+) 410.0957 ([M+Na]+, 100%) C18H17N3O7Na requires 
410.0964. 
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2-Azido-2-(3,4-dimethoxyphenyl)-1-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)ethanol 
177 
 
Epoxide 164 (739 mg, 2 mmol) was added to a solution of ammonium chloride 
(160 mg, 3 mmol) in water (1 mL) and methanol (3 mL). Sodium azide (260 mg, 4 
mmol) was added to the mixture, which was then heated under reflux for 2 h. The 
solvent was removed under reduced pressure. DCM (50 mL) and water (10 mL) 
were added and the organic layer was separated. The organic layer was dried with 
magnesium sulfate and the solvent was removed under reduced pressure to give 
the crude product as a yellow solid. The product was purified by column 
chromatography on sillica (30% ethyl acetate/petroleum ether to 50% ethyl 
acetate/petroleum ether) to give the product 177 as a yellow solid (729 mg, 88%): 
m.p. 141-144 ˚C; νmax/cm-1 (nujol) 3430 (OH), 2118 (N3); δH (300 MHz, D6-DMSO) 
8.72-8.71 (1H, m, 2-H), 8.48-8.42 (1H, m, 4,6-H), 7.92-7.87 (1H, m, 5-H), 7.10 (1H, 
d, J= 1.9 Hz, 12-H), 7.03 (1H, dd, J= 8.4, 1.9 Hz, 16-H), 6.97 (1H, d, J= 8.4 Hz, 15-
H), 6.83 (1H, d, J= 6.0 Hz, OH), 5.33 (1H, dd, J= 8.0, 6.0 Hz, 9-H), 5.16 (1H, d, J= 
8.0 Hz, 10-H), 3.75 (3H, s, OMe), 3.74 (3H,s, OMe); δC (75 MHz, D6-DMSO) 180.4 
(C-7), 166.6 (C-8), 149.4 (C-OMe), 149.0 (C-OMe), 148.7 (C-3), 133.4 (C-6), 131.7 
(C-5), 127.9, 127.7, 126.7 (C-4), 122.0 (C-2), 121.3 (C-16), 111.9 (C-12), 111.8 (C-
15), 68.5 (C-9), 67.2 (C-10), 55.9 (OMe), 55.8 (OMe); m/z (ES+) 435 ([M+Na]+, 
100%). 
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5-(2-Azido-1-((tert-butyldimethylsilyl)oxy)-2-(3,4-dimethoxyphenyl)ethyl)-3-(3-
nitrophenyl)-1,2,4-oxadiazole 178 
 
Imidazole (345 mg, 5 mmol) and TBSCl (300 mg, 2 mmol) were added to a solution 
of azido alcohol 177 (578 mg, 1.4 mmol) in DCM (40 mL). The solution was stirred 
for 16 h. The solution was diluted with DCM (100 mL) and washed with a saturated 
solution of sodium bicarbonate. The organic layer was dried with magnesium 
sulfate and the solvent was removed under reduced pressure. The product was 
purified by column chromatography on silica (ethyl acetate/petroleum ether) to give 
the product 178 a yellow oil (520mg, 71%): νmax/cm-1 (thin film) 3556, 3437, 3341, 
3086, 2927, 2856, 2113, 1717, 1593, 1514, 1466, 1267, 1142, 1028, 841; δH (300 
MHz, CDCl3) 8.99 (1H, ddd, J= 2.3, 1.5, 0.3 Hz, 2-H), 8.46 (1H, ddd, J= 7.8, 1.5, 
1.1 Hz, 4-H), 8.39 (1H, ddd, J= 8.2, 2.3, 1.1 Hz, 6-H), 7.71 (1H, ddd, J= 8.2, 7.8, 
0.3 Hz, 5-H), 6.99 (1H, dd, J= 8.1, 1.9 Hz, 16-H), 6.96 (1H, d, J= 1.9 Hz, 12-H), 
6.90 (1H, d, J= 8.1 Hz, 15-H), 5.03 (1H, d, J= 8.1 Hz, 9-H), 4.97 (1H, d, J= 8.1 Hz, 
10-H), 3.91 (3H, s, OMe), 3.90 (3H, s, OMe), 0.75 (9H, s, (CH3)3), -0.11 (3H, s, 
Me), -0.18 (3H, s, Me); δC (75 MHz, CDCl3) 178.9 (C-8), 166.8 (C-7), 149.8 (C-
OMe), 149.3 (C-OMe), 148.7 (C-3), 133.1 (C-6), 130.1 (C-5), 128.4 (C-1), 127.7 
(C-11), 125.9 (C-4), 122.8 (C-2), 121.1 (C-16), 111.1 (C-15), 111.0 (C-12), 70.9 (C-
9), 68.5 (C-10), 56.0 (OMe × 2), 25.4 (C-21), 18.0 (C-20), -5.5 (C-19) -5.6(C-19); 
HRMS m/z (ES+) 549.1894 ([M+Na]+, 100%) C24H30N6O6NaSi requires 549.1894. 
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2-((tert-Butyldimethylsilyl)oxy)-1-(3,4-dimethoxyphenyl)-2-(3-(3-nitrophenyl)-1,2,4-
oxadiazol-5-yl)ethanamine 179 
 
method 1: using polymer supported triphenyl phosphine 
Silyl protected azido alcohol 178 (1.28 g, 2.4 mmol) was added to a solution of 
THF/H2O (100/20 mL). Polymer supported triphenyl phospine (2.6 g, 3.6 mmol) 
was added to the solution and the mixture was heated under reflux overnight. The 
mixture was left cool to room temperature. The mixture was filtered and water (100 
mL) was added to the filtrate. The suspension was extracted with ethyl acetate (3 × 
100 mL). The organic layer was dried with magnesium sulfate and the solvent was 
removed under reduced pressure. The product was purified by column 
chromatography on silica (30% ethyl acetate/ petroleum ether to 40% ethyl 
acetate/petroleum ether) to give the product 179 as a yellow oil (746 mg, 62%). 
method 2: using trimethylphosphine 
Silyl protected azido alcohol 178 (1.15 g, 2.2 mmol) was added to a solution of 
THF/H2O (50/10 mL). A solution of trimethylphospine in THF (1N, 2.6 mL, 2.6 
mmol) was added dropwise to the azide solution. The mixture was stirred for 45 
min before sodium hydroxide (235 mg, 5.9 mmol) was added and the solution was 
stirred overnight. Water (50 mL) was added and the product was extracted with 
ethyl acetate (3 × 50 mL). The organic layer was dried with magnesium sulfate and 
the solvent was removed under reduce pressure. The product was purified by 
column chromatography on silica (30% ethyl acetate/petroleum ether to 40% ethyl 
acetate/petroleum ether) to give the product 179 as a yellow oil (606 mg, 55%): δH 
(300 MHz, CDCl3) 9.06- 9.05 (1H, m, 2-H), 8.53 (1H, ddd, J= 7.8, 1.5, 1.1 Hz, 4-H), 
8.47 (1H, ddd, J= 8.3, 2.3, 1.1 Hz, 6-H), 7.82-7.76 (1H, m, 5-H) 7.04- 6.99 (2H, m, 
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12,16-H), 6.94 (1H, d, J=8.8 Hz, 15-H), 5.11 (1H, d, J= 7.3 Hz, 9-H), 4.48 (1H, d, 
J= 7.3 Hz, 10-H), 3.97 (3H, s, OMe), 3.96 (3H, s, OMe), 1.80 (2H, s, NH2), 0.88 
(9H, s, (CH3)3), 0.00 (3H, s, Me), -0.06 (3H,s, Me); δC (75 MHz, CDCl3) 180.0 (C-8), 
166.6 (C-7), 149.0 (C-OMe), 148.8 (C-OMe), 148.7 (C-3), 133.8 (C-11), 133.1 (C-
4), 130.1 (C-5), 128.6 (C-1), 125.8 (C-6), 122.7 (C-2), 119.8 (C-16), 111.1 (C-15), 
110.5 (C-12), 73.1 (C-9), 59.9 (C-10), 56.0 (OMe), 55.9 (OMe), 25.5 ((CH3)3), 18.1 
(C(CH3)3), -5.3 (Me), -5.5 (Me); m/z (ES+) 523.1984 (M+Na+, 20%), 
C24H32N4O6SiNa requires  523.1989. 
 
(2-Amino-2-(3,4-dimethoxyphenyl)-1-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)ethanol 
180 
 
TBAF (1.1 mL, 1 M in THF 1.1 mmol) was added dropwise to a solution of silyl 
protected amino alcohol 179 (278 mg, 0.55 mmol) in THF (20 mL) and the mixture 
was stirred for 3 h. The solvent was removed under reduced pressure and the 
product was purified by column chromatography on silica (10% methanol/DCM) to 
give a yellow oil. The oil was dissolved in DCM and HCl (1M, 30 mL) was added 
and the aqueous layer was retained. The aqueous layer was basified with sodium 
hydroxide and the product was extracted with DCM (3 × 30 mL). The organic layer 
was dried with magnesium sulfate and most of the solvent was removed under 
reduced pressure. The product was triturated by the addition of petroleum ether to 
give 180 as a yellow solid (145 mg, 68%): m.p 142-148 ˚C; νmax/cm-1 (nujol) 3464, 
3391, 3329, 3072, 1686, 1593, 1539, 1517; δH (300 MHz, D6-DMSO) 8.73 (1H, dd, 
J= 1.9, 1.9 Hz, 2-H), 8.46 (1H, dd, J= 8.1, 1.0 Hz, 6-H), 8.45 (1H, d, J= 8.2 Hz, 4-
H), 7.90 (1H, dd, J= 8.2, 8.1 Hz, 5-H), 7.06 (1H, d, J= 1.5 Hz, 12-H), 6.92 (1H, dd, 
J= 8.3, 1.5 Hz, 16-H), 6.87 (1H, d, J= 8.3 Hz, 15-H), 6.26 (1H, s, OH), 4.94 (1H, d, 
5
4
3
2
1
6
NO2
7 N
8ON
9 10
OH
11H2N 12 13
14
1516
O
O
18
17
  187 
J= 8.0 Hz, 9-H), 4.17 (1H, d, J= 8.0 Hz, 10-H), 3.74 (6H, s, OMe), 2.09 (2H, s, 
NH2); δC (75 MHz, D6-DMSO) 181.7 (C-8), 165.9 (C-7), 148.4 (C-1), 148.3 (C-
OMe), 147.8 (C-OMe), 135.8 (C-11), 133.0 (C-4), 131.2 (C-5), 127.8 (C-3), 126.1 
(C-6), 121.6 (C-2), 119.6 (C-16), 111.3 (C-15), 111.1 (C-12), 70.8 (C-9), 59.2 (C-
10), 55.5 (OMe), 55.4 (OMe); m/z  (ES+) 409.1113 ([M+Na]+, 100%) C18H18N4O6Na 
requires 409.1124. 
 
N-((2-((tert-Butyldimethylsilyl)oxy)-1-(3,4-dimethoxyphenyl)-2-(3-(3-nitrophenyl)-
1,2,4-oxadiazol-5-yl)ethyl))acetamide 181 
 
 
DMAP (120 mg, 1.0 mmol) was added to a solution of silyl proected amino alcohol 
179 (514 mg, 1.02 mmol) in DCM (20 mL). Acetic anhydride (116 µl, 1.2 mmol) 
was added to the solution. The mixture was stirred overnight. A solution of 
saturated sodium bicarbonate was added until the effervescence was finished. The 
product was extracted using DCM (3 × 50 mL). The organic layer was dried using 
magnesium sulfate and the solvent was removed under reduced pressure. The 
product was purified by column chromatography on silica (40% ethyl acetate/ 
petroleum ether) to give the product 181 as a yellow oil (283 mg, 51%): νmax/cm-1 
(thin film) 3296, 3083, 2929, 2856, 1654, 1593, 1567, 1518, 1464, 1349, 1263, 
1143, 1028; δH (300 MHz, CDCl3) 8.82 (1H, ddd, J= 2.0, 1.9, 0.4 Hz, 2-H), 8.31 
(1H, d, J= 2.0 Hz, 4-H), 8.29-8.28 (1H, m, 6-H), 7.65-7.58 (1H, m, 5-H), 6.85 (1H, 
d, J= 2.0 Hz, 12-H), 6.82 (1H, dd, J= 8.2, 2.0 Hz, 16-H), 6.69 (1H, d, J= 8.2 Hz, 15-
H), 6.13 (1H, d, J= 7.0 Hz, NH), 5.45-5.38 (2H, m, 9,10-H), 3.76 (3H, s, OMe), 3.75 
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(3H, s, OMe), 1.98 (3H, s, 23-H), 0.89 (9H, s, 21-H), 0.02 (3H, s, Me), 0.00 (3H, s, 
Me); δC (125 MHz, CDCl3) 178.8 (C-22), 169.4 (C-8), 166.5 (C-7), 149.0 (C-OMe), 
148.9 (C-OMe), 148.6 (C-3), 133.0 (C-4), 130.1 (C-5), 129.1 (C-11), 128.3 (C-1), 
125.8 (C-6), 122.6 (C-2), 120.2 (C-16), 111.1 (C-12, C-15), 70.3 (C-10), 56.8 (C-9), 
55.9 (OMe), 55.8 (OMe), 25.6 (C-21), 23.4 (C-23), 18.2 (C-20), -5.2 (C-19), -5.3 
(C-19); HRMS m/z (ES+) 565.2090 ([M+Na]+, 100%) C26H34N4O7SiNa requires 
565.2094. 
 
N-(1-(3,4-Dimethoxyphenyl)-2-hydroxy-2-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-
yl)ethyl)acetamide 182 
 
 
TBAF (1.44 mL, 1 M in THF 1.44 mmol) was added dropwise to a solution of 
acetamide 181 (523 mg, 0.9 mmol) in THF (20 mL). The solution was stirred for 2 
h. Ethyl acetate (30 mL) and water (30 mL) were added and the layers were 
separated. The aqueous layer was re-extracted with ethyl acetate (2 × 30 mL). The 
combined organic layers were washed with brine solution (30 mL). The organic 
layer was dried with magnesium sulfate and the solvent was removed under 
reduced pressure. The product was purified by column chromatography on silica 
(80% ethyl acetate/petroleum ether to 100% ethyl acetate) to give the product 182 
as a yellow solid (275 mg, 71%): m.p 63-66 ˚C; νmax/cm-1 (nujol) 3344, 1743, 1717, 
1656, 1594, 1540, 1517, 1262, 1145, 1025; δH (300 MHz, CDCl3) 8.88 (1H, dd, J= 
1.9, 1.7 Hz, 2-H), 8.40-8.39 (1H, m, 6-H), 8.37-8.36 (1H, m, 4-H), 7.70 (1H, dd, J= 
8.0, 8.0, Hz, 5-H), 6.88-6.80 (2H, m, 15,16-H), 6.79 (1H, d, J= 1.7 Hz, 12-H), 6.62 
(1H, d, J= 7.3 Hz, OH), 5.58 (1H, dd, J= 7.3, 3.7 Hz, 9-H), 5.46 (1H, d, J= 3.7 Hz, 
10-H), 3.84 (3H, s, OMe), 3.80 (3H, s, OMe), 2.16 (3H, s, 20-H); δC (75 MHz, 
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CDCl3) 179.0 (C-8), 171.6 (C-19), 166.8 (C-7), 149.7 (C-OMe), 149.6 (C-OMe), 
149.0 (C-3), 133.4 (C-6), 130.6 (C-5), 128.4 (C-10), 128.3 (C-11), 126.4 (C-4), 
123.0 (C-1), 119.9 (C-16), 111.7 (C-15), 111.0 (C-12), 70.8 (C-10), 58.0 (C-9), 56.3 
(OMe), 56.3 (OMe), 23.7 (C-18); HRMS m/z (ES+) 451.1223 ([M+Na]+, 100%) 
C20H20O7N4Na requires 451.1230. 
 
5-(1-Bromo-2-((tert-butyldimethylsilyl)oxy)-2-(3,4-dimethoxyphenyl)ethyl)-3-(3-
nitrophenyl)-1,2,4-oxadiazole 185 
 
Imidazole (793 mg, mmol) and TBSCl (1.17 g, 7.8 mmol) were added to a solution 
of bromohydrin 165 (1.75 g, 3.9 mmol) in DCM (40 mL). The mixture was stirred for 
8 h. The solution was diluted with DCM (100 mL) and then washed with saturated 
sodium bicarbonate solution. The organic layer was dried with magnesium sulfate. 
The solvent was removed under reduced pressure. The product was purified by 
column chromatography on silica (10% ethyl acetate/petroleum ether to 15 % ethyl 
acetate/petroleum ether) to give the product 185 a colourless solid (1.72 g, 78%): 
m.p 98-100 ˚C; νmax/cm-1 (nujol) 1684, 1594, 1546, 1519; δH (300 MHz, CDCl3) 8.88 
(1H, ddd, J= 2.3, 1.6, 0.5 Hz, 2-H), 8.35 (1H, ddd, J= 7.8, 1.6, 1.1 Hz, 4-H), 8.30 
(1H, ddd, J= 8.3, 2.3, 1.1 Hz, 6-H), 7.62 (1H, ddd, J= 8.3, 7.8, 0.5 Hz, 5-H), 6.92 
(1H, dd, J= 8.2, 1.9 Hz, 16-H), 6.88 (1H, d, J= 1.9 Hz, 12-H), 6.79 (1H, d, J= 8.2 
Hz, 15-H), 5.16 (1H, d, J= 9.3 Hz, 10-H), 4.97 (1H, d, J= 9.3 Hz, 9-H), 3.82 (6H, s, 
OMe), 0.56 (9H, s, (CH3)3), -0.19 (3H, s, Me), -0.34 (3H, s, Me); δC (75 MHz, 
CDCl3) 178.4 (C-8), 167.5 (C-7), 149.9 (C-OMe), 149.5 (C-OMe), 149.1 (C-1), 
133.4 (C-4), 132.5 (C-11), 130.6 (C-5), 128.7 (C-3), 126.4 (C-6), 123.0 (C-2), 120.9 
(C-16), 110.9 (C-15), 109.9 (C-12), 77.8 (C-10), 56.3 (OMe), 56.3 (OMe), 42.8 (C-
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9), 25.7 (C-21), 18.2 (C-20), -4.3 (Me), -5.1 (Me); HRMS m/z (ES+) 586.0981 
([M+Na]+, 100%), C24H30N3O6Si79BrNa requires 586.0985. 
 
5-(1-Bromo-2-(3,4-dimethoxyphenyl)-2-((trimethylsilyl)oxy)ethyl)-3-(3-nitrophenyl)-
1,2,4-oxadiazole 186 
 
 
Imidazole (228 mg, 3.3 mmol) and TMSCl (281 µl, 2.2 mmol) were added to a 
solution bromohydrin 165 (500 mg, 1.1 mmol) in DCM (40 mL). The solution was 
stirred for 8 h. The solution was diluted with DCM (100 mL) and then washed with 
saturated sodium bicarbonate solution. The organic layer was dried with 
magnesium sulfate. The solvent was removed under reduced pressure. The 
product was purified by column chromatography on silica (15% ethyl 
acetate/petroleum ether) to give the product 186 as a white solid (377 mg, 66%): 
m.p 104-108 ˚C; νmax/cm-1 (nujol) 1738, 1621, 1592, 1567, 1540, 1517, 1254, 1162, 
1134, 1076, 1025, 916, 869, 845, 709; δH (300 MHz, CDCl3) 9.09 (1H, ddd, J= 2.3, 
1.6, 0.4 Hz, 2-H), 8.56 (1H, ddd, J= 7.8, 1.6, 1.1 Hz, 4-H), 8.49 (1H, ddd, J= 8.2, 
2.3, 1.1 Hz, 6-H), 7.82 (1H, ddd, J= 8.2, 7.8, 0.4 Hz, 5-H), 7.12 (1H, dd, J= 8.2, 2.0 
Hz, 16-H), 7.09 (1H, d, J= 2.0 Hz, 12-H), 6.98 (1H, d, J= 8.2 Hz, 15-H), 5.36 (1H, d, 
J= 9.4 Hz, 10-H), 5.15 (1H, d, J= 9.4 Hz, 9-H), 4.02 (3H, s, OMe), 4.01 (3H, s, 
OMe), 0.00 (9H, s, 3 × CH3); δC (75 MHz, CDCl3) 178.2 (C-8), 167.2 (C-7), 149.7 
(C-OMe), 149.3 (C-OMe), 148.9 (C-1), 133.2 (C-4), 132.2 (C-11), 130.4 (C-5), 
128.5 (C-3), 126.1 (C-6), 122.9 (C-2), 120.6 (C-16), 110.8 (C-15), 109.8 (C-12), 
77.4 (C-10), 56.2 (OMe), 56.1 (OMe), 42.6 (C-9), 0.0 (3 × CH3); HRMS m/z (ES+) 
544.0516 ([M+Na]+, 100%) C21H24N3O6SiBrNa requires 544.0515. 
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2-Bromo-1-(3,4-dimethoxyphenyl)-2-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)ethyl 
acetate 188 
 
Acetic anhydride (99 µl, 1.05 mmol) and pyridine (85 µl, 1.05 mmol) were added to 
a solution of bromohydrin 165 (190 mg, 0.42 mmol) in DCM (20 mL). The mixture 
was left to sir for 16 h. The solution was diluted with DCM (100 mL) and washed 
with saturated sodium bicarbonate solution. The organic layer was dried with 
magnesium sulfate and the solvent was removed under reduced pressure. The 
product was purified by column chromatography on silica (10% ethyl 
acetate/petroleum ether to 20% ethyl acetate/petroleum ether) to give the product 
188 as a yellow oil (181 mg, 87%): δH (300 MHz, CDCl3) 8.98 (1H, ddd, J= 2.2, 1.7, 
0.5 Hz, 2-H), 8.46 (1H, ddd, J= 7.8, 1.7, 1.1 Hz, 4-H), 8.42 (1H, ddd, J= 8.2, 2.2, 
1.1 Hz, 6-H), 7.74 (1H, ddd, J= 8.2, 7.8, 0.5 Hz, 5-H), 7.07 (1H, dd, J= 8.4, 2.1 Hz, 
16-H), 6.97 (1H, d, J= 2.1 Hz, 12-H), 6.91 (1H, d, J= 8.4 Hz, 15-H), 6.42 (1H, d, J= 
9.1 Hz, 10-H), 5.40 (1H, d, J= 9.1 Hz, 9-H), 3.93 (3H, s, OMe), 3.92 (3H, s, OMe), 
2.02 (3H, s, Me); δC (125 MHz, CDCl3) 176.4 (C-8), 168.7 (C-19), 167.2 (C-7), 
149.9 (C-OMe), 149.10 (C-OMe), 148.7 (C-3), 133.1 (C-6), 130.2 (C-5), 127.9 (C-
1), 127.8 (C-11), 126.1 (C-4), 122.7 (C-2), 120.4 (C-16), 111.0 (C-15), 110.4 (C-
12), 75.7 (C-10), 56.0 (OMe), 55.9 (OMe), 39.1 (C-9), 20.8 (C-20); HRMS m/z 
(ES+) 514.0219 ([M+Na]+, 100%) C20H18N3O779BrNa requires 514.0226, 516.0187 
([M+Na]+, 78.55) C20H18N3O781BrNa requires 516.0205. 
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(Z)-5-(1-Bromo-2-(3,4-dimethoxyphenyl)vinyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole 
189 
 
Sodium azide (63 mg, 0.9 mmol) was added to a solution of bromo-acetate 188 
(160 mg, 0.3 mmol) in DMSO (5 mL). The solution was heated at 50 ˚C for 2 h and 
a precipitate formed. The mixture was allowed to cool before water (10 mL) and 
DCM (10 mL) were added. The layers were separated and the aqueous layer was 
extracted with DCM (3 × 20 mL) the combined organic layers were washed with 
brine solution (50 mL). The organic layer was dried with magnesium sulfate and 
the solvent was removed under reduced pressure. The product was purified by 
column chromatography on silica (20% ethyl acetate/ petroleum ether) to give the 
product 189 as a yellow solid (82 mg, 58%): m.p 158-160 ˚C; νmax/cm-1 (nujol) 
1615, 1589, 1574, 1540, 1516, 1245, 1144,1023; δH (300 MHz, CDCl3) 9.04 (1H, 
ddd, J= 2.3, 1.6, 0.5 Hz, 2-H), 8.51 (1H, ddd, J= 7.8, 1.6, 1.1 Hz, 6-H), 8.42 (1H, 
ddd, J= 8.3, 2.3, 1.1 Hz, 4-H), 8.40 (1H, s, 10-H), 7.77- 7.71 (2H, m, 5,12-H), 7.61 
(1H, ddd, J= 8.5, 2.1, 0.5 Hz, 16-H), 7.00 (1H, d, J= 8.5 Hz, 15-H), 4.01 (3H, s, 
OMe), 4.00 (3H,s, OMe); δC (75 MHz, D6-DMSO) 175.8 (C-8), 167.6 (C-7), 152.2 
(C-OMe), 149.1 (C-OMe), 149.0 (C-3), 141.2 (C-10), 133.9 (C-6), 132.0 (C-5), 
128.3 (C-1), 127.1 (C-4), 126.4 (C-11), 125.9 (C-16), 122.4 (C-2), 114.4 (C-12), 
112.3 (C-15), 99.7 (C-9), 56.5 (OMe), 56.4 (OMe); m/z (ES+) 454.0020 ([M+Na]+, 
26%), 376.0913 ([M+Na–Br]+, 21), 136.0760 (100), 118.0654 (62); HRMS m/z 
(ES+) 454.0020 ([M+Na]+, 26%) C18H14O5N3BrNa requires 454.0015. 
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N'-Acetoxy-3-nitrobenzimidamide 198 
 
Triethylamine (2.05 mL, 14.6 mmol) was added to a solution of amidoxime 140 
(1.33 g, 7.3 mmol) in DCM (20 mL). Acetic anhydride (900 µl, 9.5 mmol) was 
added dropwise. After 16 h a saturated solution of sodium bicarbonate (20 mL) 
was added and the layers were separated. The aqueous phase was re-extracted 
with DCM (3 × 20 mL). The combined organic layers were washed with a saturated 
solution of brine (20 mL). The organic layer was dried with magnesium sulfate and 
the solvent was removed under reduced pressure. The product was purified by 
column chromatography on silica (20% ethyl acetate/ petroleum ether to 50% ethyl 
acetate/ petroleum ether) to give the product 198 as a white solid (1.22 g, 75%): 
m.p. 118-120 ˚C; νmax/cm-1 (nujol) 3473 (NH), 3359 (NH), 3309 (NH), 1751 (C=O); 
δH (400 MHz, CDCl3) 8.46-8.42 (1H, m, 2-H), 8.26 (1H, ddd, J= 8.2, 2.3, 1.1 Hz, 4-
H), 8.04-8.00 (1H, m, 6-H), 7.57-7.52 (1H, m, 5-H), 5.21 (2H, br s, 8-H), 2.19 (3H, 
s, 10-H); δC (125 MHz, CDCl3) 168.5 (C-9), 154.0 (C-7), 148.2 (C-3), 132.9 (C-1), 
132.9 (C-6), 129.9 (C-5), 125.6 (C-4), 121.7 (C-2), 19.8 (C-10); m/z (ES+) 246 
([M+Na]+, 100%). 
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5-Methyl-3-(3-nitrophenyl)-1,2,4-oxadiazole 191 207  
 
TBAF (1.7 mL, 1 M in THF, 1.7 mmol) was added to a solution of O-acyl amidoxme 
198 (763 mg, 3.4 mmol) in THF (20 mL). The mixture was stirred for 16 h. Water 
(10 mL) was added and the product was extracted with DCM (3 × 50 mL). The 
organic phase was dried with magnesium sulfate and the solvent was removed 
under reduced pressure. The product was purified by column chromatography on 
silica (20% ethyl acetate/petroleum ether to 30% ethyl acetate/petroleum ether) to 
give the product 191 as a white solid (585 mg, 83%): m.p. 102-104 ˚C (Lit. 207 109-
100 ˚C); νmax/cm-1 (nujol) 1600, 1579; δH (400 MHz, CDCl3) 8.87 (1H, ddd, J= 2.3, 
1.6, 0.5 Hz, 2-H), 8.33 (1H, ddd, J= 7.8, 1.6, 1.1 Hz, 4-H), 8.29 (1H, ddd, J= 8.2, 
2.3, 1.1 Hz, 6-H), 7.62 (1H, ddd, J= 8.2, 7.8, 0.5 Hz, 5-H), 2.63 (3H, s, 9-H); δC 
(125 MHz, CDCl3) 177.4 (C-8), 166.8 (C-7), 148.6 (C-3), 132.0 (C-4), 130.0 (C-5), 
128.6 (C-1), 125.6 (C-6), 122.4 (C-2), 12.4 (C-9); m/z (ES+) 228 ([M+Na]+, 100%). 
 
(E)-3-Nitrobenzaldehyde oxime 202 208, 209 
 
Hydroxylamine hydrochloride (5.11 g, 79.4 mmol) and sodium acetate (8.74 g, 99.3 
mmol) were added to a solution of 3-nitrobenzaldehyde (10.0 g, 66 mmol) in 
acetonitrile and water (2:1, 120 mL). DCM (100 mL) was addded and the organic 
layer was separated. The organic layer was neutralised with NaHCO3 solid then 
decolourising charcoal was added. The solution was filtered and the filtrate was 
dried with magnesium sulfate. The solvent was removed under reduced pressure 
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to give the product 202 as an off-white solid (9.63 g, 88%): m.p. 112-114 ˚C (Lit.209 
125 ˚C); νmax/cm-1 (nujol) 3290, 1618, 1537, 1308, 1218, 1104, 980, 939; δH (300 
MHz, CDCl3) 8.47 (1H, dd, J= 2.2, 1.1 Hz, 2-H), 8.27 (1H, ddd, J= 8.0, 2.2, 1.1 Hz, 
4-H), 8.24 (1H, s, OH), 7.97-7.91 (1H, m, 6-H), 7.70 (1H, s, 7-H), 7.64-7.58 (1H, m, 
5-H); δC (75 MHz, CDCl3) 148.6 (C-3), 148.2 (C-7), 133.9 (C-1) 132.5 (C-6), 129.8 
(C-5), 124.4 (C-4), 121.8 (C-2); m/z (ES-) 165 ([M-H]-,100%). 
 
(Z)-3-Amino-3-(3,4-dimethoxyphenyl)acrylonitrile 204210 
 
Potassium tert-butoxide (16.8 g, 150 mmol) was slowly added to a solution of 3,4-
dimethoxybenzonitrile (8.16 g, 50 mmol) and acetonitrile (5.2 mL, 100 mmol) in 
toluene (200 mL) and the mixture was left to stir overnight. If the starting material 
was still present more acetonitrile was added. A solution of saturated sodium 
bicarbonate was added (100 mL). DCM (100 mL) was added and the organic layer 
was separated. The aqueous layer was washed with DCM (3 × 100 mL). The 
organic layer was dried with magnesium sulfate and the solvent was removed 
under reduced pressure to give a yellow solid. This solid was recrystalised from 
50% ethyl acetate/ petroleum ether to give the product 204 as a colourless solid 
(7.23 g, 71%): m.p. 116-118 ˚C (Lit. 210 122-124 ˚C); νmax/cm-1 (nujol) 3410 (NH), 
3332 (NH), 3244 (NH), 2186 (C≡N), 1648 (C=C); δH (300 MHz, CDCl3) 7.14 (1H, 
dd, J= 8.4, 2.2 Hz, 6-H), 7.02 (1H, d, J= 2.2 Hz, 2-H), 6.93 (1H, d, J= 8.4 Hz, 5-H), 
4.92 (2H, br s, NH2), 4.25 (1H, s, 8-H), 3.97 (6H, s, OMe); δC (75 MHz, CDCl3) 
161.3 (C-1), 151.4 (C-4), 149.2 (C-3), 128.0 (C-7), 119.7 (C-9), 119.0 (C-6), 111.1 
(C-5), 109.1 (C-2), 63.1 (C-8), 56.1 (2 × OMe); m/z (ES+) 227.0793 ([M+Na]+, 100) 
C11H12N2O2Na requires 227.0796. 
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(Z)-1-(3,4-Dimethoxyphenyl)-2-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)ethenamine 
200 
 
Oxime 202 (598 mg, 3.6 mmol), was dissolved in DCM (300 mL). The solution was 
shaken with bleach (9 mL, 1.6M) for 3 min. The organic layer was separated and 
added to a solution of enaminonitrile 204 (750 mg, 3.6 mmol) in triethylamine (1 
mL). The mixture was left to stir for 24 h. Triethylamine hydrochloride was filtered 
off and the solvent was removed under reduced pressure. The product was purified 
by column chromatography on silica (20% ethyl acetate/ petroleum ether to 30% 
ethyl acetate petroleum ether), to give a yellow solid. This solid was recrystallised 
from ethanol to give the product 200 as a yellow solid (23 mg, 1.7%): m.p. 212-216 
˚C; νmax/cm-1 (nujol) 3396 (NH), 3311 (NH), 3204 (NH), 1634 (C=C); δH (400 MHz, 
CDCl3) 8.99-8.97 (1H, m, 2-H), 8.49 (1H, ddd, J = 7.8, 1.5, 1.1 Hz, 4-H), 8.38 (1H, 
ddd, J= 8.3, 2.3, 1.1 Hz, 6-H), 7.74-7.69 (1H, m, 5-H), 7.28 (1H, dd, J= 8.4, 2.1 Hz, 
16-H), 7.17 (1H, d, J= 2.1 Hz, 12-H), 6.98 (1H, d, J= 8.4 Hz, 15-H), 5.58 (1H, s, 9-
H), 3.99 (3H, s, OMe), 3.97 (3H, s, OMe), 1.63 (2H, s, NH2); δC (100 MHz, CDCl3) 
177.2 (C-8), 165.5 (C-7), 151.2 (COMe), 151.1 (COMe), 149.3 (C-3), 148.6 (C-10), 
133.0 (C-6), 129.9 (C-5), 129.6 (C-11), 129.6 (C-1), 125.3 (C-4), 122.5 (C-2), 119.1 
(C-16), 111.2 (C-15), 109.3 (C-12), 72.3 (C-9), 56.1 (OMe), 56.1 (OMe); m/z (ES+) 
391.12 ([M+Na]+, 19%), 259.91 ([M+Na-C7H4NO2]+, 100), HRMS m/z (ES+) 
391.1212 ([M+Na]+, 19%) C18H16N4O5Na requires 391.1018. 
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1-(3,4-Dimethoxyphenyl)-2-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)ethanone 193 
 
Concentrated HCl (0.5 mL) was added to a solution of enamine 200 (56 mg, 0.15 
mmol) in ethanol (2 mL). The mixture was heated under reflux for 3 h. A saturated 
solution of sodium bicarbonate was added until the solution was neutral. The 
product was extracted with DCM (3 × 50 mL) and the organic layer was dried with 
magnesium sulfate. The solvent was removed under reduced pressure and the 
product was purified by column chromatography on silica (20% ethyl 
acetate/petroleum ether) followed by recrystallisation from ethanol to give the 
product 193 as a white solid (7 mg, 12.5%): m.p 140-142 ˚C; νmax/cm-1 (nujol) 1693 
(C=O); δH (400 MHz, CDCl3) 8.98 (1H, ddd, J= 2.3, 1.6,  0.5 Hz, 2-H), 8.46 (1H, 
ddd, J= 7.8, 1.6, 1.1 Hz, 4-H), 8.40 (1H, ddd, J= 8.3, 2.3, 1.1 Hz, 6-H), 7.72 (1H, 
ddd, J= 8.3, 7.8, 0.5 Hz, 5-H), 7.68 (1H, dd, J= 8.5, 2.1 Hz, 16-H), 7.60 (1H, d, J= 
2.1 Hz, 12-H), 6.98 (1H, d, J= 8.5 Hz, 15-H), 4.71 (2H, s, 9-H), 4.01 (3H, s, OMe), 
3.98 (3H, s, OMe); δC (100 MHz, CDCl3) 189.3 (C-10), 174.7 (C-8), 167.1 (C-7), 
154.4 (COMe), 149.5 (COMe), 148.6 (C-3), 133.1 (C-6), 130.1 (C-5), 128.5 (C-11), 
128.4 (C-1), 125.8 (C-4), 123.6 (C-16), 122.7 (C-2), 110.4 (C-15), 110.3 (C-12), 
56.3 (OMe), 56.1 (OMe), 37.0 (C-9). 
 
3-(3,4-Dimethoxyphenyl)-3-oxopropanenitrile 206211 
 
HCl (5 mL, 3 N, 15 mmol) was added to a solution of enaminonitrile 206 (1g, 4.9 
mmol) in DCM (10 mL) and the biphasic system was stirred for 16 h. The orgainc 
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layer was then separated and washed with a saturated solution of sodium 
bicarbonate (50 mL). The organic layer was dried with magnesium sulfate and the 
solvent was removed under reduced pressure. The product was purified by 
recrystallisation from 50% ethyl acetate/petroleum ether to give the product as a 
colourless solid (609 mg, 60%): m.p. 137-138 ˚C (Lit. 211 138-139 oC); νmax/cm-1 
(nujol) 2251 (C≡N), 1674 (C=O); δH (400 MHz, CDCl3) 7.45-7.41 (2H, m, 2,6-H), 
6.85 (1H, d, J= 8.6 Hz, 5-H), 3.97 (2H, s, 8-H), 3.91 (3H, s, OMe), 3.88 (3H, s, 
OMe); δC (100 MHz, CDCl3) 185.5 (C-7), 154.7 (COMe), 149.6 (COMe), 127.5 (C-
1), 123.5 (C-6), 114.1 (C-9), 110.3 (C-5), 110.2 (C-2), 56.3 (OMe), 56.2 (OMe), 
29.0 (C-8); HRMS m/z (ES+) 228.0638 ([M+Na]+, 100%) C11H11NO3 requires 
228.0637. 
 
3-(3-Nitrophenyl)-1,2,4-oxadiazol-5-amine 208212 
 
Oxime 202 (5 g, 30 mmol), was dissolved in DCM (300 mL). The solution was 
shaken with bleach (75 mL, 1.6M) for 3 min. The organic layer was separated and 
added to a solution of cyanamide (5.05 g, 120 mmol) in triethylamine (4.2 mL, 30 
mmol) and the mixture was stirred for 16 h. Saturated sodium bicarbonate (25 mL) 
was then added. The mixture was extracted with ethyl acetate (3 × 50 mL). The 
organic layer was dried with magnesium sulfate. The solvent was removed under 
reduced pressure. The product was purified by column chromatography on silica 
(20% ethyl acetate/petroleum ether to 30% ethyl acetate/petroleum ether) to give 
the product 208 as a white solid (334 mg, 68%): m.p. 214-218 ˚C (Lit. 212 228 ˚C); 
νmax/cm-1 (nujol) cm-1 3200 (NH2), 3100(NH2), 1688 (C=N); δH (300 MHz, D6-
DMSO) 8.57 (1H, ddd, J= 2.3, 1.6, 0.4 Hz, 2-H), 8.35 (1H, ddd, J= 8.3, 2.4, 1.1 Hz, 
4-H), 8.27 (1H, ddd, J= 7.8, 1.6 1.1 Hz, 6-H), 8.11 (2H, s, NH2), 7.82-7.78 (1H, m, 
5-H); δC (100 MHz, D6-DMSO) 172.4 (C-8), 166.0 (C-7), 148.0 (C-3), 132.5 (C-6), 
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130.7 (C-5), 129.0 (C-1), 125.3 (C-4), 121.0 (C-2); HRMS m/z (CI+) 207.0520 
([M+H]+, 100%); C8H7N4O3 requires 207.0518. 
 
3,4-Dimethoxy-N-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)benzamide 207 
 
3,4-Dimethoxybenzoic acid (102 mg, 0.56 mmol) was added to a solution of 5-
amino-1,2,4-oxadiazole 208 (106 mg, 0.51 mmol) in DCM (5 mL). DCC (115 mg, 
0.56 mmol) was added and the mixture was stirred for 16 h. The mixture was 
filtered and the filtrate was washed with a solution of saturated sodium 
bicarbonate. The product was extracted with DCM (3 × 50 mL). The organic phase 
was dried with magnesium sulfate and the solvent was removed under reduced 
pressure. The product was purified by column chromatography on silica (30% ethyl 
acetate/ petroleum ether to 40% ethyl acetate/petroleum ether). The product was 
then purified further by recrystallisation from ethanol/water to give the product 207 
as a white solid (39 mg, 21%): m.p. 182-184 ˚C; νmax/cm-1 (nujol) 3290 (NH), 1687 
(C=O); δH (400 MHz, CDCl3) 9.01 (1H, s, NH), 8.84 (1H, ddd, J= 2.3, 1.6, 0.4 Hz, 2-
H), 8.34 (1H, ddd, J= 7.8, 1.6, 1.1 Hz, 4-H), 8.31 (1H, ddd, J= 8.2, 2.3, 1.1 Hz, 6-
H), 7.62 (1H, ddd, J= 8.2, 7.8, 0.4 Hz, 5-H), 7.49 (1H, d, J= 2.2 Hz, 12-H), 7.45 
(1H, dd, J= 8.4, 2.2 Hz, 16-H), 6.90 (1H, d, J= 8.4 Hz, 15-H), 3.91 (6H, s, OMe); δC 
(75 MHz, D6-DMSO) 168.6 (C-8), 166.3 (C-7), 163.9 (C-10), 153.4 (C-14), 148.8 
(C-15), 148.7 (C-3), 133.2 (C-6), 131.6 (C-5), 128.4 (C-1), 126.5 (C-4), 124.3 (C-
11), 123.1 (C-16), 121.9 (C-2), 111.8 (C-12), 111.6 (C-15), 56.2 (OMe), 56.1 
(OMe); m/z (ES+) 393.00 ([M+Na]+, 55%), 247.01 ([M+Na-C7H4N2O2]+, 100); 
HRMS (ES-) 369.0832 ([M-H]-, 100%) C17H13N4O6 requires 369.0835. 
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2-(3,4-Dimethoxyphenyl)-N-(3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl)acetamide 213 
 
2-(3,4-dimethoxyphenyl)acetic acid (314 mg, 1.6 mmol) and DMAP (196 mg, 1.60 
mmol) were added to a solution of 5-amino-1,2,4-oxadiazole 208 (300 mg, 1.46 
mmol) in DCM (10 mL). DCC (330 mg, 1.6 mmol) was added to the solution. After 
16 h the mixture was filtered and the filtrate was washed with a saturated solution 
of sodium bicarbonate. The product was extracted with DCM (3 × 30 mL) and the 
organic phase was dried with magnesium sulfate. The solvent was removed under 
reduced pressure. The product was then purified by column chromatography (20% 
ethyl acetate/petroleum ether to 40 % ethyl acetate/petroleum ether). The product 
was then recrystallised from ethanol to give the product 213 as a white solid (23 
mg, 4%): m.p. 176-178 ˚C; νmax/cm-1 (nujol) 3250 (NH), 1739 (NC=O); δH (300 
MHz, CDCl3) 8.86 (1H, s, NH), 8.80-8.79 (1H, m, 2-H), 8.32-8.28 (2H, m, 6,4-H), 
7.63-7.58 (1H, m, 5-H), 6.86-6.83 (2H, m, 16,17-H), 6.79 (1H, s, 13-H), 3.86 (2H, s, 
11-H), 3.84 (3H, s, OMe), 3.83 (3H, s, OMe); δC (75 MHz, D6-DMSO) 169.2 (C-10), 
167.7 (C-8), 166.3 (C-7), 149.0 (C-OMe), 148.6 (C-3), 148.3 (C-OMe), 133.3 (C-6), 
131.6 (C-5), 128.3 (C-1), 126.9 (C-11), 126.5 (C-4), 121.9 (C-17), 121.8 (C-2), 
113.7 (C-13), 112.3 (C-16), 56.0 (OMe), 55.9 (OMe), 42.6 (C-11); HRMS m/z (ES+) 
407.0963 ([M+Na]+, 100%) C18H16N4O6Na requires 407.0968. 
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N'-hydroxybenzimidamide 217205 
 
Hydoxylamine hydrochloride (8.45 g, 131 mmol), and potassium carbonate (18.1 g, 
131 mmol) were added to a solution of benzonitrile (10 g, 97 mmol) in methanol. 
The mixture was heated under reflux for 4 h. The mixture was cooled and stirred 
for 16 h. The mixture was filtered and the solvent was removed under reduced 
pressure to give a colourless oil. The product was purified by column 
chromatography on silica (30% ethyl acetate/ petroleum ether) to give the product 
217 as a white solid (3.56 g, 32%); m.p 72-74 ˚C (Lit.205 67-68 ˚C); νmax/cm-1 (nujol) 
3453, 3360, 3212, 1649, 1050; δH (300 MHz, D6-DMSO) 9.62 (1H, s, OH), 7.69-
7.66 (2H, m, 2-H), 7.39-7.35 (3H, m, 3,4-H), 5.79 (2H, s, NH2); δC (75 MHz, D6-
DMSO) 150.8 (C-5), 133.3 (C-1), 128.8 (C-4), 128.1 (C-3), 125.4 (C-2); HRMS m/z 
(ES+) 159.0530 ([M+Na]+, 100%) C7H8N2ONa requires 159.0534. 
 
2-((tert-Butoxycarbonyl)amino)acetic acid 219 213 
 
 
Sodium hydroxide (2.66 g, 66 mmol) was added to a solution of glycine (5 g, 66 
mmol) in a mixture of water and 1,4-dioxan (1:1, 200 mL). The mixture was cooled 
to 0 ˚C. Di-tert-butyl dicarbonate (14.5 g, 66 mmol) was added in small batches. 
After stirring at 0 °C for 15 min the reaction was warmed up to room temperature 
and stirring was continued for 8 h. Once the reaction was complete the solvent was 
removed under reduced pressure. The product was redissolved in water (200 mL) 
and washed with diethyl ether (3 × 100 mL). The aqueous layer was then acidified 
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to pH 4 using citric acid solution (10% w/v) and the product was extracted with 
ethyl acetate (3 × 200 mL). The organic layer was dried with magnesium sulfate 
and the solvent was removed under reduced pressure to furnish the product 219 
as a white solid (10.19 g, 87%): m.p 81-85 ˚C (Lit. 213 84-86 oC); νmax/cm-
1 (nujol) 3406, 3341, 1748, 1669; δH (500 MHz, CDCl3) 9.43 (1H, s, NH), 3.98 (1H, 
d, J= 5.5 Hz, 2-H), 3.92 (1H, d, J= 3.7 Hz, 2-H), 1.47 (9H, s, H); δC (125 MHz, 
CDCl3) 174.8 (C-1), 157.2 (C-4), 80.5 (C-2), 42.2 (C-5), 28.3 (C-6); HRMS m/z 
(ES+) 198.0737 ([M+Na]+, 100%) C7H13NO4Na requires 198.0742. 
 
tert-Butyl (2-(((amino(phenyl)methylene)amino)oxy)-2-oxoethyl)carbamate 220 
 
Carboxylic acid 219 (965 mg, 5.5 mmol) and DMAP (448 mg, 3.6 mmol) were 
added to a solution of amidoxime 217 (500 mg, 3.6 mmol) in DCM (20 mL). DCC 
(1.14 g, 5.5 mmol) was added and the solution was stirred for 8 h. The mixture was 
filtered and the filtrate was concentrated under reduce pressure. The product was 
purified by column chromatography on silica (30% ethyl acetate/petroleum ether) to 
give 220 as a white solid (333 mg, 32%): m.p 140-143 ˚C; (nujol) 3373, 3325, 
1754, 1719, 1622, 1520, 1163, 946; δH (300 MHz, CDCl3) 7.71-7.67 (2H, m, 3-H), 
7.53-7.47 (1H, m, 4-H), 7.47-7.39 (2H, m, 2-H), 5.19 (2H, s, NH2), 4.17 (2H, d, J= 
5.6 Hz, 7-H), 1.47 (9H, s, (CH3)3); δC (75 MHz, CDCl3) 169.5 (C-6), 157.1 (C-5) 
156.2 (C-9), 131.7 (C-4), 131.2 (C-1), 129.2 (C-2), 127.1 (C-3), 80.0 (C(CH3)3), 
42.7 (C-7), 28.8 (CH3)3; HRMS m/z (ES-) 292.1302 ([M-H]-, 100%) C14H18N3O4 
requires 292.1303. 
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tert-Butyl ((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)carbamate 221 
 
 
TBAF (1 M in THF, 2.1 mL, 2.1 mmol) was added to a solution of O-acyl 
amidoxime 220 (1.26 g, 4.3 mmol) in THF (20 mL). The solution was stirred for 2 h. 
The solution was diluted with ethyl acetate. The solvent was removed under 
reduced pressure. The product was purified by column chromatography on silica 
(10% ethyl actetate/ petroleum ether to 20% ethyl acetate petroleum ether) to give 
the product 221 as a white solid (1.18 g, 75%): m.p 59-61 ˚C; νmax/cm-1 (nujol) 
3365, 1680, 1595, 1575, 1524, 1169, 1160; δH (500 MHz, CDCl3) 8.08 (2H, dd, J= 
8.1, 1.4 Hz, 3-H), 7.53-7.48 (3H, m, 2,4-H), 5.29 (1H, s, NH), 4.66 (2H, d, J= 5.7 
Hz, 7-H), 1.5 (9H, s, 11-H); δC (125 MHz, CDCl3) 176.5 (C-6), 168.4 (C-5), 155.4 
(C-9), 131.3 (C-4), 128.9 (C-2), 127.5 (C-3), 126.4 (C-1), 80.7 (C-10), 37.2 (C-7), 
28.3 (C-11); HRMS m/z (ES+) 298.1173 ([M+Na]+, 100%) C14H17N3O3Na requires 
298.1168 
 
(3-Phenyl-1,2,4-oxadiazol-5-yl)methanaminium chloride 222 
 
HCl in 1,4-dioxan (4N, 2.3 mL, 9.3 mmol) was added to a solution of 1,2,4-
oxadiazole 221 (852 mg, 3 mmol) in DCM (5 mL) and the mixture was stirred for 2 
h. The precipitate was filtered and dissolved in water and ethanol. The solution was 
lyphoilised to give the product 222 a white solid (400 mg, 63%): m.p. 176-180 ˚C 
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(decomp.); νmax/cm-1 (nujol) 3394, 1605, 1462, 1377; δH (300 MHz, D6-DMSO) 9.13 
(3H, s, 8-NH), 8.04-7.99 (2H, m, 2-H), 7.64-7.60 (2H, m, 3-H), 7.59-7.55 (1H, m, 4-
H), 4.54 (2H, s, 7-H); δC (75 MHz, D6-DMSO) 174.7 (C-6), 168.0 (C-5), 132.3 (C-4), 
129.8 (C-3), 127.4 (C-2), 125.9 (C-1), 35.0 (C-7); m/z (ES+) 176.0818 ([M+H]+, 
100%) C9H10N3O requires 176.0824. 
 
N-((3-Phenyl-1,2,4-oxadiazol-5-yl)methyl)benzenesulfonamide 215 
 
Benzenesulfonyl chloride (217 µl, 1.7 mmol) was added to a solution of amine 222 
(300 mg, 1.4 mmol) in pyridine (10 mL). The solution was stirred for 8 h. HCl (2N, 
100mL) was added to the solution and the product was extracted with ethyl acetate 
(3 × 100 mL). The organic layer was dried with magnesium sulfate and the solvent 
was removed under reduced pressure. The product was purified by column 
chromatography on silica (10% ethyl acetate/petroleum ether to 20% ethyl 
acetate/petroleum ether) to give a white solid (447 mg, quant.): m.p 122-126 
˚C; νmax/cm-1 (nujol) 3259 (NH), 1680 (C=N), 1457, 1378; δH (300 MHz, CDCl3) 
7.94-7.91 (2H, m, 2-H), 7.89-7.86 (2H, m, 10-H), 7.54-7.47 (3H, m, Ar-H), 7.47-
7.43 (3H, m, Ar-H), 5.39 (1H, t, J= 6.2 Hz, NH), 4.56 (2H, d, J= 6.2 Hz, 7-H); δC (75 
MHz, CDCl3) 174.9 (C-6), 168.6 (C-5), 139.5 (C-9), 133.6 (C-12), 131.9 (C-4), 
129.6 (C-Ar), 129.3 (C-Ar), 127.8 (C-2), 127.6 (C-10), 126.4 (C-Ar), 39.4 (C-7); 
HRMS m/z (ES+) 338.0587 ([M+Na]+, 100%) C15H13N3O3SNa requires 338.0575. 
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(E)-Benzaldehyde oxime 226a 214 
 
Benzaldehyde (10 mL, 10.45 g, 98 mmol), hydroxylamine hydrochloride (7.62 g, 
118 mmol) and sodium acetate (12.11 g, 147 mmol) were added to a solution of 
acetonitrile and water (2:1, 120 mL). The mixture was stirred for 8 h. DCM (100 
mL) was added and the organic layer was separated. The organic layer was 
neutralised with sodium bicarbonate, then decolourising charcoal was added. The 
solution was filtered and the filtrate was dried with magnesium sulfate and the 
solvent was removed under reduced pressure to give the product 226a as an off-
white solid (9.6 g, 81%):  m.p. 28-30 ˚C (Lit. 214 30-33 ˚C); νmax/cm-1 (nujol) 3330, 
1634, 1074; δH (300 MHz, CDCl3) 8.97 (1H, s, OH), 8.17 (1H, s, 5-H), 7.60-7.56 
(2H, m, 2-H), 7.41-7.37 (3H, m, 3,4-H); δC (75 MHz, C6D6) 150.6 (C-5), 132.7 (C-1), 
130.2 (C-4), 129.1 (C-3), 127.5 (C-2); m/z (ES+) 122.06 ([M+H]+, 100%). 
 
(E)-3-Methylbenzaldehyde oxime 226b215 
 
3-Methylbenzaldehyde (4.00 g, 3.9 mL, 33.3 mmol), hydroxylamine hydrochloride 
(2.58 g, 39.9 mmol) and sodium acetate (4.10 g, 49.9 mmol) were added to a 
solution of acetonitrile and water (3:1, 120 mL). The mixture was stirred for 8 h. 
DCM (100 mL) was added and the organic layer was separated. The organic layer 
was neutralised with sodium bicarbonate then decolourising charcoal was added. 
The solution was filtered and the filtrate was dried with magnesium sulfate and the 
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solvent was removed under reduced pressure to give the product 226b as a brown 
solid (3.33 g, 74%): m.p. 55-57 ˚C(Lit.215 51-53 ˚C); νmax/cm-1 (nujol) 3178, 3085, 
1636, 1605; δH (300 MHz, CDCl3) 8.17 (1H, s, 8-H), 7.88 (1H, br s, OH), 7.46-7.40 
(2H, m, 2,6-H), 7.31 (1H, d, J= 7.0 Hz, 5-H), 7.27-7.23 (1H, m, 4-H), 2.42 (3H, s, 
Me); δC (75 MHz, CDCl3) 150.6 (C-8), 138.55 (C-3), 131.8 (C-1), 131.0 (C-4), 128.7 
(C-5), 127.6 (C-2), 124.4 (C-6), 21.4 (C-7); m/z (CI+) 136.08 ([M+H]+, 100%), 
118.07 ([M-OH]+, 60); HRMS m/z (CI+) 136.0764 ([M+H]+, 100) C8H10NO requires 
136.0762. 
 
(E)-3-(Trifluoromethyl)benzaldehyde oxime 226c216 
 
3-(Trifluoromethyl)benzaldehyde (16.75 g, 96.2 mmol), hydroxylamine 
hydrochloride (7.43 g, 115 mmol) and sodium acetate (11.83 g, 144 mmol) were 
added to a solution of acetonitrile and water (3:1, 200 mL). The mixture was stirred 
for 8 h. DCM (100 mL) was added and the organic layer was separated. The 
organic layer was neutralised with sodium bicarbonate then decolourising charcoal 
was added. The solution was filtered and the filtrate was dried with magnesium 
sulfate and the solvent was removed under reduced pressure to give an oil. The 
excess 3-(trifluoromethyl)benzaldehyde was  removed by distillation under reduced 
pressure to give the product 226c as a white solid (14.56 g, 80%): m.p. 37-39 ˚C 
(Lit. 216 46-47 ˚C); δH (300 MHz, CDCl3) 8.19 (1H, s, 8-H), 7.86-7.83 (1H, m, 2-H), 
7.78-7.73 (1H, m, 6-H), 7.65 (1H, dddd, J= 7.8, 1.8, 1.2, 0.6, 4-H), 7.56-7.48 (1H, 
m, 5-H); δC (75 MHz, CDCl3) 149.5 (C-8) 133.3 (C-1), 131.7 (d, J= 32.6 Hz, C-3), 
130.5 (q, J= 1.2 Hz, C-6), 129.7 (C-5), 126.9 (q, J= 3.7 Hz, C-4), 124.2 (q, J= 3.9 
Hz, C-2); δF{1H} (282 MHz, CDCl3) -63.4 (s); m/z (CI+) 190.05 ([M+H]+, 95%), 172.04 
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([M-OH]+, 50), 170.04 ([M-F]+, 100); HRMS m/z (CI+) 190.0478 ([M+H]+, 95) 
C8H7NOF3 requires 190.0480. 
 
(E)-3-Fluorobenzaldehyde oxime 226d217 
 
3-Fluorobenzaldehyde (9.00 g, 7.7 mL, 72.5 mmol), hydroxylamine hydrochloride 
(5.61 g, 87 mmol) and sodium acetate (8.92 g, 108 mmol) were added to a solution 
of acetonitrile and water (3:1, 320 mL). The mixture was stirred for 8 h. DCM (100 
mL) was added and the organic layer was separated. The organic layer was 
neutralised with solid sodium bicarbonate then decolourising charcoal was added. 
The solution was filtered and the filtrate was dried with magnesium sulfate and the 
solvent was removed under reduced pressure to give the product 226d as a white 
solid (8.64 g, 86%): m.p. 57-60 ˚C (Lit.217 63 ˚C); νmax/cm-1 (nujol) 3334, 1675, 
1611, δH (300 MHz, CDCl3) 8.93 (1H, br s, OH), 8.15 (1H, s, 7-H), 7.38-7.31 (3H, 
m, 2,5,6-H), 7.13-7.06 (1H, m, 4-H); δC (75 MHz, CDCl3) 163.4 (d, J= 246.6 Hz, C-
3), 149.9 (d, J= 2.9 Hz, C-7), 134.5 (d, J= 7.8 Hz, C-1), 130.8 (d, J= 8.3 Hz, C-5), 
123.6 (d, J= 3.1 Hz, C-6), 117.5 (d, J= 21.5 Hz,. C-4), 113.8 (d, J= 22.7 Hz, C-
2); δF (376 MHz, CDCl3) -112.30 (td, J= 8.9, 5.5 Hz); m/z (CI+) 140.05 ([M+H]+, 
100), 122.04 ([M-OH]+, 56); HRMS m/z (CI+) 140.0510 ([M+H]+, 100) C7H7NOF 
requires 140.0512. 
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(E)-3-Chlorobenzaldehyde oxime 226e218 
 
3-Chlorobenzaldehyde (10.0 g, 8 mL, 71.1 mmol), hydroxylamine hydrochloride 
(5.5 g, 85.3 mmol) and sodium acetate (8.75 g, 107 mmol) were added to a 
solution of acetonitrile and water (2:1, 120 mL). The mixture was stirred for 8 h. 
DCM (100 mL) was added and the organic layer was separated. The organic layer 
was neutralised with sodium bicarbonate then decolourising charcoal was added. 
The solution was filtered and the filtrate was dried with magnesium sulfate and the 
solvent was removed under reduced pressure to give the product 226e as a white 
solid (8.45 g, 76%): m.p. 60-63 ˚C (Lit.218 69-69.5 ˚C); νmax/cm-1 (nujol) 3183, 1685, 
1629, 1594, 1560, 1209; δH (300 MHz, CDCl3) 8.13 (1H, s, 7-H), 7.99 (1H, br s, 
OH), 7.64-7.62 (1H, m, 2-H), 7.50-7.47 (1H, m, 6-H), 7.41-7.38 (1H, m, 4-H), 7.37 
(1H, dd, J= 7.9, 0.7 Hz, 5-H); δC (75 MHz, CDCl3) 149.6 (C-7), 135.3 (C-3), 134.1 
(C-1), 130.5 (Ar-H), 130.5 (Ar-H), 127.5 (C-2), 125.7 (C-6); m/z (CI+) 186.05 
([M37Cl+C2H5]+, 8%), 184.06 ([M35Cl+C2H5]+, 21), 158.02 ([M37Cl+H]+, 31), 156.02 
([M35Cl+H]+, 100), 140.02 ([M37Cl-OH]+, 32), 138.01 ([M35Cl-OH]+, 66); HRMS m/z 
(CI+) 156.0214 ([M35Cl+H]+, 100%), C7H7NO35Cl requires 156.0216. 
 
(E)-3-Bromobenzaldehyde oxime 226f219 
 
3-Bromobenzaldehyde (10 mL, 15.77 g, 85.2 mmol), hydroxylamine hydrochloride 
(6.59 g, 102 mmol) and sodium acetate (10.48 g, 127 mmol) were added to a 
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solution of acetonitrile and water (2:1, 120 mL). The mixture was stirred for 8 h. 
DCM (100 mL) was added and the organic layer was separated. The organic layer 
was neutralised with sodium bicarbonate then decolourising charcoal was added. 
The solution was filtered and the filtrate was dried with magnesium sulfate and the 
solvent was removed under reduced pressure to give the product 226f as a white 
solid (13.29 g, 78%): m.p. 65-69 ˚C (Lit.219 73 ˚C); νmax/cm-1 (nujol) 3173, 3103, 
1684 (C=N) δH (300 MHz, CDCl3) 8.55 (1H, s, OH), 8.10 (1H, s, 7-H), 7.74 (1H, dd, 
J= 2.0, 1.6 Hz, 2-H), 7.53-7.47 (2H, m, 4,6-H), 7.29-7.22 (1H, m, 5-H); δC (75 MHz, 
CDCl3) 149.5 (C-7), 134.3 (C-1), 133.4 (C-4), 130.7 (C-5), 130.2 (C-2), 126.1 (C-6), 
123.4 (C-3); m/z (ES-) 197.96 ([M79Br-H]-, 100%), 199.96 ([M81Br-H]-, 85). 
 
(E)-4-Bromobenzaldehyde oxime 226g220 
 
4-Bromobenzaldehyde (2.77 g, 14.9 mmol), hydroxylamine hydrochloride (1.16 g, 
17.9 mmol) and sodium acetate (1.84 g, 22.4 mmol) were added to a solution of 
acetonitrile and water (2:1, 75 mL). The mixture was stirred for 8 h. DCM (100 mL) 
was added and the organic layer was separated. The organic layer was neutralised 
with sodium bicarbonate then decolourising charcoal was added. The solution was 
filtered and the filtrate was dried with magnesium sulfate and the solvent was 
removed under reduced pressure to give the product 226g as awhite solid (2.14 g, 
72%): m.p. 108-110 ˚C (Lit.220 112 ˚C); νmax/cm-1 (nujol) 3298, 1641, 1609, 1586; δH 
(300 MHz, CDCl3) 8.55 (1H, s, OH), 7.52 (2H, d, J= 8.5 Hz, 2-H), 7.44 (2H, d, J= 
8.5 Hz, 3-H); δC (75 MHz, CDCl3) 149.9 (C-5), 131.5 (C-3), 131.2 (C-1), 128.9 (C-
2), 124.8 (C-4); HRMS m/z (ES-) 199.9531 ([M81Br-H]-, 97%) C7H5NO81Br requires 
199.9534; 197.9550 ([M79Br-H]-, 100) C7H5NO79Br requires 197.9554. 
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(E)-3,4-Dichlorobenzaldehyde oxime 226h221 
 
3,4-Dichlorobenzaldehyde (10 g, 57.1 mmol), hydroxylamine hydrochloride (4.42 g, 
68.5 mmol) and sodium acetate (7.03g, 85.7 mmol) were added to a solution of 
acetonitrile and water (2:1, 120 mL). The mixture was stirred for 8 h. DCM (100 
mL) was added and the organic layer was separated. The organic layer was 
neutralised with sodium bicarbonate then decolourising charcoal was added. The 
solution was filtered and the filtrate was dried with magnesium sulfate and the 
solvent was removed under reduced pressure to give the product 226h as a white 
solid (9.64 g, 88%): m.p. 118-120 ˚C (Lit.221 120-122 ˚C); νmax/cm-1 (nujol) 3309, 
1632, 1554; δH (300 MHz, CDCl3) 8.06 (1H, s, 7-H), 7.80 (1H, OH), 7.68 (1H, d, J= 
1.9 Hz, 2-H), 7.46 (1H, d, J= 8.3 Hz, 5-H), 7.40 (1H, dd, J= 8.3, 1.9 Hz, 6-H); δC (75 
MHz, CDCl3) 148.3 (C-7), 134.0 (C-3), 133.2 (C-4), 132.1 (C-1), 130.8 (C-5), 128.6 
(C-2), 126.1 (C-6); m/z (CI+) 191.98 ([M37Cl2+H]+, 53% 189.98 ([M35Cl2+H]+, 100), 
173.97 ([M37Cl2-OH]+, 35), 171.97 ([M35Cl2-OH]+, 48); HRMS m/z (CI+) 189.9825 
([M+H]+, 100) C7H6NO35Cl2 requires 189.9826. 
 
(E)-3-Methoxybenzaldehyde oxime 226i222 
 
3-Methoxybenzaldehyde (10.0 g, 8.9 mL, 73.5 mmol), hydroxylamine hydrochloride 
(5.68 g, 88.1 mmol) and sodium acetate (9.04 g, 110 mmol) were added to a 
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solution of acetonitrile and water (2:1, 120 mL). The mixture was stirred for 8 h. 
DCM (100 mL) was added and the organic layer was separated. The organic layer 
was neutralised with sodium bicarbonate then decolourising charcoal was added. 
The solution was filtered and the filtrate was dried with magnesium sulfate and the 
solvent was removed under reduced pressure. The product was purified by 
distillation under reduced pressure to give the product 226i as a yellow oil (6.62 g, 
60%): b.p 175 ˚C at 10 mbar; νmax/cm-1 (thin film) 3331, 1934, 1628, 1601, 1579, 
1492, 1456, 1321, 1289, 1169, 1158; δH 8.05 (1H, s, 7-H), 7.83 (1H, br s, OH), 
7.23 (1H, m, 5-H), 7.10 (1H, dd, J= 2.6, 1.5 Hz, 2-H), 7.05 (1H, dddd, J= 7.6, 
1.5,1.1, 0.4 Hz, 6-H), 6.88 (1H, ddd, J=8.3, 2.6, 1.1 Hz, 4-H), 3.76 (3H, s, 9-H); δC 
(75 MHz, CDCl3) 159.8 (C-3), 150.4 (C-7), 133.2 (C-1), 129.9 (C-5), 120.2 (C-6), 
116.5 (C-4), 111.3 (C-2), 55.4 (C-9); HRMS m/z (ES+) 152.0701 ([M+H]+, 100%) 
C8H10O2N requires 152.0707. 
 
3-Phenyl-1,2,4-oxadiazol-5-amine 224a223 
 
Oxime 226a (1 g, 8.25 mmol), was dissolved in DCM (100 mL). The solution was 
shaken with bleach (21 mL, 1.6 M, 33.6 mmol) for 3 min. The organic layer was 
separated and added to a solution of cyanamide (1.39 g, 33 mmol) in triethylamine 
(4.6 mL, 30 mmol) and the mixture was stirred for 8 h. The solvent was removed 
under reduce pressure to give a yellow solid. The product was purified by 
recrystallisation using ethanol and water, to give the product 224a as a white solid 
(956 mg, 72%): m.p 142-145 ˚C (Lit. 223 147-148 ˚C); νmax/cm-1 (nujol) 3286, 3113, 
1675, 1599; δH (300 MHz, D6-DMSO) 7.93 (2H, s, NH2), 7.90-7.85 (2H, m, 2-H), 
7.53-7.46 (3H, m, 3,4-H); δC (75 MHz, D6-DMSO) 172.1 (C-6), 167.5 (C-5), 130.8 
(C-4), 128.9 (C-3), 127.6 (C-1), 126.5 (C-2); m/z (CI+) 162.07 ([M+H]+,100%), 
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161.06 ([M]+, 37), 119.06 ([M-CN2H2]+, 48); HRMS m/z (CI+) 162.0668 ([M+H]+, 
100) C8H8N3O requires 162.0667. 
3-(m-Tolyl)-1,2,4-oxadiazol-5-amine 224b 
 
Oxime (1 g, 7.4 mmol), was dissolved in DCM (300 mL). The solution was shaken 
with bleach (18.5 mL, 1.6 M, 29.5 mmol) for 3 min. The organic layer was 
separated and added to a solution of cyanamide (1.24 g, 29.5 mmol) in 
triethylamine (4.1 mL, 29.5 mmol) and the mixture was stirred for 8 h. The solvent 
was removed under reduce pressure to give a yellow solid. The product was 
purified by recrystallisation using ethanol and water, to give the product as a white 
solid (958 mg, 74%): m.p 198-201 ˚C; νmax/cm-1 (nujol) 3240, 3201, 3098, 1682, 
1605; δH (300 MHz, D6-DMSO) 7.90 (2H, s, NH2), 7.70-7.65 (2H, m, 2,6-H), 7.41-
7.36 (1H, m, 5-H), 7.31-7.34 (1H, m, 4-H), 2.36 (3H,s Me); δC (75 MHz, D6-DMSO), 
172.0 (C-9), 167.5 (C-8), 138.1 (C-3), 131.4 (C-4), 128.7 (C-5), 127.5 (C-1), 127.0 
(C-2), 123.7 (C-6), 20.9 (C-7); HRMS m/z (ES+) 198.0640 ([M+Na]+) C9H9N3ONa 
requires 198.0643. 
 
3-(3-(Trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-amine 224c 
 
Oxime 226c (1 g, 5.3 mmol), was dissolved in DCM (65 mL). The solution was 
shaken with bleach (13 mL, 1.6 M, 20.8 mmol) for 3 min. The organic layer was 
separated and added to a solution of cyanamide (869 mg, 21.1 mmol) in 
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triethylamine (2.9 mL, 21.1 mmol) and the mixture was stirred for 8 h. The solvent 
was removed under reduce pressure to give a yellow solid. The product was 
purified by recrystallisation using ethanol and water, to give the product 224c as a 
colourless solid (847 mg, 70%): m.p 208-210 ˚C; νmaxcm-1 (nujol) 3294 (NH), 3126 
(NH), 1684 (C=N); δH (300 MHz, D6-DMSO) 8.15 (1H, dd, J= 7.5, 0.7 Hz, 6-H), 
8.10 (1H, m, 2-H), 8.07 (2H, s, 10-NH2), 7.88-7.91 (1H, m, 4-H), 7.78-7.72 (1H, m, 
5-H);  δC (300 MHz, D6-DMSO) 172.7 (C-9), 166.8 (C-8), 130.8 (d, J= 1.2 Hz, C-6), 
130.7 (C-5), 130.0 (d, J= 32.1 Hz, C-3), 129.0 (C-1), 127.8 (q, J= 3.7 Hz, C-4), 
124.2 (q, J= 272.3 Hz, C-7), 123.2 (q, J= 4.0 Hz, C-2); δF (282 MHz, D6-DMSO) -
62.1 (s); HRMS m/z (ES-) 228.0392 ([M-H]-, 100%) C9H5N3OF3  requires  
228.0390. 
 
3-(3-Fluorophenyl)-1,2,4-oxadiazol-5-amine 224d 
 
Oxime 226d (1 g, 7.2 mmol), was dissolved in DCM (90 mL). The solution was 
shaken with bleach (18 mL, 1.6 M, 28.8 mmol) for 3 min. The organic layer was 
separated and added to a solution of cyanamide (1.2 g, 28.8 mmol) in triethylamine 
(4 mL, 28.8 mmol) and the mixture was stirred for 8 h. The solvent was removed 
under reduce pressure to give a yellow solid. The product was purified by 
recrystallisation using ethanol and water, to give the product 224d as a white solid 
(928 mg, 72 %): m.p 177-181 ˚C; νmax/cm-1 (nujol) 3342, 3268, 3128, 1685; δH (300 
MHz, D6-DMSO) 8.01 (2H, s, 9-NH2), 7.71 (1H, ddd, J= 7.8, 1.2, 1.2 Hz, 6-H), 7.60-
7.51 (2H, m, 2,5-H), 7.37 (1H, dddd, J= 9.2, 8.2, 2.5, 0.9 Hz, 4-H); δC (75 MHz, D6-
DMSO) 172.6 (C-8) 167.0 (d, J= 2.9 Hz, C-7)), 162.5 (d, J= 247.2 Hz, C-3), 131.6 
(d, J= 8.3 Hz, C-5), 130.2 (d, J= 8.4 Hz, C-1), 123.1 (d, J= 2.9 Hz, C-6), 118.1 (d, 
J= 21Hz, C-4), 113.5 (d, J=23.3 Hz, C-2); δF (282 MHz, D6-DMSO) -112.7 (1F, dt, 
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J= 9.2, 6.0 Hz); m/z (CI+) 180.06 ([M+H]+,100%), 179.05 ([M]+, 45), 137.05 
([M-CN2H2]+, 40); HRMS m/z (CI+) 180.0569 ([M+H]+, 100%), C8H7N3OF requires 
180.0573. 
 
3-(3-Chlorophenyl)-1,2,4-oxadiazol-5-amine 224e 
 
Oxime 226e (1 g, 6.42 mmol), was dissolved in DCM (65 mL). The solution was 
shaken with bleach (16 mL, 1.6 M, 25.7 mmol) for 3 min. The organic layer was 
separated and added to a solution of cyanamide (1.08 g,  25.7 mmol) in 
triethylamine (3.58 mL, 25.7 mmol) and the mixture was stirred for 8 h. The solvent 
was removed under reduce pressure to give a yellow solid. The product was 
purified by recrystallisation using ethanol and water, to give the product 224e as a 
white solid (955 mg, 76%): m.p 218-222 ˚C; νmax/cm-1 (nujol) 3254, 3115, 3068, 
1685, 1609, 1531; δH (300 MHz, D6-DMSO) 8.03 (2H, s, 9-NH2), 7.85-7.81 (2H, m, 
2,6-H), 7.61 (1H, ddd, J= 8.1, 2.1, 1.4 Hz, 4-H), 7.57-7.52 (1H, m, 5-H); δC (75 
MHz, D6-DMSO) 172.2 (C-8), 166.4 (C-7), 133.6 (C-3), 131.0 (C-5), 130.7 (C-4), 
129.6 (C-1), 126.1 (C-2), 125.2 (C-6); HRMS m/z (ES-) 194.0125 ([M-H]-, 100%) 
C8H5N3OCl requires 194.0121. 
 
3-(3-Bromophenyl)-1,2,4-oxadiazol-5-amine 224f 
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Oxime 226f (1 g, 5 mmol), was dissolved in DCM (65 mL). The solution was 
shaken with bleach (12.5 mL, 1.6 M, 20 mmol) for 3 min. The organic layer was 
separated and added to a solution of cyanamide (840 mg, 20 mmol) in 
triethylamine (2.7 mL, 20 mmol) and the mixture was stirred for 8 h. The solvent 
was removed under reduce pressure to give a yellow solid. The product was 
purified by recrytsallisation using ethanol and water, to give the product 224f as a 
white solid (910 mg, 76 %): m.p 222-225 ˚C; νmax/cm-1 (nujol) 3248, 3112, 1683, 
1608; δH (300 MHz, D6-DMSO) 8.00 (2H, s, 9-NH2), 7.97-7.95 (1H,m, 2-H), 7.88-
7.83 (1H, m, 6-H), 7.72 (1H, ddd, J= 8.0, 2.0, 1.0 Hz, 4-H), 7.46 (1H, m, 5-H); δC 
(75 MHz, CDCl3) 172.2 (C-8), 166.3 (C-7), 133.5 (C-4), 131.2 (C-5), 129.78 (C-3), 
129.0 (C-2), 125.5 (C-6), 122.0 (C-1); m/z (CI+) 241.98 ([M81Br+H]+, 90%), 239.98 
([M+79Br], 100), 198.97 ([M+81Br-CH2N2]+, 58), 196.97 ([M79Br-CH2N2]+, 55); HRMS 
m/z (CI+) 239.9768 ([M79Br+H]+, 100) C8H7N3O79Br requires 239.9772. 
 
3-(4-Bromophenyl)-1,2,4-oxadiazol-5-amine 224g 
 
Oxime 226g (5 g, 30 mmol), was dissolved in DCM (300 mL). The solution was 
shaken with bleach (75 mL, 1.6 M, 120 mmol) for 3 min. The organic layer was 
separated and added to a solution of cyanamide (5.05 g, 120 mmol) in 
triethylamine (4.2 mL, 30 mmol) and the mixture was stirred for 8 h. The solvent 
was removed under reduce pressure to give a yellow solid. The product was 
purified by recrytsalisation using ethanol and water, to give the product 224g as a 
white solid (841 mg, 70%): m.p 250-254 ˚C; νmax/cm-1 (nujol) 3315, 3114, 1672, 
1592, 1576; δH (300 MHz, D6-DMSO) 7.90 (2H, s, NH2), 7.80 (2H, d, J= 8.5 Hz, 2-
H), 7.71 (2H, d, J= 8.5 Hz, 3-H); δC (75 MHz, D6-DMSO) 172.2 (C-6), 166.8 (C-5), 
132.0 (C-3), 128.5 (C-2), 126.8 (C-4), 124.2 (C-1); HRMS m/z (ES-) 237.9613 
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([M79Br-H]-, 100%) C8H5N3O79Br requires 237.9616; 239.9599 ([M81Br-H]-, 81) 
C8H5N3O81Br requires 239.9596. 
3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-amine 224h 
 
Oxime 226h (5 g, 26.3 mmol), was dissolved in DCM (330 mL). The solution was 
shaken with bleach (66 mL, 1.6 M, 105 mmol) for 3 min. The organic layer was 
separated and added to a solution of cyanamide (4.42 g, 105 mmol) in 
triethylamine (14.6 mL, 105 mmol) and the mixture was stirred for 8 h. The solvent 
was removed under reduce pressure to give a yellow solid. The product was 
purified by recrystalisation using ethanol and water, to give the product 224h as a 
colourless solid (3.01 g, 50 %): m.p 103-107 ˚C; δH (300 MHz, D6-DMSO) 8.07 (2H, 
s, 9-NH2), 7.99 (1H, d, J= 1.8 Hz, 2-H), 7.83 (1H, dd, J= 8.4, 1.8 Hz, 6-H), 7.78 
(1H, d, J= 8.4 Hz, 5-H); δC (75 MHz, D6-DMSO) 172.3 (C-8), 165.8 (C-7), 133.4 (C-
4), 131.7 (C-3), 131.4 (C-5), 128.1 (C-2), 128.1 (C-1), 126.6 (C-6); HRMS m/z 
(ES-) 227.9740 ([M-H]-, 100%) C8H4N3OCl2 requires 227.9731. 
 
3-(3-Methoxyphenyl)-1,2,4-oxadiazol-5-amine 224i 
 
Oxime 226i (1 g, 6.6 mmol), was dissolved in DCM (80 mL). The solution was 
shaken with bleach (16.5 mL, 1.6 M, 26.5 mmol) for 3 min. The organic layer was 
separated and added to a solution of cyanamide (1.11 g, 26.5 mmol) in 
triethylamine (3.7 mL, 26.5 mmol) and the mixture was stirred for 8 h. The solvent 
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was removed under reduce pressure to give a yellow solid. The product was 
purified by recrytsallisation using ethanol and water, to give the product 224i as a 
colourless solid (776 mg, 61%): m.p 187-189 ˚C; νmax/cm-1 (nujol) 3285, 3121, 
1678, 1608, 1535; δH (300 MHz, D6-DMSO) 7.94 (2H, s, 9-NH2), 7.46 (1H, ddd, J= 
7.6, 1.4, 1.4 Hz, 6-H), 7.42 (1H, d, J= 7.9 Hz, 5-H), 7.39-7.37 (1H, m, 2-H), 7.09 
(1H, ddd, J= 7.9, 2.7, 1.4 Hz, 4-H), 3.78 (3H, s, 10-H); δC (75 MHz, D6-DMSO) 
172.1 (C-8), 167.4 (C-7), 159.4 (C-3), 130.1 (C-5), 128.9 (C-1), 118.8 (C-6), 116.6 
(C-4), 111.5 (C-2), 55.1 (C-10); m/z (CI+) 192.08 ([M+H]+, 100%), 192.07 ([M]+, 45), 
149.07 ([M-CN2H2]+, 48); HRMS m/z (CI+) 192.0771 ([M+H]+,100%) C9H10N3O2 
requires 192.0773. 
 
N-(3-Phenyl-1,2,4-oxadiazol-5-yl)benzamide 228 
 
Benzoic acid (208 mg, 1.7 mmol) and DMAP (189 mg, 1.55 mmol) were added to a 
solution of 5-amino-1,2,4-oxadizole 224a (250 mg, 1.55 mmol) in acetonitrile (20 
mL). DCC (352 mg, 1.7 mmol) was added and the mixture was stirred for 8 h. The 
mixture was filtered to remove the urea byproduct. The filtrate was concentrated 
under reduced pressure to give a yellow oil. The product was purified by column 
chromatography on silica (10% ethyl acetate/ petroleum ether). The oil was 
triturated with diethyl ether to give the product 228 as a white solid (198 mg, 48%): 
m.p 98-100 ˚C; Anal. RP HPLC: tR 13.18 min (purity 99.97%); νmax/cm-1 (nujol) 
3499, 1708, 1694, 1557; δH (300 MHz, D6-DMSO) 9.79 (1H, br s, NH), 8.00-7.97 
(2H, m, Ar-H), 7.96 (2H, dd, J= 2.8, 1.5 Hz, Ar-H), 7.63-7.57 (1H, m), 7.51-7.47 
(2H, m, Ar-H), 7.47-7.45 (1H, m, Ar-H), 7.44-7.39 (2H, m, Ar-H); δC (75 MHz, D6-
DMSO) 162.8 (C-8), 161.2 (C-6), 158.2 (C-5), 128.3 (Ar-H), 126.5 (Ar), 126.1 (Ar-
H), 123.8 (Ar-H), 123.5 (Ar-H), 122.7 (Ar-H), 122.2 (Ar-H), 121.1 (Ar); HRMS m/z 
(ES+) 288.0746 C15H11N3O2Na requires 288.0749.  
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N-(3-(m-Tolyl)-1,2,4-oxadiazol-5-yl)benzamide 229 
 
Benzoic acid (191 mg, 1.6 mmol) and DMAP (17 mg, 0.14 mmol) were added to a 
solution of 5-amino-1,2,4-oxadizole 224b (250 mg, 1.4 mmol) in acetonitrile (20 
mL). DCC (323 mg, 1.6 mmol) was added and the mixture was stirred for 8 h. The 
mixture was filtered to remove the urea byproduct. The filtrate was concentrated 
under reduced pressure to give a yellow oil. The product was purified by column 
chromatography on silica (15% ethyl acetate/ petroleum ether) to give the product 
229 as a white solid (252 mg, 63%): m.p 108-111 ˚C; Anal. RP HPLC: tR 16.53 min 
(purity 99.72%); νmax/cm-1 (nujol) 3178, 1695, 1568, 1487; δH (300 MHz, D6-DMSO) 
12.65 (1H, s, NH), 8.02-8.05 (2H, m, 12-H), 7.81-7.77 (2H, m, 2,6-H), 7.69- 7.64 
(1H, m, 14-H), 7.58-7.53 (2H, m, 13-H), 7.48-7.41 (1H, m, 4-H), 7.41-7.36 (1H, m, 
5-H), 2.39 (3H, s, 15-H); δC (75 MHz, D6-DMSO) 167.8 (C-7), 167.8 (C-8), 164.8 
(C-10), 138.9 (C-3), 133.5 (C-14), 132.6 (C-5), 132.5 (C-11), 129.5 (C-4), 129.0 (C-
12), 128.9 (C-13), 127.6 (C-2), 126. 7 (C-1), 124.4 (C-6), 21.3 (C-15); HRMS m/z 
(ES+) 302.0897 ([M+Na]+, 100%) C16H13N3O2Na requires 302.0905. 
 
N-(3-(3-(Trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)benzamide 230 
 
Benzoic acid (147 mg, 1.2 mmol) and DMAP (133 mg, 1.09 mmol) were added to a 
solution of 5-amino-1,2,4-oxadizole 224c (250 mg, 1.09 mmol) in acetonitrile (20 
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mL). DCC (247 mg, 1.2 mmol) was added and the mixture was stirred for 8 h. The 
mixture was filtered to remove the urea byproduct. The filtrate was concentrated 
under reduced pressure to give a yellow oil. The product was purified by column 
chromatography on silica (15% ethyl acetate/ petroleum ether) to give the product 
230 as a white solid (125 mg, 34%): m.p 130-132 ˚C; νmax/cm-1 (nujol) 3246, 3170, 
1708, 1629, 1616; δH (300 MHz, D6-DMSO) 12.76 (1H, s, NH), 8.31 (1H, d, J= 7.8 
Hz, 6-H), 8.25-8.23 (1H, m, 2-H), 8.07-8.03 (2H, m, 12-H), 8.02-8.00 (1H, m, 4-H) 
7.89-7.82 (1H, m, 5-H), 7.72-7.67 (1H, m, 14-H), 7.61-7.55 (2H, m, 13-H); δC (75 
MHz, D6-DMSO) 167.9 (C-8), 166.3 (C-7), 164.3 (C-10), 133.2 (C-14), 132.1 (C-
11), 130.7 (C-6,5), 129.9 (d, J= 32.2 Hz, C-3), 128.7 (C-13), 128.5 (C-12), 128.2-
128.1 (m, C-4), 127.5 (C-1), 123.2-123.0 (m, C-2), 123.7 (d, J= 271 Hz, C-15); δF 
(376 MHz, D6-DMSO) -61.52 (s); HRMS m/z (ES+) 356.0611 ([M+Na]+, 100%) 
C16H10N3O2F3Na requires 356.0618. 
 
N-(3-(3-Fluorophenyl)-1,2,4-oxadiazol-5-yl)benzamide 231 
 
Benzoic acid (188 mg, 1.5 mmol) and DMAP (17 mg, 0.14 mmol) were added to a 
solution of 5-amino-1,2,4-oxadizole 224d (250 mg, 1.4 mmol), in acetonitrile (20 
mL). DCC (317 mg, 1.5 mmol) was added and the mixture was stirred for 8 h. The 
mixture was filtered to remove the urea byproduct. The filtrate was concentrated 
under reduced pressure to give a yellow oil. The product was purified by column 
chromatography on silica (15% ethyl acetate/petroleum ether to 20% ethyl 
acetate/petroluem ether) to give the product 231 as a white solid (211 mg, 53 %): 
m.p 108-110 ˚C; Anal. RP HPLC: tR 15.19 min, (purity 98.25%); νmax/cm-1 (nujol) 
3515, 3456, 1700; δH (300 MHz, D6-DMSO) 12.73 (1H, s, NH), 8.05-8.02 (2H, m, 
12-H), 7.85 (1H, dd, J= 7.7, 1.3, 1.2 Hz, 6-H), 7.71 (1H, ddd, J= 9.6, 2.7, 1.3 Hz, 2-
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H), 7.68 (1H, t, J= 2.2 Hz, 14-H), 7.64 (1H, dd, J= 8.2, 1.8 Hz, 5-H) 7.60-7.54 (2H, 
m, 13-H), 7.5-7.43 (1H, m, 4-H); δC (75 MHz, DMSO- d6) 168.1 (C-8), 166.9 (d, J= 
2.9 Hz, C-7), 164.8 (C-10), 162.6 (d, J= 245.2 Hz, C-3), 133.6 (C-14), 132.5 (C-11), 
132.0 (d, J= 8.4 Hz, C-5), 129.0 (C-13), 128.9 (C-12), 123.5 (d, J= 2.9 Hz, C-6), 
118.9 (d, J=21.0 Hz, C-4), 113.8 (d, J= 23.4 Hz, C-2); δF (282 MHz, 
D6-DMSO) -112.2 (1F, td, J= 9.2, 6.0 Hz); HRMS m/z (ES+) 306.0659 ([M+Na]+, 
100%) C15H10N3O2FNa requires 306.0655. 
 
N-(3-(3-Chlorophenyl)-1,2,4-oxadiazol-5-yl)benzamide 232 
 
Benzoic acid (171 mg, 1.4 mmol) and DMAP (16 mg, 0.14 mmol) were added to a 
solution of 5-amino-1,2,4-oxadizole 234e (250 mg, 1.3 mmol) in acetonitrile (20 
mL). DCC (290 mg, 1.4 mmol) was added and the mixture was stirred for 8 h. The 
mixture was filtered to remove the urea byproduct. The filtrate was concentrated 
under reduced pressure to give a yellow oil. The product was purified by column 
chromatography on silica (15% ethyl acetate/petroleum ether) to give the product 
232 as a colourless solid (136 mg, 35%): m.p 94-99 ˚C; νmax/cm-1 (nujol) 3301, 
3233, 3158, 1706, 1624, 1536, 1250; δH (300 MHz, D6-DMSO) 12.72 (1H, s, NH), 
8.05- 8.02 (2H, m, 12-H), 7.96 (1H, dd, J= 3.3, 1.7 Hz, 2-H), 7.94 (1H, dd, J= 2.7, 
1.3 Hz, 6-H), 7.65-7.70 (2H, m, 4,11-H), 7.64-7.61 (1H, m, 5-H), 7.57 (2H, dd, J= 
6.6, 1.2 Hz, 13-H); δC (75 MHz, D6-DMSO) 168.1 (C-8), 166.7 (C-7), 164.8 (C-10), 
134.2 (C-3), 133.6 (C-11), 132.5 (C-1), 131.8 (C-4), 131.7 (C-5), 129.0 (C-13), 
128.9 (C-12), 128.8 (C-14), 126.8 (C-2), 125.9 (C-6); HRMS m/z (ES+) 322.0359 
([M+Na]+, 100%), C15H10N3O2ClNa requires 322.0359. 
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N-(3-(3-Bromophenyl)-1,2,4-oxadiazol-5-yl)benzamide 233 
 
Benzoic acid (128 mg, 1.14 mmol) and DMAP (127 mg, 1.04 mmol) were added to 
a solution of 5-amino-1,2,4-oxadizole 224f (250 mg, 1.04 mmol) in acetonitrile (50 
mL). DCC (236 mg, 1.14 mmol) was added and the mixture was stirred for 8 h. The 
mixture was filtered to remove the urea byproduct. The filtrate was concentrated 
under reduced pressure to give a yellow oil. The product was purified by column 
chromatography on silica (15% ethyl acetate/petroleum ether) to give the product 
233 as a colourless solid (51 mg, 14.2%): m.p 140-144 ˚C; Anal. RP HPLC: tR 
19.41 min (purity 99.41%); νmax/cm-1 (nujol) 3281, 1700, 1598, 1539; δH (300 MHz, 
D6-DMSO) 12.72 (1H, s, 9-NH), 8.09 (1H, ddd, J= 2.0, 1.6, 0.4 Hz, 2-H), 8.05-8.01 
(2H, m, 12-H), 7.99 (1H, ddd, J= 7.8, 1.6, 1.1 Hz, 4-H), 7.82 (1H, ddd, J= 8.1, 2.0, 
1.1 Hz, 6-H), 7.71-7.65 (1H, m, 14-H), 7.60-7.52 (3H, m, 5,13-H); δC (75 MHz, D6-
DMSO) 168.1 (C-7), 166.6 (C-10), 164.7 (C-8), 134.7 (C-4), 133.5 (C-14), 132.5 
(C-11), 131.9 (C-5), 129.6 (C-2), 129.0 (C-13), 129.0 (C-3), 128.9 (C-12), 126.2 (C-
6), 122.6 (C-1); HRMS m/z (ES-) 341.9885 ([M79Br-H]+, 100%) C15H9N3O279Br 
requires 341.9878; 343.9858 ([M81Br-H]+, 95) C15H9N3O281Br requires 343.9853. 
 
N-(3-(4-Bromophenyl)-1,2,4-oxadiazol-5-yl)benzamide 234 
 
Benzoic acid (128 mg, 1.14 mmol) and DMAP (127 mg, 1.04 mmol) were added to 
a solution of 5-amino-1,2,4-oxadizole 224g (250 mg, 1.04 mmol) in acetonitrile (20 
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mL). DCC (236 mg, 1.14 mmol) was added and the mixture was stirred for 8 h. The 
mixture was filtered to remove the urea byproduct. The filtrate was concentrated 
under reduced pressure to give a yellow oil. The product was purified by column 
chromatography on silica (12.5% ethyl acetate/ petroleum ether) to give the 
product 234 as a white solid (45 mg, 12.6%): m.p 118-120 ˚C; Anal. RP HPLC: tR 
20.05 min (purity 98.27%); νmax/cm-1 (nujol) 3508, 3466, 1700, 1573; δH (300 MHz, 
D6-DMSO) 12.71 (1H, s, NH), 8.06-8.02 (2H, m, 9-H), 7.94 (2H, d, J= 8.8 Hz, 2-H), 
7.80 (2H, d, J= 8.8 Hz, 3-H), 7.72-7.66 (1H, m, 11-H), 7.60-7.55 (2H, m, 10-H); δC 
(75 MHz, D6-DMSO) 168.1 (C-6), 167.1 (C-5), 164.8 (C-8), 133.5 (C-11), 132.7 (C-
3), 132.5 (C-12), 129.2 (C-10), 129.0 (C-2), 128.9 (C-9), 126.0 (C-4), 125.5 (C-1); 
m/z (ES-) 341.9879 ([M-H]-, 100%) C15H9N3O2Br requires 341.9884. 
 
N-(3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)benzamide 235 
 
Benzoic acid (145 mg, 1.2 mmol) and DMAP (132 mg, 1.09 mmol) were added to a 
solution of 5-amino-1,2,4-oxadizole 224h (250 mg, 1.09 mmol) in acetonitrile (20 
mL). DCC (g, mmol) was added and the mixture was stirred for 8 h. The mixture 
was filtered to remove the urea byproduct. The filtrate was concentrated under 
reduced pressure to give a yellow oil. The product was purified by column 
chromatography on silica (15% ethyl acetate/petroleum ether) to give the product 
235 as a colourless solid (57 mg, 16%): m.p 134-136 ˚C; νmax/cm-1 (nujol) 3182, 
1707, 1651, 1586; δH (300 MHz, D6-DMSO) 12.74 (1H, s, NH), 8.13 (1H, d, J= 1.9 
Hz, 2-H), 8.04 (2H, dt, J= 8.3, 1.6 Hz, 13-H), 7.96 (1H, dd, J= 8.4, 1.9 Hz, 6-H), 
7.87 (1H, d, J= 8.4 Hz, 5-H), 7.72-7.66 (1H, m, 14-H), 7.58 (2H, td, J= 7.4, 1.2 Hz, 
12-H); δC (75 MHz, D6-DMSO) 167.9 (C-9), 165.7 (C-7), 164.4 (C-8), 134.3 (C-1), 
133.2 (C-13), 132.1 (C-10), 132.1 (C-4), 131.7 (C-5), 128.6 (C-12), 128.5 (C-11), 
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128.4 (C-2), 127.0 (C-6), 126.9 (C-3); HRMS m/z (ES+) 355.9968 ([M+Na]+, 100%) 
C15H9Cl2N3O2Na requires 355.9970. 
 
N-(3-(3-Methoxyphenyl)-1,2,4-oxadiazol-5-yl)benzamide 236 
 
Benzoic acid (175 mg, 1.4 mmol) and DMAP (16 mg, 0.13 mmol) were added to a 
solution of 5-amino-1,2,4-oxadizole 224i (250 mg, 1.3 mmol) in acetonitrile (20 
mL). DCC (297 mg, 1.4 mmol) was added and the mixture was stirred for 8 h. The 
mixture was filtered to remove the urea byproduct. The filtrate was concentrated 
under reduced pressure to give a yellow oil. The product was purified by column 
chromatography on silica (15% ethyl acetate/petroleum ether) to give the product 
236 as a colourless solid (90 mg, 23 %): m.p 110-114 ˚C; Anal. RP HPLC: tR 14.68 
min (purity 99.02%); νmax/cm-1 (nujol) 3505, 3438, 1695, 1562; δH (300 MHz, D6-
DMSO) 8.06-8.03 (2H, m, 12-H), 7.71-7.65 (1H, m, 14-H), 7.61-7.54 (3H, m, 6,13-
H), 7.52-7.47 (2H, m, 2,5-H), 7.17 (1H, ddd, J= 8.2, 2.7, 1.0 Hz, 4-H), 3.84 (3H, s, 
15-H); δC (75 MHz, D6-DMSO) 167.6 (C-8), 167.2 (C-7), 164.5 (C-10), 159.6 (C-3), 
133.1 (C-14), 132.2 (C-11), 130.5 (C-5), 128.6 (C-13), 128.5 (C-12), 127.7 (C-1), 
119.1 (C-6), 117.4 (C-4), 111.7 (C-2), 55.3 (C-15); HRMS m/z (ES+) 318.0857 
([M+Na]+, 100%) C16H13N3O3Na requires 318.0855. 
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3,4-Dimethoxy-N-(3-phenyl-1,2,4-oxadiazol-5-yl)benzamide 238 
 
3,4-Dimethoxybenzoic acid (310 mg, 1.7 mmol) and DMAP (182 mg, 1.55 mmol) 
were added to a solution of 5-amino-1,2,4-oxadizole 224a (250 mg, 1.55 mmol) in 
acetonitrile (20 mL). DCC (352 mg, 1.7 mmol) was added and the mixture was 
stirred for 8 h. The mixture was filtered to remove the urea byproduct. The filtrate 
was concentrated under reduced pressure to give a yellow oil. The product was 
purified by column chromatography on silica (25% ethyl acetate/ petroleum ether to 
30% ethyl acetate/petroleum ether) to give the product 238 as a colourless solid 
(216 mg, 43%): m.p 110-115 ˚C; Anal. RP HPLC: tR 12.56 min (purity 
96.00%); νmax/cm-1 (nujol) 3562, 3410, 1709, 1627, 1550; δH (300 MHz, D6-DMSO) 
12.51 (1H, s, NH), 8.02-7.99 (2H, m, 2-H), 7.74 (1H, dd, J=8.5, 2.2 Hz, 14-H), 7.67 
(1H, d, J= 2.2 Hz, 10-H), 7.62-7.56 (3H, m, 3,4-H), 7.13 (1H, d, J= 8.5 Hz, 13-H), 
3.86 (6H, OMe); δC (75 MHz, D6-DMSO) 167.7 (C-6), 167.2 (C-5), 163.5 (C-8), 
152.9 (C-OMe), 148.3 (C-OMe), 131.5 (C-4), 129.2 (C-3), 126.8 (C-2), 126.5 (C-1), 
123.9 (C-9), 122.6 (C-14), 111.3 (C-10), 111.1 (C-13), 55.8 (OMe), 55.7 (OMe); 
HRMS m/z (ES+) 348.0949 ([M+Na]+, 100%) C17H15O4N3Na requires 348.0955. 
 
3,4-Dimethoxy-N-(3-(m-tolyl)-1,2,4-oxadiazol-5-yl)benzamide 239 
 
3,4-Dimethoxybenzoic acid (285 mg, 1.6 mmol) and DMAP (174 mg, 1.4 mmol) 
were added to a solution of 5-amino-1,2,4-oxadizole 224b (250 mg, 1.4 mmol) in 
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DCM (20 mL). EDCI (410 mg, 2.1 mmol) was added and the mixture was stirred for 
8 h. The mixture was washed with hydrochloric acid (2 M, 40 mL). The aqueous 
layer was washed with DCM (3 × 20 mL) and the organic fractions were combined 
and dried with magnesium sulfate. The solvent was removed under reduced 
pressure to give a yellow oil. The product was purified by column chromatography 
on silica (20% ethyl acetate/petroleum ether to 25% ethyl acetate/petroleum ether) 
to give the product 239 as a colourless solid (365 mg, 76%): m.p 167-170 ˚C; 
νmax/cm-1 (nujol) 3200, 1772, 1685, 1514; δH (300 MHz, D6-DMSO) 12.49 (1H, s, 
NH), 7.81-7.77 (2H, m, 2,6-H), 7.72 (1H, dd, J= 8.5, 1.8 Hz, 16-H), 7.65 (1H, d, J= 
1.8 Hz, 12-H), 7.48-7.37 (2H, m, 4,5-H), 7.11 (1H, d, J= 8.5 Hz, 15-H) 3.84 (6H, s, 
OMe), 2.40 (3H, s, Me); δC (75 MHz, D6-DMSO) 168.0 (C-8), 167.7 (C-7), 163.9 (C-
10), 153.2 (C-OMe), 148.7 (C-OMe), 138.9 (C-3), 132.5 (C-4), 129.5 (C-5), 127.6 
(C-2), 126.8 (C-1), 124.4 (C-6), 124.3 (C-11), 123.0 (C-16), 111.7 (C-12), 111.5 (C-
15), 56.1 (OMe), 56.0 (OMe), 21.3 (C-17); HRMS m/z (ES+) 362.1120 ([M+Na]+, 
100%) C18H17N3O4Na requires 362.1117. 
 
3,4-Dimethoxy-N-(3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)benzamide 240 
 
3,4-Dimethoxybenzoic acid (262 mg, 1.4 mmol) and DMAP (80 mg, 0.65 mmol) 
were added to a solution of 5-amino-1,2,4-oxadizole 244c (300 mg, 1.3 mmol) in 
DCM (20 mL). EDCI (376 mg, 1.96 mmol) was added and the mixture was stirred 
for 8 h. The mixture was washed with hydrochloric acid (2 M, 40 mL). The aqueous 
layer was washed with DCM (3 × 20 mL) and the organic layers were combined 
and dried with magnesium sulfate. The solvent was removed under reduced 
pressure to give a yellow oil. This oil was purified by column chromatography on 
silica (20% ethyl acetate/ petroleum ether to 30% ethyl acetate/ petroleum ether) to 
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give the product 240 as a white solid (338 mg, 66%): m.p 166-170 ˚C; νmax/cm-1 
(nujol) 3269, 1695, 1559; δH (300 MHz, D6-DMSO) 12.56 (1H,s, 9-NH), 8.30-8.27 
(1H, m, 6-H), 8.24-8.21 (1H, m, 2-H), 8.01-7.98 (1H, m, 4-H), 7.87-7.80 (1H, m, 5-
H), 7.72 (1H, dd, J= 8.6, 2.1 Hz, 16-H), 7.65 (1H, d, J= 2.1 Hz, 12-H), 7.12 (1H, d, 
J= 8.6 Hz, 15-H), 3.85 (6H, s, OMe); δC (75 MHz, D6-DMSO) 168.4 (C-8), 166.6 (C-
7), 163.8 (C-10), 153.3 (C-OMe), 148.7 (C-OMe), 131.1-131.0 (m, C-5,6), 130.5 
(C-1), 130.4 (d, J= 32.3 MHz, C-3), 127.9 (C-4), 124.2 (C-11), 123.6- 123.4 (m, C-
2), 123.0 (C-16), 111.7 (C-12), 111.5 (C-15), 56.2 (OMe), 56.0 (OMe); δF (282 
MHz, D6-DMSO) -61.56 (s); HRMS m/z (ES+) 416.0838 ([M+Na]+, 100%) 
C18H14N3O4F3Na requires 416.0834. 
 
N-(3-(3-Fluorophenyl)-1,2,4-oxadiazol-5-yl)-3,4-dimethoxybenzamide 241 
 
3,4-Dimethoxybenzoic acid (336 mg, 1.8 mmol) and DMAP (20 mg, 0.16 mmol) 
were added to a solution of 5-amino-1,2,4-oxadizole 224d (300 mg, 1.7 mmol) in 
DCM (20 mL). EDCI (353 mg, 1.8 mmol) was added and the mixture was stirred for 
8 h. The mixture was washed with hydrochloric acid (2 M, 40 mL). The aqueous 
layer was washed with DCM (3 × 20 mL) and the organic fractions were combined 
and dried with magnesium sulfate. The solvent was removed under reduced 
pressure to give a yellow oil. This oil was purified by column chromatography on 
silica (25% ethyl acetate/petroleum ether to 30% ethyl acetate/petroleum ether) to 
give the product 241 as a colourless solid (133 mg, 23%): m.p 114-118 ˚C; 
νmax/cm-1 (nujol) 3494, 3204, 1703, 1461; δH (300 MHz, D6-DMSO) 12.55 (1H, s, 
NH), 7.84 (1H, ddd, J= 7.7, 1.4, 1.0 Hz, 6-H), 7.74-7.66 (2H, m, 2,16-H) 7.66-7.60 
(2H, m, 5,12-H), 7.50-7.43 (1H, m, 4-H) 7.12 (1H, d, J= 8.6 Hz, 15-H), 3.85 (6H, s, 
OMe); δC (75 MHz, D6-DMSO) 168.3 (C-8), 164.2 (C-7), 163.9 (C-10) 153.3 (C-
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OMe), 148.7 (C-OMe), 132.0 (d, J= 8.5 Hz, C-5), 129.1 (1), 129.0 (11), 123.4 (d, J= 
3.1 Hz, C-6), 123.0 (C-16), 119.0 (C-4), 113.8 (d, J= 23.2 Hz, C-2), 111.7 (C-15), 
111.5 (C-12), 56.2 (OMe), 56.0 (OMe); δF (282 MHz, D6-DMSO) -111.67 (1F, td, J= 
9.1, 5.8 Hz); HRMS m/z (CI+) 344.1042 ([M+H]+, 20%), C17H15N3O4F requires 
344.1047. 
 
N-(3-(3-Chlorophenyl)-1,2,4-oxadiazol-5-yl)-3,4-dimethoxybenzamide 242 
 
3,4-Dimethoxybenzoic acid (307 mg, 1.7 mmol) and DMAP (93 mg, 0.75 mmol) 
were added to a solution of 5-amino-1,2,4-oxadizole 224e (300 mg, 1.5 mmol) in 
DCM (20 mL). EDCI (441 mg, 2.3 mmol) was added and the mixture was stirred for 
8 h. The mixture was washed with hydrochloric acid (2 M, 40 mL). The aqueous 
layer was washed with DCM (3 × 20 mL) and the organic layers were combined 
and dried with magnesium sulfate. The solvent was removed under reduced 
pressure to give a yellow oil. This oil was purified by column chromatography on 
silica (20% ethyl acetate/ petroleum ether to 30% ethyl acetate/ petroleum ether) to 
give the product 242 as a white solid (348 mg, 63%): m.p 119-122 ˚C; νmax/cm-1 
(nujol) 3279, 1691, 1599, 1539, 1506; δH (300 MHz, D6-DMSO) 12.55 (1H, s, 9-
NH), 7.98-7.95 (2H, m, 2,6-H), 7.75-7.68 (2H, m, 4,16-H), 7.66-7.60 (2H, m, 5,12-
H), 7.13 (1H, d, J= 8.6 Hz, 15-H), 3.85 (6H, s, OMe); δC (75 MHz, D6-DMSO) 168.0 
(C-8), 166.2 (C-7), 163.5 (C-10), 152.9 (C-OMe), 148.3 (C-OMe), 133.8 (C-3), 
131.4 (C-4), 131.3 (C-5), 128.5 (C-1), 126.4 (C-6), 125.5 (C-2) 123.9 (C-11), 122.7 
(C-16), 111.4 (C-12), 111.1 (C-15), 55.8 (OMe), 55.7 (OMe); HRMS m/z  (ES+) 
382.0567 ([M+Na]+, 100%) C17H14N3O4ClNa requires 382.0571. 
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N-(3-(3-Bromophenyl)-1,2,4-oxadiazol-5-yl)-3,4-dimethoxybenzamide 243 
 
3,4-Dimethoxybenzoic acid (250 mg, 1.4 mmol) and DMAP (76 mg, 0.6 mmol) 
were added to a solution of 5-amino-1,2,4-oxadizole 224f (300 mg, 1.2 mmol) in 
DCM (20 mL). EDCI (264 g, 1.4 mmol) was added and the mixture was stirred for 8 
h. The mixture was washed with hydrochloric acid (2 M, 40 mL). The aqueous layer 
was washed with DCM (3 × 20 mL) and the organic fractions were combined and 
dried with magnesium sulfate. The solvent was removed under reduced pressure 
to give a yellow oil. This oil was purified by column chromatography on silica (25% 
ethyl acetate/petroleum ether to 30% ethyl acetate/petroleum ether) to give the 
product 243 as a white solid (198 mg, 41%): m.p 138-142 ˚C; νmax/cm-1 (nujol) 
3231, 3176, 1770, 1684; δH (300 MHz, D6-DMSO) 12.54 (1H, s, NH), 8.13-8.10 
(1H, m, 2-H), 8.00 (1H, ddd, J= 7.8, 1.5, 1.1 Hz, 4-H), 7.83 (1H, ddd, J= 8.1, 2.1, 
1.1 Hz, 6-H), 7.73 (1H, dd, J= 8.6, 2.1 Hz, 16-H), 7.66 (1H, d, J= 2.1 Hz, 12-H), 
7.60-7.53 (1H, m, 5-H), 7.14 (1H, d, J= 8.6 Hz, 15-H), 3.86 (6H,s, OMe); δc (75 
MHz, D6-DMSO) 167.9 (C-8), 166.1 (C-7), 163.4 (C-10), 152.9 (C-OMe), 148.3 (C-
OMe), 134.6 (C-6), 131.8 (C-5), 131.5 (C-1), 129.2 (C-2), 125.8 (C-4), 123.9 (C-
11), 122.6 (C-16), 122.2 (C-3), 111.4 (C-12), 111.1 (C-15), 55.8 (OMe), 55.7 
(OMe); HRMS m/z (ES+) 426.0067 ([M+Na]+, 100%) C17H14N3O4Na79Br requires 
426.0065. 
 
  
5
4
3
2
1
6
7 N
8ON
NH
9
10
O
11
16 15
14
1312 O
O
18
17
Br
  229 
N-(3-(4-Bromophenyl)-1,2,4-oxadiazol-5-yl)-3,4-dimethoxybenzamide 244 
 
3,4-dimethoxybenzoic acid (209 mg, 1.14 mmol) and DMAP (127 mg, 1.04 mmol) 
were added to a solution of 5-amino-1,2,4-oxadizole 224g (250 mg, 1.04 mmol) in 
DCM (20 mL). EDCI (300 mg, 1.56 mmol) was added and the mixture was stirred 
for 8 h. The mixture was washed with hydrochloric acid (2 M, 40 mL). The aqueous 
layer was washed with DCM (3 × 20 mL) and the organic layers were combined 
and dried with magnesium sulfate. The solvent was removed under reduced 
pressure to give a yellow oil. This oil was purified by column chromatography on 
silica (20% ethyl acetate/petroleum ether to 30% ethyl acetate/petroleum ether) to 
give the product 244 a white solid (298 mg, 71%); m.p 140-144 ˚C; Anal. RP 
HPLC: tR 19.43 min (99.52%);  νmax/cm-1 (nujol) 3545, 3434, 1713, 1629, 1600, 
1552; δH (300 MHz, D6-DMSO) 12.49 (1H, br s, 9-NH), 7.92 (2H, d, J= 8.6 Hz, 2-
H), 7.78 (2H, d, J= 8.6 Hz, 3-H), 7.71 (1H, dd, J= 8.6, 2.1 Hz, 14-H), 7.64 (1H, d, 
J= 2.1 Hz, 10-H), 7.11 (1H, d, J=8.6 Hz, 13-H), 3.83 (6H, s, OMe); δC (75 MHz, D6-
DMSO) 167.9 (C-5), 166.6 (C-6), 163.5 (C-8), 152.9 (C-OMe), 148.3 (C-OMe), 
132.3 (C-3), 128.8 (C-2), 125.7 (C-4), 125.0 (C-1), 123.9 (C-9), 122.6 (C-14), 111.4 
(C-10), 111.1 (C-13), 55.8 (OMe), 55.7 (OMe); m/z (ES+) 427.77 ([M81Br+Na]+, 
90%), 425.77 ([M79Br+Na]+, 100); HRMS m/z (ES+) 426.0059 ([M+Na]+, 100), 
C17H14N3O4BrNa requires 426.0065. 
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N-(3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)-3,4-dimethoxybenzamide 245 
 
3,4-Dimethoxybenzoic acid (261 mg, 1.4 mmol) and DMAP (16 mg, 0.13 mmol) 
were added to a solution of 5-amino-1,2,4-oxadizole 224h (300 mg, 1.3 mmol) in 
DCM (20 mL). EDCI (275 mg, 1.4 mmol) was added and the mixture was stirred for 
8 h. The mixture was washed with hydrochloric acid (2 M, 40 mL). The aqueous 
layer was washed with DCM (3 × 20 mL) and the organic layer was dried with 
magnesium sulfate. The solvent was removed under reduced pressure to give a 
yellow oil. This oil was purified by column chromatography on silica (25% ethyl 
acetate/petroleum ether) to give the product 245 as a colourless solid (90 mg, 
18%): m.p 178-180 ˚C; Anal. RP HPLC: tR 24.15 min (purity 96.68%); νmax/cm-1 
(nujol) 3412 (NH), 1692, 1661, 1625; δH (300 MHz, D6-DMSO) 12.55 (1H, s, 9-NH), 
8.10 (1H, d, J= 1.9 Hz, 2-H), 7.93 (1H, dd, J= 8.4, 1.9 Hz, 6-H), 7.85 (1H, d, J= 8.4 
Hz, 5-H), 7.71 (1H, dd, J= 8.5, 2.1 Hz, 12-H), 7.63 (1H, d, J= 2.1 Hz, 16-H), 7.11 
(1H, d, J= 8.5 Hz, 13-H), 3.84 (6H, s, OMe); δC (75 MHz, D6-DMSO) 168.1 (C-8), 
165.6 (C-7), 163.5 (C-10), 152.9 (C-15), 148.3 (C-14), 134.2 (C-4), 132.1 (C-3). 
131.7 (C-5), 128.4 (C-2), 127.1 (C-1), 126.9 (C-6), 122.6 (C-12), 111.4 (C-16), 
111.1 (C-13), 55.8 (OMe), 55.6 (OMe); HRMS m/z (ES-) 392.0199 ([M-H]-, 100%) 
C17H12N3O4Cl2 requires 392.0205. 
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3,4-Dimethoxy-N-(3-(3-methoxyphenyl)-1,2,4-oxadiazol-5-yl)benzamide 246 
 
3,4-Dimethoxybenzoic acid (314 mg, 1.7 mmol) and DMAP (95 mg, 0.78 mmol) 
were added to a solution of 5-amino-1,2,4-oxadizole 224i (300 mg, 1.6 mmol) in 
DCM (20 mL). EDCI (451 mg, 2.3 mmol) was added and the mixture was stirred for 
8 h. The mixture was washed with hydrochloric acid (2 M, 40 mL). The aqueous 
layer was washed with DCM (3 × 20 mL) and the organic layers were combined 
and dried with magnesium sulfate. The solvent was removed under reduced 
pressure to give a yellow oil. This oil was purified by column chromatography on 
silica (20% ethyl acetate/petroleum ether to 30% ethyl acetate/petroleum ether) to 
give the product 246 as a white solid (130 mg, 23%): m.p 100-104 ˚C; νmax/cm-1 
(nujol mull) 3500, 3428, 1693, 1568; δH (300 MHz, D6-DMSO) 12.50 (1H, s, 9-NH), 
7.74 (1H, dd, J= 8.5, 2.1 Hz, 16-H), 7.67 (1H, d, J= 2.1 Hz, 12-H), 7.59 (1H, ddd, 
J= 7.7, 1.1, 1.1 Hz, 6-H), 7.52-7.47 (2H, m, 2,5-H), 7.18 (1H, ddd, J= 8.2, 2.7, 1.1 
Hz, 4-H), 7.13 (1H, d, J= 8.5, Hz, 15-H), 3.86 (6H,s ,OMe), 3.84 (3H, s, OMe); δC 
(75 MHz, D6-DMSO) 167.7 (C-7), 167.1 (C-8), 163.5 (C-10), 159.6 (C-3), 152.9 (C-
14), 148.3 (C-13), 130.5 (C-5), 127.7 (C-1), 123.9 (C-11), 122.6 (C-16), 119.1 (C-
6), 117.4 (C-4), 111.6 (C-2), 111.4 (C-12), 111.1 (C-15), 55.8 (OMe), 55.7 (OMe), 
55.3 (OMe); HRMS m/z (ES+) 378.1072 ([M+Na]+, 100%) C18H17N3O5Na requires 
378.1066. 
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N-(3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)acetamide 247 
 
DMAP (238 mg, 1.9 mmol) and acetic anhydride (183 µl, 1.9 mmol) were added to 
a solution of 5-amino-1,2,4-oxadiazole 224h (300 mg, 1.3 mmol) in toluene. The 
mixture was heated under reflux for 16 h. DCM (100 mL) was added to the 
solution. The solution was washed with saturated sodium bicarbonate solution and 
the organic layer was dried with magnesium sulfate. The solvent was removed 
under reduced pressure. The product was purified by column chromatography on 
silica (20% ethyl acetate/petroleum ether) to give the product 247 as a colourless 
solid (287 mg, 81%): m.p 174-178 ˚C; Anal. RP HPLC: tR 16.90 min (purity 
99.22%); νmax/cm-1 (nujol) 3091, 1692, 1605, 1569; δH (300 MHz, CDCl3) 8.50 (1H, 
s, 9-NH), 8.06 (1H, d, J= 2.0 Hz, 2-H), 7.81 (1H, dd, J= 8.4, 2.0 Hz, 6-H), 7.49 (1H, 
d, J= 8.4 Hz, 5-H), 2.48 (3H, s, Me); δC (75 MHz, CDCl3) 168.2 (C-10), 167.4 (C-8), 
165.8 (C-7), 134.6 (C-4), 132.4 (C-3), 132.0 (C-5), 128.7 (C-2), 127.2 (C-6), 127.2 
(C-1), 24.1 (C-11); HRMS m/z (ES+) 293.9824 ([M+Na]+, 100) C10H7N3O235Cl2Na 
requires 293.9813. 
 
N-(3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)cyclohexanecarboxamide 248 
 
DMAP (476 mg, 3.9 mmol) and cyclohexanecarbonyl chloride (208 µl, 1.55 mmol) 
were added to a solution of 5-amino-1,2,4-oxadiazole 244h (265 mg, 1.15 mmol) in 
DCM (20 mL). The solution was stirred for 16 h. The solvent was removed under 
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reduce pressure. The product was purified by column chromatography on silica 
(10% ethyl acetate/petroleum ether) to give the product 248 as a colourless solid 
(329 mg, 84%): m.p 193-198 ˚C; νmax/cm-1 (nujol) 3218, 3085, 1709, 1598, 1566; δH 
(300 MHz, D6-DMSO) 12.21 (1H, s, 9-H), 8.03 (1H, d, J= 1.9 Hz, 2-H), 7.87 (1H, 
dd, J= 8.4, 1.9 Hz, 6-H), 7.81 (1H, d, J= 8.4 Hz, 5-H), 2.51-2.49 (1H, m, 11-H), 1.84 
(2H, d, J= 12.8 Hz, 12-H), 1.74 (2H, d, J= 10.6 Hz, 13-H), 1.63 (1H, d, J= 8.4 Hz, 
14-H), 1.45-1.16 (5H, m, 12-H, 13-H, 14-H); δC (75 MHz, D6-DMSO) 173.7 (C-10), 
167.7 (C-8), 165.9 (C-7), 134.6 (C-4), 132.5 (C-3), 132.0 (C-5), 128.8 (C-2), 127.4 
(C-1), 127.3 (C-6), 44.5 (C-11), 29.0 (C-12), 25.7 (C-14), 25.4 (C-13); HRMS m/z 
(ES+) 362.0439 ([M+Na]+, 100%) C15H15N3O235Cl2Na requires 362.0439/ 
 
Methyl 3,4-dihydroxybenzoate 252169, 224 
 
Concentrated sulfuric acid (3 mL) was added to a solution of 3,4-dihydroxy benzoic 
acid (4.62 g, 30 mmol) in methanol (60 mL). The solution was heated under reflux 
for 4 h. When TLC analysis indicated consumption of the starting material the 
solution was cooled and the solvent was removed under reduced pressure. Water 
(60 mL) and ethyl acetate (60 mL) were added and the layers were seperated. The 
aqueous layer was re-extracted with ethyl acetate (3 × 60 mL). The combined 
organic layers were washed with brine solution (60 mL). The organic layer was 
dried with magnesium sulfate and the solvent was removed under reduced 
pressure. The product was purified by column chromatography on silica (50% ethyl 
acetate/petroleum ether) to give the product 252 as a white solid (4.49 g, 89%): 
m.p 120-122 ˚C (Lit.224 126-128 ˚C);  νmax/cm-1 (nujol) 3467, 3259, 1687, 1610, 
1295, 984; δH (300 MHz, CDCl3) 7.63 (1H, d, J= 2 Hz, 2-H), 7.58 (1H, dd, J= 8.3, 2 
Hz, 6-H), 6.91 (1H, d, J= 8.3 Hz, 5-H), 5.80 (2H, s, OH), 3.89 (3H, s, Me); δC (75 
MHz, CDCl3) 167.6 (C-7), 149.2 (C-3), 143.0 (C-4), 124.2 (C-6), 123.1 (C-1), 117.0 
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(C-2), 115.1 (C-5), 52.5 (C-8); m/z (ES-) 167.01 ([M-H]-, 100%), (ES+) 190.99 
([M+Na]+, 100), 169.03 ([M+H]+, 63), HRMS m/z (ES+) 191.0325 ([M+Na]+,100%) 
C8H8O4Na requires 191.0320. 
 
Methyl 3,4-bis((tert-butyldimethylsilyl)oxy)benzoate 25334 
 
Imidazole (3.56 g, 52.3 mmol) and TBSCl (3.94 g, 26.9 mmol) was added to a 
solution of methyl ester 252 (2 g, 11.9 mmol) in DCM (20 mL) at 0 ˚C. The mixture 
was warmed to room temperature and stirred for 16 h. Water (40 mL) and DCM (40 
mL) were added and the layers were separated. The aqueous layer was re-
extracted with DCM (3 × 30 mL). The combined organic layers were washed with 
brine solution. The organic layer was dried with magnesium sulfate and the solvent 
was removed under reduced pressure. The product was purified by column 
chromatography on silica (5% ethyl acetate/petroleum ether) to give the product 
253 as a colourless solid (3.61 g, 77%): m.p 44-46 ˚C (Lit. 34 46-47 ˚C); νmax/cm-
1 (thin film) 3434, 2955, 2856, 1726, 1598, 1577, 1509; δH (500 MHz, CDCl3) 7.54 
(1H, dd, J= 8.3, 2.1 Hz, 6-H), 7.51 (1H, d, J= 2.1 Hz, 2-H), 6.84 (1H, d, J= 8.3 Hz, 
5-H), 3.86 (3H, s, 8-H), 0.99 (9H, s, (CH3)3), 0.98 (9H, s, (CH3)3), 0.22 (6H, s, CH3), 
0.21 (6H, s, CH3); δC (125 MHz, CDCl3) 167.0 (C-7), 151.8 (C-4), 146.8 (C-3), 
123.7 (C-6), 123.5 (C-1), 122.4 (C-2), 120.6 (C-5), 52.1 (C-8), 26.0 ((CH3)3), 26.0 
((CH3)3), 18.7 (C(CH3)3), 18.6 (C(CH3)3), -3.9 (Si-CH3), -4.0 (Si-CH3); HRMS m/z 
(ES+) 419.2050 ([M+Na]+, 100%) C20H36O4Si2Na requires 419.2050. 
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Methyl 3-((tert-butyldimethylsilyl)oxy)-4-hydroxybenzoate 254 
 
Hunigs base (9.6 mL, 53.5 mmol) was added to a solution of methyl ester 252 (6 g, 
35.7 mmol) in DMF (30 mL) at 0 ˚C. TBSCl (5.92 g, 39.3 mmol) was added 
portionwise. The solution was stirred at 0 ˚C for 20 min. Water (50 mL) and ethyl 
acetate (50 mL) were added and the layers were separated. The aqueous layer 
was washed with ethyl acetate (2 × 20 mL). The combined organic layers were 
washed with water (3 × 30 mL). The organic layer was dried with magnesium 
sulfate and the solvent was removed under reduced pressure. The product was 
purified by column chromatography on silica (5% ethyl acetate/ petroleum ether to 
give the product 254 as a white solid (3.13 g, 31%): 
m.p 64-68 ˚C; νmax/cm-1 (nujol) 3321, 1726, 1688; δH (300 MHz, CDCl3) 7.66 (1H, 
dd, J= 8.4, 2.0 Hz, 6-H), 7.55 (1H, d, J= 2.0 Hz, 2-H), 6.98 (1H, d, J= 8.4 Hz, 5-H), 
5.95 (1H, s, OH), 3.91 (3H, s, 8-H), 1.06 (9H, s, 11-H), 0.34 (6H, s, 9-H); δC (75 
MHz, CDCl3) 166.7 (C-7), 151.7 (C-4), 142.1 (C-3), 124.7 (C-6), 122.2 (C-1), 118.9 
(C-2), 114.5 (C-5), 51.9 (C-8), 25.7 (C-11), 18.2 (C-10), -4.3 (C-9); HRMS m/z 
(ES-) 281.1203 ([M-H]-, 100%), C14H21O4Si requires 281.1209. 
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Methyl 3-((tert-butyldimethylsilyl)oxy)-4-((diethoxyphosphoryl)oxy)benzoate 255 
 
Sodium hydride (60% in mineral oil, 310 mg, 7.8 mmol) was added to a solution of 
silyl ether 254 (2 g, 7 mmol) in THF (25 mL) and the solution was cooled to 0 ˚C. 
Once the evolution of hydrogen was complete diethyl chlorophosphate (1.2 mL, 7 
mmol) was added dropwise. The mixture was warmed to 4 ˚C and stirred for 16 h. 
Saturated ammonium chloride solution (20 mL) and DCM (30 mL) were added and 
the layers were separated. The aqueous layer was washed with DCM (3 × 30 mL). 
The combined organic layers were washed with brine solution (30 mL). The 
organic layer was dried with magnesium sulfate and the solvent was removed 
under reduced pressure. The product was purified by column chromatography 
(10% ethyl acetate/petroleum ether) to give the product 255 as a colourless oil 
(2.11 g, 71%): νmax/cm-1 (thin film) 3430, 3181, 2932, 1724, 1588; δH (300 MHz, 
CDCl3) 7.64 (1H, dd, J= 8.5, 2.1 Hz, 6-H), 7.6-7.57 (1H, m, 2-H), 7.49- 7.46 (1H, m, 
5-H), 4.3-4.19 (4H, m, 12-H), 3.91 (3H, s, 8-H), 1.38-1.33 (6H, m, 13-H), 1.04 (9H, 
s, 11-H), 0.25 (3H, s, 9-H), 0.25 (3H, s, 9-H); δC (75 MHz, CDCl3) 166.3 (C-7), 
146.2 (d, J=7.4 Hz, C-4), 146.0 (d, J= 6.5 Hz, C-3), 127.2 (d, J= 0.9 Hz, C-1), 123.4 
(d, J= 0.9 Hz, C-6), 122.5 (C-2), 120.5 (d, J= 2.5 Hz, C-5), 64.7 (d, J= 6.1 Hz,  C-
12), 52.2 (8), 25.6 (C-11), 18.3 (C-10), 16.1 (d, J= 6.9 Hz, C-13), -4.5 (C-9); m/z 
(CI+) 419.16 ([M+H]+, 100%), 361.09 ([M-C4H9]+, 52) HRMS m/z (CI+) 419.1660 
([M+H]+, 100%) C18H32O7SiP requires 419.1655. 
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Benzyl 3,4-dihydroxybenzoate 258 171 
 
Ceasium carbonate (5.29 g 16.2 mmol) was added to a solution of 
3,4-dihydroxybenzoic acid (5 g, 32.4 mmol) in DMF (100 mL). The mixture was 
stirred for 10 min. Benzyl bromide (4.2 mL, 35.6 mmol) was added and the mixture 
was stirred for 16 h. Water (100 mL) and diethyl ether (100 mL) was added and the 
layers were separated. The aqueous layer was washed with diethyl ether (2 × 
50 mL). The combined organic layers were washed with water (2 × 50 mL) and 
brine solution (50 mL). The organic layer was dried with magnesium sulfate and 
the solvent was removed under reduced pressure. The product was purified by 
recrystallisation (water/ethanol) to give the product 258 as a colourless solid (3.49 
g, 44%): m.p 139-142 ˚C (Lit.171 120-122 ˚C);  νmax/cm-1 (nujol mull)  3497, 3335, 
1687, 1609; δH (500 MHz, D6-DMSO) 9.82 (1H, s, Ar-OH), 9.45 (1H, s, Ar-OH), 
7.46-7.44 (2H, m, 11-H), 7.42 (1H, d, J= 2.0 Hz, 2-H), 7.42-7.40 (2H, m, 10-H), 
7.38 (1H,dd, J= 8.3, 2.0 Hz, 6-H), 7.36-7.33 (1H, m, 12-H), 6.84 (1H, d, J= 8.3 Hz, 
5-H), 5.28 (2H, s, 8-H); δC (125 MHz, D6-DMSO) 166.0 (C-7), 151.0 (C-4), 145.6 
(C-3), 137.0 (C-9), 129.0 (C-11), 128.5 (C-12), 128.4 (C-10), 122.4 (C-6), 120.8 (C-
1), 116.7 (C-2), 115.8 (C-5), 66.0 (C-8); m/z (CI+) 245.08 ([M+H]+, 8%), 244.07 (M+, 
29), 137.02 ([M-C7H7O]+, 33), 91.05 ([M-C7H5O4]+, 100), HRMS m/z (CI+) 245.0819 
([M+H]+, 20%) C14H13O4 requires 245.0814; 244.0742 (M+, 100) C14H12O4 requires 
244.0736 
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Benzyl 3,4-bis((tert-butyldimethylsilyl)oxy)benzoate 260 
 
TBSCl (2.28 g, 15.1 mmol), and imidazole (2.32 g, 34.5 mmol) were added to a 
solution of benzyl ester 258 (1.68 g, 6.9 mmol) was dissolved in DMF (30 mL). The 
mixture was heated to 50 ˚C for 2 h. Once TLC analysis confirmed consumption of 
the starting material the mixture was cooled and water (30 mL) and DCM (30 mL) 
were added. The layers were seperated and the aqueous layer was washed with 
DCM (2 × 30 mL). The combined organic layers were washed with water (3 × 30 
mL). The organic layer was dried with magnesium sulfate and the solvent was 
removed under reduced pressure. The product was purified by column 
chromatography on silica (5% ethyl acetate/petroleum ether) to give the product 
260 as a colourless oil (2.93 g, 90%): νmax/cm-1 (thin film) 2956, 2931, 2886, 2859, 
1720, 1599, 1576, 1509, 1421; δH (300 MHz, CDCl3) 7.63 (1H, dd, J= 8.9, 2.0 Hz, 
6-H), 7.62 (1H, d, J= 2.0 Hz, 2-H), 7.49-7.39 (5H, m, 10,11,12-H), 6.89 (1H, d, J= 
8.9 Hz, 5-H), 5.37 (2H, s, 8-H), 1.04 (9H, s, ((CH3)3), 1.03  (9H, s, ((CH3)3), 0.27 
(6H,s, CH3), 0.26 (6, s, CH3); δC (75 MHz, CDCl3) 166.1 (C-7), 151.8 (C-OTBS), 
146.8 (C-OTBS), 136.4 (C-9), 128.5 (C-11), 128.1 (C-12), 127.9 (C-10), 123.7 (C-
6), 123.3 (C-1), 122.4 (C-2), 120.5 (C-5), 66.3 (C-8), 25.9 ((CH3)3), 25.9 ((CH3)3), 
18.5 (C(CH3)3), 18.5 (C(CH3)3), -4.1 (Me), -4.1 (Me). 
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3,4-bis((tert-butyldimethylsilyl)oxy)benzoic acid 261 
 
Palladium black (200 mg, 1.88 mmol) was added to a solution of benzyl ester 260 
(2.51 g, 5.3 mmol) in methanol (30 mL). The mixture was stirred over a hydrogen 
atmosphere for 36 h. The mixture was filtered through a plug of celite. The celite 
was washed with methanol (3 × 50 mL) and the solvent was removed under 
reduced pressure from the combined filtrate and washings. The product was 
purified by recrystallisation from water ethanol to give the product as a colourless 
solid (923 mg, 45%): m.p 140-144 ˚C; δH (400 MHz, CDCl3) 7.62 (1H, dd, J= 8.3, 
2.2 Hz, 6-H), 7.58 (1H, d, J= 2.2 Hz, 2-H), 6.88 (1H, d, J= 8.3 Hz, 5-H), 1.01 (9H, s, 
(CH3)3), 1.01 (9H, s, (CH3)3), 0.25 (6H, s, CH3), 0.24 (6H, s, CH3); δC (125 MHz, 
CDCl3) 165.7 (C-7), 160.2 (C-4), 157.4 (C-2), 136.5 (C-1), 133.1 (C-6), 128.5 (C-
10), 128.3 (C-11), 128.0 (C-12), 115.7 (C-1), 113.3 (C-5), 112.6 (C-3), 66.1 (C-8), 
25.7 ((CH3)3), 25.6 ((CH3)3), 18.4 (C(CH3)3), 18.3 (C(CH3)3), -4.3 (CH3), -4.3 (CH3). 
 
3,4-bis((tert-Butyldimethylsilyl)oxy)-N-(3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-
yl)benzamide 262 
 
DMAP (160 mg, 1.3 mmol) and silylprotected carboxylic acid 261 (550 mg, 1.4 
mmol) were added to a solution of 5-amino-1,2,4-oxadiazole 224h (300 mg, 1.3 
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mmol) in DCM (20 mL). EDCI (325 mg, 1.7 mmol) was added and the mixture was 
stirred for 16 h. Water (30 mL) and DCM (30 mL) were added and the layers 
separated. The aqueous layer was washed with DCM (3 × 30 mL). The combined 
organic layers were washed with 2N HCl (20 mL) and brine solution (20 mL). The 
organic layer was dried with magnesium sulfate and the solvent was removed 
under reduced pressure. The product was purified by column chromatography (10 
% ethyl acetate/petroleum ether) to give the product 262 as an oil (230 mg, 30%): 
νmax/cm-1 (nujol) 3243, 1694, 1611, 1599, 900, 840; δH (300 MHz, CDCl3) 8.92 (1H, 
s, 9-NH), 8.23 (1H, d, J= 1.9 Hz, 2-H), 7.96 (1H, dd, J= 8.4, 1.9 Hz, 6-H), 7.60 (1H, 
d, J= 8.4 Hz, 5-H), 7.55 (1H, d, J= 2.3 Hz, 12-H), 7.39 (1H, dd, J= 8.4, 2.3 Hz, 16-
H), 6.97 (1H, d, J= 8.4 Hz, 15-H), 1.05 (9H, s, (CH3)3), 1.04 (9H, s, (CH3)3), 0.30 
(6H, s, CH3), 0.28 (6H, s, CH3); δC (75 MHz, CDCl3) 166.6 (C-8), 166.5 (C-7), 162.1 
(C-6), 152.6 (C-13), 147.9 (C-14), 135.7 (C-4), 133.4 (C-3), 130.9 (C-5), 129.3 (C-
2), 126.5 (C-6), 124.5 (C-11), 122.7 (C-1), 121.3 (C-12), 120.9 (C-15), 120.8 (C-
16), 25.9 ((CH3)3), 25.8 ((CH3)3), 18.6 (C(CH3)3), 18.5 (C(CH3)3), -4.0 (CH3), -4.1 
(CH3); m/z (ES-) 591.75 ([M-H]-, 100%), 593.78 ([M-H]-, 80), (ES+) 615.73 
([M+Na]+, 100), 617.77 ([M+Na]+, 80), HRMS m/z (ES-) 592.1628 ([M-H]-, 100%) 
C27H36N3O4Si2Cl2 requires 592.1621. 
 
N-(3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)-3,4-dihydroxybenzamide 249 
 
TBAF (1N solution in THF, 0.68 mL, 0.68 mmol) was added dropwise to a solution 
of silyl-protected amide 262 (188 mg, 0.31 mmol) in THF (10 mL). The solution was 
left to stir for 30 min. A saturated solution of sodium bircabonate (20 mL) was 
added. The product was extracted with DCM (3 × 50 mL). The organic layer was 
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dried with magnesium sulfate. The product was purified by column chromatography 
on silica (5% methanol/DCM) to give the product 249 as a white solid (99 mg, 
85%): m.p 228-230 ˚C (decomp.); νmax/cm-1 (nujol) 3335, 1703, 1626, 1600,1564, 
1538, 1200; δH (500 MHz, D6-DMSO) 12.37 (1H, s, 9-H), 9.96 (1H, s, 14-OH), 9.44 
(1H, s, 13-OH), 8.13 (1H, dd, J= 1.0, 0.8 Hz, 2-H), 7.96 (1H, ddd, J= 8.3, 0.9, 0.9 
Hz, 6-H), 7.88 (1H, d, J= 8.3 Hz, 5-H), 7.49- 7.46 (2H, m, 12,16-H), 6.86 (1H, d, J= 
8.2 Hz, 15-H); δC (125 MHz, D6-DMSO) 168.6 (C-8), 166.1 (C-7), 164.2 (C-10), 
151.1 (C-13), 145.7 (C-14), 134.7 (C-4), 132.5 (C-3), 132.2 (C-5), 128.9 (C-2), 
127.6 (C-1), 127.4 (C-6), 123.3 (C-11), 121.6 (C-16), 116.5 (C-12), 115.5 (C-15); 
HRMS m/z (ES-) 363.9892 ([M-H]-, 100%) C15H8O4N3Cl2 requires 363.9897. 
 
Benzyl 3-hydroxy-4-methoxybenzoate 265 171 
 
Ceasium carbonate (4.84g 14.9 mmol) was added to a solution of 3-hydroxy-4-
methoxybenzoic acid (5 g, 29.7 mmol) in DMF (60 mL). The mixture was stirred for 
10 min. Benzyl bromide (3.9 mL, 32.7 mmol) was added and the mixture was 
stirred for 16 h. Water (100 mL) and diethyl ether (100 mL) was added and the 
layers were separated. The aqueous layer was washed with diethyl ether (2 × 50 
mL). The combined organic layers were washed with water (2 × 50 mL) and brine 
solution (50 mL). The organic layer was dried with magnesium sulfate and the 
solvent was removed under reduced pressure. The product was purified by column 
chromatography on silica (10% ethyl acetate/petroleum ether to 20% ethyl 
acetate/petroleum ether to 25% ethyl acetate/petroleum ether) to give the product 
265 as a colourless solid (6.122 g, 80%): m.p 69-72 ˚C (Lit.171 72-74 ˚C); νmax/cm-
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1 (nujol) 3404, 1709, 1616; δH (500 MHz, C6D6) 8.03 (1H, d, J=2.1 Hz, 2-H), 7.81 
(1H, dd, J= 8.4, 2.1 Hz, 6-H), 7.21-7.20 (2H, m, H), 7.10-7.04 (3H, m, H), 6.25 (1H, 
d, J= 8.5 Hz, 5-H), 5.46 (1H, s, OH), 5.18 (2H, s, 8-H), 2.98 (3H, s, 13-H); δC (125 
MHz, C6D6) 165.6 (C-7), 150.3 (C-4), 145.7 (C-3), 136.6 (C-9), 128.4 (C-12), 128.1 
(C-10), 127.8 (C-11), 123.8 (C-1), 122.8 (C-6), 115.8 (C-2), 109.8 (C-5), 66.2 (C-8), 
54.9 (C-13); m/z (ES-) 256.86 ([M-H]-, 100%), HRMS m/z (ES-) 257.0813 ([M-H]-, 
100%), C15H13O4 requires 257.0814. 
 
Benzyl 4-hydroxy-3-methoxybenzoate 266 171 
 
Ceasium carbonate (4.84g 14.9 mmol) was added to a solution of 4-hydroxy-3-
methoxybenzoic acid (5 g, 29.7 mmol) in DMF (60 mL). The mixture was stirred for 
10 min. Benzyl bromide (3.9 mL, 32.7 mmol) was added and the mixture was 
stirred for 16 h. Water (100 mL) and diethyl ether (100 mL) was added and the 
layers were separated. The aqueous layer was washed with diethyl ether (2 × 50 
mL). The combined organic layers were washed with water (2 × 50 mL) and brine 
solution (50 mL). The organic layer was dried with magnesium sulfate and the 
solvent was removed unde reduced pressure. The product was purified by column 
chromatography on silica (10% ethyl acetate/petroleum ether to 20% ethyl 
acetate/petroleum ether) to give the product 266 as a colourless oil (6.41 g, 83%): 
νmax/cm-1 (thin film) 3401, 2940, 1709, 1596; δH (300 MHz, CDCl3) 7.72 (1H, dd, J= 
8.3, 1.9 Hz, 6-H), 7.62 (1H, d, J= 1.9 Hz, 2-H), 7.50- 7.46 (2H, m, H), 7.45-7.34 
(3H, m, 12-H), 6.97 (1H, d, J= 8.3 Hz, 5-H), 5.38 (2H, s, 8-H), 3.95 (3H, s, 13-H); 
δC (75 MHz, CDCl3) 166.4 (C-7), 150.3 (C-4), 146.3 (C-3), 136.3 (C-9), 128.6 (C-1), 
128.2 (C-12), 128.2 (C-10), 124.39 (C-6), 122.2 (C-1), 114.2 (C-5), 111.9 (C-2), 
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66.6 (C-8), 56.1 (C-13); m/z (ES+) 280.85 ([M+Na]+, 100%), (ES-) 256.86 ([M-H]-, 
100), HRMS m/z (ES-) 257.0816 ([M-H]-, 100%) C15H13O4 requires 257.0814. 
 
Benzyl 3-((diethoxyphosphoryl)oxy)-4-methoxybenzoate 267 
 
Sodium hydride (60% dispersion in mineral oil, 851 mg, 21.2 mmol) was added 
portionwise to a solution of benzyl ester 265 (5 g, 19.4 mmol) in THF (30 mL) at 0 
˚C. The mixture was stirred at 0 ˚C for 30 min. Diethyl chlorophosphate (3.1 mL, 
21.2 mmol) was added dropwise. The mixture was warmed to R.T over 3 h. Water 
(30 mL) and DCM (30 mL) was added and the layers were separated. The 
aqueous layer was washed with DCM (3 × 30 mL). The combined organic layers 
were washed with brine solution (30 mL). The organic layer was dried with 
magnesium sulfate and the solvent was removed under reduced pressure. The 
product was purified by column chromatography on silica (30% ethyl acetate/ 
petroleum ether to 40% ethyl acetate/ petroleum ether) to give the product 267 as 
a colourless oil (6.994 g, 92%): νmax/cm-1 (thin film) 3489, 2984, 2939, 1717, 1609, 
1516; δH (500 MHz, CDCl3) 7.96- 7.94 (1H, m, 2-H), 7.91 (1H, ddd, J= 8.6, 2.1, 1.0 
Hz, 6-H), 7.44- 7.42 (2H, m, 10-H), 7.39- 7.33 (3H, m, 11,12-H,), 6.97 (1H, d, J= 
8.6 Hz, 5-H), 5.33 (2H, s, 8-H), 4.31- 4.21 (4H, m, 14-H), 1.36 (6H, dt, J= 7.1, 1.1 
Hz, 15-H); δC (125 MHz, CDCl3) 165.4 (C-7), 154.8 (d, J= 5.3 Hz, C-4), 139.5 (d, J= 
7.3 Hz, C-3), 136.1 (C-9), 128.6 (C-11), 128.2 (C-12), 128.2 (C-6), 128.1 (C-10), 
122.7 (d, J= 3.0 Hz, C-2), 122.7 (d, J= 2.0 Hz, C-1), 111.8 (C-5), 66.6 (C-8), 64.7 
(d, J= 6.3 Hz, C-14), 56.1 (C-13), 16.1 (d, J= 7.1 Hz, C-15); δP (121 MHz, CDCl3) -
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5.97 (quintet, J= 7.9 Hz); HRMS m/z (ES+) 417.1073 ([M+Na]+, 100%) 
C19H23O7NaP requires 417.1079. 
 
Benzyl 4-((diethoxyphosphoryl)oxy)-3-methoxybenzoate 268 
 
Sodium hydride (60% dispersion in mineral oil, 851 mg, 21.2 mmol) was added 
portionwise to a solution of benzyl ester 266 (5 g, 19.4 mmol) in THF (30 mL) at 
0 ˚C. The mixture was stirred at 0 ˚C for 30 min. Diethyl chlorophosphate (3.1 mL, 
21.2 mmol) was added dropwise. The mixture was warmed to R.T over 3 h. Water 
(30 mL) and DCM (30 mL) was added and the layers were separated. The 
aqueous layer was washed with DCM (3 × 30 mL). The combined organic layers 
were washed with brine solution (30 mL). The organic layer was dried with 
magnesium sulfate and the solvent was removed under reduced pressure. The 
product was purified by column chromatography on silica (30% ethyl acetate/ 
petroleum ether to 40% ethyl acetate/ petroleum ether) to give the product 268 as 
a colourless oil (6.08 g, 80%): νmax/cm-1 (thin film) 3489 (C-O), 2984 (C-H), 2912 
(C-H), 1719 (C=O), 1600, 1509, 1415, 1287; δH (500 MHz, CDCl3) 7.70 (1H, dd, J= 
8.3, 1.7 Hz, 6-H), 7.68-7.66 (1H, m, 2-H), 7.56 (1H, dd, J= 8.3, 1.2 Hz, 5-H), 7.25-
7.23 (2H, m, 11-H), 7.14-7.10 (2H, m, 10-H), 7.09- 7.05 (1H, m, 12-H), 5.19 (2H, s, 
8-H), 4.07-3.95 (4H, m, 14-H), 3.19 (3H, s, 13-H), 0.99 (6H, dt, J= 7.1, 1.0 Hz, 15-
H); δC (125 MHz, CDCl3) 165.3 (C-7), 150.8 (C-3), 144.3 (d, J= 6.6 Hz, C-4), 136.3 
(C-9) 128.4 (C-10), 128.2 (C-11), 128.0 (C-12), 127.6 (C-1), 122.7 (d, J= 1.3 Hz, C-
6), 121.1 (d, J= 3Hz, C-5), 113.8 (C-2), 66.5 (C-8), 64.1 (d, J= 6.2 Hz, C-14), 55.0 
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(C-13), 15.7 (d, J= 6.6 Hz, C-15); δP (121 MHz, CDCl3) -6.51 (quintet, J= 8.1 Hz); 
HRMS m/z (ES+) 417.1082 ([M+Na]+, 100%) C19H23O7NaP requires 417.1079. 
 
3-((Diethoxyphosphoryl)oxy)-4-methoxybenzoic acid 269 
 
Pd/C (10%, 150 mg, 1.9 mmol) was added to a solution of benzyl ester 267 (1.53 
g, 3.9 mmol) in ethyl acetate (30 mL). The mixture was stirred under a hydrogen 
atmosphere for 48 h. The mixture was filtered through a pad of celite and the celite 
was washed with methanol (3 × 30 mL). The filtrate and washings were combined 
and the solvent was removed under reduced pressure. The product was purified by 
recrystallisation ethanol/ water to give the product 269 as a colourless solid. (790 
mg, 68%): m.p 86-90 ˚C; νmax/cm-1 (nujol) 3409, 1713, 1610; δH (500 MHz, CDCl3) 
8.00 (1H, dd, J= 1.9, 1.5 Hz, 2-H), 7.94 (1H, ddd, J= 8.6, 1.9, 0.6 Hz, 6-H), 7.01 
(1H, d, J= 8.6 Hz, 5-H), 4.36-4.28 (4H, m, 9-H), 3.96 (3H, s, 8-H) 1.41 (6H, dt, J= 
7.1, 1.0 Hz, 10-H); δC (125 MHz, CDCl3) 169.6 (C-7), 155.2 (d, J= 4.6 Hz, C-4), 
139.4 (d, J=7.0 Hz, C-3),  128.8 (C-6) 123.3 (d, J= 3.1 Hz, C-2), 122.2 (d, J= 1.3 
Hz, C-1), 111.8 (C-5), 64.9 (d, J= 5.8 Hz, C-9), 56.1 (C-8), 16.1 (d, J= 7.0 Hz, C-
10); δP{H} (202 MHz, CDCl3) -5.95 (s); m/z (ES+) 326.82 ([M+Na]+, 100%), (ES-) 
302.83 ([M-H]-, 100); HRMS m/z (ES+) 327.0607 C12H17O7PNa requires 327.0610 
 
  
6
5
4
3
2
1
O
O
8
7
O OH
PO
O
O
10
9
  246 
4-((Diethoxyphosphoryl)oxy)-3-methoxybenzoic acid 270 
 
Palladium black (200 mg, 1.9 mmol) was added to a solution of benzyl ester 268 
(1.88 g, 4.8 mmol) in ethyl acetate (30 mL). The mixture was stirred under a 
hydrogen atmosphere for 48 h. The mixture was filtered through a pad of celite and 
the celite was washed with methanol (3 × 30 mL). The filtrate and washings were 
combined and the solvent was removed under reduced pressure. The product was 
purified by column chromatography (5% methanol/DCM) to give the product 270 as 
a colourless solid (817 mg, 56%): m.p 76-78 ˚C; νmax/cm-1 (nujol)  1715, 1605; δH 
(300 MHz, CDCl3) 7.68 (1H, ddd, J= 8.3, 2.0, 0.4 Hz, H6), 7.65-7.63 (1H, m, 2-H), 
7.37 (1H, dd, J= 8.3, 1.3 Hz, 5-H), 4.32 (4H, ddq, J= 8.3, 7.1, 1.2, 9-H), 3.95 (3H, s, 
8-H), 1.41 (6H, td, J= 7.1, 1.1 Hz, 10-H); δC (125 MHz, CDCl3) 169.6 (C-7), 150.5 
(d, J= 5.5 Hz, C-3), 143.8 (d, J= 7.1 Hz, C-4), 127.3 (C-1), 123.3 (C-6), 121.1 (d, J= 
2.7 Hz, C-5), 113.9 (C-2), 65.1 (d, J= 6.2 Hz, C-9), 56.1 (C-8), 16.1 (d, J= 6.9 Hz, 
C-10); δP (282 MHz, CDCl3) -6.48 (t, J= 7.7 Hz); m/z (ES+) 326.85 ([M+Na]+, 
100%), (ES-) 302.75 ([M-H]-,100); HRMS m/z (ES+) 327.0602 ([M+Na]+, 100%) 
C12H17O7PNa requires 327.0610. 
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5-((3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)carbamoyl)-2-methoxyphenyl 
diethyl phosphate 271 
 
Benzoic acid 269 (436 mg, 1.43 mmol) and DMAP (160 mg, 1.3 mmol) were 
dissolved in a solution of 5-amino-1,2,4-oxadiazole 224h (300 mg, 1.3 mmol) in 
DCM (30 mL) and THF (20 mL). EDCI (375 mg, 1.95 mmol) was added and the 
mixture was stirred for 16 h after which an additional portion of benzoic acid 269 
(250 mg, 0.82 mmol) and EDCI (400 mg, 2 mmol) were added and the mixture was 
stirred for an additional 6 h. DCM (20 mL) and water (20 mL) were added and the 
product was extracted using DCM (3 × 50 mL). The organic layer was washed with 
1N HCl (25 mL). The organic layers were dried with magnesium sulfate and the 
solvent was removed under reduced pressure. The white solid was dissolved in 
methanol and magnesium sulfate (10 g) was added. The methanol was removed 
under reduced pressure. The magnesium sulfate/ product mixture was dry loaded 
on to a silica column. The product was purified by column chromatography on silica 
(30% ethyl acetate/petroleum ether to 50% ethyl acetate/ petroleum ether to 2% 
methanol/DCM) to give the product 271 as a white solid (331 mg, 49%): m.p 194-
197 ˚C; νmax/cm-1 (nujol) 3396, 3218, 3125, 1705, 1611; δH (500 MHz, D6-DMSO) 
12.72 (1H, s, 9-NH), 8.13 (1H, d, J= 1.9 Hz, 2-H), 8.00 (1H, dd, J= 8.8, 1.9 Hz, 16-
H), 7.96 (1H, dd, J= 8.4, 1.9 Hz, 6-H), 7.91-7.90 (1H, m, 12-H), 7.87 (1H, d, J= 8.4 
Hz, 5-H), 7.32 (1H, d, J= 8.8 Hz, 15-H), 4.23-4.15 (4H, m, 18-H), 3.93 (3H, s, 17-
H), 1.29 (6H, t, J= 7.0 Hz, 19-H); δC (125 MHz, D6-DMSO) 168.4 (C-8), 166.1 (C-7), 
163.3 (C-10), 155.0 (d, J= 5.0 Hz, C-14), 139.5 (d, J= 6.0 Hz, C-13), 134.7 (C-4), 
132.6 (C-3), 132.2 (C-5), 128.9 (C-2), 127.6 (C-16), 127.5 (C-6), 127.4 (C-1), 124.5 
(C-11), 121.9 (d, J= 2.5 Hz, C-12), 113.2 (C-15), 64.9 (d, J= 5.5 Hz, C-18), 56.8 (C-
18), 16.4 (d, J= 7.0 Hz, C-19); δP (162 MHz, D6-DMSO) -6.60 (1P, quin, J= 8.8 Hz); 
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m/z (ES-) 515.99 ([M-H]-, 91%), 513.98 ([M-H]-, 100); HRMS m/z (ES+) 538.0308 
([M+Na]+, 100%) C20H20N3O7PCl2Na requires 538.0314. 
 
4-((3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)carbamoyl)-2-methoxyphenyl 
diethyl phosphate 272 
 
Benzoic acid 270 (365 mg, 1.2 mmol) and DMAP (122 mg, 1 mmol) were added to 
a solution of 5-amino-1,2,4-oxadiazole (230 mg, 1mmol) in THF (10 mL). EDCI 
(287 mg, 1.5 mmol) was added to the solution. The mixture was stirred for 16 h 
when an additional portion of benzoic acid 270 (200 mg, 0.66 mmol) and EDCI 
(200 mg, 1.0 mmol) were added and the mixture was stirred for an additional 6 h. 
DCM (20 mL) and water (20 mL) were added and the product was extracted using 
DCM (3 × 50 mL). The organic layer was washed with 1N HCl (25 mL). The 
organic layers were dried with magnesium sulfate and the solvent was removed 
under reduced pressure. The white solid was dissolved in methanol and 
magnesium sulfate (10 g) was added. The methanol was removed under reduced 
pressure. The magnesium sulfate/ product mixture was dry loaded on to a silica 
column. The product was purified by column chromatography on silica (30% ethyl 
acetate/petroleum ether to 50% ethyl acetate/petroleum ether to 2% 
methanol/DCM where the product was collected) to give the product 272 as a white 
solid (437 mg, 85%): m.p. 216-218 ˚C; Anal. RP HPLC: tR 27.36 min (purity 
96.60%); νmax/cm-1 (nujol) 3431, 1708, 1618; δH (500 MHz, D6-DMSO) 12.78 (1H, s, 
9-NH), 8.13 (1H, d, J= 1.9 Hz, 2-H), 7.96 (1H, dd, J= 8.5, 1.9 Hz, 6-H), 7.87 (1H, d, 
J= 8.5 Hz, 5-H), 7.79 (1H, d, J= 1.8Hz, 12-H), 7.66 (1H, dd, J= 8.5, 1.8 Hz, 16-H), 
7.39 (1H, d, J= 8.5 Hz, 15-H), 4.22-4.16 (4H, m, 18-H), 3.93 (3H, s, 17-H), 1.29 
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(6H, t, J= 7.0 Hz, 19-H); δC (125 MHz, D6-DMSO) 168.3 (C-8), 166.1 (C-7), 163.7 
(C-10), 150.6 (d, J= 5.2 Hz, C-13), 143.4 (d, J= 7.1 Hz, C-14), 134.8 (C-1), 132.6 
(C-2, C-3), 132.2 (C-5), 129.8 (C-11), 128.9 (C-2), 127.4 (C-6), 122.2 (C-16), 121.4 
(d, J= 2.6 Hz, C-15), 113.5 (C-12), 65.0 (d, J= 6.7 Hz, C-18), 56.7 (C-17), 16.3 (d, 
J= 5.8 Hz, C-19); δP (162 MHz, D6-DMSO) -6.49 (1P, quin, J= 8.4Hz); HRMS m/z 
(ES+) 538.0305 ([M+Na]+, 100) C20H20N3O7NaCl2P requires 538.0314. 
 
Benzyl 3-((tert-butyldimethylsilyl)oxy)-4-methoxybenzoate 285 
 
TBSCl (3.2 g, 21.2 mmol) and imidazole (2.63 g, 38 mmol) were added to a 
solution of benzyl ester 265 (5 g, 19.4 mmol) in DCM (60 mL). The mixture was 
stirred for 16 h. Water (60 mL) was added and the layers were seperated. The 
aqueous layer was washed with DCM (3 × 30 mL). The combined organic layers 
were washed with brine solution (50 mL). The organic layer was dried with 
magnesium sulfate and the solvent was removed under reduced pressure. The 
product was purified by column chromatography on silica (5% ethyl 
acetate/petroleum ether) to give the product 285 as a colourless oil (7.0 g, 97%): 
νmax/cm-1 (thin film) 2955, 2895, 2858, 1716, 1602, 1583, 1512, 1375,1131; δH (500 
MHz, CDCl3) 7.74 (1H, dd, J= 8.5, 2.1 HZ, 6-H), 7.61 (1H, d, J= 2.1 Hz, 2-H), 7.48 
(2H, d, J= 7.3 Hz, 10-H), 7.45-7.40 (2H, m, 11-H), 7.38-7.35 (1H, m, 12-H), 6.89 
(1H, d, J= 8.5 Hz, 5-H), 5.37 (2H, s, 8-H), 3.89 (3H, s, 16-H), 1.04 (9H, s, 15-H), 
0.20 (6H, s, 13-H); δC (125 MHz, CDCl3) 166.2 (C-7), 155.2 (C-4), 144.6 (C-3), 
136.4 (C-9), 128.6 (C-11), 128.1 (C-12), 128.0 (C-10), 124.41 (C-6), 122.7 (C-1) 
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122.0 (C-2), 110.9 (C-5), 66.4 (C-8), 55.5 (C-16), 25.7 (C-15), 18.5 (C-14), -4.6 (C-
13); HRMS m/z (ES+) 395.1658 ([M+Na]+, 100%) C21H28O4SiNa requires 395.1655. 
 
Benzyl 4-((tert-butyldimethylsilyl)oxy)-3-methoxybenzoate 286 
 
TBSCl (3.2 g, 21.2 mmol) and imidazole (2.63 g, 38 mmol) were added to a 
solution of benzyl ester 266 (5 g, 19.4 mmol) in DCM (60 mL). The mixture was 
stirred for 16 h. Water (60 mL) was added and the layers were seperated. The 
aqueous layer was washed with DCM (3 × 30 mL). The combined organic layers 
were washed with brine solution (50 mL). The organic layer was dried with 
magnesium sulfate and the solvent was removed under reduced pressure. The 
product was purified by column chromatography on silica (5% ethyl acetate/ 
petroleum ether) to give the product 286 as a colourless oil (6.07 g, 84%): 
νmax/cm-1 (thin film) 3412, 3034, 2956, 2885, 2858, 1718, 1599, 1511, 1464, 1376, 
1362, 1290, 1179, 1125, 1036, 969, 912, 804, 784, 765; δH (300 MHz, CDCl3) 7.69 
(1H, dd, J= 8.2, 2.0 Hz, 6-H), 7.64 (1H, d, J= 2.0 Hz, 2-H), 7.52-7.48 (2H, m, 10-H), 
7.47-7.38 (3H, m, 11-H, 12-H), 6.93 (1H, d, J= 8.2 Hz, 5-H), 5.40 (2H, s, 8-H), 3.90 
(3H, s, 13-H), 1.06 (9H, s, 16-H), 0.24 (6H, s, 14-H); δC (75 MHz, CDCl3) 166.3 (C-
7), 150.8 (C-3), 149.8 (C-4), 136.3 (C-9), 128.6 (C-11), 128.2 (C-10), 123.6 (C-1), 
123.5 (C-6), 120.5 (C-5), 113.1 (C-2), 66.5 (C-8), 55.5 (C-13), 25.7 (C-16), 18.6 (C-
15), -4.6 (C-14); m/z (ES+) 395.16 ([M+Na]+, 100%), 373.18 ([M+H]+, 36), HRMS 
m/z (ES+) 395.1640 ([M+Na]+, 100%), C21H28O4SiNa requires 395.1655. 
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3-((tert-Butyldimethylsilyl)oxy)-4-methoxybenzoic acid 287225 
 
Palladium black (300 mg, 2.8 mmol) was added to a solution of benzyl ester 285 
(7.0 g, 18.8 mmol) in methanol (30 mL) and the mixture was stirred under a 
hydrogen atmosphere for 72 h. The mixture was filtered through a pad of celite and 
the celite was washed with methanol (2 × 30 mL). The filtrate and washings were 
combined and the solvent was removed under reduced pressure to give a solid. 
The product was purified by column chromatography on silica (30 % ethyl 
acetate/petroleum ether) to give the product 287 as a colourless solid (1.8 g, 34%): 
m.p 148-152 ˚C (Lit.225 163.5-164.5 ˚C); νmax/cm-1 (nujol) 3454, 1775, 1682, 1602; 
δH (300 MHz, D6-DMSO) 12.64 (1H, s, 7-OH), 7.56 (1H, dd, J= 8.5, 2.1 HZ, 6-H), 
7.33 (1H, d, J= 2.1 Hz, 2-H), 7.05 (1H, d, J= 8.5 Hz, 5-H), 3.81 (3H, s, 11-H), 0.94 
(9H, s, 10-H), 0.11 (6H, s, 8-H); δC (75 MHz, D6-DMSO) 167.7 (C-7), 155.3 (C-4), 
144.6 (C-3), 125.0 (C-1), 124.0 (C-6), 121.8 (C-2), 112.6 (C-5), 56.4 (C-11), 26.4 
(C-10), 19.0 (C-9), -3.9 (C-8); HRMS m/z (ES-) 281.1215 ([M-H]-, 100%) 
C14H21O4Si requires 281.1209. 
 
4-((tert-Butyldimethylsilyl)oxy)-3-methoxybenzoic acid 288 
 
Palladium black (250 mg, 2.3 mmol) was added to a solution of benzyl ester 286 
(5.0 g, 13.4 mmol) in methanol (30 mL) and the mixture was stirred under a 
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hydrogen atmosphere for 72 h. The mixture was filtered through a pad of celite and 
the celite was washed with methanol (2 × 30 mL). The filtrate and washings were 
combined and the solvent was removed under reduced pressure to give a solid. 
The product was purified by column chromatography on silica (20% ethyl 
acetate/petroleum ether to 30 % ethyl acetate/petroleum ether) to give the product 
288 as a white solid (3.09 g, 82%): m.p 125-128 ˚C;  νmax/cm-1 (nujol) 3443, 1677, 
1599, 1580, 1290, 1230; δH (300 MHz, CDCl3) 7.72 (1H, dd, J= 8.3, 2.0 Hz, 6-H), 
7.64 (1H, d, J= 2.0 Hz, 2-H), 6.94 (1H, d, J= 8.3 Hz, 5-H), 3.91 (3H, s, 8-H), 1.05 
(9H, s, 11-H), 0.23 (6H, s, 9-H); δC (75 MHz, CDCl3) 172.2 (C-7), 150.8 (C-3), 
150.5 (C-4), 124.3 (C-6), 122.6 (C-1), 120.6 (C-5), 113.4 (C-2), 55.5 (C-8), 25.6 (C-
11), 18.5 (C-10), -4.6 (C-9); m/z (ES-) 281.12 ([M-H]-, 100%), (ES+) 305.12 
([M+Na]+, 86), 265.13 ([M-OH]+, 100), HRMS m/z (ES-) 281.1215 ([M-H]-, 100%) 
C14H21O4Si requires 281.1209. 
 
3-((tert-Butyldimethylsilyl)oxy)-N-(3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl)-4-
methoxybenzamide 289 
 
Benzoic acid 287 (736 mg, 2.6 mmol) and DMAP (797 mg, 6.5 mmol) were added 
to a solution of 5-amino-1,2,4-oxadiazole (500 mg, 2.2 mmol) in THF (20 mL). 
EDCI (625 mg, 3.3 mmol) was added to the solution which was stirred for 16 h. 
Water was added and the layers were separated. The aqueous layer was washed 
with DCM (3 × 30 mL). The combined organic layers were washed with 2N HCl (30 
mL) and brine solution (30 mL). The organic layer was dried with magnesium 
sulfate and the solvent was removed under reduced pressure. The product was dry 
loaded onto magnesium sulfate. The product was purified by sequential column 
chromatography on sillica (50% diethyl ether/petroleum ether) followed by (20% 
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ethyl acetate/petroleum ether) to give the product 289 as a colourless solid (479 
mg, 52%): m.p 98-102 ˚C;  νmax/cm-1 (nujol) 3210, 1687, 1607, 1552; δH (300 MHz, 
CDCl3) 9.52 (1H,s, 9-NH), 8.20 (1H, d, J= 1.8 Hz, 2-H), 7.93 (1H, dd, J= 8.4, 1.8 
Hz, 6-H), 7.63 (1H, dd, J= 8.3, 2.2 Hz, 16-H), 7.60 (1H, d, J= 8.4 Hz, 5-H), 7.54 
(1H, d, J= 2.2 Hz, 12-H), 6.98 (1H, d, J= 8.3 Hz, 15-H), 3.94 (3H, s, 20-H), 1.05 
(9H, s, 19-H), 0.22 (6H, s, 17-H); δC (75 MHz, CDCl3) 166.9 (C-8), 166.4 (C-7), 
162.6 (C-10), 155.8 (C-14), 145.5 (C-13), 135.7 (C-1), 133.3 (C-3), 130.9 (C-5), 
129.3 (C-2), 126.4 (C-4), 126.4 (C-6), 123.9 (C-11), 122.3 (C-16), 120.6 (C-12), 
111.4 (C-15), 55.6 (C-20), 25.7 (C-19), 18.5 (C-18), -4.6 (C-17); HRMS m/z (ES+) 
516.0872 ([M+Na]+, 100%) C22H25Cl2N3O4SiNa requires 516.0889. 
 
4-((tert-Butyldimethylsilyl)oxy)-N-(3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl)-3-
methoxybenzamide 290 
 
Benzoic acid 288 (736 mg, 2.6 mmol) and DMAP (797 mg, 6.5 mmol) were added 
to a solution of 5-amino-1,2,4-oxadiazole 224h (500 mg, 2.1 mmol) in DCM (40 
mL). EDCI (625 mg, 3.25 mmol) was added to the mixture, which was stirred for 16 
h. Water (30 mL) and DCM (30 mL) were added and the layers were sperated. The 
aqueous layer was washed with DCM (30 mL). The combined organic layers were 
washed with 2N HCl (30 mL) and brine solution (30 mL). The organic layer was 
dried with magnesium sulfate. The product was purified by sequential column 
chromatography on silica (50% diethyl ether/DCM followed by 10% ethyl 
acetate/petroleum ether) to give the product 290 as a colourless solid (550 mg, 
51%): m.p 117-120 ˚C; νmax/cm-1  (nujol) 3463, 1701, 1635, 1592, 1122, 1035, 903, 
837, 810, 786, 758; δH (300 MHz, CDCl3) 10.08 (1H, 9-NH), 8.02 (1H, d J= 1.9 Hz, 
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2-H), 7.76 (1H, dd, J= 8.4, 1.9 Hz, 6-H), 7.62 (1H, d, J= 2.2 Hz, 12-H), 7.55 (1H, 
dd, J= 8.3, 2.2 Hz, 16-H), 7.46 (1H, d, J= 8.4 Hz, 5-H), 6.91 (1H, d, J= 8.3 Hz, 15-
H), 3.87 (3H, s, 17-H), 1.01 (9H, s, 20-H), 0.19 (6H, s, 18-H); δC (75 MHz, CDCl3) 
167.0 (C-8), 166.5 (C-7), 163.3 (C-10), 151.4 (C-13), 150.5 (C-14), 135.6 (C-1), 
133.2 (C-3), 130.8 (C-5), 129.1 (C-2), 126.3 (C-6), 126.3 (C-4), 124.8 (C-11), 121.2 
(C-16), 120.7 (C-15), 112.2 (C-12), 55.6 (C-17), 25.6 (C-20), 18.5 (C-19), -4.6 (C-
18); m/z (ES+) 516.09 ([M+Na]+, 100%), (ES-) 492.09 ([M-H]-, 100), HRMS m/z 
(ES+) 516.0875 ([M+Na]+, 100%) C22H25Cl2N3O4SiNa requires 516.0889. 
 
N-(3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl)-3-hydroxy-4-methoxybenzamide 
291 
 
TBAF (1N solution in THF, 530 µl, 0.53 mmol) was added dropwise to a solution of 
silyl-protected amide 289 (175 mg, 0.35 mmol) in THF (10 mL). The solution was 
stirred for 30 min after which TLC analysis indicated that all of the starting material 
was consumed. Water (20 mL) and ethyl acetate (20 mL) was added and the 
layers were separated. The aqueous layer was re-extracted with ethyl acetate (2 × 
20 mL). The combined organic layers were washed with brine solution (30 mL). 
The organic layer was dried with magnesium sulfate and the solvent was removed 
under reduced pressure. The product was purified by column chromatography on 
silica (2% methanol/ DCM) to give the product 291 as a colourless solid (78 mg, 
58%): m.p 237-240 ˚C;  νmax/cm-1 (nujol) 3386, 3337, 1705, 1687; δH (300 MHz, D6-
DMSO) 12.47 (1H, s, 9-NH), 9.48 (1H, s, 17-H), 8.13 (1H, d, J= 1.8 Hz, 2-H), 7.96 
(1H, dd, J= 8.4, 1.8 Hz, 6-H), 7.87 (1H, d, J= 8.4 Hz, 5-H), 7.60 (1H, dd, J= 8.5, 2.3 
Hz, 16-H), 7.47 (1H, d, J= 2.3 Hz, 12-H), 7.08 (1H, d, J= 8.5 Hz, 15-H), 3.87 (3H, s, 
18-H); δC (75 MHz, D6-DMSO) 168.4 (C-8), 166.1 (C-7), 164.0 (C-10), 152.5 (C-
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14), 146.8 (C-13), 134.6 (C-1), 132.5 (C-3), 132.1 (C-5), 128.8 (C-2), 127.5 (C-4), 
127.3 (C-6), 124.6 (C-11), 121.3 (C-16), 116.0 (C-12), 111.7 (C-15), 56.2 (C-18); 
HRMS m/z (ES-) 378.0050 ([M-H]-, 100%) C16H10O4N3Cl2 requires 378.0054. 
 
N-(3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)-4-hydroxy-3-methoxybenzamide 
292 
 
TBAF (1N solution in THF, 1.4 ml, 1.4 mmol) was added dropwise to a solution of 
silyl-protected amide 290 (451 mg, 0.91 mmol) in THF (10 mL). The mixture was 
stirred for 30 min after which TLC analysis indicated that all of the starting material 
was consumed. Water (20 mL) and ethyl acetate (20 mL) was added and the 
layers were separated. The aqueous layer was re-extracted with ethyl acetate (2 × 
20 mL). The combined organic layers were washed with brine solution (30 mL). 
The organic layer was dried with magnesium sulfate and the solvent was removed 
under reduced pressure. The product was purified by column chromatography on 
silica (50% ethyl acetate/ petroleum ether) to give the product 290 as a white solid 
(235 mg, 68%): m.p 190-193 ˚C;  νmax/cm-1 (nujol mull) 3362, 1722, 1620, 1598, 
1256, 1193; δH (300 MHz, D6-DMSO) 12.47 (1H, s, 9-NH), 10.06 (1H, s, 18-H), 
8.12 (1H, d, J= 1.9 Hz, 2-H), 7.95 (1H, dd, J= 8.4, 1.9 Hz, 6-H), 7.87 (1H, d, J= 8.4 
Hz, 5-H), 7.65 (1H, d, J= 2.1 Hz, 12-H), 7.60 (1H, dd, J= 8.3, 2.1 Hz, 16-H), 6.91 
(1H, d, J= 8.3 Hz, 15-H), 3.87 (3H, s, 17-H); δC (75 MHz, D6-DMSO) 168.6 (C-8), 
166.1 (C-7), 164.0 (C-10), 152.0 (C-14), 147.8 (C-13), 134.7 (C-1), 132.5 (C-3), 
132.2 (C-5), 128.9 (C-2), 127.5 (C-4), 127.4 (C-6), 123.5 (C-11), 123.0 (C-16), 
115.6 (C-15), 112.6 (C-12), 56.2 (C-17); HRMS m/z (ES-) 378.0049 ([M-H]-, 100%) 
C16H10O4N3Cl2 requires 378.0054. 
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Sulfamoyl chloride 294178 
 
Chlorosulfonyl isocyanate (4.95 g, 3.1 mL, 35 mmol) was dissolved in DCM (35 
mL) and the solution was cooled to 0 ˚C. Formic acid (1.7 g, 1.4 mL, 36.8 mmol) 
was added dropwise to the solution. The solution was stirred for 1 h at 0 ˚C then 
warmed to room temperature for 16 h. A gas was evolved and a precipitate formed 
which redissolved after 16 h. The product was used without any further purification 
as a 1N solution. 
 
5-((3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)carbamoyl)-2-methoxyphenyl 
sulfamate 281 
 
Amide 291 (105 mg, 0.28 mmol) was dissolved in dimethylacetamide (1 mL) and 
the solution was cooled to 0 ˚C. Sulfamoyl chloride (1N solution in DCM, 550 µl, 
0.55 mmol) was added to the solution. The solution was warmed to room 
temperature and the solution was stirred for 16 h. Water (15 mL) and ethyl acetate 
(15 mL) were added and the layers were separated. The aqueous layer was 
rextracted with ethyl acetate (2 × 15 mL). The combined organic layers were 
washed with brine solution (30 mL). The organic layer was dried with magnesium 
sulfate and the solvent was removed under reduced pressure. The product was 
purified by column chromatography on silica (50% ethyl acetate/ petroleum ether) 
to give the product 281 as a colourless solid (110 mg, 87%): m.p. 210-214 
˚C;  νmax/cm-1 (nujol) 3318, 3220, 1708, 1606, 1597, 1560, 1508, 116; δH (500 MHz, 
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D6-DMSO) 12.69 (1H, s, 9-NH), 8.14 (1H, d, J= 2.0 Hz, 2-H), 8.08 (2H, s, 17-H), 
8.06 (1H, dd, J= 8.7, 2.3 Hz, 16-H), 8.02 (1H, d, J= 2.3 Hz, 12-H), 7.96 (1H, dd, J= 
8.4, 2.0 Hz, 6-H), 7.88 (1H, d, J= 8.4 Hz, 5-H), 7.35 (1H, d, J= 8.7 Hz, 15-H), 3.92 
(3H, s, 18-H); δC (125 MHz, D6-DMSO) 168.3 (C-8), 166.1 (C-7), 163.3 (C-10), 
156.4 (C-14), 139.0 (C-13), 134.7 (C-1), 132.6 (C-3), 132.2 (C-5), 129.0 (C-16), 
128.9 (C-2), 127.4 (C-6), 124.4 (C-11), 124.3 (C-12), 113.5 (C-15), 56.8 (C-18); 
HRMS m/z (ES-) 456.97779 ([M-H]-, 100%) C16H11O6N4Cl2S requires 456.9782. 
4-((3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)carbamoyl)-2-methoxyphenyl 
sulfamate 293 
 
Amide 292 (105 mg, 0.28 mmol) was dissolved in dimethylacetamide (1 mL) and 
the solution was cooled to 0 ˚C. Sulfamoyl chloride (1N solution in DCM, 550 µl, 
0.55 mmol) was added to the solution. The solution was warmed to room 
temperature and the solution was stirred for 16 h. Water (15 mL) and ethyl acetate 
(15 mL) were added and the layers were separated. The aqueous layer was 
re-extracted with ethyl acetate (2 × 15 mL). The combined organic layers were 
washed with brine solution (30 mL). The organic layer was dried with magnesium 
sulfate and the solvent was removed under reduced pressure. The product was 
purified by column chromatography on silica (50% ethyl acetate/ petroleum ether) 
to give the product 293 as a colourless solid (78 mg, 61%): m.p 
199-204 ˚C;  νmax/cm-1 (nujol) 3432, 3340, 3188, 1712, 1600, 1168, 1129; δH (500 
MHz, D6-DMSO) 12.83 (1H, s, 9-NH), 8.17 (2H, s, 18-H), 8.14 (1H, d, J= 1.8 Hz, 2-
H), 7.97 (1H, dd, J= 8.3, 1.8 Hz, 6-H), 7.88 (1H, d, J= 8.3 Hz, 5-H), 7.82 (1H, d, J= 
1.8 Hz, 12-H), 7.69 (1H, dd, J= 8.4, 1.8 Hz, 16-H), 7.49 (1H, d, J= 8.4 Hz, 15-H), 
3.92 (3H, s, 17-H); δC (125 MHz, D6-DMSO) 168.3 (C-8), 168.2 (C-7), 163.8 (C-10), 
152.0 (C-13), 142.9 (C-14), 134.8 (C-4), 132.6 (C-3), 132.2 (C-5), 131.1 (C-11), 
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128.9 (C-2), 127.4 (C-6), 127.4 (C-1), 123.5 (C-15), 121.8 (C-16), 113.7 (C-12), 
56.6 (C-17); HRMS m/z (ES-) 456.9781 ([M-H]-, 100%) C16H11O6N4Cl2S requires 
456.9782. 
 
3-(Allyloxy)-4-methoxybenzaldehyde 296 180, 226 
 
Allyl bromide (4.25 mL, 49.2 mmol) and potassium carbonate (6.8 g, 49.2 mmol) 
were added to a solution of 3-hydroxy-4-methoxybenzaldehyde (3 g, 19.7 mmol) in 
DMF (30 mL). The mixture was heated to 50 ˚C for 3 h. Water (30 mL) was added. 
Ethyl acetate (60 ml) was added and the layers were separated. The aqueous layer 
was washed with ethyl acetate (2 × 50 mL). The combined organic layers were 
washed with water (3 × 30 mL) and brine solution (30 mL). The organic layer was 
dried with magnesium sulfate and the solvent was removed under reduced 
pressure. The product was purified by column chromatography on silica (10% ethyl 
acetate/petroleum ether to 20% ethyl acetate/ petroleum ether to 25% ethyl 
acetate/petroleum ether) to give the product 296 as a pale yellow oil (3.82 g, 
quant.): νmax/cm-1 (thin film) 3081, 2935, 1683, 1595, 1508; δH (500 MHz, CDCl3) 
9.83 (1H, s, 7-H), 7.46 (1H, dd, J= 8.2, 1.8 Hz, 6-H), 7.40 (1H, d, J= 1.8 Hz, 2-H), 
6.99 (1H, d, J= 8.2 Hz, 5-H), 6.09 (1H, ddt, J= 17.1, 10.7, 5.5 Hz, 9-H), 5.44 (1H, 
dd, J= 17.1, 1.2 Hz, 10 cis-H), 5.32 (1H, dd, J= 10.7 ,1.2 Hz, 10 trans-H), 4.67 (2H, 
d, J= 5.5 Hz, 8-H), 3.96 (3H, s, 11-H); δC (125 MHz, CDCl3) 190.9 (C-7), 154.8 (C-
4), 148.5 (C-3), 132.5 (C-9), 130.0 (C-1), 126.8 (C-6), 118.6 (C-10), 110.7 (C-2) 
110.6 (C-5), 69.7 (C-8), 56.2 (C-11); HRMS m/z (ES+) 215.0682 ([M+Na]+, 100%) 
C11H12O3Na requires 215.0684. 
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3-(Allyloxy)-4-methoxybenzoic acid 297180 
 
Aldehyde 296 (3g, 15.6 mmol) was dissolved in acetone (50 mL) and cooled to 0 
˚C. Chromium trioxide (3.28 g, 32.7 mmol) and concentrated sulfuric acid (2.79 mL, 
52.2 mmol) were dissolved in 5.3 mL of water. The chromium mixture was added 
dropwise to the acetone solution. The mixture was stirred for 30 min at 0 ˚C and 
then warmed to room temperature for 3 h. Excess chromium trioxide was 
destroyed by the addition of 2-propanol. The solvent was mostly removed under 
reduced pressure. Diethyl ether (50 mL) was added and the organic layer was 
removed. The aqueous layer was washed with diethyl ether (2 × 50 mL). The 
organic layers were combined and dried with magnesium sulfate. The solvent was 
removed under reduced pressure to give a yellow solid. The product was purified 
by column chromatography on silica (50% ethyl acetate/petroleum ether) to give 
the product 297 as a white solid (1.42 g, 44%): m.p 126-130 ˚C (Lit. 180 146-147 
˚C); νmax/cm-1 (nujol) 3450, 3197, 1679, 1599, 1586, 1518, 1266 δH (300 MHz, D6-
DMSO) 12.66 (1H, s, 7-OH), 7.55 (1H, dd, J= 8.5, 2.0 Hz, 6-H), 7.43 (1H, d, J= 2.0 
Hz, 2-H), 7.05 (1H, d, J= 8.5 Hz, 5-H), 6.03 (1H, ddt, J= 17.3, 10.5, 5.2 Hz, 9-H), 
5.38 (1H, dq, J= 17.3, 1.7 Hz, 10 trans-H), 5.25 (1H, dq, J= 10.5, 1.7 Hz, 10 cis-H), 
4.58 (2H, dt, J= 5.2, 1.7 Hz, 8-H), 3.82 (3H, s, 11-H); δC (75 MHz, D6-DMSO) 167.9 
(C-7), 153.7 (C-3), 147.9 (C-4), 134.4 (C-9), 124.2 (C-6), 123.7 (C-1), 118.5 (C-10), 
114.4 (C-2), 112.1 (C-5), 69.7 (C-8), 56.5 (C-11); HRMS m/z (ES-) 207.0660 ([M-
H]-, 100%) C11H11O4 requires 207.0657. 
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3-(Allyloxy)-N-(3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl)-4-methoxybenzamide 
298 
 
Benzoic acid 297 (260 mg, 1.25 mmol) and DMAP (478 mg, 3.9 mmol) were added 
to a solution of 5-amino-1,2,4-oxadiazole 224h (230 mg, 1mmol) in DCM (20 mL). 
EDCI (300 mg, 1.6 mmol) was added to the solution. The mixture was stirred for 16 
h. Water was added and the mixture was separated. The aqueous layer was 
washed with DCM (2 × 30 mL). The combined organic layers were washed with 2N 
HCl solution (30 mL) and a saturated solution of brine (30 mL). The organic layer 
was dried with magnesium sulfate and the solvent was removed under reduced 
pressure. The product was dry loaded on magnesium sulfate and purified by 
column chromatography (2% diethyl ether/DCM to 5% diethyl ether/DCM) to give 
the product 298 as a colourless solid (335 mg, 80%): m.p 134-138 ˚C;  νmax/cm-1 
(nujol mull) 3320, 1687, 1599, 1561, 1265; δH (300 MHz, CDCl3) 9.21 (1H, s, 9-
NH), 8.18 (1H, d, J= 1.9 Hz, 2-H), 7.92 (1H, dd, J= 8.4, 1.9 Hz, 6-H), 7.60-7.57 
(2H, m, 5,12-H), 7.54 (1H, dd, J= 8.4, 2.2 Hz, 16-H), 6.99 (1H, d, J= 8.4 Hz, 15-H), 
6.13 (ddt, J= 17.3, 10.5, 5.5 Hz, 18-H), 5.49 (1H, dq, J= 17.3, 1.5 Hz, 19 trans-H), 
5.38 (1H, dq, J= 10.5, 1.3 Hz, 19 cis-H), 4.73 (2H, dt, J= 5.5, 1.5 Hz, 17-H), 4.00 
(3H, s, 20-H); δC (100 MHz, D6-DMSO) 168.5 (C-8), 166.1 (C-7), 163.8 (C-10), 
153.7 (C-14), 147.6 (C-13),134.7 (C-1), 133.9 (C-18), 132.6 (C-3), 132.2 (C-5), 
128.9 (C-2), 127.5 (C-4), 127.4 (C-6), 124.2 (C-11), 123.4 (C-16), 118.3 (C-19), 
113.3 (C-12), 111.8 (C-15), 69.6 (C-17), 56.3 (C-20); m/z (ES+) 442.03 ([M+Na]+, 
100%), (ES-) 418.04 ([M-H]-, 100), HRMS m/z (ES+) 442.0323 ([M+Na]+, 100%) 
C19H15O4N3Cl2Na requires 442.0337. 
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Benzyl 3-(2-ethoxy-2-oxoethoxy)-4-methoxybenzoate 300 
 
Ethyl bromoacetate (1.03 mL, 9.2 mmol) and potassium carbonate (1.34 g, 9.6 
mmol) were added to a solution of benzyl ester 265 (2g, 7.7 mmol) in DMF (50 
mL). The mixture was stirred at 60 ˚C for 3 h. Water (50 mL) was added and the 
product was extracted with ethyl acetate. The aqueous layer was washed with 
ethyl acetate (3 × 50 mL). The combined organic layers were washed with water (3 
× 30 mL) and brine solution (30 mL). The organic layer was dried with magnesium 
sulfate and the solvent was removed under reduced pressure. The product was 
purified by column chromatography on silica (20% ethyl acetate/petroleum ether to 
25% ethyl acetate/petroleum ether) to give the product 300 as a colourless oil (2.56 
g, 96%): νmax/cm-1 (thin film) 3204, 2980, 2937, 1758, 1712, 1603, 1515; δH (500 
MHz, CDCl3) 7.80  (1H, dd, J= 8.5, 2.0 Hz, 6-H), 7.54 (1H, d, J= 2.0 Hz, 2-H), 7.46 
(2H, dd, J= 7.8, 1.0Hz, 10-H), 7.43-7.36 (3H, m, 11,12-H), 6.94 (1H, d, J= 8.5 Hz, 
5-H), 5.36 (2H, s, 8-H), 4.75 (2H, s, 13-H), 4.28 (2H, q, J= 7.1 Hz, 15-H), 3.96 (3H, 
s, 17-H), 1.30 (3H, t, J= 7.1 Hz, 16-H); δC (125 MHz, CDCl3) 168.5 (C-14), 165.9 
(C-7), 153.6 (C-4), 146.8 (C-3), 136.2 (C-9), 128.6 (C-11), 128.2 (C-12), 128.1 (C-
10), 125.1 (C-6), 122.5 (C-1), 114.6 (C-2), 111.0 (C-5), 66.6 (C-8), 66.2 (C-13), 
61.4 (C-15), 56.1 (C-17), 14.2 (C-16); HRMS m/z (ES+) 367.1143 ([M+Na]+, 100%) 
C19H20O6Na requires 367.1158. 
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3-(2-Ethoxy-2-oxoethoxy)-4-methoxybenzoic acid 301 
 
10% Pd/C (200 mg, 0.19 mmol) was added to a solution of benzyl ester 300 (2g, 
5.81 mmol) in methanol (30 mL). The mixture was stirred under a hydrogen 
atmosphere for 48 h. The mixture was filtered through a pad of celite and the celite 
was washed with methanol (2 × 30 mL). The filtrate and washings were combined 
and the solvent was removed under reduced pressure to give a solid. The product 
was purified by column chromatography on silica (50 % ethyl acetate/petroleum 
ether) or by recrystallisation (ethyl acetate/ hexane) to give the product 301 as a 
white solid (882 mg, 60%): m.p. 118-122 ˚C; νmax/cm-1 (nujol) 3474, 3197, 1749, 
1686, 1601, 1269; δH (500 MHz, D6-DMSO) 7.59 (1H, dd, J= 8.4, 1.2 Hz, 6-H), 7.37 
(1H, d, J= 1.2 HZ, 2-H), 7.07 (1H, d, J= 8.4 Hz, 5-H), 4.82 (2H, s, 8-H), 4.12 (2H, q, 
J= 7.1 Hz, 10-H), 3.85 (3H, s, 12-H), 1.22 (3H, t, J= 7.1 Hz, 11-H); δC (75 MHz, D6-
DMSO) 169.1 (C-9), 167.6 (C-7), 152.8 (C-4), 146.9 (C-3), 124.6 (C-1), 124.4 (C-
6), 114.4 (C-2), 111.9 (C-5), 65.8 (C-8), 61.1 (C-10), 56.2 (C-12), 14.5 (C-11); 
HRMS m/z (ES+) 277.0676 ([M+Na]+, 100%) C12H14O6Na requires 277.0688. 
 
Benzyl 4-methoxy-3-(2-methoxy-2-oxoethoxy)benzoate 303 
 
Potasium carbonate (2 g, 14.5 mmol) and methyl bromoacetate (1.32 mL, 13.9 
mmol) were added to a solution of benzyl ester 265 (3 g, 11.6 mmol) in DMF (50 
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mL). The mixture was heated to 60 ˚C for 3 h. Water (30 mL) and DCM (30 mL) 
were added and the layers were separated. The aqueous layer was washed with 
DCM (3 × 30 mL). The combined organic layers were washed with water (2 × 30 
mL) and brine solution (30 mL). The organic layer was dried with magnesium 
sulfate and the solvent was removed under reduced pressure. The product was 
purified by column chromatography on silica (30% ethyl acetate/petroleum ether) to 
give the product 303 as a colourless oil (3.41 g, 88%):  νmax/cm-1 (thin film) 3405, 
3088, 3007, 2954, 2842, 2614, 2038, 1880, 1760, 1716, 1603, 1588, 1515, 1427, 
1294; δH (400 MHz, CDCl3) 7.80 (1H, dd, J= 8.5, 2.0 Hz, 6-H), 7.54 (1H, d, J= 2.0 
Hz, 2-H), 7.47- 7.36 (5H, m, 10,11,12-H), 6.94 (1H, d, J= 8.5 Hz, 5-H), 5.35 (2H, s, 
8-H), 4.76 (2H, s, 13-H), 3.96 (3H, s, 16-H), 3.81 (3H, s, 15-H); δC (100 MHz, 
CDCl3) 168.9 (C-14), 165.9 (C-7), 153.6 (C-4), 146.7 (C-3), 136.2 (C-9), 128.6 (C-
10), 128.2 (C-12), 128.1 (C-11), 125.1 (C-6), 122.5 (C-1), 114.5 (C-2), 111.0 (C-5), 
66.6 (C-8), 66.1 (C-13), 56.1 (C-16), 52.3 (C-15); HRMS m/z (ES+) 353.0986 
([M+Na]+, 100%) C18H18O6Na requires 353.1001. 
 
4-Methoxy-3-(2-methoxy-2-oxoethoxy)benzoic acid 304 
 
10% Pd/C (200 mg, 0.19 mmol) was added to a solution of benzyl ester 303 (2.06 
g, 6.2 mmol) in methanol (30 mL). The mixture was stirred under a hydrogen 
atmosphere for 48 h. The mixture was filtered through a pad of celite. The celite 
was washed with methanol (2 × 30 mL). The filtrate and the washings were 
combined and the solvent was removed under reduced pressure. The product was 
purified by column chromatography on silica (5% methanol/DCM) to give the 
product 304 as a colourless solid (1.07 g, 71%): m.p 147-150 ˚C; νmax/cm-1 (nujol) 
1770, 1752, 1724, 1690, 1602, 1587, 15211216, 763; δH (300 MHz, CDCl3) 7.86 
(1H, dd, J= 8.5, 2.0 Hz, 6-H), 7.56 (1H, d, J= 2.0 Hz, 2-H), 6.99 (1H, d, J= 8.5 Hz, 
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5-H), 4.80 (2H, s, 8-H), 4.00 (3H, s, 11-H), 3.86 (3H, s, 10-H); δC (75 MHz, CDCl3) 
171.5 (C-7), 168.9 (C-9), 154.2 (C-4), 146.8 (C-3), 125.9 (C-6), 121.6 (C-1), 114.7 
(C-2), 111.1 (C-5), 66.0 (C-8), 56.2 (C-11), 52.4 (C-10); HRMS m/z (ES+) 263.0522 
([M+Na]+, 100%) C11H12O6Na requires 263.0532. 
 
Ethyl 2-(5-((3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl)carbamoyl)-2-
methoxyphenoxy)acetate 284 
 
Benzoic acid 301 (398 mg, 1.5 mmol) and DMAP (478 mg, 3.9 mmol) were added 
to a solution of 5-amino-1,2,4-oxadiazole 224h (300 mg, 1.3 mmol) in DCM (20 
mL). EDCI (375 mg, 1.95 mmol) was added to the mixture, which was stirred for 16 
h. Water (30 mL) and DCM (30 mL) were added to the yellow solution and the 
layers were separated. The aqueous layer was washed with DCM (2 × 30 mL). The 
combined organic layers were washed with HCl solution (2N, 30 mL) and brine 
solution. The organic layer was dried with magnesium sulfate and the solvent was 
removed under reduced pressure. The product was purified by recrystallisation 
from ethanol to give 284 as a colourless solid (459 mg, 75%): m.p 189-192 
˚C;  νmax/cm-1 (nujol mull) 3481, 3318, 1735, 1705, 1602, 1565, 1506, 1203, 1181; 
δH (300 MHz, D6-DMSO) 12.53 (1H, s, 9-NH), 8.13 (1H, d, J= 1.9Hz, 2-H), 7.96 
(1H, dd, J= 8.4, 1.9 Hz, 6-H), 7.88 (1H, d, J= 8.4 Hz, 5-H), 7.77 (1H, dd, J= 8.6 ,2.1 
Hz, 16-H), 7.59 (1H, d, J= 2.1 Hz, 12-H), 7.18 (1H, d, J= 8.6 Hz, 15-H), 4.88 (2H, s, 
17-H), 4.20 (2H, q, J= 7.1 Hz, 19-H), 3.89 (3H, s, 21-H), 1.23 (3H, t, J= 7.1 Hz, 20-
H); δC (125 MHz, D6-DMSO) 168.9 (C-18), 168.5 (C-8), 166.1 (C-7), 163.7 (C-10), 
153.5 (C-14), 147.1 (C-13), 134.7 (C-1), 132.6 (C-3), 132.2 (C-5), 128.9 (C-2), 
127.5 (C-4), 127.4 (C-6), 124.1 (C-11), 124.0 (C-16), 113.3 (C-12), 112.1 (C-15), 
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65.7 (C-17), 61.2 (C-19), 56.4 (C-21), 14.5 (C-20); HRMS m/z (ES-) 464.0422 ([M-
H]-, 100%) C20H16O6N3Cl2 requires 464.0422. 
 
Methyl 2-(5-((3-(3,4-dichlorophenyl)-1,2,4-oxadiazol-5-yl)carbamoyl)-2-
methoxyphenoxy)acetate 283 
 
Benzoic acid 304 (376 mg, 1.6 mmol) and DMAP (478 mg, 3.9 mmol) were added 
to a solution of 5-amino-1,2,4-oxadiazole 224h (300 mg, 1.3 mmol) in DCM (20 
mL). EDCI (375 mg, 1.96 mmol) was added to the mixture, which was then stirred 
for 16 h. Water (30 mL) and DCM (30 mL) were added to the yellow solution and 
the layers were separated. The aqueous layer was washed with DCM (2 × 30 mL). 
The combined organic layers were washed with HCl solution (2N, 30 mL) and brine 
solution. The organic layer was dried with magnesium sulfate and the solvent was 
removed under reduced pressure. The product was purified by column 
chromatography on silica (30% ethyl acetate/petroleum ether to 50% ethyl 
acetate/petroleum ether to 10% diethyl ether/ DCM) to give the product 283 as a 
white solid (435 mg, 74%): m.p 212-216 ˚C; νmax/cm-1  (nujol) 3333, 1727, 1711, 
1609, 1529, 754, 745; δH (400 MHz, D6-DMSO) 12.51 (1H, s, 9-NH), 8.11 (1H, d, 
J= 1.9 Hz, 2-H), 7.94 (1H, dd, J= 8.5, 1.9 Hz, 6-H), 7.85 (1H, d, J= 8.5 Hz, 5-H), 
7.75 (1H, dd, J= 8.6, 2.1 Hz, 16-H), 7.58 (1H, d, J= 2.1 Hz, 12-H), 7.16 (1H, d, J= 
8.6 Hz, 15-H), 4.89 (2H, s, 17-H), 3.87 (3H, s, 20-H), 3.71 (3H, s, 19-H); δC (75 
MHz, D6-DMSO) 169.8 (C-18), 168.8 (C-8), 166.5 (C-7), 164.0 (C-10), 153.9 (C-
14), 147.4 (C-13), 135.1 (C-1), 132.9 (C-3), 132.6 (C-5), 129.3 (C-2), 127.8 (C-4), 
127.8 (C-6), 124.5 (C-11), 124.4 (C-16), 113.6 (C-12), 112.5 (C-15), 66.0 (C-17), 
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56.8 (C-20), 52.8 (C-19); HRMS m/z (ES-) 450.0263 ([M-H]-, 100%) C19H14O6N3Cl2 
requires 450.0265. 
 
2-(5-((3-(3,4-Dichlorophenyl)-1,2,4-oxadiazol-5-yl)carbamoyl)-2-
methoxyphenoxy)acetic acid 282 
 
Methyl ester 283 (100 mg, 0.22 mmol) was added to a sodium hydroxide solution 
(1M, 2 mL) and the mixture was stirred for 30 min. THF (2 mL) was added and the 
mixture was stirred for a further 30 min after which TLC analysis showed complete 
consumption of the starting material. The solvent was removed under reduced 
pressure. Water (5 mL) was added and the solution was acidified with HCl solution 
(2M) to give a precipitate. The precipitate was collected and dried to give the 
product 282 as a white solid (59 mg, 61%): m.p. decomposition 258-
262 ˚C; νmax/cm-1 (nujol) 3326, 3188, 1741, 1716, 1615, 1377, 1080, 761; δH (300 
MHz, D6-DMSO) 12.58 (1H, s, 9-NH), 8.11 (1H, d, J=1.9 Hz, 2-H), 7.94 (1H, dd, J= 
8.4, 1.9 Hz, 6-H), 7.85 (1H, d, J= 8.4 Hz, 5-H), 7.74 (1H, dd, J= 8.6, 2.1 Hz, 16-H), 
7.56 (1H, d, J= 2.1 Hz, 12-H), 7.15 (1H, d, J= 8.6 Hz, 15-H), 4.78 (2H, s, 17-H), 
3.87 (3H, s, 19-H); δC (75 MHz, D6-DMSO) 170.8 (C-18), 168.8 (C-8), 166.4 (C-7), 
164.1 (C-10), 153.8 (C-14), 147.6 (C-13), 135.1 (C-1), 132.9 (C-3), 132.6 (C-5), 
129.3 (C-2), 127.8 (C-6), 127.8 (C-4), 124.4 (C-11), 124.1 (C-6), 113.3 (C-12), 
112.4 (C-15), 65.8 (C-17), 56.7 (C-19); HRMS m/z (ES-) 436.0105 ([M-H]-, 100%) 
C18H12O6N3Cl2 requires 436.0103. 
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N-(Pyridin-2-yl)pivalamide 343190 
 
2-Aminopyridine (15 g, 159 mmol) was added to a solution of DMAP (29 g, 239 
mmol) in DCM (125 mL). The solution was cooled to 0 ˚C and trimethylacetyl 
chloride (23.5 mL, 191 mmol) was added dropwise. Once the addition was 
complete the solution was warmed to room temperature and stirred for 16 h. When 
TLC analysis indicated that all of the starting material had been consumed, a 
saturated solution of sodium bicarbonate (50 mL) was added. The layers were 
seperated and the aqueous layer was re-extracted with DCM (2 × 50 mL). The 
combined organic layers were dried with magnesium sulfate and the solvent was 
removed under reduced pressure. The product was purified by column 
chromatography on silica (20% ethyl acetate/petroleum ether) to give the product 
343 as a colourless solid (25.9 g, 91%): m.p 44-49 ˚C (Lit.190 71-73 ˚C); νmax/cm-1 
(nujol) 3440, 3303, 1698, 1685, 1578, 1149; δH (300 MHz, CDCl3) 8.31-8.25 (3H, 
m, 4,5,7-H), 7.73 (1H, dddd, J= 8.4, 7.4, 1.9, 0.5 Hz, 3-H), 7.06 (1H, ddd, J= 7.4, 
5.0, 1.1 Hz, 5-H), 1.35 (9H, s, 9-H); δC (75 MHz, CDCl3) 177.6 (C-7), 151.9 (C-1), 
147.5 (C-5), 139.2 (C-2), 120.1 (C-4), 114.6 (C-3), 40.3 (C-8), 27.9 (C-9); HRMS 
m/z (CI+) 179.1181 ([M+H]+, 100%) C10H15N2O requires 179.1184 
 
N-(3-Acetylpyridin-2-yl)pivalamide 344227 
 
Pyridyl amide 343 (2 g, 11.2 mmol) was dissolved in THF (50 mL). The solution 
was cooled to -50 ˚C. N-Butyl lithium (1.6 N solution in hexane, 17.6 mL, 28.0 
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mmol) was added dropwise keeping the temperature of the solution below -40 ˚C. 
The solution turned yellow after addition of all of the n-butyl lithium. When all of the 
n-butyl lithium had been added the solution was warmed to 0 ˚C for 1.5 h, during 
which time a yellow precipitate formed. The mixture was cooled to -40 ˚C and a 
solution of 4-acetylmorpholine (2.2 g, 1.97 mL) in THF (10 mL) was added 
dropwise. The mixture was stirred for 30 min at -40 ˚C during which time the 
precipitate disappeared. The reaction was quenched by the addition of saturated 
ammonium chloride solution (40 mL). DCM (40 mL) was added and the layers 
were separated. The aqueous layer was re-extracted with DCM (2 × 40 mL). The 
combined organic layers were washed with water (30 mL) and brine solution (30 
mL). The organic layer was dried with magnesium sulfate and the solvent was 
removed under reduced pressure. The product was purified by column 
chromatography on silica (50% ethyl acetate/petroleum ether to 100% ethyl 
acetate) to give the product 344 as a white solid (1.55 g, 63%): m.p 32-34 ˚C 
(Lit.227 67-68 ˚C); νmax/cm-1 (nujol) 3444 1708, 1698, 1661, 1601, 1578; δH (300 
MHz, CDCl3) 11.55 (1H, s, 6-NH), 8.65 (1H, dd, J= 4.8, 1.9 Hz, 4-H), 8.21 (1H, dd, 
J= 7.9, 1.9 Hz, 3-H), 7.11 (1H, dd, J= 7.9, 4.8 Hz, 5-H), 2.66 (3H, s, 11-H), 1.35 
(9H, s, 9-H); δC (75 MHz, CDCl3) 201.3 (C-10), 177.3 (C-7), 153.7 (C-4), 152.4 (C-
1), 140.6 (C-3), 118.4 (C-2, C-5), 41.1 (C-8), 28.4 (C-11), 27.8 (C-9); HRMS m/z 
(ES+) 243.1113 ([M+Na]+, 58%) C12H16N2O2Na requires 243.1109; 221.1295 
([M+H]+, 100) C12H17N2O2 requires 221.1290. 
 
Ethyl 2-((tert-butyldimethylsilyl)oxy)acetate 350194 
 
Imidazole (18.6 g, 288 mmol) and TBSCl (31.8 g, 212 mmol) were added 
portionwise to a solution of ethyl glycolate (20 g, 182 mmol) was dissolved in DCM 
(150 mL) that was cooled to 0 ˚C. The mixture was stirred for 16 h. Water (50 mL) 
was added and the layers were seperated. The aqueous layer was re-extracted 
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with DCM (2 × 50 mL). The combined organic layers were washed with water (50 
mL) and brine solution (50 mL). The oranic layer was dried with magenisum sulfate 
and the solvent was removed under reduced pressure. The product was purified by 
column chromatography on silica (5% ethyl acetate/petroleum ether) to give the 
product 350 as a colourless oil (37.4 g, 89%): νmax/cm-1 (thin film) 2955, 2931, 
2858, 1762, 1736, 1475, 1445.62, 1256, 1148; δH (300 MHz, CDCl3) 4.13 (2H,s, 1-
H), 4.09 (2H, q, J= 7.2 Hz, 3-H), 1.17 (3H, t, J= 7.2 Hz, 4-H), 0.81 (9H, s, 7-H), 
0.00 (6H, s, 5-H); δC (75 MHz, CDCl3) 172.1 (C-2), 62.2 (C-1), 61.1 (C-3), 26.1 (C-
7), 18.8 (C-6), 14.6 (C-4), -5.7 (C-5); HRMS m/z (ES+) 241.1240 ([M+Na]+, 100%) 
C10H22O3SiNa requires 241.1236. 
 
2-((tert-Butyldimethylsilyl)oxy)acetic acid 351228 
 
A solution of potassium hydroxide (2.68 g, 47.8 mmol) in ethanol (50 mL) was 
added to a solution of ethyl ester 350 (7.85 g, 35.9 mmol) in ethanol (240 mL). The 
mixture was stirred for 16 h. The solvent was removed under reduced pressure. 
DCM (200 mL) was added and the organic layer was washed with saturated 
ammonium chloride solution (100 mL). The organic layer was dried with 
magnesium sulfate and the solvent was removed under reduced pressure to give 
the product 351 as a colourless solid (4.70 g, 67%); m.p 74-76°C (Lit.228 48-49 
˚C); νmax/cm-1 (nujol) 3364, 1731; δH (500 MHz, CDCl3) 4.19 (2H, s, 1-H), 0.91 (9H, 
s, 5-H), 0.1 (6H, s, 3-H); δC (125 MHz, CDCl3) 172.0 (C-2), 62.4 (C-1), 25.6 (C-5), 
18.5 (C-4), -5.4 (C-3); HRMS m/z (ES-) 189.0949 ([M-H]-, 100%) C8H17O3Si 
requires 189.0947. 
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2-((tert-Butyldimethylsilyl)oxy)-1-morpholinoethanone 352 
 
Morpholine (4.14 mL, 47.9 mmol) and DMAP (585 mg, 4.8 mmol) were added to a 
solution of carboxylic acid 351 (7.02 g, 36.8 mmol) in DCM (50 mL). DCC (9.89 g, 
47.9 mmol) was added to the solution and a precipitate formed. The mixture was 
stirred for 16 h. The precipitate was filtered off and water (50 mL) was added to the 
filtrate and the layers were separated. The aqueous layer was re-extracted with 
DCM (2 × 50 mL). The combined organic layers were washed with brine solution 
(30 mL). The organic layer was dried with magnesium sulfate and the solvent was 
removed under reduced pressure. The product was purified by column 
chromatography on silica to give the product 352 as a colourless oil (3.68 g, 
38%): νmax/cm-1 (thin film) 3490, 2956, 2929, 2857, 1654; δH (300 MHz, CDCl3) 4.18 
(2H, s, 1-H), 3.59-3.56 (4H, m, H), 3.51-3.47 (4H, m, H), 0.8 (9H, s, 7-H), 0.00 (6H, 
s, 5-H); δC (125 MHz, CDCl3) 169.3 (C-2), 66.8 (C-4), 66.8 (C-4), 64.0 (C-1), 45.8 
(C-3), 42.2 (C-3), 25.7 (C-7), 18.2 (C-6), -5.5 (C-5); HRMS m/z (ES+) 282.1512 
([M+Na]+, 100%) C12H25NO3SiNa requires 282.1501. 
 
N-(3-(2-((tert-butyldimethylsilyl)oxy)acetyl)pyridin-2-yl)pivalamide 353 
 
Pyridyl amide 343 (4 g, 22.4 mmol) was dissolved in THF (50 mL). The solution 
was cooled to -50 ˚C. N-Butyl lithium (1.6 N solution in hexane, 35.2 mL, 56.0 
mmol) was added dropwise keeping the temperature of the solution below -40 ˚C. 
The solution turned yellow after addition of all of the n-butyl lithium. After the 
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addition of n-butyl lithium was complete the solution was warmed to 0 ˚C for 1.5 h, 
during which time a yellow precipitate formed. The mixture was cooled to -40 ˚C 
and ethyl ester 350 (7.34 g, 33.6 mmol) was added dropwise. The mixture was 
stirred for 30 min at -40 ˚C during which time the precipitate disappeared. The 
reaction was quenched by the addition of saturated ammonium chloride solution 
(40 mL). DCM (40 mL) was added and the layers were separated. The aqueous 
layer was re-extracted with DCM (2 × 40 mL). The combined organic layers were 
washed with water (30 mL) and brine solution (30 mL). The organic layer was dried 
with magnesium sulfate and the solvent was removed under reduced pressure. 
The product was purified by column chromatography on silica (20% ethyl acetate/ 
petroleum ether to 30% ethyl acetate/ petroleum ether) to give the product 353 as 
a yellow oil (4.77 g, 61%): νmax/cm-1 (thin film) 3288, 2955, 2858, 1711, 1579, 1507, 
971; δH (300 MHz, CDCl3) 11.06 (1H, s, NH), 8.53 (1H, dd, J= 4.8, 1.9 Hz, 4-H), 
8.05 (1H, dd, J= 7.9, 1.9 Hz, 5-H), 6.96 (1H, dd, J= 7.9, 4.8 Hz, 3-H), 4.73 (2H, s, 
7-H), 1.24 (9H, s, 13-H), 0.80 (9H, s, 10-H), 0.00 (6H, s, 8-H); δC (75 MHz, CDCl3) 
200.5 (C-6), 177.1 (C-11), 153.9 (C-4), 152.3 (C-2), 139.1 (C-5), 118.3 (C-3), 116.9 
(C-1), 68.3 (C-7), 41.0 (C-12), 27.9 (C-13), 26.2 (C-10), 18.8 (C-9), -4.9 (C-8); 
HRMS m/z (ES+) 373.1931 ([M+Na]+, 100%) C18H30N2O3SiNa requires 373.1923. 
 
2-(2-Aminopyridin-3-yl)-2-oxoethyl pivalate 354 
 
TBAF (1N solution in THF, 2.7 mL, 2.7 mmol) was added dropwise to a solution of 
ketone 353 (872 mg, 2.5 mmol) in THF (10 mL). The solution turned black and 
stirring was continued for 2 h. Ethyl acetate (30 mL) and water (30 mL) were added 
and the layers were separated. The aqueous layer was re-extracted with ethyl 
acetate (3 × 40 mL). The combined organic layers were washed with brine solution 
(30 mL). The organic layer was dried with magnesium sulfate and the solvent was 
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removed under reduced pressure. The product was purified by column 
chromatography on silica (30% ethyl acetate/petroleum ether to 40% ethyl 
acetate/petroleum ether) to give the product 354 as a colourless solid (186 mg, 
32%): m.p 115-119 ˚C; νmax/cm-1 (nujol) 3400, 1741, 1670, 1624, 1563, 1142, 967, 
764, 722; δH (500 MHz, CDCl3) 8.27 (1H, dd, J= 4.7, 1.7 Hz, 4-H), 7.89 (1H, dd, J= 
7.9, 1.7 Hz, 5-H), 6.65 (1H, dd, J= 7.9, 4.7 Hz, 3-H), 5.26 (2H, s, 7-H), 1.31 (9H, s, 
10-H); δC (125 MHz, CDCl3) 192.4 (C-6), 177.9 (C-8), 158.4 (C-2), 154.7 (C-4), 
138.0 (C-5), 112.0 (C-3), 110.3 (C-1), 65.1 (C-7), 38.9 (C-9), 27.0 (C-10); m/z 
(ES+) 259.23 ([M+Na]+, 100%), 237.25 ([M+H]+, 48); HRMS m/z (ES+) 237.1240 
([M+H]+, 100%) C12H17N2O3 requires 237.1239. 
 
N-(3-(2-Hydroxyacetyl)pyridin-2-yl)pivalamide 357 
 
Acetyl chloride (883 µl, 12.4 mmol) was added to a solution of ketone 353 (3.96 g, 
11.3 mmol) in methanol (20 mL). The solution was stirred for 3 h. When TLC 
indicated consumption of all the strating material, water (30 mL) and DCM (40 mL) 
were added and the layers were separated. The aqueous layer was re-extracted 
with DCM (3 × 30 mL). The combined organic layers were washed with brine 
solution. The organic layer was dried with magnesium sulfate and the solvent was 
removed under reduced pressure. The product was purified by column 
chromatography on silica (1% methanol/DCM to 2% methanol/DCM to 5% 
methanol/DCM) to give the product 357 as brown solid (1.53 g, 57%): m.p 104-106 
°C; νmax/cm-1 (nujol mull) 3350, 3079, 1714, 1650, 1601, 1579, 1259, 1157, 1051; 
δH (400 MHz, CDCl3) 11.1 (1H, s, NH), 8.54 (1H, dd, J= 4.8, 1.9 Hz, 5-H), 8.01 (1H, 
dd, J= 7.9, 1.9 Hz, 3-H), 7.06 (1H, dd, J= 7.9, 4.8 Hz, 4-H), 4.83 (2H, s, 11-H), 1.28 
(9H, s, 9-H); δC (75 MHz, CDCl3) 200.5 (C-10), 176.8 (C-7), 154.2 (C-5), 151.5 (C-
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1), 137.7 (C-3), 118.3 (C-4), 115.7 (C-2), 65.8 (C-11), 40.6 (C-8), 27.4 (C-9); 
HRMS m/z (ES+) 259.1058 ([M+Na]+, 100%) C12H16N2O3Na requires 259.1059. 
 
N-(3-(2-Bromoacetyl)pyridin-2-yl)pivalamide 345 
 
Triphenylphosphine (113 mg, 0.43 mmol) and carbontetrabromide (144 mg, 0.43 
mmol) were added to a solution of alcohol 357 (93 mg, 0.4 mmol) in DCM (5 mL). 
The solution was stirred in the dark for 8 h. The solvent was removed under 
reduced pressure and the oil was dry loaded onto magnesium sulfate. The product 
was purified by column chromatography on silica (30% ethyl acetate/petroleum 
ether to 40% ethyl acetate/petroleum ether) to give the product as a yellow oil (38 
mg, 32%): δH (300 MHz, CDCl3) 10.72 (1H, s, NH), 8.65 (1H, dd, J= 4.8, 1.8 Hz, 5-
H), 8.18 (1H, dd, J= 7.9, 1.8 Hz, 3-H), 7.15 (1H, dd, J= 7.9, 4.8 Hz, 4-H), 4.43 (2H, 
s, 11-H), 1.36 (9H, s, 9-H); δC (75 MHz, CDCl3) 193.5 (C-10), 176.9 (C-7), 153.7 
(C-5), 151.6 (C-1), 139.6 (C-3), 118.4 (C-4), 117.1 (C-2), 40.5 (C-8), 31.2 (C-11), 
27.4 (C-9); m/z (ES+) 330.86 ([M79Br+Na]+, 100%), 322.86 ([M81Br+Na]+, 82), 
HRMS m/z (ES+) 299.0392 ([M+H]+,14%) C12H16O2N2Br requires 299.0395 
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2-Amino-3-fluorobenzoic acid 364196 
 
7-Fluoroisatin (10 g, 60.6 mmol) was  added to a solution of sodium hydroxide 
(8.34 g, 208 mmol) in water (300 mL). Hydrogen peroxide (30% w/w, 40 mL) was 
added dropwise. A gas was evolved. The solution was warmed to 50 ˚C for 30 min. 
The solution was allowed to cool before HCl (2N solution) was added dropwise 
until a pH of 4 was reached. A precipitate formed which was filtered and the 
precipitate was recrystallised from ethanol/water to give the product 364 as a 
brown solid (5.14 g, 55%): m.p 179-183 ˚C (Lit.196 183-184 ˚C); δH (300 MHz, 
CDCl3) 7.72 (1H, ddd, J= 8.1, 1.5, 1.2 Hz, 6-H), 7.16 (1H, ddd, J= 11.3, 7.9, 1.5 Hz, 
4-H), 6.60 (1H, ddd, J= 8.1, 7.9, 5.0 Hz, 5-H), 5.81 (2H, s, NH2); δC (75 MHz, 
CDCl3) 172.6 (C-7), 151.5 (d, J= 239.7 Hz, C-3), 140.5 (d, J= 14 Hz, C-2), 127.2 
(d, J= 3.5 Hz, C-6), 119.4 (d, J= 18.2 Hz, C-4), 114.9 (d, J= 7.2 Hz, C-5), 111.3 (d, 
J= 4.2 Hz, C-1); δF (282 MHz, CDCl3) -136.59 (1F, ddd, J= 11.3, 5, 1.2 Hz); m/z 
(CI+) 156.05 ([M+H]+, 22%), 155.04 ([M]+, 28), 138.03 ([M-OH]+, 100), HRMS m/z 
(CI+) 156.0458 ([M+H]+, 22%) C7H7NO2F requires 156.0461. 
 
2-((tert-Butoxycarbonyl)amino)-3-fluorobenzoic acid 361229 
 
Benzoic acid 364 (900 mg, 5.8 mmol) was added to a solution of THF/Water (20:20 
mL). Sodium hydroxide (580 mg, 14.5 mmol) was added to the solution. Di-tert-
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butyl dicarbonate (1.52 g, 6.9 mmol) was added and the solution was stirred for 16 
h. The volatile solvent was removed under reduced pressure the pH was adjusted 
to 6 and ethyl acetate (40 mL) was added. The aqueous layer was re-extracted 
with ethyl acetate (2 × 40 mL). The combined organic layers were dried with 
magnesium sulfate and the solvent was removed under reduced pressure. The 
product was purified by column chromatography on silica (20% ethyl 
acetate/petroleum ether to 30% ethyl acetate/petroleum ether) to give the product 
361 as a brown solid (961 mg, 65%): m.p 180-182 °C; νmax/cm-1 (nujol) 3518, 3393, 
1717, 1667; δH (300 MHz, CDCl3) 7.55 (1H, ddd, J= 8.1, 1.3, 1.3 Hz, 6-H), 7.23 
(1H, ddd, J= 11.7, 7.9, 1.5 Hz, 4-H), 6.52 (1H, ddd, J= 8.1, 7.9, 5.0 Hz, 5-H), 1.46 
(9H, s, 10-H); δC (75 MHz, CDCl3) 168.9 (d, J= 3.5 Hz, C-11), 150.9 (d, J= 238.2 
Hz, C-3), 146.2 (C-8), 140.0 (d, J= 14.3 Hz, C-2), 126.6 (d, J= 3.1 Hz, C-6), 118.3 
(d, J= 18.0 Hz, C-4), 113.6 (d, J= 7.2 Hz, C-5), 112.3 (d, J= 4.6 Hz, C-1), 85.6 (C-
9), 26.8 (C-10); δF (282 MHz, CDCl3) -135.14 (1F, dd, J= 11.7, 5 Hz). 
 
2-((tert-Butoxycarbonyl)amino)benzoic acid 368198 
 
Anthranilic acid (5 g, 36.4 mmol) was added to a solution of water and 1,4-dioxan 
(1:1, 200 mL). Sodium hydroxide (4.38 g, 109 mmol) was added to the solution. Di-
tert-butyl dicarbonate (9.55 g, 43.7 mmol) was added to the solution, which was 
stirred for 16 h. The solvent was removed under reduced pressur. Water (100 mL) 
was added and the product was precipitated by the addition of 1 N HCl until pH 4 
was reached. The product was purified by recrystilisation from ethanol and water to 
give the product 368 as a brown solid (4.44 g, 51%): m.p 150-154 °C (Lit.198 150-
152 ˚C); νmax/cm-1 (nujol) 3308, 1728, 1670, 1587, 1534, 1523, 1268, 1151, 759; δH 
(300 MHz, D6-DMSO) 10.66 (1H, s, NH), 8.27 (1H, dd, J=8.5, 0.9 Hz, 3-H), 7.96 
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(1H, dd, J= 7.9, 1.6 Hz, 6-H), 7.55 (1H, ddd, J= 8.5, 7.2, 1.6 Hz, 5-H), 7.06 (1H, 
ddd, J= 7.9, 7.2, 1.1 Hz, 4-H), 1.45 (9H, s, 11-H); δC (75 MHz, D6-DMSO) 170.5 (C-
7), 152.8 (C-9), 142.4 (C-1), 135.1 (C-5), 132.1 (C-6), 122.3 (C-4), 118.8 (C-3), 
115.9 (C-2), 81.0 (C-10), 28.8 (C-11); m/z (ES-) 236.0924 ([M-H]-, 95%), 162.0190 
([M-C4H10O]-, 100), (ES+) 260.0888 ([M+Na]+, 62), 138.0546 ([M-C5H9O2]+, 100), 
HRMS m/z (ES-) 236.0924 ([M-H]-, 95%) C12H14NO4 requires 236.0928. 
 
tert-Butyl (3-acetylphenyl)carbamate 369230 
 
Methylmagnesium bromide (3 M solution in Et2O, 5 mL, 15 mmol) was added 
dropwise, under argon, to a solution of benzoic acid 368 (711 mg, 3 mmol) in THF 
(10 mL) at 0 ˚C. The solution was allowed to warm to room temperature and the 
mixture was stirred for 16 h. The mixture was poured onto ice and the pH was 
adjusted to 4 and ethyl acetate (50 mL) was added. The layers were separated and 
the aqueous layer was re-extracted with ethyl acetate (2 × 20 mL), The combined 
organic layers were dried with magnesium sulfate and the solvent was removed 
under reduced pressure the product was purified by column chromatography on 
silica (10% ethyl acetate/petroleum ether) to give the product 369 as a colourless 
solid (343 mg, 49%): m.p 52- 55 ˚C; νmax/cm-1 (nujol) 3518, 3393, 3254, 3229, 
1735, 1712, 1657, 1587, 1531, 1249, 1157, 1054, 1028, 956, 837, 741; δH (400 
MHz, CDCl3) 10.94 (1H, s, NH), 8.47 (1H, dd, J= 8.6, 0.8 Hz, H), 7.85 (1H, dd, J= 
8.0, 1.5, H), 7.53-7.49 (1H, m, H), 7.02 (1H, ddd, J= 8, 7.3, 1.2 Hz, H), 2.64 (3H, s, 
Me), 1.52 (9H, s, (CH3)3); δC (75 MHz, CDCl3) 202.2 (C-11), 153.1 (C-7), 141.8 (C-
1), 134.9 (C-5), 131.6 (C-3), 121.4 (C-2), 120.9 (C-4), 119.2 (C-6), 80.5 (C-9), 28.6 
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(C-12), 28.3 (C-10); HRMS m/z (ES+) 258.1101 ([M+Na]+, 100%) C13H17NO3Na 
requires 258.1106. 
2-Acetylbenzenaminium chloride 370 199 
 
HCl (4N in 1,4-dioxan, 2.5 mL, 10.1 mmol) was added to a solution of ketone 369 
(795 mg, 3.4 mmol) in diethyl ether (2.5 mL). The mixture was stirred for 1 h. The 
precipitate was filtered which gave the product 370 as a yellow solid (305 mg, 
53%): m.p 136-140 ˚C; δH (300 MHz, D6DMSO) 8.72 (3H, s, NH3), 7.77 (1H, dd, J= 
8.1, 1.5 Hz, 6-H), 7.29 (1H, ddd, J= 8.4, 7, 1.5 Hz, 5-H), 6.87 (1H, dd, J= 8.4, 1.2 
Hz, 3-H), 6.67 (1H, ddd, J= 8.1, 7.0, 1.2 Hz, 4-H), 2.50 (3H, s, Me); δC (75 MHz, 
D6DMSO) 200.5 (C-7), 148.4 (C-1), 134.5 (C-5), 132.5 (C-6), 119.2 (C-2), 118.4 
(C-3), 116.8 (C-4), 28.3 (C-8); m/z (ES+) 158.06 ([M+Na]+, 85%), 136.09 ([M+H]+, 
100), HRMS m/z (ES+) 136.0766 ([M+H]+, 85%) C8H10NO requires 136.0762. 
 
N-(2-Acetylphenyl)acetamide 371 200 
 
Acetic anhydride (205 µl, 2.1 mmol) was added to a solution of amine 370 (250 mg, 
1.5 mmol) in pyridine (10 mL). The mixture was stirred for 16 h. The reaction was 
quenched by the addition of saturated sodium bicarbonate solution (20 mL). DCM 
(20 mL) was added and the layers were separated. The aqueous layer was re-
extracted with DCM (2 × 20 mL). The combined organic layers were washed with 
water (30 mL) and brine solution (30 mL). The organic layer was dried with 
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magnesium sulfate and the solvent was removed under reduced pressure. The 
product was purified by column chromatography on silica (20% ethyl 
acetate/petroleum ether) to give the product 371 as a colourless solid 209 mg, 
73%): m.p 68-70 ˚C (Lit.200 70-75 ˚C); νmax/cm-1 (nujol) 3222, 1688, 1652, 1605, 
1584, 1528, 1249, 1240, 1169, 1010, 963, 765, 754; δH (300 MHz, CDCl3) 11.63 
(1H, s, 7-NH), 8.67 (1H, dd, J= 8.5, 1.1 Hz, 6-H), 7.82 (1H, dd, J= 8.0, 1.5 Hz, 3-H), 
7.51-7.45 (1H, m, 4-H), 7.04 (1H, ddd, J= 8, 7.3, 1.2 Hz, 5-H), 2.60 (3H, s, 9-H), 
2.16 (3H, s, 11-H); δC (75 MHz, CDCl3) 202.9 (C-10), 169.5 (C-8), 141.1 (C-2), 
135.2 (C-4), 131.6 (C-3), 122.3 (C-5), 121.7 (C-1), 120.8 (C-6), 28.7 (C-11), 25.6 
(C-9); HRMS m/z (ES+) 200.0688 ([M+Na]+, 100%) C10H11NO2Na requires 
200.0687. 
 
tert-Butyl (2-fluorophenyl)carbamate 374231 
 
2-Fluoroaniline (10 mL, 11.51 g, 104 mmol) was added to di-tert-butyl dicarbonate 
(16.68 g, 71.85 mmol) and the mixture was heated at 80 ˚C for 2 h. The solution 
was allowed to cool. The product was purified by column chromatography on silica 
(10% ethyl acetate/ petroleum ether) to give the product 374 as a white solid (9.12 
g, 56%): m.p 44-46 ˚C (Lit.231 48-49 ˚C); νmax/cm-1 (nujol) 3452, 3292, 1742, 1621, 
1595, 1531, 1233, 1158, 1050, 749; δH (300 MHz, CDCl3) 8.12 (1H, dd, J= 8 Hz, 4-
H), 7.16-7.05 (2H, m, 3,5-H), 6.99 (1H, dddd, J= 8.3, 7.1, 5.3, 1.7 Hz, 6-H), 6.76 
(1H, s, NH), 1.57 (9H,s, 9-H); δC (75 MHz, CDCl3) 152.4 (C-7), 152.1 (d, J= 242.1 
Hz, C-2), 126.9 (d, J= 10 Hz, C-1), 124.5 (d, J= 3.7 Hz, C-5), 122.9 (d, J= 7.5 Hz, 
C-6), 120.1 (C-4), 114.7 (d, J= 19 Hz, C-3), 81.0 (C-8), 28.3 (C-9); δF{H} (282 MHz , 
CDCl3) 132.77 (s); HRMS m/z (ES+) 234.0895 ([M+Na]+, 100%) C11H14NO2FNa 
requires 234.0906.  
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(2S)-2-(3-((Benzyloxy)carbonyl)-5-oxooxazolidin-4-yl)acetic acid 376 202 
 
Paraformaldehyde (1.8 g, 59.8 mmol) and p-toluenesulfonic acid (342 mg, 1.8 
mmol) were added to a solution of (2-S)-(((benzyloxy)carbonyl)amino)succinic acid 
(8 g, 30 mmol) in toluene (200 mL). The mixture was heated to reflux and the water 
was removed using dean-stark apparatus. After 5 h when no more water was 
produced the mixture was allowed to cool. The solvent was removed under 
reduced pressure. The product was purified by column chromatography (30 % 
ethyl acetate/ petroleum ether) to give the product 376 as a colourless oil which 
solidified with scratching (7.41 g, 87%): m.p 78-82 ˚C (Lit.202 82-84 ˚C); [α]D20 
+131.1 (c 1.06 in CHCl3) (Lit +124 c 3.53 in CHCl3 202); νmax/cm-1 (nujol) 3594, 
3113, 1823, 1798, 1668; δH (300 MHz, CDCl3) 8.71 (1H, s, H), 7.42-7.36 (5H, m, 
10,11,12-H), 5.52 (1H, s, 2-H), 5.34 (1H, d, J= 3.1 Hz, 2-H), 5.28-5.11 (2H, m, 8-
H), 4.38 (1H, s, 4-H), 3.39-3.05 (2H, m, 5-H); δC (75 MHz, CDCl3) 175.7 (3), 172.0 
(6), 153.3 (7), 135.5 (Ar), 129.2 (Ar-H), 129.1 (Ar-H), 128.8 (Ar-H), 78.7 (2), 68.7 
(8), 51.8 (4), 34.4 (5); HRMS m/z (ES-) 278.0658 ([M-H]-, 100%) C13H12NO6 
requires 278.0665. 
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(2S)-Benzyl 4-(2-chloro-2-oxoethyl)-5-oxooxazolidine-3-carboxylate 318184, 204 
 
Carboxylic acid 376 (7 g, 25 mmol) was dissolved in toluene (50 mL). A few drops 
of DMF were added followed by oxalyl chloride (10 mL, 117 mmol). The solution 
was refluxed for 3 h. The solution was allowed to cool and the solvent was 
removed under reduced pressure to give the product as a dark oil which was used 
without further purification (5.32 g, 71%): δH (300 MHz, CDCl3) 7.47- 7.37 (5H, m, 
10,11,12-H), 5.52 (1H, s, 2-H), 5.36 (1H, d, J= 3.3 Hz, 2-H), 5.26 (1H, d, J= 12.1 
Hz, 8-H), 5.21 (1H, d, J= 12.1 Hz, 8-H), 4.38-4.36 (1H, m, 4-H), 3.89-3.56 (2H, m, 
5-H), δC (75 MHz, CDCl3) 172.1 (C-6), 170.3 (C-3), 152.6 (C-7), 135.0 (Ar), 128.9 
(Ar-H), 128.8 (Ar-H), 128.5 (Ar-H), 78.4 (C-2), 68.4 (C-8), 51.6 (C-4), 46.4 (C-5). 
 
N-(2-Fluorophenyl)acetamide 379232 
 
Acetic anhydride (850 µl, 9 mmol) was added a solution of 2-fluoroaniline (1g, 9 
mmol) and triethylamine (1.4 mL, 9.9 mmol) in DCM (20 mL). The mixture was 
stirred for 16 h. Aqueous saturated sodium bicarbonate (20 mL) was added. The 
product was extracted with DCM (2 × 20 mL) and the combined organic layer was 
washed with brine solution (20 mL). The organic layer was dried with magnesium 
sulfate and the solvent was removed under reduced pressure. The product was 
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purified by recystalisation from ethanol/ water to give the product 379 as a 
colourless solid (742mg, 54%): m.p 74-78 ˚C (Lit.232 78-80 ˚C); νmax/cm-1 (nujol) 
3246, 3132, 1663, 1615, 1547; δH (500 MHz, CDCl3) 8.31 (1H, t, J= 7.8 Hz, 4-H), 
7.50 (1H, s, NH), 7.16-7.06 (3H, m, 3,5,6-H), 2.25 (3H, s, 9-H); δC (125 MHz, 
CDCl3) 168.4 (C-8), 152.4 (d, J= 243.2 Hz, C-2), 126.3 (d, J= 10.3 Hz, C-1), 124.6 
(d, J= 3.5 Hz, C-5), 124.3 (d, J= 7.6 Hz, C-6), 121.9 (C-4), 114.8 (d, J= 18.8 Hz, C-
3), 24.7 (C-9); δF (470 MHz, CDCl3) -131.35 (1F, ); HRMS m/z (ES+) 176.0482 
([M+Na]+, 100%) C8H8NOFNa requires 176.0488. 
 
N-(2-Fluorophenyl)pivalamide 380233 
 
Triethylamine (12.5 mL, 90 mmol) was added to a solution of 2-fluoroaniline (5 g, 
45 mmol) in DCM (100 mL) and the solution was cooled to 0 ˚C. Trimethylacetyl 
chloride (6.6 mL, 54 mmol) was added dropwise to the solution. The solution was 
warmed to room temperature once the addition was complete and the solution was 
stirred for 16 h. A saturated solution of sodium bicarbonate was added (100 mL) 
and the layers were separated. The aqueous layer was extracted with DCM (2 × 
100 mL). The combined organic layers were dried with magnesium sulfate and the 
solvent was removed under reduced pressure. To give the product 380 as a white 
solid (9.8 g, quant.) which was dried under high vacumn for 6 h and then used 
without any further purification: m.p 61-64 ˚C (Lit.233 68 ˚C); νmax/cm-1 (nujol) 3347, 
1661, 1256; δH (300 MHz, CDCl3) 8.37-8.31 (1H, m, 4-H), 7.63 (1H, s, NH), 7.16-
6.19 (3H, m, 3,5,6-H), 1.33 (9H, s, H9); δC (75 MHz, CDCl3) 176.7 (C-7), 152.6 (d, 
J= 242.2 Hz, C-2), 126.7 (d, J= 9.8 Hz, C-1), 124.6 (d, J= 3.7 Hz, C-5), 124.1 (d, J= 
7.8 Hz, C-6), 121.7 (C-4), 114.6 (d, J= 19.3 Hz, C-3), 40.0 (C-8), 27.6 (C-9); δF{H} 
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(282 MHz, CDCl3) -132.1 (s); HRMS m/z (ES+) 196.1127 ([M+H]+, 100%) 
C11H15NOF requires 196.1138. 
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Appendix 
Single crystal X-ray diffraction data 
 
Crystallographic information for 146 
 
                     A. Crystal Data     B. Intensity Measurements  
 
Empirical Formula C21H36N4O8 Radiation CuKα (λ = 1.54187 Å) 
Formula Weight 472.54 Voltage, Current 40kV, 20mA 
Crystal Color, Habit colorless, platelet Temperature -100.0 ˚C 
Crystal Dimensions 0.280 X 0.030 X 
0.010 mm 
Detector 
Aperture 
0 x 0 mm 
Crystal System monoclinic 2θmax 136.6o 
Lattice Type Primitive No. of 
Reflections 
Measured 
Total: 29215 
Lattice Parameters a =   5.463(2) Å  Unique: 8099 (Rint = 0.0458) 
 b =  23.038(7) Å  Friedel pairs: 3731 
 c =  19.067(6) Å   
 β =  97.464(8) o Corrections Lorentz-polarization 
 V = 2379.5(12) 
Å3 
 Absorption 
Space Group P21 (#4)  trans. factors: 0.839 - 0.992) 
Z value 4 
Dcalc 1.319 g/cm3 
F000 1016.00 
µ(CuKα) 8.487 cm-1 
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C. Structure Solution and Refinement 
Structure Solution Direct Methods 
Refinement Full-matrix least-squares on F2 
Function Minimized Σ w (Fo2 - Fc2)2  
Least Squares Weights w = 1/ [ σ2(Fo2) + (0.2000 . P)2  
  + 0.0000 .  P ] 
  where P = (Max(Fo2,0) + 2Fc2)/3 
2θmax cutoff 136.6o 
Anomalous Dispersion All non-hydrogen atoms 
No. Observations (All 
reflections) 
8099 
No. Variables 266 
Reflection/Parameter Ratio 30.45 
Residuals: R1 (I>2.00σ(I)) 0.1140 
Residuals: R (All reflections) 0.1213 
Residuals: wR2 (All 
reflections) 
0.3463 
Goodness of Fit Indicator 1.460 
Flack Parameter (Friedel pairs 
= 3731) 
-0.1(4) 
Max Shift/Error in Final Cycle 0.072 
Maximum peak in Final Diff. 
Map 
0.97 e-/Å3 
Minimum peak in Final Diff. 
Map 
-0.79 e-/Å3 
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Crystallographic information for 152 
 
        A. Crystal Data     B. Intensity Measurements 
 
Empirical Formula C18H18N4O7S Diffractometer Saturn70 
Formula Weight 434.42 Radiation MoKα (λ = 0.71075 Å) 
Crystal Color, Habit colorless, needle Voltage, Current 50kV, 16mA 
Crystal Dimensions 0.240 X 0.020 X 
0.010 mm 
Temperature -180.0 ˚C 
Crystal System monoclinic Detector Aperture 70 x 70 mm 
Lattice Type C-centered ω oscillation Range  1.0 - 0.0o 
Lattice Parameters a =  23.300(7) Å Pixel Size 0.034 mm 
 b =   5.1253(13) Å 2θmax 53.6o 
 c =  14.015(4) Å No. of Reflections Measured Total: 4542 
 β = 107.583(10) o  Unique: 2460 (Rint = 
0.1104) 
 V = 1595.4(8) Å3  Friedel pairs: 974 
Space Group C2 (#5) Corrections Lorentz-polarization 
Z value 3 
Dcalc 1.356 g/cm3 
F000 678.00 
µ(MoKα) 1.984 cm-1 
 
C. Structure Solution and Refinement  
Structure Solution Direct Methods Residuals: R (All 
reflections) 
0.1769 
Refinement Full-matrix least-squares on F2 Residuals: wR2 (All 
reflections) 
0.3646 
Function Minimized Σ w (Fo2 - Fc2)2  Goodness of Fit 
Indicator 
1.204 
Least Squares 
Weights 
w = 1/ [ σ2(Fo2) + (0.0738 . P)2  Flack Parameter 
(Friedel pairs = 974) 
5(6) 
  + 29.6061 .  P ] Max Shift/Error in Final 
Cycle 
0.062 
  where P = (Max(Fo2,0) + 2Fc2)/3 Maximum peak in Final 
Diff. Map 
0.59 e-/Å3 
2θmax cutoff 53.6o Minimum peak in Final 
Diff. Map 
-0.45 e-/Å3 
Anomalous 
Dispersion 
All non-hydrogen atoms Residuals: R1 
(I>2.00σ(I)) 
0.1606 
No. Observations 
(All reflections) 
2460 
No. Variables 97 
Reflection/Parameter 
Ratio 
25.36 
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Crystallographic information for 165 
 
 
A. Crystal Data     B. Intensity Measurements  
Empirical Formula C18H16BrN3O6 Diffractometer Mercury70 
Formula Weight 450.24 Radiation MoKα (λ = 0.71075 Å) 
Crystal Color, Habit colorless, prism Voltage, Current 50kV, 16mA 
Crystal Dimensions 0.120 X 0.120 X 
0.100 mm 
Temperature -180.0 ˚C 
Crystal System monoclinic Detector Aperture 70 x 70 mm 
Lattice Type Primitive ω oscillation Range  1.0 - 0.0o 
Lattice Parameters a =  15.182(4) Å Pixel Size 0.068 mm 
 b =  14.698(3) Å 2θmax 50.7o 
 c =   8.280(2) Å No. of Reflections 
Measured 
Total: 11619 
 β =  93.572(7) o  Unique: 3353 (Rint = 0.0365) 
 V = 1844.0(8) Å3 Corrections Lorentz-polarization 
Space Group P21/c (#14)  Absorption 
Z value 4  (trans. factors: 0.664 - 0.796) 
Dcalc 1.622 g/cm3   
F000 912.00   
µ(MoKα) 22.777 cm-1   
 
C. Structure Solution and Refinement  
Structure Solution Direct Methods 
Refinement Full-matrix least-squares on F2 
Function Minimized Σ w (Fo2 - Fc2)2  
Least Squares Weights w = 1/ [ σ2(Fo2) + (0.0597 . P)2  
  + 38.6462 .  P ] 
  where P = (Max(Fo2,0) + 2Fc2)/3 
2θmax cutoff 50.7o 
Anomalous Dispersion All non-hydrogen atoms 
No. Observations (All reflections) 3353 
No. Variables 113 
Reflection/Parameter Ratio 29.67 
Residuals: R1 (I>2.00σ(I)) 0.0603 
Residuals: R (All reflections) 0.0636 
Residuals: wR2 (All reflections) 0.1394 
Goodness of Fit Indicator 0.697 
Max Shift/Error in Final Cycle 12.832 
Maximum peak in Final Diff. Map 2.01 e-/Å3 
Minimum peak in Final Diff. Map -1.15 e-/Å3 
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Crystallographic information for 167 
 
 
A. Crystal Data     B. Intensity Measurements  
Empirical Formula C18H19N3O8 Diffractometer Mercury70 
Formula Weight 405.36 Radiation MoKα (λ = 0.71075 Å) 
Crystal Color, Habit colorless, prism Voltage, Current 50kV, 16mA 
Crystal Dimensions 0.100 X 0.100 X 
0.100 mm 
Temperature -100.0 ˚C 
Crystal System triclinic Detector Aperture 70 x 70 mm 
Lattice Type Primitive Pixel Size 0.068 mm 
Lattice Parameters a =   7.158(2) Å 2θmax 50.7o 
 b =   7.924(2) Å No. of Reflections 
Measured 
Total: 5750 
 c =  17.511(6) Å  Unique: 3218 (Rint = 0.0423) 
 α =  81.23(2) o Corrections Lorentz-polarization 
 β =  89.94(3) o  Absorption 
 γ =  68.73(2) o  (trans. factors: 0.539 - 0.988) 
 V = 913.1(5) Å3 
Space Group P-1 (#2) 
Z value 2 
Dcalc 1.474 g/cm3 
F000 424.00 
µ(MoKα) 1.176 cm-1 
 
C. Structure Solution and Refinement  
Structure Solution Direct Methods Residuals: R1 (I>2.00σ(I)) 0.1066 
Refinement Full-matrix least-squares on F2 Residuals: R (All 
reflections) 
0.1253 
Function Minimized Σ w (Fo2 - Fc2)2  Residuals: wR2 (All 
reflections) 
0.3619 
Least Squares 
Weights 
w = 1/ [ σ2(Fo2) + (0.2000 . P)2  Goodness of Fit Indicator 1.373 
  + 0.0000 .  P ] Max Shift/Error in Final 
Cycle 
0.247 
  where P = (Max(Fo2,0) + 2Fc2)/3 Maximum peak in Final Diff. 
Map 
0.84 e-/Å3 
2θmax cutoff 50.7o Minimum peak in Final Diff. 
Map 
-0.41 e-/Å3 
Anomalous Dispersion All non-hydrogen atoms Reflection/Parameter Ratio 12.28 
No. Observations (All 
reflections) 
3218 
No. Variables 262 
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Crystallographic information for 173 
 
 
 
 
 
 
 
                 A. Crystal Data             B. Intensity Measurements  
Empirical Formula C21H21N2O7 Radiation CuKα (λ = 1.54187 Å) 
Formula Weight 413.41  multi-layer mirror 
monochromated 
Crystal Color, Habit colorless, prism Take-off Angle 2.8o 
Crystal Dimensions 0.150 X 0.030 X 
0.030 mm 
Detector Aperture 2.0 - 2.5 mm horizontal 
Crystal System monoclinic  2.0 mm vertical 
Lattice Type Primitive Crystal to Detector 
Distance 
21 mm 
No. of Reflections 
Used for Unit 
 Voltage, Current 40kV, 20mA 
Cell Determination 
(2θ range) 
1590 ( 82.2 - 138.6o 
) 
Temperature -100.0 ˚C 
Lattice Parameters a =  19.6141(10) Å Scan Type ω-2θ 
 b =   5.182(2) Å Scan Rate 0.0o/min (in ω) (up to 0 scans) 
 c =  22.043(11) Å Scan Width (0.00 + 0.00 tan θ)o 
 β = 114.340(10) o 2θmax 137.0o 
 V = 2041.3(13) Å3 No. of Reflections 
Measured 
Total: 20103 
Space Group P21/c (#14)  Unique: 3739 (Rint = 0.0671) 
Z value 4 Corrections Lorentz-polarization 
Dcalc 1.345 g/cm3  Absorption 
F000 868.00  (trans. factors: 0.769 - 0.975) 
µ(CuKα) 8.597 cm-1 
 
C. Structure Solution and Refinement  
Structure Solution Direct Methods 
(SHELX97) 
Reflection/Parameter 
Ratio 
13.35 
Refinement Full-matrix least-
squares on F2 
Residuals: R1 (I>2.00σ(I)) 0.0503 
Function Minimized Σ w (Fo2 - Fc2)2  Residuals: R (All 
reflections) 
0.0570 
Least Squares Weights w = 1/ [ σ2(Fo2) 
+ (0.1820 . P)2  
Residuals: wR2 (All 
reflections) 
0.1724 
  + 1.9876 .  P ] Goodness of Fit Indicator 0.652 
  where P = 
(Max(Fo2,0) + 2Fc2)/3 
Max Shift/Error in Final 
Cycle 
0.084 
2θmax cutoff 137.0o Maximum peak in Final 
Diff. Map 
0.50 e-/Å3 
Anomalous Dispersion All non-
hydrogen atoms 
Minimum peak in Final 
Diff. Map 
-0.26 e-/Å3 
No. Observations (All reflections) 3739 No. Variables 280 
  304 
 
Crystallographic information for 174 
 
 
             A. Crystal Data                                                      B. Intensity Measurements 
Empirical Formula C21H21N3O7 Diffractometer Saturn70 
Formula Weight 427.41 Radiation CuKα (λ = 1.54187 Å) 
Crystal Color, Habit colorless, prism Voltage, Current 40kV, 20mA 
Crystal Dimensions 0.200 X 0.010 X 
0.010 mm 
Temperature -100.0 ˚C 
Crystal System monoclinic Detector Aperture 70 x 70 mm 
Lattice Type Primitive Pixel Size 0.034 mm 
Lattice Parameters a =   6.420(5) Å 2θmax 136.2o 
 b =  27.13(2) Å No. of Reflections 
Measured 
Total: 56813 
 c =  23.82(2) Å  Unique: 7445 (Rint = 
0.3694) 
 β =  95.84(2) o Corrections Lorentz-polarization 
 V = 4127(5) Å3  Absorption 
Space Group P21/n (#14)  (trans. factors: 0.508 - 
0.991) 
Z value 8 
Dcalc 1.376 g/cm3 
F000 1792.00 
µ(CuKα) 8.839 cm-1 
 
C. Structure Solution and Refinement 
Structure Solution Direct Methods (SHELX97) No. Variables 559 
Refinement Full-matrix least-squares on F2 Reflection/Parameter Ratio 13.32 
Function Minimized Σ w (Fo2 - Fc2)2  Residuals: R1 (I>2.00σ(I)) 0.1658 
Least Squares 
Weights 
w = 1/ [ σ2(Fo2) + (0.1000 . P)2  Residuals: R (All reflections) 0.2755 
  + 0.0000 .  P ] Residuals: wR2 (All reflections) 0.3519 
  where P = (Max(Fo2,0) + 2Fc2)/3 Goodness of Fit Indicator 1.342 
2θmax cutoff 136.2o Max Shift/Error in Final Cycle 0.389 
Anomalous 
Dispersion 
All non-hydrogen atoms Maximum peak in Final Diff. 
Map 
0.26 e-/Å3 
No. Observations 
(All reflections) 
7445 Minimum peak in Final Diff. Map -0.37 e-/Å3 
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Crystallographic information for 175 
 
 
 
Empirical formula  C18 H17 N3 O7 
Formula weight  387.35 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 4.7534(16) Å α= 87.096(16)°. 
 b = 12.188(4) Å β= 85.011(14)°. 
 c = 16.651(5) Å γ = 89.637(15)°. 
Volume 959.8(5) Å3 
Z 2 
Density (calculated) 1.340 Mg/m3 
Absorption coefficient 0.105 mm-1 
F(000) 404 
Crystal size 0.12 x 0.05 x 0.03 mm3 
Theta range for data collection 2.46 to 25.34°. 
Index ranges -5<=h<=5, -14<=k<=12, -16<=l<=19 
Reflections collected 6015 
Independent reflections 3369 [R(int) = 0.0352] 
Completeness to theta = 25.00° 96.4 %  
Absorption correction Multiscan 
Max. and min. transmission 1.000 and 0.550 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3369 / 0 / 274 
Goodness-of-fit on F2 1.505 
Final R indices [I>2sigma(I)] R1 = 0.0990, wR2 = 0.3413 
R indices (all data) R1 = 0.1103, wR2 = 0.3677 
Extinction coefficient 0.07(3) 
Largest diff. peak and hole 1.165 and -0.396 e.Å-3 
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Crystallographic information for 176 
 
 
                      A. Crystal Data                                                B. Intensity Measurements  
 
Empirical Formula C18H7N3O7 Diffractometer Saturn70 
Formula Weight 377.27 Radiation CuKα (λ = 1.54187 Å) 
Crystal Color, Habit colorless, prism Voltage, Current 40kV, 20mA 
Crystal Dimensions 0.120 X 0.120 X 
0.030 mm 
Temperature -100.0 ˚C 
Crystal System triclinic Detector Aperture 70 x 70 mm 
Lattice Type Primitive Pixel Size 0.034 mm 
Lattice Parameters a =   7.368(5) Å 2θmax 136.0o 
 b =   8.445(6) Å No. of Reflections Measured Total: 2987 
 c =  14.827(8) Å  Unique: 2987 (Rint = 0.0000) 
 α =  92.813(7) o Corrections Lorentz-polarization 
 β =  94.34(2) o  Absorption 
 γ = 107.44(3) o  (trans. factors: 0.788 - 0.971) 
 V = 875.1(10) Å3 
Space Group P-1 (#2) 
Z value 2 
Dcalc 1.432 g/cm3 
F000 384.00 
µ(CuKα) 9.784 cm-1 
C. Structure Solution and Refinement 
 
Structure Solution Direct Methods Reflection/Parameter Ratio 11.81 
Refinement Full-matrix least-squares 
on F2 
Residuals: R1 (I>2.00σ(I)) 0.0951 
Function Minimized Σ w (Fo2 - Fc2)2  Residuals: R (All reflections) 0.0993 
Least Squares 
Weights 
w = 1/ [ σ2(Fo2) + (0.2000 
. P)2  
Residuals: wR2 (All reflections) 0.3553 
  + 0.0000 .  P ] Goodness of Fit Indicator 1.614 
  where P = (Max(Fo2,0) + 
2Fc2)/3 
Max Shift/Error in Final Cycle 1.004 
2θmax cutoff 136.0o Maximum peak in Final Diff. Map 0.78 e-/Å3 
Anomalous Dispersion All non-hydrogen atoms Minimum peak in Final Diff. Map -0.39 e-/Å3 
No. Observations (All 
reflections) 
2987 Maximum peak in Final Diff. Map 0.78 e-/Å3 
No. Variables 253 Minimum peak in Final Diff. Map -0.39 e-/Å3 
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Crystallographic information for 189 
 
 
                      A. Crystal Data                                                B. Intensity Measurements  
 
Empirical Formula C18H14BrN3O5 
Formula Weight 432.23 
Crystal Color, Habit colorless, prism 
Crystal Dimensions 0.120 X 0.030 X 
0.030 mm 
Crystal System triclinic 
Lattice Type Primitive 
Lattice Parameters a =   7.272(3) Å 
 b =  10.669(3) Å 
 c =  12.039(3) Å 
 α =  66.43(2) o 
 β =  85.54(3) o 
 γ =  80.06(3) o 
 V = 843.3(5) Å3 
Space Group P-1 (#2) 
Z value 2 
Dcalc 1.702 g/cm3 
F000 436.00 
µ(MoKα) 24.822 cm-1 
Diffractometer Mercury70 
Radiation MoKα (λ = 0.71075 Å) 
Voltage, Current 50kV, 16mA 
Temperature -180.0 ˚C 
Detector Aperture 70 x 70 mm 
Pixel Size 0.068 mm 
2θmax 50.7o 
No. of Reflections 
Measured 
Total: 5404 
 Unique: 2970 (Rint = 
0.0426) 
Corrections Lorentz-polarization 
 Absorption 
 (trans. factors: 0.737 - 
0.928) 
 
C. Structure Solution and Refinement 
 
Structure Solution Direct Methods No. Variables 244 
Refinement Full-matrix least- Reflection/Parameter Ratio 12.17 
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squares on F2 
Function Minimized Σ w (Fo2 - Fc2)2 Residuals: R1 (I>2.00σ(I)) 0.0594 
Least Squares 
Weights 
w = 1/ [ σ2(Fo2) + 
(0.1122 . P)2 
Residuals: R (All reflections) 0.0732 
 + 4.5702 .  P ] Residuals: wR2 (All reflections) 0.1692 
 where P = (Max(Fo2,0) 
+ 2Fc2)/3 
Goodness of Fit Indicator 0.804 
2θmax cutoff 50.7o Max Shift/Error in Final Cycle 0.014 
Anomalous 
Dispersion 
All non-hydrogen 
atoms 
Maximum peak in Final Diff. 
Map 
0.94 e-/Å3 
No. Observations 
(All reflections) 
2970 Minimum peak in Final Diff. 
Map 
-0.68 e-/Å3 
 
